{"PMC3983293": [["Nucleotide sequence accession number. ::: GENOME ANNOUNCEMENTThe genome sequence of the swine Deltacoronavirus strain SDCV/USA/Illinois121/2014 was deposited in GenBank with the accession no. KJ481931.", [["KJ481931", "CHEMICAL", 192, 200], ["KJ481931", "CHEMICAL", 192, 200], ["swine", "ORGANISM", 88, 93], ["Deltacoronavirus strain", "ORGANISM", 94, 117], ["KJ481931", "SIMPLE_CHEMICAL", 192, 200], ["swine", "SPECIES", 88, 93], ["swine Deltacoronavirus strain SDCV/USA/Illinois121/2014", "SPECIES", 88, 143]]]], "c0b835b01daa1b3194342d1b33bb1473c5b44404": [["volume, contact angle and environmental temperature were analyzed and the lifetime of droplets under those conditions was investigated.", [["environmental temperature", "TEST", 26, 51]]], ["The evaporation of droplets will also be affected by the dust in the air, and this factor should be also considered in the future.", [["The evaporation of droplets", "TREATMENT", 0, 27], ["droplets", "OBSERVATION", 19, 27], ["air", "ANATOMY", 69, 72]]]], "7a05a177703485d0b3ff4f03132db5b6e7f2a2eb": [["IntroductionThe Global Virus Network (GVN) was established in 2011 to strengthen research in response to human viral diseases and to prepare for new viral pandemic threats (Mann, 2011) .", [["viral diseases", "DISEASE", 111, 125], ["viral pandemic", "DISEASE", 149, 163], ["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["The Global Virus Network (GVN)", "TREATMENT", 12, 42], ["human viral diseases", "PROBLEM", 105, 125]]], ["These international conferences have become critical platforms for the exchange of ideas.IntroductionThe 2017 international GVN meeting was held from September 25-27 in Melbourne, Australia, in partnership with the Peter Doherty Institute for Infection and Immunity, and the Institut Pasteur.", [["Infection", "DISEASE", 243, 252], ["Infection", "PROBLEM", 243, 252], ["Infection", "OBSERVATION", 243, 252]]], ["The main objectives of the meeting were to present and discuss current findings in medical virology, including advances in Fig. 1 .", [["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Each centre has a director who has made significant contributions to the literature; high productivity in terms of publications; has served as a regional resource for research, diagnostics and treatment; programs that interact with other centers in the region, and outreach programs with less developed countries.", [["treatment", "TREATMENT", 193, 202]]], ["Current Centre Directors are listed at: http://gvn.org/gvn-centers. alphavirus encephalomyelitis, which have delineated the role of host immune responses in virus clearance, vaccine-induced protection from infection, tissue damage and immune suppression.", [["tissue", "ANATOMY", 217, 223], ["alphavirus encephalomyelitis", "DISEASE", 68, 96], ["infection", "DISEASE", 206, 215], ["tissue damage", "DISEASE", 217, 230], ["tissue", "TISSUE", 217, 223], ["alphavirus encephalomyelitis", "SPECIES", 68, 96], ["alphavirus encephalomyelitis", "SPECIES", 68, 96], ["alphavirus encephalomyelitis", "PROBLEM", 68, 96], ["host immune responses", "TREATMENT", 132, 153], ["virus clearance", "TREATMENT", 157, 172], ["vaccine", "TREATMENT", 174, 181], ["infection", "PROBLEM", 206, 215], ["tissue damage", "PROBLEM", 217, 230], ["immune suppression", "PROBLEM", 235, 253], ["encephalomyelitis", "OBSERVATION", 79, 96], ["infection", "OBSERVATION", 206, 215], ["immune suppression", "OBSERVATION", 235, 253]]], ["Dr. Griffin also was cited for her leadership role within the GVN's international conferences and virology training programs, for making important basic science contributions to medical virology.IntroductionThe award is named for Robert C. Gallo, MD, co-founder and director, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Institute of Human Virology, University of Maryland School of Medicine, and Co-Founder and Scientific Director of the GVN.", [["Human", "ORGANISM", 354, 359], ["GVN", "CANCER", 459, 462], ["Human", "SPECIES", 354, 359], ["virology training programs", "TREATMENT", 98, 124]]], ["Dr. Gallo and his co-workers discovered interleukin-2 (IL-2), followed by the discovery of the first human retroviruses, Human T-Cell Leukemia Virus-1 (HTLV-1) and HTLV-2.", [["interleukin-2", "GENE_OR_GENE_PRODUCT", 40, 53], ["IL-2", "GENE_OR_GENE_PRODUCT", 55, 59], ["human", "ORGANISM", 101, 106], ["retroviruses", "ORGANISM", 107, 119], ["Human T-Cell Leukemia Virus-1", "ORGANISM", 121, 150], ["HTLV-1", "ORGANISM", 152, 158], ["HTLV-2", "ORGANISM", 164, 170], ["interleukin-2", "PROTEIN", 40, 53], ["IL", "PROTEIN", 55, 57], ["human", "SPECIES", 101, 106], ["Human", "SPECIES", 121, 126], ["Leukemia Virus-1", "SPECIES", 134, 150], ["HTLV-1", "SPECIES", 152, 158], ["human", "SPECIES", 101, 106], ["Human T-Cell Leukemia Virus-1", "SPECIES", 121, 150], ["HTLV-1", "SPECIES", 152, 158], ["HTLV-2", "SPECIES", 164, 170], ["interleukin", "TEST", 40, 51], ["Human T-Cell Leukemia Virus", "PROBLEM", 121, 148], ["HTLV", "TEST", 152, 156], ["HTLV", "PROBLEM", 164, 168], ["Cell Leukemia", "OBSERVATION", 129, 142]]], ["He and his colleagues co-discovered HIV as the cause of AIDS and developed the first HIV blood test.Pre-meeting and public forum on HTLV-1 in remote indigenous AustraliansWhile not part of the formal GVN meeting, there was a morning session on HTLV-1 infection chaired by Damian Purcell of the Peter Doherty Institute and a closing summary by Robert Gallo.", [["blood", "ANATOMY", 89, 94], ["AIDS", "DISEASE", 56, 60], ["HTLV-1 infection", "DISEASE", 244, 260], ["HIV", "ORGANISM", 36, 39], ["HIV", "ORGANISM", 85, 88], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["HTLV-1", "ORGANISM", 132, 138], ["HTLV-1", "ORGANISM", 244, 250], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 85, 88], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 85, 88], ["HTLV-1", "SPECIES", 132, 138], ["HTLV-1", "SPECIES", 244, 250], ["HIV", "PROBLEM", 36, 39], ["AIDS", "PROBLEM", 56, 60], ["the first HIV blood test", "TEST", 75, 99], ["HTLV-1 infection", "PROBLEM", 244, 260]]], ["Some of what was discussed has been published Gallo et al., 2017) , and it is anticipated that additional publications by other speakers will be forthcoming.Re-awaking to HTLV-1 in indigenous communitiesAntoine Gessain (Institut Pasteur, Paris) reviewed the epidemiology, origin and genetic diversity of HTLV-1.", [["HTLV-1", "ORGANISM", 171, 177], ["HTLV-1", "ORGANISM", 304, 310], ["HTLV-1", "SPECIES", 171, 177], ["HTLV-1", "SPECIES", 304, 310], ["HTLV", "OBSERVATION", 304, 308]]], ["In 2012, the EU Commission requested the European Centre for Disease Prevention and Control (ECDC) to construct a map indicating all the HTLV-1 highprevalence areas in the world.", [["HTLV-1", "ORGANISM", 137, 143], ["HTLV-1", "SPECIES", 137, 143], ["Disease Prevention", "TREATMENT", 61, 79], ["a map", "TEST", 112, 117]]], ["In most of the highly endemic areas, HTLV-1 is mainly disseminated and maintained in the human population through intra-familial transmission.Re-awaking to HTLV-1 in indigenous communities(mother-to-child and by sexual intercourse).", [["HTLV-1", "ORGANISM", 37, 43], ["human", "ORGANISM", 89, 94], ["HTLV-1", "ORGANISM", 156, 162], ["human", "SPECIES", 89, 94], ["HTLV-1", "SPECIES", 37, 43], ["human", "SPECIES", 89, 94], ["HTLV-1", "SPECIES", 156, 162], ["highly", "OBSERVATION_MODIFIER", 15, 21], ["endemic", "OBSERVATION_MODIFIER", 22, 29], ["areas", "OBSERVATION", 30, 35], ["HTLV", "OBSERVATION", 37, 41], ["mainly", "OBSERVATION_MODIFIER", 47, 53], ["disseminated", "OBSERVATION", 54, 66], ["human population", "OBSERVATION", 89, 105]]], ["More rarely, transmission may also occur by transfusion or intravenous drug use.", [["intravenous", "ANATOMY", 59, 70], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 59, 70]]], ["HTLV-1 originated from a simian retrovirus called simian T-leukemia virus type 1 (STLV-1), which is widespread in Old World monkey and ape species.", [["simian retrovirus", "DISEASE", 25, 42], ["simian T-leukemia virus", "DISEASE", 50, 73], ["HTLV-1", "ORGANISM", 0, 6], ["simian retrovirus", "ORGANISM", 25, 42], ["simian T-leukemia virus type 1", "ORGANISM", 50, 80], ["STLV-1", "ORGANISM", 82, 88], ["monkey", "ORGANISM", 124, 130], ["ape", "ORGANISM", 135, 138], ["simian", "SPECIES", 25, 31], ["simian", "SPECIES", 50, 56], ["T-leukemia virus type 1", "SPECIES", 57, 80], ["monkey", "SPECIES", 124, 130], ["HTLV-1", "SPECIES", 0, 6], ["simian retrovirus", "SPECIES", 25, 42], ["simian T-leukemia virus type 1", "SPECIES", 50, 80], ["STLV-1", "SPECIES", 82, 88], ["Old World monkey", "SPECIES", 114, 130], ["HTLV", "TEST", 0, 4], ["a simian retrovirus", "PROBLEM", 23, 42], ["leukemia virus type", "PROBLEM", 59, 78], ["ape species", "PROBLEM", 135, 146], ["widespread", "OBSERVATION_MODIFIER", 100, 110], ["ape species", "OBSERVATION", 135, 146]]], ["The idea that HTLV-1 originated from STLV-1 is mainly based on the very high sequence homology (African subtypes b, d, e, f) found between some STLV-1 strains and HTLV-1 found in individuals, including hunters, living in Central/West Africa.", [["HTLV-1", "ORGANISM", 14, 20], ["STLV-1", "ORGANISM", 37, 43], ["STLV-1", "ORGANISM", 144, 150], ["HTLV-1", "ORGANISM", 163, 169], ["STLV-1", "DNA", 37, 43], ["HTLV-1", "SPECIES", 163, 169], ["HTLV-1", "SPECIES", 14, 20], ["STLV-1", "SPECIES", 37, 43], ["STLV-1", "SPECIES", 144, 150], ["HTLV-1", "SPECIES", 163, 169], ["HTLV", "TEST", 14, 18], ["some STLV", "PROBLEM", 139, 148], ["HTLV", "PROBLEM", 163, 167], ["Central", "ANATOMY_MODIFIER", 221, 228]]], ["However, data concerning transmission of STLV-1 to humans in natura and modes of acquisition remain quite scarce.", [["STLV-1", "ORGANISM", 41, 47], ["humans", "ORGANISM", 51, 57], ["humans", "SPECIES", 51, 57], ["STLV-1", "SPECIES", 41, 47], ["humans", "SPECIES", 51, 57], ["STLV", "TEST", 41, 45]]], ["Gessain also reviewed reported cases of HTLV-3 and -4, and speculated on the future emergence of these viruses and Simian Foamy viruses (Gessain et al., 2013) .Re-awaking to HTLV-1 in indigenous communitiesLloyd Einsiedel (Baker Heart and Diabetes Institute, Australia) reported on HTLV-1 subtype C as a major cause of morbidity and mortality among indigenous Australians.", [["HTLV-1 subtype C", "DISEASE", 282, 298], ["HTLV-3", "ORGANISM", 40, 46], ["-4", "CELL", 51, 53], ["Simian Foamy viruses", "ORGANISM", 115, 135], ["HTLV-1", "ORGANISM", 174, 180], ["HTLV-1 subtype C", "ORGANISM", 282, 298], ["Australians", "ORGANISM", 360, 371], ["HTLV-1", "SPECIES", 282, 288], ["Simian Foamy viruses", "SPECIES", 115, 135], ["HTLV-1", "SPECIES", 174, 180], ["HTLV-1", "SPECIES", 282, 288], ["HTLV", "TEST", 40, 44], ["these viruses", "PROBLEM", 97, 110], ["Diabetes", "PROBLEM", 239, 247], ["HTLV", "PROBLEM", 282, 286], ["morbidity", "PROBLEM", 319, 328], ["viruses", "OBSERVATION", 103, 110], ["Heart", "ANATOMY", 229, 234], ["morbidity", "OBSERVATION", 319, 328]]], ["The virus is highly endemic to central Australia where more than half of all indigenous adults residing in some remote communities are infected.", [["adults", "ORGANISM", 88, 94], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["highly", "OBSERVATION_MODIFIER", 13, 19], ["endemic", "OBSERVATION_MODIFIER", 20, 27], ["central", "OBSERVATION_MODIFIER", 31, 38], ["Australia", "OBSERVATION_MODIFIER", 39, 48], ["all", "OBSERVATION_MODIFIER", 73, 76], ["indigenous", "OBSERVATION_MODIFIER", 77, 87], ["adults", "OBSERVATION", 88, 94], ["some", "OBSERVATION_MODIFIER", 107, 111], ["remote", "OBSERVATION_MODIFIER", 112, 118], ["communities", "OBSERVATION_MODIFIER", 119, 130], ["infected", "OBSERVATION", 135, 143]]], ["Infection is associated with a rapidly progressive haematological malignancy (adult T-cell leukemia, ATL), inflammatory diseases involving various organ systems and an increased likelihood and severity of other infections, notably with Strongyloides stercoralis.", [["adult T-cell leukemia", "ANATOMY", 78, 99], ["ATL", "ANATOMY", 101, 104], ["organ", "ANATOMY", 147, 152], ["Infection", "DISEASE", 0, 9], ["malignancy", "DISEASE", 66, 76], ["adult T-cell leukemia, ATL", "DISEASE", 78, 104], ["infections", "DISEASE", 211, 221], ["Strongyloides stercoralis", "DISEASE", 236, 261], ["haematological malignancy", "CANCER", 51, 76], ["adult T-cell leukemia", "CANCER", 78, 99], ["ATL", "CANCER", 101, 104], ["organ", "ORGAN", 147, 152], ["Strongyloides stercoralis", "ORGANISM", 236, 261], ["Strongyloides stercoralis", "SPECIES", 236, 261], ["Strongyloides stercoralis", "SPECIES", 236, 261], ["Infection", "PROBLEM", 0, 9], ["a rapidly progressive haematological malignancy", "PROBLEM", 29, 76], ["adult T-cell leukemia", "PROBLEM", 78, 99], ["ATL)", "PROBLEM", 101, 105], ["inflammatory diseases", "PROBLEM", 107, 128], ["various organ systems", "PROBLEM", 139, 160], ["an increased likelihood", "PROBLEM", 165, 188], ["other infections", "PROBLEM", 205, 221], ["Strongyloides stercoralis", "PROBLEM", 236, 261], ["associated with", "UNCERTAINTY", 13, 28], ["rapidly", "OBSERVATION_MODIFIER", 31, 38], ["progressive", "OBSERVATION_MODIFIER", 39, 50], ["haematological", "OBSERVATION_MODIFIER", 51, 65], ["malignancy", "OBSERVATION", 66, 76], ["cell leukemia", "OBSERVATION", 86, 99], ["inflammatory", "OBSERVATION_MODIFIER", 107, 119], ["increased", "OBSERVATION_MODIFIER", 168, 177], ["likelihood", "OBSERVATION_MODIFIER", 178, 188], ["severity", "OBSERVATION_MODIFIER", 193, 201], ["infections", "OBSERVATION", 211, 221], ["Strongyloides stercoralis", "OBSERVATION", 236, 261]]], ["In central Australia, each of the major HTLV-1associated diseases has been described; however, in this setting HTLV-1 infection is most often associated with chronic respiratory disease, including life-threatening, severe bronchiectasis, and with invasive bacterial infections (Einsiedel et al., 2012) .", [["respiratory", "ANATOMY", 166, 177], ["HTLV-1associated diseases", "DISEASE", 40, 65], ["HTLV-1 infection", "DISEASE", 111, 127], ["chronic respiratory disease", "DISEASE", 158, 185], ["bronchiectasis", "DISEASE", 222, 236], ["bacterial infections", "DISEASE", 256, 276], ["HTLV", "ORGANISM", 40, 44], ["HTLV-1", "ORGANISM", 111, 117], ["HTLV-1", "SPECIES", 111, 117], ["HTLV-1", "SPECIES", 111, 117], ["the major HTLV-1associated diseases", "PROBLEM", 30, 65], ["HTLV-1 infection", "PROBLEM", 111, 127], ["chronic respiratory disease", "PROBLEM", 158, 185], ["severe bronchiectasis", "PROBLEM", 215, 236], ["invasive bacterial infections", "PROBLEM", 247, 276], ["central", "OBSERVATION_MODIFIER", 3, 10], ["Australia", "OBSERVATION_MODIFIER", 11, 20], ["major", "OBSERVATION_MODIFIER", 34, 39], ["HTLV", "OBSERVATION", 40, 44], ["1associated", "OBSERVATION_MODIFIER", 45, 56], ["diseases", "OBSERVATION", 57, 65], ["infection", "OBSERVATION", 118, 127], ["most often associated with", "UNCERTAINTY", 131, 157], ["chronic", "OBSERVATION_MODIFIER", 158, 165], ["respiratory disease", "OBSERVATION", 166, 185], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["bronchiectasis", "OBSERVATION", 222, 236], ["invasive", "OBSERVATION_MODIFIER", 247, 255], ["bacterial", "OBSERVATION_MODIFIER", 256, 265], ["infections", "OBSERVATION", 266, 276]]], ["The region has the highest reported prevalence of adult bronchiectasis, and among the highest bloodstream infection incidence rates, worldwide.", [["bloodstream", "ANATOMY", 94, 105], ["bronchiectasis", "DISEASE", 56, 70], ["bloodstream infection", "DISEASE", 94, 115], ["adult bronchiectasis", "PROBLEM", 50, 70], ["the highest bloodstream infection incidence rates", "PROBLEM", 82, 131], ["highest", "OBSERVATION_MODIFIER", 19, 26], ["adult", "OBSERVATION_MODIFIER", 50, 55], ["bronchiectasis", "OBSERVATION", 56, 70], ["highest", "OBSERVATION_MODIFIER", 86, 93], ["bloodstream", "OBSERVATION_MODIFIER", 94, 105], ["infection", "OBSERVATION", 106, 115]]], ["The risk of bronchiectasis and the extent of pulmonary injury are strongly associated with the HTLV-1 proviral load (pVL), which also predicts risk of invasive bacterial infection.", [["pulmonary", "ANATOMY", 45, 54], ["bronchiectasis", "DISEASE", 12, 26], ["pulmonary injury", "DISEASE", 45, 61], ["bacterial infection", "DISEASE", 160, 179], ["pulmonary", "ORGAN", 45, 54], ["HTLV-1", "ORGANISM", 95, 101], ["HTLV-1", "SPECIES", 95, 101], ["bronchiectasis", "PROBLEM", 12, 26], ["pulmonary injury", "PROBLEM", 45, 61], ["the HTLV-1 proviral load (pVL)", "PROBLEM", 91, 121], ["invasive bacterial infection", "PROBLEM", 151, 179], ["bronchiectasis", "OBSERVATION", 12, 26], ["extent", "OBSERVATION_MODIFIER", 35, 41], ["pulmonary", "ANATOMY", 45, 54], ["injury", "OBSERVATION", 55, 61], ["invasive", "OBSERVATION_MODIFIER", 151, 159], ["bacterial", "OBSERVATION_MODIFIER", 160, 169], ["infection", "OBSERVATION", 170, 179]]], ["The association between HTLV-1 pVL and these life-threatening conditions is consistent with recent findings that higher HTLV-1 pVL are associated with an increased risk of death in a large prospective cohort of Indigenous adults (Einsiedel et al., 2016) .", [["death", "DISEASE", 172, 177], ["HTLV-1", "ORGANISM", 24, 30], ["pVL", "ORGANISM", 31, 34], ["HTLV-1", "ORGANISM", 120, 126], ["pVL", "ORGANISM", 127, 130], ["HTLV-1", "SPECIES", 24, 30], ["HTLV-1", "SPECIES", 120, 126], ["HTLV", "TEST", 24, 28], ["pVL", "PROBLEM", 31, 34], ["higher HTLV-1 pVL", "PROBLEM", 113, 130], ["death", "PROBLEM", 172, 177], ["consistent with", "UNCERTAINTY", 76, 91], ["increased", "OBSERVATION_MODIFIER", 154, 163], ["large", "OBSERVATION_MODIFIER", 183, 188]]], ["High rates of HTLV-1 infection and HTLV-1-associated diseases contribute substantially to the burden of ill health and early mortality among indigenous people in central Australia.Re-awaking to HTLV-1 in indigenous communitiesCharles R. M. Bangham (Imperial College, U.K.) noted that HTLV-1 causes disabling chronic inflammatory diseases or an aggressive, rapidly fatal malignancy, adult T-cell leukemia/lymphoma, in about 10% of infected people.", [["malignancy", "ANATOMY", 370, 380], ["adult T-cell leukemia", "ANATOMY", 382, 403], ["lymphoma", "ANATOMY", 404, 412], ["HTLV-1 infection", "DISEASE", 14, 30], ["ill", "DISEASE", 104, 107], ["HTLV-1", "DISEASE", 284, 290], ["inflammatory diseases", "DISEASE", 316, 337], ["malignancy", "DISEASE", 370, 380], ["adult T-cell leukemia/lymphoma", "DISEASE", 382, 412], ["HTLV-1", "ORGANISM", 14, 20], ["HTLV-1", "ORGANISM", 35, 41], ["people", "ORGANISM", 152, 158], ["HTLV-1", "ORGANISM", 194, 200], ["HTLV-1", "ORGANISM", 284, 290], ["malignancy", "CANCER", 370, 380], ["adult T-cell leukemia", "CANCER", 382, 403], ["lymphoma", "CANCER", 404, 412], ["people", "ORGANISM", 439, 445], ["HTLV-1", "SPECIES", 14, 20], ["HTLV-1", "SPECIES", 35, 41], ["people", "SPECIES", 152, 158], ["people", "SPECIES", 439, 445], ["HTLV-1", "SPECIES", 14, 20], ["HTLV-1", "SPECIES", 35, 41], ["HTLV-1", "SPECIES", 194, 200], ["HTLV-1", "SPECIES", 284, 290], ["High rates of HTLV", "PROBLEM", 0, 18], ["1 infection", "PROBLEM", 19, 30], ["HTLV", "PROBLEM", 35, 39], ["associated diseases", "PROBLEM", 42, 61], ["disabling chronic inflammatory diseases", "PROBLEM", 298, 337], ["rapidly fatal malignancy", "PROBLEM", 356, 380], ["adult T-cell leukemia", "PROBLEM", 382, 403], ["lymphoma", "PROBLEM", 404, 412], ["HTLV", "OBSERVATION", 14, 18], ["infection", "OBSERVATION", 21, 30], ["diseases", "OBSERVATION", 53, 61], ["central", "ANATOMY_MODIFIER", 162, 169], ["Australia", "ANATOMY_MODIFIER", 170, 179], ["disabling", "OBSERVATION_MODIFIER", 298, 307], ["chronic", "OBSERVATION_MODIFIER", 308, 315], ["inflammatory", "OBSERVATION", 316, 328], ["aggressive", "OBSERVATION_MODIFIER", 344, 354], ["rapidly", "OBSERVATION_MODIFIER", 356, 363], ["fatal", "OBSERVATION_MODIFIER", 364, 369], ["malignancy", "OBSERVATION", 370, 380], ["cell leukemia", "OBSERVATION", 390, 403], ["lymphoma", "OBSERVATION", 404, 412]]], ["In addition, HTLV-1 predisposes to and exacerbates infections with Mycobacterium tuberculosis, Strongyloides stercoralis and Staphylococcus aureus, with severe and sometimes fatal consequences.", [["infections", "DISEASE", 51, 61], ["Mycobacterium tuberculosis", "DISEASE", 67, 93], ["Strongyloides stercoralis", "DISEASE", 95, 120], ["Staphylococcus aureus", "DISEASE", 125, 146], ["HTLV-1", "ORGANISM", 13, 19], ["Mycobacterium tuberculosis", "ORGANISM", 67, 93], ["Strongyloides stercoralis", "ORGANISM", 95, 120], ["Staphylococcus aureus", "ORGANISM", 125, 146], ["Mycobacterium tuberculosis", "SPECIES", 67, 93], ["Strongyloides stercoralis", "SPECIES", 95, 120], ["Staphylococcus aureus", "SPECIES", 125, 146], ["HTLV-1", "SPECIES", 13, 19], ["Mycobacterium tuberculosis", "SPECIES", 67, 93], ["Strongyloides stercoralis", "SPECIES", 95, 120], ["Staphylococcus aureus", "SPECIES", 125, 146], ["HTLV", "TEST", 13, 17], ["exacerbates infections", "PROBLEM", 39, 61], ["Mycobacterium tuberculosis", "PROBLEM", 67, 93], ["Strongyloides stercoralis", "PROBLEM", 95, 120], ["Staphylococcus aureus", "PROBLEM", 125, 146], ["severe and sometimes fatal consequences", "PROBLEM", 153, 192], ["Mycobacterium tuberculosis", "OBSERVATION", 67, 93], ["Strongyloides stercoralis", "OBSERVATION", 95, 120], ["Staphylococcus aureus", "OBSERVATION", 125, 146], ["severe", "OBSERVATION_MODIFIER", 153, 159]]], ["It has recently been shown that HTLV-1 also causes and exacerbates bronchiectasis, bronchitis and bronchiolitis.", [["bronchiectasis", "DISEASE", 67, 81], ["bronchitis", "DISEASE", 83, 93], ["bronchiolitis", "DISEASE", 98, 111], ["HTLV-1", "ORGANISM", 32, 38], ["HTLV-1", "SPECIES", 32, 38], ["HTLV", "PROBLEM", 32, 36], ["bronchiectasis", "PROBLEM", 67, 81], ["bronchitis", "PROBLEM", 83, 93], ["bronchiolitis", "PROBLEM", 98, 111], ["HTLV", "OBSERVATION", 32, 36], ["exacerbates", "OBSERVATION_MODIFIER", 55, 66], ["bronchiectasis", "OBSERVATION", 67, 81], ["bronchitis", "OBSERVATION", 83, 93], ["bronchiolitis", "OBSERVATION", 98, 111]]], ["The risk of these HTLV-1associated diseases is strongly correlated with the proviral load, which frequently exceeds 10% of peripheral blood mononuclear cells (PBMCs).", [["peripheral blood mononuclear cells", "ANATOMY", 123, 157], ["PBMCs", "ANATOMY", 159, 164], ["HTLV-1associated diseases", "DISEASE", 18, 43], ["HTLV", "ORGANISM", 18, 22], ["peripheral blood mononuclear cells", "CELL", 123, 157], ["PBMCs", "CELL", 159, 164], ["peripheral blood mononuclear cells", "CELL_TYPE", 123, 157], ["PBMCs", "CELL_TYPE", 159, 164], ["these HTLV-1associated diseases", "PROBLEM", 12, 43], ["the proviral load", "TEST", 72, 89], ["peripheral blood mononuclear cells", "TREATMENT", 123, 157], ["HTLV", "OBSERVATION", 18, 22], ["mononuclear cells", "OBSERVATION", 140, 157]]], ["The virus, which is non-cytolytic, drives proliferation of the infected CD4 + T cell, and the high proviral load is limited by a strong, chronically activated cytotoxic T lymphocyte (CTL) response to HTLV-1.", [["CD4 + T cell", "ANATOMY", 72, 84], ["cytotoxic T lymphocyte", "ANATOMY", 159, 181], ["CD4", "GENE_OR_GENE_PRODUCT", 72, 75], ["cytotoxic T lymphocyte", "CELL", 159, 181], ["CTL", "CELL", 183, 186], ["HTLV-1", "ORGANISM", 200, 206], ["infected CD4 + T cell", "CELL_TYPE", 63, 84], ["cytotoxic T lymphocyte", "CELL_TYPE", 159, 181], ["HTLV-1", "SPECIES", 200, 206], ["The virus", "PROBLEM", 0, 9], ["non-cytolytic", "PROBLEM", 20, 33], ["the infected CD4 + T cell", "PROBLEM", 59, 84], ["the high proviral load", "PROBLEM", 90, 112], ["chronically activated cytotoxic T lymphocyte", "PROBLEM", 137, 181], ["HTLV", "TEST", 200, 204], ["virus", "OBSERVATION", 4, 9], ["proliferation", "OBSERVATION_MODIFIER", 42, 55], ["infected", "OBSERVATION_MODIFIER", 63, 71], ["CD4 + T cell", "OBSERVATION", 72, 84], ["high", "OBSERVATION_MODIFIER", 94, 98], ["proviral load", "OBSERVATION", 99, 112], ["cytotoxic T lymphocyte", "OBSERVATION", 159, 181]]], ["Until recently, it was believed that HTLV-1 persisted in vivo chiefly by continuous oligoclonal proliferation of about 100 clones of HTLV-1infected CD4 + T cells.", [["clones", "ANATOMY", 123, 129], ["CD4 + T cells", "ANATOMY", 148, 161], ["HTLV-1", "ORGANISM", 37, 43], ["HTLV", "ORGANISM", 133, 137], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["HTLV-1infected CD4 + T cells", "CELL_LINE", 133, 161], ["HTLV-1", "SPECIES", 37, 43], ["HTLV", "TEST", 37, 41], ["continuous oligoclonal proliferation", "PROBLEM", 73, 109], ["HTLV", "TEST", 133, 137], ["T cells", "PROBLEM", 154, 161], ["oligoclonal proliferation", "OBSERVATION", 84, 109]]], ["However, Bangham and colleagues have shown that a typical individual carries between 10 4 and 10 5 clones, and the proviral loadthe chief correlate of diseaseis determined by the number of clones, not by oligoclonal proliferation.", [["clones", "CELL", 189, 195], ["diseaseis", "PROBLEM", 151, 160], ["oligoclonal proliferation", "PROBLEM", 204, 229], ["oligoclonal proliferation", "OBSERVATION", 204, 229]]], ["It was also believed that HTLV-1 was latent in vivo, but the existence of the persistently activated CTL response in virtually all hosts strongly argues that the virus is not latent but is frequently expressed.", [["HTLV-1", "ORGANISM", 26, 32], ["CTL", "CELL", 101, 104], ["HTLV-1", "SPECIES", 26, 32], ["HTLV", "TEST", 26, 30], ["the persistently activated CTL response", "PROBLEM", 74, 113], ["the virus", "PROBLEM", 158, 167], ["CTL response", "OBSERVATION", 101, 113], ["virus", "OBSERVATION", 162, 167]]], ["This suggests that the virus undergoes intermittent bursts of expression in vivo.Re-awaking to HTLV-1 in indigenous communitiesBangham presented data from single-molecule RNA fluorescence in situ hybridization (smFISH) that the provirus indeed undergoes intermittent, intense bursts of expression.", [["HTLV-1", "ORGANISM", 95, 101], ["provirus", "ORGANISM", 228, 236], ["HTLV-1", "SPECIES", 95, 101], ["the virus", "PROBLEM", 19, 28], ["the provirus", "PROBLEM", 224, 236], ["virus", "OBSERVATION", 23, 28], ["intermittent", "OBSERVATION_MODIFIER", 39, 51], ["bursts", "OBSERVATION_MODIFIER", 52, 58]]], ["Work is under way to identify the factors that regulate the frequency, size and duration of these bursts.", [["size", "OBSERVATION_MODIFIER", 71, 75]]], ["In addition, spontaneous reactivation of HTLV-1 from latency in fresh PBMCs is governed by the molecular oxygen availability and by glycolysis.", [["PBMCs", "ANATOMY", 70, 75], ["oxygen", "CHEMICAL", 105, 111], ["oxygen", "CHEMICAL", 105, 111], ["HTLV-1", "ORGANISM", 41, 47], ["PBMCs", "CELL", 70, 75], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["PBMCs", "CELL_TYPE", 70, 75], ["HTLV-1", "SPECIES", 41, 47], ["spontaneous reactivation of HTLV", "PROBLEM", 13, 45], ["spontaneous", "OBSERVATION_MODIFIER", 13, 24], ["reactivation", "OBSERVATION", 25, 37], ["HTLV", "OBSERVATION", 41, 45]]], ["Finally, he and colleagues discovered that HTLV-1 alters host chromatin structure in the infected cell, by binding the chromatin architectural protein CTCF, which regulates higher-order chromatin structure and gene expression in vertebrates.", [["chromatin", "ANATOMY", 62, 71], ["cell", "ANATOMY", 98, 102], ["chromatin", "ANATOMY", 119, 128], ["chromatin", "ANATOMY", 186, 195], ["HTLV-1", "ORGANISM", 43, 49], ["chromatin", "CELLULAR_COMPONENT", 62, 71], ["cell", "CELL", 98, 102], ["chromatin", "CELLULAR_COMPONENT", 119, 128], ["CTCF", "GENE_OR_GENE_PRODUCT", 151, 155], ["chromatin", "CELLULAR_COMPONENT", 186, 195], ["chromatin architectural protein", "PROTEIN", 119, 150], ["CTCF", "PROTEIN", 151, 155], ["chromatin", "DNA", 186, 195], ["HTLV-1", "SPECIES", 43, 49], ["HTLV", "PROBLEM", 43, 47], ["the infected cell", "PROBLEM", 85, 102], ["the chromatin architectural protein CTCF", "PROBLEM", 115, 155], ["gene expression in vertebrates", "PROBLEM", 210, 240], ["chromatin structure", "OBSERVATION", 62, 81], ["infected cell", "OBSERVATION", 89, 102], ["protein CTCF", "OBSERVATION", 143, 155], ["higher", "OBSERVATION_MODIFIER", 173, 179], ["gene expression", "OBSERVATION", 210, 225]]], ["This observation implies that HTLV-1 does a remarkable experiment of nature, by changing the conformation of chromatin in tens of thousands of different ways in each infected host (Satou et al., 2016) .", [["chromatin", "ANATOMY", 109, 118], ["HTLV-1", "ORGANISM", 30, 36], ["chromatin", "CELLULAR_COMPONENT", 109, 118], ["chromatin", "DNA", 109, 118], ["HTLV-1", "SPECIES", 30, 36], ["This observation", "TEST", 0, 16], ["HTLV", "PROBLEM", 30, 34]]], ["Studies are under way to test the hypotheses that CTCF regulates HTLV-1 latency, and that the abnormal chromatin looping caused by CTCF can deregulate host gene expression and so may act as an oncogenic driver.Re-awaking to HTLV-1 in indigenous communitiesFabiola Martin (University of Queensland, Australia; University of York, U.K.) discussed the clinical diagnosis and treatment of HTLV-1 diseases.", [["chromatin", "ANATOMY", 103, 112], ["HTLV-1 diseases", "DISEASE", 385, 400], ["CTCF", "GENE_OR_GENE_PRODUCT", 50, 54], ["HTLV-1", "ORGANISM", 65, 71], ["chromatin", "CELLULAR_COMPONENT", 103, 112], ["CTCF", "GENE_OR_GENE_PRODUCT", 131, 135], ["HTLV-1", "ORGANISM", 224, 230], ["HTLV-1", "ORGANISM", 385, 391], ["CTCF", "PROTEIN", 50, 54], ["CTCF", "PROTEIN", 131, 135], ["HTLV-1", "SPECIES", 65, 71], ["HTLV-1", "SPECIES", 224, 230], ["HTLV-1", "SPECIES", 385, 391], ["HTLV", "TEST", 65, 69], ["the abnormal chromatin looping", "PROBLEM", 90, 120], ["HTLV-1 diseases", "PROBLEM", 385, 400], ["abnormal", "OBSERVATION_MODIFIER", 94, 102], ["chromatin looping", "OBSERVATION", 103, 120]]], ["The discovery of a cure for HTLV-1, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL) has been an ongoing process of refinement since the early 1980s.", [["adult T-cell leukemia", "ANATOMY", 108, 129], ["lymphoma", "ANATOMY", 130, 138], ["ATLL", "ANATOMY", 140, 144], ["myelopathy", "DISEASE", 54, 64], ["tropical spastic paraparesis", "DISEASE", 65, 93], ["HAM", "DISEASE", 95, 98], ["adult T-cell leukemia/lymphoma", "DISEASE", 108, 138], ["ATLL", "DISEASE", 140, 144], ["HTLV-1", "ORGANISM", 28, 34], ["HTLV-1", "ORGANISM", 36, 42], ["adult T-cell leukemia/lymphoma", "CANCER", 108, 138], ["ATLL", "CANCER", 140, 144], ["HTLV-1", "SPECIES", 36, 42], ["HTLV-1", "SPECIES", 28, 34], ["HTLV-1", "SPECIES", 36, 42], ["HTLV", "TEST", 28, 32], ["HTLV", "TEST", 36, 40], ["myelopathy", "PROBLEM", 54, 64], ["tropical spastic paraparesis", "PROBLEM", 65, 93], ["HAM/TSP)", "PROBLEM", 95, 103], ["adult T-cell leukemia", "PROBLEM", 108, 129], ["lymphoma", "PROBLEM", 130, 138], ["myelopathy", "OBSERVATION", 54, 64], ["tropical", "OBSERVATION_MODIFIER", 65, 73], ["spastic", "OBSERVATION_MODIFIER", 74, 81], ["paraparesis", "OBSERVATION", 82, 93], ["cell leukemia", "OBSERVATION", 116, 129], ["lymphoma", "OBSERVATION", 130, 138]]], ["Martin presented summaries of more than 35 years of published and empirical intervention options, including HTLV prevention strategies as part of the international HTLV eradication efforts (Einsiedel et al., 2018) .Re-awaking to HTLV-1 in indigenous communitiesToshiki Watanabe (University of Tokyo, Japan) described recent government responses to HTLV-1 infection in Japan.", [["HTLV-1 infection", "DISEASE", 348, 364], ["HTLV", "ORGANISM", 108, 112], ["HTLV-1", "ORGANISM", 229, 235], ["HTLV-1", "ORGANISM", 348, 354], ["HTLV-1", "SPECIES", 348, 354], ["HTLV-1", "SPECIES", 229, 235], ["HTLV-1", "SPECIES", 348, 354], ["empirical intervention options", "TREATMENT", 66, 96], ["HTLV prevention strategies", "TREATMENT", 108, 134], ["the international HTLV eradication efforts", "TREATMENT", 146, 188], ["HTLV-1 infection", "PROBLEM", 348, 364], ["infection", "OBSERVATION", 355, 364]]], ["Since the first report of ATL by Takatsuki's group in 1977, Japanese clinicians and researchers have made major contributions to understanding the virology of HTLV-1 and the pathophysiology of ATL, as well as identifying other HTLV-1-associated diseases such as HAM/TSP and HTLV-1 uveitis (HU).", [["ATL", "ANATOMY", 26, 29], ["ATL", "ANATOMY", 193, 196], ["ATL", "DISEASE", 26, 29], ["ATL", "DISEASE", 193, 196], ["HAM/TSP", "DISEASE", 262, 269], ["HTLV-1 uveitis", "DISEASE", 274, 288], ["HU", "DISEASE", 290, 292], ["ATL", "CANCER", 26, 29], ["HTLV-1", "ORGANISM", 159, 165], ["ATL", "CANCER", 193, 196], ["HTLV-1", "ORGANISM", 227, 233], ["HTLV-1", "ORGANISM", 274, 280], ["HTLV-1", "SPECIES", 274, 280], ["HTLV-1", "SPECIES", 159, 165], ["HTLV-1", "SPECIES", 227, 233], ["HTLV-1", "SPECIES", 274, 280], ["associated diseases", "PROBLEM", 234, 253], ["HAM", "PROBLEM", 262, 265], ["TSP", "PROBLEM", 266, 269], ["HTLV", "PROBLEM", 274, 278], ["uveitis", "PROBLEM", 281, 288], ["uveitis", "OBSERVATION", 281, 288]]], ["In the first decade of 2000, groups of Japanese patients with HTLV-1-associated diseases petitioned the government for improved health care and treatment, as well as continuous and strong support for clinical and basic research.", [["HTLV-1-associated diseases", "DISEASE", 62, 88], ["patients", "ORGANISM", 48, 56], ["HTLV-1", "ORGANISM", 62, 68], ["patients", "SPECIES", 48, 56], ["HTLV-1", "SPECIES", 62, 68], ["HTLV", "PROBLEM", 62, 66], ["associated diseases", "PROBLEM", 69, 88], ["treatment", "TREATMENT", 144, 153], ["diseases", "OBSERVATION", 80, 88]]], ["In 2010, the government organized a HTLV-1 Task Force composed of the Prime Minister and government officials, representatives of patient groups, and medical specialists.", [["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137]]], ["Subsequently, a nationwide campaign began in 2011 with screening for HTLV-1 antibody in all pregnant women to prevent new mother-tochild transmissions.", [["HTLV-1", "ORGANISM", 69, 75], ["women", "ORGANISM", 101, 106], ["HTLV-1 antibody", "PROTEIN", 69, 84], ["women", "SPECIES", 101, 106], ["HTLV-1", "SPECIES", 69, 75], ["screening", "TEST", 55, 64], ["HTLV-1 antibody", "TREATMENT", 69, 84]]], ["Counseling also was initiated for HTLV-1 carriers and HAM/ATL patients.", [["ATL", "ANATOMY", 58, 61], ["HAM/ATL", "DISEASE", 54, 61], ["HTLV-1", "ORGANISM", 34, 40], ["ATL", "CANCER", 58, 61], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["HTLV-1", "SPECIES", 34, 40], ["HTLV-1 carriers", "TREATMENT", 34, 49]]], ["Some of the results of stepped-up government support for HTLV-1 research and care have been reported (Satake et al., 2016; Nosaka et al., 2017) .New and emerging viruses in Australasia and beyondLinfa Wang (Duke-NUS Medical School, Singapore) presented a review of his 20 years of research on the importance of bats as natural reservoir of viruses.", [["HTLV-1", "ORGANISM", 57, 63], ["bats", "ORGANISM", 311, 315], ["HTLV-1", "SPECIES", 57, 63], ["viruses", "OBSERVATION", 162, 169]]], ["Specifically, he addressed three questions:New and emerging viruses in Australasia and beyond1.", [["viruses", "OBSERVATION", 60, 67]]], ["Are bats true reservoirs of emerging viruses?", [["emerging viruses", "PROBLEM", 28, 44], ["viruses", "OBSERVATION", 37, 44]]], ["Since the discovery of rabies virus in bats more than 100 years ago, bats have been known to carry zoonotic viruses.", [["rabies virus", "DISEASE", 23, 35], ["zoonotic viruses", "DISEASE", 99, 115], ["rabies virus", "ORGANISM", 23, 35], ["bats", "ORGANISM", 69, 73], ["rabies virus", "SPECIES", 23, 35], ["rabies virus", "SPECIES", 23, 35], ["rabies virus", "PROBLEM", 23, 35], ["rabies virus", "OBSERVATION", 23, 35]]], ["But the field remained relatively \"quiet\" until the discovery of Hendra virus in Australian bats, which was responsible for lethal outbreaks in horses and humans.", [["Hendra virus", "DISEASE", 65, 77], ["Hendra virus", "ORGANISM", 65, 77], ["horses", "ORGANISM_SUBDIVISION", 144, 150], ["humans", "ORGANISM", 155, 161], ["horses", "SPECIES", 144, 150], ["humans", "SPECIES", 155, 161], ["Hendra virus", "SPECIES", 65, 77], ["horses", "SPECIES", 144, 150], ["humans", "SPECIES", 155, 161], ["Hendra virus", "PROBLEM", 65, 77], ["lethal outbreaks in horses", "PROBLEM", 124, 150]]], ["Since then, bats have been confirmed or suspected as reservoirs of several emerging viruses, including Nipah, SARS, MERS, Ebola and Marburg viruses.", [["Nipah, SARS, MERS, Ebola and Marburg viruses", "DISEASE", 103, 147], ["Nipah", "ORGANISM", 103, 108], ["Ebola", "ORGANISM", 122, 127], ["Marburg viruses", "ORGANISM", 132, 147], ["Nipah", "SPECIES", 103, 108], ["Marburg viruses", "SPECIES", 132, 147], ["several emerging viruses", "PROBLEM", 67, 91], ["Nipah", "PROBLEM", 103, 108], ["viruses", "OBSERVATION", 84, 91], ["Marburg viruses", "OBSERVATION", 132, 147]]], ["Although scientists working in this field still debate whether bats are the true reservoir of Ebola virus, for example, Wang pointed out that it took an international collaborative team more than ten years to obtain convincing evidence of the bat origin of the SARS coronavirus (Ge et al., 2013) .", [["Ebola virus", "DISEASE", 94, 105], ["SARS coronavirus", "DISEASE", 261, 277], ["bats", "ORGANISM", 63, 67], ["Ebola virus", "ORGANISM", 94, 105], ["SARS coronavirus", "ORGANISM", 261, 277], ["Ebola virus", "SPECIES", 94, 105], ["Ebola virus", "SPECIES", 94, 105], ["SARS coronavirus", "SPECIES", 261, 277], ["Ebola virus", "PROBLEM", 94, 105], ["the SARS coronavirus", "PROBLEM", 257, 277], ["Ebola virus", "OBSERVATION", 94, 105]]], ["First, it is difficult to induce experimental infections in bats with many viruses lethal to humans and livestock.", [["infections", "DISEASE", 46, 56], ["bats", "ORGANISM", 60, 64], ["humans", "ORGANISM", 93, 99], ["humans", "SPECIES", 93, 99], ["humans", "SPECIES", 93, 99], ["experimental infections in bats", "PROBLEM", 33, 64], ["infections", "OBSERVATION", 46, 56]]], ["Second, bats can harbor more viruses on a per species basis and there is a greater genetic diversity of viruses in bats than in other mammals.", [["bats", "ORGANISM", 8, 12], ["greater", "OBSERVATION_MODIFIER", 75, 82], ["viruses", "OBSERVATION", 104, 111]]], ["Evidence has been gathered to support these hypotheses, although most of them are based on retrospective studies of past literature.", [["retrospective studies", "TEST", 91, 112]]], ["The most significant study examined a database of 2805 mammal-virus associations and concluded that bats harbor a significantly higher proportion of zoonotic viruses than any other mammalian order (Olival et al., 2017) .", [["zoonotic viruses", "DISEASE", 149, 165], ["bats", "ORGANISM", 100, 104]]], ["Wang noted that bats have a long lifespan and are less prone to cancer.", [["cancer", "ANATOMY", 64, 70], ["cancer", "DISEASE", 64, 70], ["cancer", "CANCER", 64, 70], ["cancer", "OBSERVATION", 64, 70]]], ["He hypothesized that the evolutionary adaptation to flight has resulted in a unique immune system significantly different from terrestrial mammals.", [["immune system", "ANATOMY", 84, 97], ["a unique immune system", "PROBLEM", 75, 97], ["terrestrial mammals", "OBSERVATION", 127, 146]]], ["He presented genomic data indicating a more robust positive selection of genes responsible for DNA damage pathways (Zhang et al., 2013) .", [["DNA", "CELLULAR_COMPONENT", 95, 98], ["DNA damage pathways", "PROBLEM", 95, 114]]], ["The most recently data obtained from his group suggests that the overall dampening of inflammatory responses may be key to why bats can carry so many viruses, yet seldom develop symptomatic infections.New and emerging viruses in Australasia and beyondAlex Greenwood (Leibniz Institute for Zoo and Wildlife Research, Berlin, Germany) introduced the concept of exogenous and endogenous retroviruses.", [["infections", "DISEASE", 190, 200], ["bats", "ORGANISM", 127, 131], ["retroviruses", "ORGANISM", 384, 396], ["inflammatory responses", "PROBLEM", 86, 108], ["many viruses", "PROBLEM", 145, 157], ["symptomatic infections", "PROBLEM", 178, 200], ["New and emerging viruses", "PROBLEM", 201, 225], ["exogenous and endogenous retroviruses", "PROBLEM", 359, 396], ["dampening", "OBSERVATION_MODIFIER", 73, 82], ["inflammatory", "OBSERVATION", 86, 98], ["viruses", "OBSERVATION", 150, 157], ["symptomatic", "OBSERVATION_MODIFIER", 178, 189], ["infections", "OBSERVATION", 190, 200], ["viruses", "OBSERVATION", 218, 225], ["endogenous retroviruses", "OBSERVATION", 373, 396]]], ["While it is known that the mammalian genome is composed of up to 11% endogenous retroviral elements (ERVs), most of them completed their invasion millions of years ago obscuring the changes in virus and host associated with them.", [["mammalian genome", "DNA", 27, 43], ["endogenous retroviral elements", "DNA", 69, 99], ["ERVs", "DNA", 101, 105], ["the mammalian genome", "PROBLEM", 23, 43], ["the changes in virus", "PROBLEM", 178, 198], ["mammalian genome", "OBSERVATION", 27, 43], ["retroviral elements", "OBSERVATION", 80, 99]]], ["The koala retrovirus (KoRV) is one of the few examples of a virus that is currently in the earliest stages of transitioning from an exogenous retrovirus to an ERV (Tarlinton et al., 2006) .", [["koala retrovirus", "ORGANISM", 4, 20], ["KoRV", "GENE_OR_GENE_PRODUCT", 22, 26], ["retrovirus", "ORGANISM", 142, 152], ["koala retrovirus", "SPECIES", 4, 20], ["KoRV", "SPECIES", 22, 26], ["a virus", "PROBLEM", 58, 65], ["an exogenous retrovirus", "PROBLEM", 129, 152], ["koala retrovirus", "OBSERVATION", 4, 20], ["virus", "OBSERVATION", 60, 65], ["exogenous retrovirus", "OBSERVATION", 132, 152]]], ["By going through a collection of archived samples of modern wild and zoo koalas dating back to 1891, Greenwood and his collaborators found crucial early events in endogenization involving recombination, often mediated by existing retroviral-like elements already resident in the host genome.", [["retroviral-like elements", "DNA", 230, 254], ["host genome", "DNA", 279, 290], ["host genome", "OBSERVATION", 279, 290]]], ["These recombination events disable the exogenous retrovirus making it less potentially harmful to the host while at the same time, the ancient retroviral-like elements may re-establish themselves as actively propagating retroelements (Hobbs et al., 2017) .", [["retrovirus", "ORGANISM", 49, 59], ["ancient retroviral-like elements", "DNA", 135, 167], ["the exogenous retrovirus", "PROBLEM", 35, 59], ["the ancient retroviral-like elements", "PROBLEM", 131, 167], ["exogenous retrovirus", "OBSERVATION", 39, 59], ["retroviral", "OBSERVATION", 143, 153]]], ["In the context of trying to find the origin of KoRV, Greenwood, et al. confirmed its close relationship to the gibbon ape leukemia virus (GALV).", [["gibbon ape leukemia virus", "ORGANISM", 111, 136], ["GALV", "ORGANISM", 138, 142], ["gibbon ape leukemia virus", "SPECIES", 111, 136], ["gibbon ape leukemia virus", "SPECIES", 111, 136], ["GALV", "SPECIES", 138, 142], ["the gibbon ape leukemia virus", "PROBLEM", 107, 136], ["gibbon ape leukemia virus", "OBSERVATION", 111, 136]]], ["Both are likely from recent interspecies transmissions.New and emerging viruses in Australasia and beyondPhylogenetically, two rodent viruses, Melomys bertoni retrovirus (MbRV) and Melomys woolly monkey-like virus (MelWMV) are the closest to the KoRV/GALV-like viruses identified to date (Alfano et al., 2016) .", [["Melomys bertoni retrovirus", "ORGANISM", 143, 169], ["MbRV", "ORGANISM", 171, 175], ["Melomys woolly monkey-like virus", "ORGANISM", 181, 213], ["MelWMV", "ORGANISM", 215, 221], ["KoRV", "GENE_OR_GENE_PRODUCT", 246, 250], ["GALV-like viruses", "ORGANISM", 251, 268], ["rodent", "SPECIES", 127, 133], ["Melomys bertoni retrovirus", "SPECIES", 143, 169], ["Melomys woolly monkey", "SPECIES", 181, 202], ["-like virus", "SPECIES", 202, 213], ["Melomys bertoni retrovirus", "SPECIES", 143, 169], ["MbRV", "SPECIES", 171, 175], ["Melomys woolly monkey-like virus", "SPECIES", 181, 213], ["MelWMV", "SPECIES", 215, 221], ["New and emerging viruses", "PROBLEM", 55, 79], ["two rodent viruses", "PROBLEM", 123, 141], ["Melomys bertoni retrovirus", "PROBLEM", 143, 169], ["Melomys woolly monkey", "PROBLEM", 181, 202], ["likely from", "UNCERTAINTY", 9, 20], ["viruses", "OBSERVATION", 72, 79], ["rodent", "OBSERVATION_MODIFIER", 127, 133], ["viruses", "OBSERVATION", 134, 141], ["GALV", "ANATOMY", 251, 255]]], ["Greenwood concluded that very close relatives of KoRV/GALV have been circulating in a variety of mammalian taxa within the Australo-Papuan region east of the Wallace Line.New and emerging viruses in Australasia and beyondLorena Brown (University of Melbourne, Australia) presented a new concept in antiviral drug design.", [["KoRV", "GENE_OR_GENE_PRODUCT", 49, 53], ["GALV", "GENE_OR_GENE_PRODUCT", 54, 58], ["KoRV", "PROTEIN", 49, 53], ["GALV", "DNA", 54, 58], ["GALV", "SPECIES", 54, 58], ["KoRV/GALV", "TREATMENT", 49, 58], ["mammalian taxa", "TREATMENT", 97, 111], ["New and emerging viruses", "PROBLEM", 171, 195], ["antiviral drug design", "TREATMENT", 298, 319], ["Wallace Line", "OBSERVATION", 158, 170], ["viruses", "OBSERVATION", 188, 195], ["antiviral drug", "OBSERVATION", 298, 312]]], ["While most current antiviral strategies tend to target specific viral proteins and inhibit their function, Brown described antiviral drugs that are modular in structure, consisting of a viral attachment domain and an effector domain.", [["viral proteins", "PROTEIN", 64, 78], ["viral attachment domain", "PROTEIN", 186, 209], ["effector domain", "PROTEIN", 217, 232], ["antiviral strategies", "TREATMENT", 19, 39], ["specific viral proteins", "PROBLEM", 55, 78], ["Brown described antiviral drugs", "PROBLEM", 107, 138], ["a viral attachment domain", "PROBLEM", 184, 209], ["antiviral drugs", "OBSERVATION", 123, 138], ["modular", "OBSERVATION_MODIFIER", 148, 155], ["viral attachment", "OBSERVATION", 186, 202], ["effector domain", "OBSERVATION", 217, 232]]], ["In general, the attachment domain can be antibody or any domain or motif structure that binds the surface of a virus.", [["surface", "ANATOMY", 98, 105], ["surface", "CELLULAR_COMPONENT", 98, 105], ["attachment domain", "PROTEIN", 16, 33], ["the attachment domain", "PROBLEM", 12, 33], ["antibody", "PROBLEM", 41, 49], ["any domain or motif structure", "PROBLEM", 53, 82], ["a virus", "PROBLEM", 109, 116], ["virus", "OBSERVATION", 111, 116]]], ["An effector domain can vary from an enzyme to a charge cloud.New and emerging viruses in Australasia and beyondIn collaboration with Aus Bio Ltd., the concept was tested against influenza virus.", [["influenza virus", "DISEASE", 178, 193], ["influenza virus", "ORGANISM", 178, 193], ["effector domain", "PROTEIN", 3, 18], ["enzyme", "PROTEIN", 36, 42], ["influenza virus", "SPECIES", 178, 193], ["An effector domain", "PROBLEM", 0, 18], ["an enzyme", "TEST", 33, 42], ["a charge cloud", "PROBLEM", 46, 60], ["New and emerging viruses", "PROBLEM", 61, 85], ["influenza virus", "PROBLEM", 178, 193], ["viruses", "OBSERVATION", 78, 85]]], ["Entry of influenza virus into cells is by receptor-mediated endocytosis.", [["cells", "ANATOMY", 30, 35], ["influenza", "DISEASE", 9, 18], ["influenza virus", "ORGANISM", 9, 24], ["cells", "CELL", 30, 35], ["influenza virus", "SPECIES", 9, 24], ["influenza virus into cells", "PROBLEM", 9, 35], ["influenza virus", "OBSERVATION", 9, 24]]], ["As the environment of the endosome becomes more acidic, the viral hemagglutinin (HA) undergoes a conformational change to reveal a hydrophobic fusion region that penetrates the endosomal membrane, thus initiating the life cycle of virus replication inside the cell.", [["endosome", "ANATOMY", 26, 34], ["endosomal membrane", "ANATOMY", 177, 195], ["cell", "ANATOMY", 260, 264], ["endosome", "CELLULAR_COMPONENT", 26, 34], ["endosomal membrane", "CELLULAR_COMPONENT", 177, 195], ["cell", "CELL", 260, 264], ["viral hemagglutinin", "PROTEIN", 60, 79], ["HA", "PROTEIN", 81, 83], ["hydrophobic fusion region", "PROTEIN", 131, 156], ["more acidic", "PROBLEM", 43, 54], ["the viral hemagglutinin (HA)", "PROBLEM", 56, 84], ["a conformational change", "PROBLEM", 95, 118], ["a hydrophobic fusion region", "PROBLEM", 129, 156], ["virus replication", "TREATMENT", 231, 248], ["acidic", "OBSERVATION_MODIFIER", 48, 54], ["hydrophobic fusion", "OBSERVATION", 131, 149], ["endosomal membrane", "OBSERVATION", 177, 195], ["cell", "ANATOMY", 260, 264]]], ["Candidate drug molecules use an attachment domain that binds to HA, and an effector domain that provides a negativelycharged environment to trigger a premature conformational change in the neighbouring HA to prevent viral replication.", [["HA", "GENE_OR_GENE_PRODUCT", 64, 66], ["HA", "GENE_OR_GENE_PRODUCT", 202, 204], ["attachment domain", "PROTEIN", 32, 49], ["HA", "PROTEIN", 64, 66], ["effector domain", "PROTEIN", 75, 90], ["an attachment domain", "TREATMENT", 29, 49], ["HA", "PROBLEM", 64, 66], ["a negativelycharged environment", "TREATMENT", 105, 136], ["a premature conformational change", "PROBLEM", 148, 181], ["the neighbouring HA", "PROBLEM", 185, 204], ["viral replication", "TREATMENT", 216, 233], ["viral replication", "OBSERVATION", 216, 233]]], ["Brown presented in vivo data on two drugs, MD185 and MD345, that provided better protection in mouse and ferret models than did zanamivir.", [["MD185", "CHEMICAL", 43, 48], ["MD345", "CHEMICAL", 53, 58], ["zanamivir", "CHEMICAL", 128, 137], ["MD185", "CHEMICAL", 43, 48], ["MD345", "CHEMICAL", 53, 58], ["zanamivir", "CHEMICAL", 128, 137], ["MD185", "SIMPLE_CHEMICAL", 43, 48], ["MD345", "SIMPLE_CHEMICAL", 53, 58], ["mouse", "ORGANISM", 95, 100], ["ferret", "ORGANISM", 105, 111], ["zanamivir", "SIMPLE_CHEMICAL", 128, 137], ["mouse", "SPECIES", 95, 100], ["ferret", "SPECIES", 105, 111], ["mouse", "SPECIES", 95, 100], ["ferret", "SPECIES", 105, 111], ["two drugs", "TREATMENT", 32, 41], ["MD185", "TREATMENT", 43, 48], ["MD345", "TREATMENT", 53, 58], ["zanamivir", "TREATMENT", 128, 137]]], ["These constructs appear to provide an extended therapeutic window until the adaptive immune system comes into play.", [["immune system", "ANATOMICAL_SYSTEM", 85, 98], ["an extended therapeutic window", "TREATMENT", 35, 65], ["the adaptive immune system", "TREATMENT", 72, 98]]], ["The long-duration activity of the drugs suggests they may be useful in prophylaxis, especially in a pandemic context.New and emerging viruses in Australasia and beyondSoren Alexandersen, (Geelong Centre for Emerging Infectious Diseases, Australia), described outbreaks of severe infections among Australian infants caused by a recombinant strain of human parechovirus type 3.", [["Infectious Diseases", "DISEASE", 216, 235], ["infections", "DISEASE", 279, 289], ["infants", "ORGANISM", 307, 314], ["human", "ORGANISM", 349, 354], ["parechovirus type 3", "ORGANISM", 355, 374], ["infants", "SPECIES", 307, 314], ["human", "SPECIES", 349, 354], ["human parechovirus type 3", "SPECIES", 349, 374], ["the drugs", "TREATMENT", 30, 39], ["prophylaxis", "TREATMENT", 71, 82], ["New and emerging viruses", "PROBLEM", 117, 141], ["severe infections", "PROBLEM", 272, 289], ["human parechovirus type 3", "PROBLEM", 349, 374], ["long-duration activity", "OBSERVATION_MODIFIER", 4, 26], ["viruses", "OBSERVATION", 134, 141], ["severe", "OBSERVATION_MODIFIER", 272, 278], ["infections", "OBSERVATION", 279, 289]]], ["Human parechovirus types 1-16 (HPeV1-16) are positive-strand RNA viruses.", [["Human parechovirus types 1-16", "ORGANISM", 0, 29], ["HPeV1-16", "ORGANISM", 31, 39], ["Human parechovirus types 1-16 (HPeV1-16", "DNA", 0, 39], ["Human", "SPECIES", 0, 5], ["Human parechovirus types 1-16", "SPECIES", 0, 29], ["Human parechovirus types", "TEST", 0, 24], ["HPeV1", "TEST", 31, 36], ["strand RNA viruses", "PROBLEM", 54, 72], ["strand RNA viruses", "OBSERVATION", 54, 72]]], ["Type 3 parechovirus (HPeV3) causes a severe disease in infants with mortality up to 6% and potential longterm sequelae.", [["Type 3 parechovirus", "ORGANISM", 0, 19], ["infants", "ORGANISM", 55, 62], ["infants", "SPECIES", 55, 62], ["Type 3 parechovirus", "SPECIES", 0, 19], ["HPeV3", "SPECIES", 21, 26], ["Type 3 parechovirus (HPeV3", "PROBLEM", 0, 26], ["a severe disease in infants", "PROBLEM", 35, 62], ["potential longterm sequelae", "PROBLEM", 91, 118], ["parechovirus", "OBSERVATION", 7, 19], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 44, 51], ["longterm sequelae", "OBSERVATION", 101, 118]]], ["As this was a newly recognized disease of infants, there was no diagnostic test available in Australia until 2013.New and emerging viruses in Australasia and beyondDuring the investigation of a 2015 HPeV3 outbreak, it was found that the genome of the Australian viruses had undergone a major recombination event that took place between March 2012 and November 2013, followed by further virus evolution and possibly recombination.", [["infants", "ORGANISM", 42, 49], ["infants", "SPECIES", 42, 49], ["a newly recognized disease of infants", "PROBLEM", 12, 49], ["diagnostic test", "TEST", 64, 79], ["New and emerging viruses", "PROBLEM", 114, 138], ["further virus evolution", "PROBLEM", 378, 401], ["disease", "OBSERVATION", 31, 38], ["viruses", "OBSERVATION", 131, 138], ["Australasia", "OBSERVATION_MODIFIER", 142, 153]]], ["Their data showed that the 2015 outbreak viruses are recombined from the Yamagata 2011 lineage and an as yet unknown virus (Nelson et al., 2017) .New and emerging viruses in Australasia and beyondThis unknown virus, the donor of the non-structural coding region, may come from a not-yet sequenced human parechovirus or alternatively, from a potential unknown animal source, as similar viruses do infect animals such as the recombinant HPeV4 detected in pigs in South America (Nix et al., 2013) .", [["human", "ORGANISM", 297, 302], ["parechovirus", "CANCER", 303, 315], ["HPeV4", "GENE_OR_GENE_PRODUCT", 435, 440], ["pigs", "ORGANISM", 453, 457], ["non-structural coding region", "DNA", 233, 261], ["recombinant HPeV4", "PROTEIN", 423, 440], ["human", "SPECIES", 297, 302], ["pigs", "SPECIES", 453, 457], ["human", "SPECIES", 297, 302], ["pigs", "SPECIES", 453, 457], ["Their data", "TEST", 0, 10], ["the 2015 outbreak viruses", "PROBLEM", 23, 48], ["New and emerging viruses", "PROBLEM", 146, 170], ["This unknown virus", "PROBLEM", 196, 214], ["human parechovirus", "PROBLEM", 297, 315], ["viruses", "OBSERVATION", 163, 170], ["virus", "OBSERVATION", 209, 214]]], ["Finally, Alexandersen observed that the HPeV3 outbreaks seem to follow a 2-3-year cycle, suggesting there may be another wave of HPeV3 outbreaks in Australia in 2017/8.Pandemic and epidemic virusesNobel Laureate Peter Doherty, (Peter Doherty Institute for Infection and Immunity, Australia), provided a review of CD8 + cytotoxic T lymphocyte contributions to antiviral immunity.", [["CD8 + cytotoxic T lymphocyte", "ANATOMY", 313, 341], ["Pandemic", "DISEASE", 168, 176], ["Infection", "DISEASE", 256, 265], ["CD8", "GENE_OR_GENE_PRODUCT", 313, 316], ["CD8", "PROTEIN", 313, 316], ["the HPeV3 outbreaks", "PROBLEM", 36, 55], ["HPeV3 outbreaks", "PROBLEM", 129, 144], ["Pandemic", "PROBLEM", 168, 176], ["epidemic viruses", "PROBLEM", 181, 197], ["Infection", "PROBLEM", 256, 265], ["antiviral immunity", "TREATMENT", 359, 377], ["may be", "UNCERTAINTY", 106, 112], ["epidemic viruses", "OBSERVATION", 181, 197], ["cytotoxic T lymphocyte", "OBSERVATION", 319, 341]]], ["The human family is constantly challenged by viruses, with epidemic/pandemic pathogens either emerging from wildlife or domestic animal reservoirs, or as a consequence of \"immune escape\" mutations in strains that are circulating in us.", [["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["epidemic/pandemic pathogens", "PROBLEM", 59, 86], ["\"immune escape\" mutations in strains", "PROBLEM", 171, 207]]], ["Vaccines that promote long-term antibody-mediated immunity to \"mop up\" invaders can provide immediate protection though, of course, as Doherty noted, we have no such products when something new and unexpected hits.", [["Vaccines", "TREATMENT", 0, 8], ["long-term antibody", "TREATMENT", 22, 40], ["long-term", "OBSERVATION_MODIFIER", 22, 31]]], ["As our most intimate parasites, viruses grow only within living cells.", [["cells", "ANATOMY", 64, 69], ["parasites", "CELL", 21, 30], ["cells", "CELL", 64, 69], ["living cells", "CELL_TYPE", 57, 69], ["viruses", "PROBLEM", 32, 39]]], ["As a consequence, part of the process of recovery requires the elimination of these cellular \"factories\" of pathogen production.", [["cellular", "ANATOMY", 84, 92], ["cellular", "CELL", 84, 92], ["pathogen production", "PROBLEM", 108, 127], ["pathogen", "OBSERVATION_MODIFIER", 108, 116]]], ["The \"hit man\" of immunity that does this job is a circulating white blood cell, the virus-specific, CD8 + \"killer\" T-cell, or cytotoxic T-lymphocyte (CTL) and the CTL is targeted to cell surfaces via recognition of viral peptide bound to self MHC class I glycoproteins.", [["white blood cell", "ANATOMY", 62, 78], ["CD8 + \"killer\" T-cell", "ANATOMY", 100, 121], ["cytotoxic T-lymphocyte", "ANATOMY", 126, 148], ["cell surfaces", "ANATOMY", 182, 195], ["white blood cell", "CELL", 62, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 100, 103], ["cytotoxic T-lymphocyte", "CELL", 126, 148], ["CTL", "CELL", 150, 153], ["CTL", "GENE_OR_GENE_PRODUCT", 163, 166], ["cell", "CELL", 182, 186], ["CD8", "PROTEIN", 100, 103], ["killer\" T-cell", "CELL_TYPE", 107, 121], ["cytotoxic T-lymphocyte", "CELL_TYPE", 126, 148], ["CTL", "CELL_TYPE", 150, 153], ["CTL", "CELL_TYPE", 163, 166], ["MHC class I glycoproteins", "PROTEIN", 243, 268], ["man", "SPECIES", 9, 12], ["a circulating white blood cell", "PROBLEM", 48, 78], ["the virus", "TEST", 80, 89], ["CD8", "TEST", 100, 103], ["cytotoxic T", "TEST", 126, 137], ["the CTL", "TEST", 159, 166], ["viral peptide bound", "PROBLEM", 215, 234]]], ["Some recent findings concerning HLA type and influenza prevention and susceptibility are of particular interest, especially with regard to the greater susceptibility of indigenous populations to influenza.Pandemic and epidemic virusesMa\u00ebl Bessaud (Institut Pasteur, Paris), reviewed genetic recombination among positive-strand RNA viruses and suggested enteroviruses as a convenient model for in vitro studies of recombination.", [["influenza", "DISEASE", 45, 54], ["influenza", "DISEASE", 195, 204], ["Pandemic", "DISEASE", 205, 213], ["HLA type", "GENE_OR_GENE_PRODUCT", 32, 40], ["HLA type and influenza prevention", "PROBLEM", 32, 65], ["susceptibility", "PROBLEM", 70, 84], ["influenza", "PROBLEM", 195, 204], ["Pandemic", "PROBLEM", 205, 213], ["epidemic viruses", "PROBLEM", 218, 234], ["strand RNA viruses", "PROBLEM", 320, 338], ["enteroviruses", "PROBLEM", 353, 366], ["HLA type", "OBSERVATION_MODIFIER", 32, 40], ["influenza", "OBSERVATION", 45, 54]]], ["In particular, mostly non-homologous recombinant genomes were seen; that is, genomes with deletions or duplications, which can subsequently evolve into homologous recombinant genomes.", [["non-homologous recombinant genomes", "DNA", 22, 56], ["homologous recombinant genomes", "DNA", 152, 182], ["mostly non-homologous recombinant genomes", "PROBLEM", 15, 56], ["deletions or duplications", "PROBLEM", 90, 115], ["mostly", "OBSERVATION_MODIFIER", 15, 21], ["non-homologous", "OBSERVATION_MODIFIER", 22, 36], ["recombinant genomes", "OBSERVATION", 37, 56]]], ["These hotspots bound genomic domains that can be considered as modules used to engender new mosaic genomes through recombination.", [["genomic domains", "DNA", 21, 36], ["mosaic genomes", "DNA", 92, 106], ["These hotspots bound genomic domains", "PROBLEM", 0, 36]]], ["These results illustrate how recombination is able to generate a wide genetic and phenotypic diversity and can promote the emergence of new viruses.Pandemic and epidemic virusesJoaquim Segales (Centre de Recerca en Sanitat Animal, Spain) described dromedary camels as models for Middle Eastern Respiratory Syndrome coronavirus (MERS-CoV) infection.", [["Pandemic", "DISEASE", 148, 156], ["Respiratory Syndrome coronavirus", "DISEASE", 294, 326], ["MERS-CoV) infection", "DISEASE", 328, 347], ["Middle Eastern Respiratory Syndrome coronavirus", "ORGANISM", 279, 326], ["MERS-CoV", "ORGANISM", 328, 336], ["Middle Eastern Respiratory Syndrome coronavirus", "SPECIES", 279, 326], ["MERS-CoV", "SPECIES", 328, 336], ["a wide genetic and phenotypic diversity", "PROBLEM", 63, 102], ["new viruses", "PROBLEM", 136, 147], ["Pandemic", "PROBLEM", 148, 156], ["epidemic viruses", "PROBLEM", 161, 177], ["Joaquim Segales (Centre de Recerca en Sanitat Animal, Spain)", "TREATMENT", 177, 237], ["Middle Eastern Respiratory Syndrome", "PROBLEM", 279, 314], ["coronavirus (MERS-CoV) infection", "PROBLEM", 315, 347], ["epidemic viruses", "OBSERVATION", 161, 177], ["infection", "OBSERVATION", 338, 347]]], ["Experimental intranasal inoculations with MERS-CoV produces only upper respiratory tract infection (URT) and mild clinical signs.", [["upper respiratory tract", "ANATOMY", 65, 88], ["respiratory tract infection", "DISEASE", 71, 98], ["URT", "DISEASE", 100, 103], ["MERS-CoV", "ORGANISM", 42, 50], ["upper respiratory", "ORGANISM_SUBDIVISION", 65, 82], ["tract", "ORGANISM_SUBDIVISION", 83, 88], ["MERS-CoV", "SPECIES", 42, 50], ["Experimental intranasal inoculations", "PROBLEM", 0, 36], ["upper respiratory tract infection", "PROBLEM", 65, 98], ["mild clinical signs", "PROBLEM", 109, 128], ["upper", "ANATOMY_MODIFIER", 65, 70], ["respiratory tract", "ANATOMY", 71, 88], ["infection", "OBSERVATION", 89, 98], ["mild", "OBSERVATION_MODIFIER", 109, 113]]], ["Infectious virus is only detected in the trachea, large bronchi and tracheobronchial lymph nodes, while viral RNA is more widely detectable in the nose, the upper and lower respiratory tracts and in extrapulmonary lymphoid and visceral tissue.", [["trachea", "ANATOMY", 41, 48], ["bronchi", "ANATOMY", 56, 63], ["tracheobronchial lymph nodes", "ANATOMY", 68, 96], ["nose", "ANATOMY", 147, 151], ["upper", "ANATOMY", 157, 162], ["lower respiratory tracts", "ANATOMY", 167, 191], ["extrapulmonary lymphoid", "ANATOMY", 199, 222], ["visceral tissue", "ANATOMY", 227, 242], ["extrapulmonary lymphoid and visceral tissue", "DISEASE", 199, 242], ["trachea", "ORGAN", 41, 48], ["bronchi", "MULTI-TISSUE_STRUCTURE", 56, 63], ["tracheobronchial lymph nodes", "MULTI-TISSUE_STRUCTURE", 68, 96], ["nose", "ORGAN", 147, 151], ["upper", "ORGANISM_SUBDIVISION", 157, 162], ["extrapulmonary lymphoid", "TISSUE", 199, 222], ["visceral tissue", "TISSUE", 227, 242], ["viral RNA", "RNA", 104, 113], ["Infectious virus", "SPECIES", 0, 16], ["Infectious virus", "PROBLEM", 0, 16], ["large bronchi and tracheobronchial lymph nodes", "PROBLEM", 50, 96], ["viral RNA", "PROBLEM", 104, 113], ["virus", "OBSERVATION", 11, 16], ["trachea", "ANATOMY", 41, 48], ["large", "OBSERVATION_MODIFIER", 50, 55], ["bronchi", "ANATOMY", 56, 63], ["tracheobronchial", "ANATOMY", 68, 84], ["lymph nodes", "OBSERVATION", 85, 96], ["viral RNA", "OBSERVATION", 104, 113], ["more widely", "OBSERVATION_MODIFIER", 117, 128], ["nose", "ANATOMY", 147, 151], ["upper", "ANATOMY_MODIFIER", 157, 162], ["lower", "ANATOMY_MODIFIER", 167, 172], ["respiratory tracts", "ANATOMY", 173, 191], ["extrapulmonary lymphoid", "ANATOMY", 199, 222], ["visceral tissue", "ANATOMY", 227, 242]]], ["Nasal, tracheal and bronchial inflammation are present, without gross lesions.", [["Nasal", "ANATOMY", 0, 5], ["tracheal", "ANATOMY", 7, 15], ["bronchial", "ANATOMY", 20, 29], ["gross lesions", "ANATOMY", 64, 77], ["inflammation", "DISEASE", 30, 42], ["Nasal", "MULTI-TISSUE_STRUCTURE", 0, 5], ["tracheal", "MULTI-TISSUE_STRUCTURE", 7, 15], ["bronchial", "MULTI-TISSUE_STRUCTURE", 20, 29], ["gross lesions", "PATHOLOGICAL_FORMATION", 64, 77], ["Nasal, tracheal and bronchial inflammation", "PROBLEM", 0, 42], ["gross lesions", "PROBLEM", 64, 77], ["tracheal", "ANATOMY", 7, 15], ["bronchial", "ANATOMY", 20, 29], ["inflammation", "OBSERVATION", 30, 42], ["without", "UNCERTAINTY", 56, 63], ["gross", "OBSERVATION_MODIFIER", 64, 69], ["lesions", "OBSERVATION", 70, 77]]], ["A similar clinical-pathological picture is seen after intranasal MERS-CoV inoculation of domestic new world camelids, producing either no clinical signs (alpacas) or mild mucus secretion (llamas), with MERS-CoV detectable in the URT (nasal swabs and trachea) of both species, and cleared from the URT 7-10 days post-infection, concomitant with antibody responses.", [["camelids", "ANATOMY", 108, 116], ["mucus", "ANATOMY", 171, 176], ["URT", "ANATOMY", 229, 232], ["nasal swabs", "ANATOMY", 234, 245], ["trachea", "ANATOMY", 250, 257], ["MERS-CoV", "ORGANISM", 65, 73], ["alpacas", "ORGANISM_SUBDIVISION", 154, 161], ["mucus", "ORGANISM_SUBSTANCE", 171, 176], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 202, 210], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 234, 245], ["trachea", "ORGAN", 250, 257], ["MERS-CoV", "SPECIES", 202, 210], ["A similar clinical-pathological picture", "PROBLEM", 0, 39], ["intranasal MERS", "PROBLEM", 54, 69], ["clinical signs (alpacas)", "PROBLEM", 138, 162], ["mild mucus secretion (llamas)", "PROBLEM", 166, 195], ["MERS", "PROBLEM", 202, 206], ["the URT (nasal swabs and trachea) of both species", "PROBLEM", 225, 274], ["no", "UNCERTAINTY", 135, 137], ["mild", "OBSERVATION_MODIFIER", 166, 170], ["mucus secretion", "OBSERVATION", 171, 186], ["URT", "ANATOMY", 229, 232], ["nasal swabs", "ANATOMY", 234, 245], ["trachea", "ANATOMY", 250, 257], ["both species", "OBSERVATION", 262, 274]]], ["Pigs also may be experimentally infected and show the presence of viral RNA in nasal swabs, trachea and bronchi until 7-10 days postinoculation.", [["nasal swabs", "ANATOMY", 79, 90], ["trachea", "ANATOMY", 92, 99], ["bronchi", "ANATOMY", 104, 111], ["Pigs", "ORGANISM", 0, 4], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 79, 90], ["trachea", "MULTI-TISSUE_STRUCTURE", 92, 99], ["bronchi", "MULTI-TISSUE_STRUCTURE", 104, 111], ["viral RNA", "RNA", 66, 75], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["viral RNA in nasal swabs", "PROBLEM", 66, 90], ["may be", "UNCERTAINTY", 10, 16], ["infected", "OBSERVATION", 32, 40], ["viral RNA", "OBSERVATION", 66, 75], ["nasal swabs", "ANATOMY", 79, 90], ["trachea", "ANATOMY", 92, 99], ["bronchi", "ANATOMY", 104, 111]]], ["Experiments performed to date suggest that other large animal domestic species such as horse, sheep and goat are not susceptible to MERS-CoV infection.Pandemic and epidemic virusesRamesh Akkina (Colorado State University, USA) described new and improved humanized mouse (hu-mouse) models that harbor a transplanted human immune system to study viral pathogenesis, evolution, latency, and human immune responses to HIV, dengue and Zika viruses (Schmitt et al., 2017) .", [["infection", "DISEASE", 141, 150], ["Pandemic", "DISEASE", 151, 159], ["dengue", "DISEASE", 419, 425], ["horse", "ORGANISM", 87, 92], ["sheep", "ORGANISM", 94, 99], ["goat", "ORGANISM", 104, 108], ["MERS-CoV", "ORGANISM", 132, 140], ["mouse", "ORGANISM", 264, 269], ["human", "ORGANISM", 315, 320], ["human", "ORGANISM", 388, 393], ["HIV", "ORGANISM", 414, 417], ["Zika viruses", "ORGANISM", 430, 442], ["horse", "SPECIES", 87, 92], ["sheep", "SPECIES", 94, 99], ["goat", "SPECIES", 104, 108], ["mouse", "SPECIES", 264, 269], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 388, 393], ["HIV", "SPECIES", 414, 417], ["horse", "SPECIES", 87, 92], ["sheep", "SPECIES", 94, 99], ["goat", "SPECIES", 104, 108], ["MERS-CoV", "SPECIES", 132, 140], ["mouse", "SPECIES", 264, 269], ["human", "SPECIES", 315, 320], ["human", "SPECIES", 388, 393], ["HIV", "SPECIES", 414, 417], ["dengue", "SPECIES", 419, 425], ["other large animal domestic species", "PROBLEM", 43, 78], ["MERS", "PROBLEM", 132, 136], ["CoV infection", "PROBLEM", 137, 150], ["Pandemic", "PROBLEM", 151, 159], ["epidemic viruses", "PROBLEM", 164, 180], ["viral pathogenesis", "PROBLEM", 344, 362], ["latency", "PROBLEM", 375, 382], ["HIV", "PROBLEM", 414, 417], ["dengue", "PROBLEM", 419, 425], ["Zika viruses", "PROBLEM", 430, 442], ["large", "OBSERVATION_MODIFIER", 49, 54], ["infection", "OBSERVATION", 141, 150], ["epidemic viruses", "OBSERVATION", 164, 180]]], ["He outlined the use of Hu-mice as an alternative to in vitro viral outgrowth assays (qVOA), which are currently the gold standard for measuring latent HIV in cure research, but often fail to detect very low levels of replication-competent virus as evidenced by the \"Boston patients (Hayden, 2013) .\"", [["Hu-mice", "SIMPLE_CHEMICAL", 23, 30], ["patients", "ORGANISM", 273, 281], ["patients", "SPECIES", 273, 281], ["HIV", "SPECIES", 151, 154], ["Hu-mice", "TREATMENT", 23, 30], ["very low levels of replication", "PROBLEM", 198, 228], ["competent virus", "PROBLEM", 229, 244]]], ["Akkina showed that Hu-mice also provide a potential animal model to study HIV-2, and for testing a three-drug formulation of anti-retrovirals (Hu et al., 2017) .", [["HIV-2", "ORGANISM", 74, 79], ["HIV", "SPECIES", 74, 77], ["HIV-2", "SPECIES", 74, 79], ["testing", "TEST", 89, 96]]], ["Hu-mice are susceptible to HIV-2 infection and show persistent viremia and CD4 T-cell loss, key hallmarks of AIDS pathogenesis.Pandemic and epidemic virusesAkkina also described how ideal animal models of human cell infections and human immune responses are lacking for the flaviviruses, dengue and Zika.", [["CD4 T-cell", "ANATOMY", 75, 85], ["cell", "ANATOMY", 211, 215], ["HIV-2 infection", "DISEASE", 27, 42], ["viremia", "DISEASE", 63, 70], ["AIDS", "DISEASE", 109, 113], ["Pandemic", "DISEASE", 127, 135], ["infections", "DISEASE", 216, 226], ["dengue", "DISEASE", 288, 294], ["Hu-mice", "ORGANISM", 0, 7], ["HIV-2", "ORGANISM", 27, 32], ["human", "ORGANISM", 205, 210], ["cell", "CELL", 211, 215], ["human", "ORGANISM", 231, 236], ["CD4", "PROTEIN", 75, 78], ["mice", "SPECIES", 3, 7], ["HIV-2", "SPECIES", 27, 32], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 231, 236], ["mice", "SPECIES", 3, 7], ["HIV-2", "SPECIES", 27, 32], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 231, 236], ["HIV-2 infection", "PROBLEM", 27, 42], ["persistent viremia", "PROBLEM", 52, 70], ["CD4 T-cell loss", "PROBLEM", 75, 90], ["AIDS pathogenesis", "PROBLEM", 109, 126], ["Pandemic", "PROBLEM", 127, 135], ["epidemic viruses", "PROBLEM", 140, 156], ["human cell infections", "PROBLEM", 205, 226], ["human immune responses", "TREATMENT", 231, 253], ["the flaviviruses", "PROBLEM", 270, 286], ["Zika", "PROBLEM", 299, 303], ["persistent", "OBSERVATION_MODIFIER", 52, 62], ["viremia", "OBSERVATION", 63, 70], ["cell loss", "OBSERVATION", 81, 90], ["epidemic viruses", "OBSERVATION", 140, 156], ["human cell infections", "OBSERVATION", 205, 226]]], ["In dengue pathogenesis studies, hu-mice were shown to be permissive for productive infection resulting in viremia lasting up to three weeks.", [["dengue", "DISEASE", 3, 9], ["infection", "DISEASE", 83, 92], ["viremia", "DISEASE", 106, 113], ["hu-mice", "ORGANISM", 32, 39], ["dengue pathogenesis studies", "TEST", 3, 30], ["hu-mice", "TEST", 32, 39], ["productive infection", "PROBLEM", 72, 92], ["viremia", "PROBLEM", 106, 113], ["productive", "OBSERVATION_MODIFIER", 72, 82], ["infection", "OBSERVATION", 83, 92], ["viremia", "OBSERVATION", 106, 113]]], ["Fever-characteristic of dengue-was noted with infected mice developing human neutralizing anti-dengue IgM and IgG antibodies.", [["Fever", "DISEASE", 0, 5], ["dengue", "DISEASE", 24, 30], ["dengue", "ORGANISM", 24, 30], ["mice", "ORGANISM", 55, 59], ["human", "ORGANISM", 71, 76], ["anti-dengue IgM", "GENE_OR_GENE_PRODUCT", 90, 105], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 110, 124], ["human neutralizing anti-dengue IgM", "PROTEIN", 71, 105], ["IgG antibodies", "PROTEIN", 110, 124], ["mice", "SPECIES", 55, 59], ["human", "SPECIES", 71, 76], ["mice", "SPECIES", 55, 59], ["human", "SPECIES", 71, 76], ["anti-dengue", "SPECIES", 90, 101], ["Fever", "PROBLEM", 0, 5], ["dengue", "PROBLEM", 24, 30], ["infected mice", "PROBLEM", 46, 59], ["human neutralizing anti-dengue IgM", "TEST", 71, 105], ["IgG antibodies", "PROBLEM", 110, 124], ["dengue", "OBSERVATION", 24, 30]]], ["Recent experiments showed that hu-mice (BLT mice) are also susceptible to Zika virus with chronic viremia lasting more than 220 days.", [["viremia", "DISEASE", 98, 105], ["hu-mice (BLT mice", "ORGANISM", 31, 48], ["Zika virus", "ORGANISM", 74, 84], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 44, 48], ["Zika virus", "SPECIES", 74, 84], ["Recent experiments", "TEST", 0, 18], ["hu-mice (BLT mice", "PROBLEM", 31, 48], ["Zika virus", "PROBLEM", 74, 84], ["chronic viremia", "PROBLEM", 90, 105], ["Zika virus", "OBSERVATION", 74, 84], ["chronic", "OBSERVATION_MODIFIER", 90, 97], ["viremia", "OBSERVATION", 98, 105]]], ["Virus-infected human monocytes/macrophages, B cells and hematopoietic stem cells were found in bone marrow (Schmitt et al., 2018) Human neutralizing antibodies are detected highlighting the use of this model for future vaccine testing.Approaches to eliminating persistent viruses, part 1Peter Revill (The Doherty Institute in Melbourne) described the International Coalition to Eliminate Hepatitis B Virus (ICE-HBV), which was established in 2016 to accelerate research on cures for hepatitis B infection.", [["monocytes", "ANATOMY", 21, 30], ["macrophages", "ANATOMY", 31, 42], ["B cells", "ANATOMY", 44, 51], ["hematopoietic stem cells", "ANATOMY", 56, 80], ["bone marrow", "ANATOMY", 95, 106], ["Hepatitis B", "DISEASE", 388, 399], ["hepatitis B infection", "DISEASE", 483, 504], ["Virus", "ORGANISM", 0, 5], ["human", "ORGANISM", 15, 20], ["monocytes", "CELL", 21, 30], ["macrophages", "CELL", 31, 42], ["B cells", "CELL", 44, 51], ["hematopoietic stem cells", "CELL", 56, 80], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 95, 106], ["Human", "ORGANISM", 130, 135], ["Hepatitis B Virus", "ORGANISM", 388, 405], ["ICE-HBV", "ORGANISM", 407, 414], ["hepatitis B", "ORGANISM", 483, 494], ["human monocytes", "CELL_TYPE", 15, 30], ["macrophages", "CELL_TYPE", 31, 42], ["B cells", "CELL_TYPE", 44, 51], ["hematopoietic stem cells", "CELL_TYPE", 56, 80], ["Human neutralizing antibodies", "PROTEIN", 130, 159], ["human", "SPECIES", 15, 20], ["Human", "SPECIES", 130, 135], ["Hepatitis B Virus", "SPECIES", 388, 405], ["human", "SPECIES", 15, 20], ["Human", "SPECIES", 130, 135], ["Hepatitis B Virus", "SPECIES", 388, 405], ["HBV", "SPECIES", 411, 414], ["hepatitis B", "SPECIES", 483, 494], ["Virus", "TEST", 0, 5], ["infected human monocytes", "TEST", 6, 30], ["macrophages", "PROBLEM", 31, 42], ["B cells", "PROBLEM", 44, 51], ["hematopoietic stem cells", "PROBLEM", 56, 80], ["Human neutralizing antibodies", "TEST", 130, 159], ["this model", "TREATMENT", 197, 207], ["future vaccine testing", "TEST", 212, 234], ["persistent viruses", "PROBLEM", 261, 279], ["Hepatitis B Virus", "PROBLEM", 388, 405], ["ICE-HBV", "TREATMENT", 407, 414], ["hepatitis B infection", "PROBLEM", 483, 504], ["infected human monocytes", "OBSERVATION", 6, 30], ["macrophages", "ANATOMY", 31, 42], ["B cells", "OBSERVATION", 44, 51], ["hematopoietic stem cells", "OBSERVATION", 56, 80], ["bone marrow", "ANATOMY", 95, 106], ["persistent", "OBSERVATION_MODIFIER", 261, 271], ["viruses", "OBSERVATION", 272, 279], ["infection", "OBSERVATION", 495, 504]]], ["The vision of ICE-HBV is to develop an international, independent, research-based and patient-centered forum to coordinate, promote and foster collaborative partnerships working towards a cure for chronic hepatitis B (CHB).", [["chronic hepatitis B", "DISEASE", 197, 216], ["CHB", "DISEASE", 218, 221], ["patient", "ORGANISM", 86, 93], ["chronic hepatitis B", "ORGANISM", 197, 216], ["CHB", "CANCER", 218, 221], ["patient", "SPECIES", 86, 93], ["chronic hepatitis B", "PROBLEM", 197, 216], ["hepatitis", "OBSERVATION", 205, 214]]], ["Over 250 million people worldwide are chronically infected with HBV, and even though a prophylactic vaccine and effective antiviral therapies are available, no post-infection cure exists.", [["people", "ORGANISM", 17, 23], ["HBV", "ORGANISM", 64, 67], ["people", "SPECIES", 17, 23], ["HBV", "SPECIES", 64, 67], ["HBV", "PROBLEM", 64, 67], ["a prophylactic vaccine", "TREATMENT", 85, 107], ["effective antiviral therapies", "TREATMENT", 112, 141], ["post-infection cure", "PROBLEM", 160, 179], ["chronically", "OBSERVATION_MODIFIER", 38, 49], ["infected", "OBSERVATION", 50, 58], ["HBV", "OBSERVATION", 64, 67]]], ["This is of concern in the Asia-Pacific region, where over 118 million people, including 239,000 Australians live with CHB.Approaches to eliminating persistent viruses, part 1Recent advances in the field, such as the identification of the NTCP receptor for viral entry and improved cell culture and animal models, are facilitating a new era in cure research worldwide (Watashi et al., 2014; Revill et al., 2016) .", [["cell culture", "ANATOMY", 281, 293], ["CHB", "DISEASE", 118, 121], ["people", "ORGANISM", 70, 76], ["NTCP receptor", "GENE_OR_GENE_PRODUCT", 238, 251], ["cell culture", "CELL", 281, 293], ["NTCP receptor", "PROTEIN", 238, 251], ["people", "SPECIES", 70, 76], ["CHB", "PROBLEM", 118, 121], ["persistent viruses", "PROBLEM", 148, 166], ["the NTCP receptor", "TREATMENT", 234, 251], ["viral entry", "PROBLEM", 256, 267], ["improved cell culture", "TEST", 272, 293], ["CHB", "OBSERVATION", 118, 121], ["persistent", "OBSERVATION_MODIFIER", 148, 158], ["viruses", "OBSERVATION", 159, 166], ["new", "OBSERVATION_MODIFIER", 332, 335]]], ["Through its global network, ICE-HBV is working to promote research collaborations aimed at developing a cure as quickly as possible.Approaches to eliminating persistent viruses, part 1Liz Bannister (Royal Melbourne Hospital, Australia) noted that children in the world's poorest countries often are not vaccinated against HBV, including much of Africa, where 75 million people are chronically infected.", [["chronically infected", "DISEASE", 381, 401], ["children", "ORGANISM", 247, 255], ["HBV", "ORGANISM", 322, 325], ["people", "ORGANISM", 370, 376], ["children", "SPECIES", 247, 255], ["people", "SPECIES", 370, 376], ["HBV", "SPECIES", 32, 35], ["HBV", "SPECIES", 322, 325], ["ICE-HBV", "TREATMENT", 28, 35], ["persistent viruses", "PROBLEM", 158, 176], ["HBV", "PROBLEM", 322, 325], ["chronically infected", "PROBLEM", 381, 401], ["persistent", "OBSERVATION_MODIFIER", 158, 168], ["viruses", "OBSERVATION", 169, 176], ["chronically", "OBSERVATION_MODIFIER", 381, 392], ["infected", "OBSERVATION", 393, 401]]], ["With immigration of peoples from highly endemic regions, including sub-Saharan Africa, Australia's HBV prevalence continues to rise.", [["HBV", "ORGANISM", 99, 102], ["HBV", "SPECIES", 99, 102], ["Australia's HBV prevalence", "TEST", 87, 113], ["highly", "OBSERVATION_MODIFIER", 33, 39], ["endemic", "OBSERVATION_MODIFIER", 40, 47]]], ["Furthermore, African HBV genotypes and the natural history of African CHB remain poorly characterized, particularly in children.", [["CHB", "DISEASE", 70, 73], ["African HBV", "ORGANISM", 13, 24], ["children", "ORGANISM", 119, 127], ["children", "SPECIES", 119, 127], ["HBV", "SPECIES", 21, 24], ["African HBV genotypes", "PROBLEM", 13, 34], ["African CHB", "PROBLEM", 62, 73], ["poorly characterized", "OBSERVATION_MODIFIER", 81, 101]]], ["African CHB is associated with unique genotypes such as E and A1, although the prevalence of these genotypes outside Australia is poorly described.Approaches to eliminating persistent viruses, part 1Bannister and colleagues found that the HBV genotypes in African children and adults living in Melbourne largely reflected their country of origin, including genotypes associated with rapid progression to hepatocellular carcinoma, reduced vaccine efficacy, and recombinant viruses.", [["hepatocellular carcinoma", "ANATOMY", 404, 428], ["CHB", "DISEASE", 8, 11], ["hepatocellular carcinoma", "DISEASE", 404, 428], ["HBV", "ORGANISM", 239, 242], ["children", "ORGANISM", 264, 272], ["hepatocellular carcinoma", "CANCER", 404, 428], ["children", "SPECIES", 264, 272], ["HBV", "SPECIES", 239, 242], ["African CHB", "PROBLEM", 0, 11], ["unique genotypes such as E and A1", "PROBLEM", 31, 64], ["persistent viruses", "PROBLEM", 173, 191], ["hepatocellular carcinoma", "PROBLEM", 404, 428], ["reduced vaccine efficacy", "TREATMENT", 430, 454], ["recombinant viruses", "PROBLEM", 460, 479], ["persistent", "OBSERVATION_MODIFIER", 173, 183], ["viruses", "OBSERVATION", 184, 191], ["hepatocellular", "ANATOMY", 404, 418], ["carcinoma", "OBSERVATION", 419, 428]]], ["Early e-antigen seroconversion was observed, and HBV variants that have previously been associated with more severe clinical disease progression were seen in around 40% of children before adulthood.", [["HBV", "ORGANISM", 49, 52], ["children", "ORGANISM", 172, 180], ["children", "SPECIES", 172, 180], ["HBV", "SPECIES", 49, 52], ["Early e-antigen seroconversion", "PROBLEM", 0, 30], ["HBV variants", "PROBLEM", 49, 61], ["more severe clinical disease progression", "PROBLEM", 104, 144]]], ["In vitro studies of these genotypes showed differences in the way the African clones replicated and produced viral proteins, which may have implications for how these strains produce disease or can be treated.", [["clones", "CELL", 78, 84], ["African clones", "CELL_LINE", 70, 84], ["viral proteins", "PROTEIN", 109, 123], ["these genotypes", "TEST", 20, 35], ["viral proteins", "PROBLEM", 109, 123], ["these strains produce disease", "PROBLEM", 161, 190], ["viral proteins", "OBSERVATION", 109, 123]]], ["These findings have important ramifications for patient monitoring and treatment guidelines, particularly in the pediatric setting, in Australia.Approaches to eliminating persistent viruses, part 1Shyamasundaran Kottilil (Institute of Human Virology, USA) reported that chronic hepatitis C virus (HCV) infections affect approximately 71 million people worldwide and is a major cause of morbidity, liver cancer, liver transplantation and mortality.", [["liver cancer", "ANATOMY", 397, 409], ["liver", "ANATOMY", 411, 416], ["chronic hepatitis C virus (HCV) infections", "DISEASE", 270, 312], ["liver cancer", "DISEASE", 397, 409], ["patient", "ORGANISM", 48, 55], ["Human", "ORGANISM", 235, 240], ["chronic hepatitis C virus", "ORGANISM", 270, 295], ["HCV", "ORGANISM", 297, 300], ["people", "ORGANISM", 345, 351], ["liver cancer", "CANCER", 397, 409], ["liver", "ORGAN", 411, 416], ["patient", "SPECIES", 48, 55], ["Human", "SPECIES", 235, 240], ["hepatitis C virus", "SPECIES", 278, 295], ["people", "SPECIES", 345, 351], ["hepatitis C virus", "SPECIES", 278, 295], ["HCV", "SPECIES", 297, 300], ["patient monitoring", "TEST", 48, 66], ["treatment guidelines", "TREATMENT", 71, 91], ["persistent viruses", "PROBLEM", 171, 189], ["chronic hepatitis C virus (HCV) infections", "PROBLEM", 270, 312], ["morbidity", "PROBLEM", 386, 395], ["liver cancer", "PROBLEM", 397, 409], ["liver transplantation", "TREATMENT", 411, 432], ["persistent", "OBSERVATION_MODIFIER", 171, 181], ["viruses", "OBSERVATION", 182, 189], ["chronic", "OBSERVATION_MODIFIER", 270, 277], ["hepatitis", "OBSERVATION", 278, 287], ["morbidity", "OBSERVATION", 386, 395], ["liver", "ANATOMY", 397, 402], ["cancer", "OBSERVATION", 403, 409], ["liver", "ANATOMY", 411, 416], ["transplantation", "OBSERVATION", 417, 432]]], ["Currently, the goal of HCV therapy is to achieve a \"functional cure,\" which is defined as a sustained virologic response (SVR) in which no detectable plasma HCV RNA is detected 12 weeks after therapy.", [["plasma", "ANATOMY", 150, 156], ["HCV", "ORGANISM", 23, 26], ["plasma", "ORGANISM_SUBSTANCE", 150, 156], ["HCV", "ORGANISM", 157, 160], ["plasma HCV RNA", "RNA", 150, 164], ["HCV", "SPECIES", 23, 26], ["HCV", "SPECIES", 157, 160], ["HCV therapy", "TREATMENT", 23, 34], ["a sustained virologic response", "PROBLEM", 90, 120], ["SVR", "TEST", 122, 125], ["detectable plasma HCV RNA", "PROBLEM", 139, 164], ["therapy", "TREATMENT", 192, 199]]], ["Recently, oral direct-acting antiviral (DAA) therapy has been shown to be safe, tolerable and highly effective in achieving SVR without the use of interferon-alpha, which has been associated with adverse events, long duration, and modest SVR.", [["oral", "ANATOMY", 10, 14], ["interferon-alpha", "CHEMICAL", 147, 163], ["oral", "ORGANISM_SUBDIVISION", 10, 14], ["DAA", "SIMPLE_CHEMICAL", 40, 43], ["interferon-alpha", "GENE_OR_GENE_PRODUCT", 147, 163], ["interferon-alpha", "PROTEIN", 147, 163], ["oral direct-acting antiviral (DAA) therapy", "TREATMENT", 10, 52], ["interferon", "TREATMENT", 147, 157], ["adverse events", "PROBLEM", 196, 210], ["modest SVR", "PROBLEM", 231, 241], ["modest", "OBSERVATION_MODIFIER", 231, 237], ["SVR", "OBSERVATION", 238, 241]]], ["This is a major milestone in the management of chronic hepatitis C. Still, most people infected with HCV are not aware of their status, only twenty percent are in care and less than ten percent are treated.", [["chronic hepatitis C.", "DISEASE", 47, 67], ["HCV", "DISEASE", 101, 104], ["people", "ORGANISM", 80, 86], ["HCV", "ORGANISM", 101, 104], ["people", "SPECIES", 80, 86], ["HCV", "SPECIES", 101, 104], ["chronic hepatitis C.", "PROBLEM", 47, 67], ["HCV", "PROBLEM", 101, 104], ["major", "OBSERVATION_MODIFIER", 10, 15], ["milestone", "OBSERVATION_MODIFIER", 16, 25], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["hepatitis", "OBSERVATION", 55, 64]]], ["Greater awareness among both providers and patients is required to optimize the care continuum.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51]]], ["Approaches that enable increased patient screening, effective task-shifting of care, and development of point-ofcare testing strategies for marginalized patients are critical to achieving elimination of hepatitis C infections (Mathur et al., 2017) .Approaches to eliminating persistent viruses, part 2HIV and HCV are important global viral pathogens, for which the landscape of prevention by vaccination and cure through drug treatment is changing substantially.Approaches to eliminating persistent viruses, part 2Glenda Gray (South African Medical Research Council) provided an update on current HIV vaccine efficacy trials.", [["hepatitis C infections", "DISEASE", 203, 225], ["HCV", "DISEASE", 309, 312], ["patient", "ORGANISM", 33, 40], ["patients", "ORGANISM", 153, 161], ["hepatitis C", "ORGANISM", 203, 214], ["HCV", "ORGANISM", 309, 312], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 153, 161], ["2HIV", "SPECIES", 300, 304], ["HCV", "SPECIES", 309, 312], ["HIV", "SPECIES", 597, 600], ["patient screening", "TEST", 33, 50], ["shifting of care", "TREATMENT", 67, 83], ["testing strategies", "TREATMENT", 117, 135], ["hepatitis C infections", "PROBLEM", 203, 225], ["persistent viruses", "PROBLEM", 275, 293], ["part 2HIV", "PROBLEM", 295, 304], ["HCV", "PROBLEM", 309, 312], ["global viral pathogens", "PROBLEM", 327, 349], ["vaccination", "TREATMENT", 392, 403], ["cure through drug treatment", "TREATMENT", 408, 435], ["persistent viruses", "PROBLEM", 488, 506], ["current HIV vaccine efficacy trials", "TREATMENT", 589, 624], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["hepatitis", "OBSERVATION", 203, 212], ["persistent", "OBSERVATION_MODIFIER", 275, 285], ["viruses", "OBSERVATION", 286, 293], ["viral pathogens", "OBSERVATION", 334, 349], ["persistent", "OBSERVATION_MODIFIER", 488, 498], ["viruses", "OBSERVATION", 499, 506]]], ["Although anti-retroviral treatment (ART) is highly successful, it is expensive, can lead to drug resistance and is difficult to fully implement.", [["anti-retroviral treatment (ART)", "TREATMENT", 9, 40], ["drug resistance", "PROBLEM", 92, 107]]], ["Further, half of all HIV infections are transmitted by subjects within the first 5 months of their infection, often before they are aware of their infection.", [["HIV infections", "DISEASE", 21, 35], ["infection", "DISEASE", 99, 108], ["infection", "DISEASE", 147, 156], ["HIV", "ORGANISM", 21, 24], ["HIV", "SPECIES", 21, 24], ["HIV", "SPECIES", 21, 24], ["all HIV infections", "PROBLEM", 17, 35], ["their infection", "PROBLEM", 93, 108], ["their infection", "PROBLEM", 141, 156], ["HIV", "OBSERVATION_MODIFIER", 21, 24], ["infections", "OBSERVATION", 25, 35], ["infection", "OBSERVATION", 99, 108], ["infection", "OBSERVATION", 147, 156]]], ["It is widely recognized that a HIV vaccine will be an essential tool in control of the HIV epidemic, especially in regions with high prevalence, such as Southern Africa.", [["HIV epidemic", "DISEASE", 87, 99], ["HIV", "ORGANISM", 31, 34], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 87, 90], ["a HIV vaccine", "TREATMENT", 29, 42], ["the HIV epidemic", "PROBLEM", 83, 99], ["high prevalence", "OBSERVATION_MODIFIER", 128, 143]]], ["Over the last 20 years, HIV vaccine strategies have evolved from simple protein approaches or single vectors designed to induce cytotoxic T cells towards heterologous prime-boost regimens designed to induce broader immunity.", [["cytotoxic T cells", "ANATOMY", 128, 145], ["HIV", "ORGANISM", 24, 27], ["cytotoxic T cells", "CELL", 128, 145], ["cytotoxic T cells", "CELL_TYPE", 128, 145], ["HIV", "SPECIES", 24, 27], ["HIV vaccine strategies", "TREATMENT", 24, 46], ["simple protein approaches", "TREATMENT", 65, 90], ["single vectors", "TREATMENT", 94, 108], ["cytotoxic T cells", "TREATMENT", 128, 145], ["heterologous prime", "TREATMENT", 154, 172], ["boost regimens", "TREATMENT", 173, 187]]], ["The Thai RV 144 trial of a canarypox vector-gp120 protein prime boost vaccine regiment showed 31.2% efficacy (Rerks-Ngarm et al., 2009 ).", [["gp120 protein", "PROTEIN", 44, 57], ["The Thai RV", "TEST", 0, 11], ["a canarypox vector", "TREATMENT", 25, 43], ["gp120 protein prime boost vaccine regiment", "TREATMENT", 44, 86], ["Rerks", "TEST", 110, 115]]], ["A two-stage follow-up of this trial is planned, to determine if any efficacy is durable.Approaches to eliminating persistent viruses, part 2Gray also reported that planning for a second prime-boost efficacy trial in southern Africa, the 2600-subject HVTN 705 trial using an adenovirus type 26 vector-gp140 boost regimen was well advanced.", [["adenovirus type 26", "ORGANISM", 274, 292], ["gp140", "PROTEIN", 300, 305], ["persistent viruses", "PROBLEM", 114, 132], ["an adenovirus type 26 vector", "TREATMENT", 271, 299], ["gp140 boost regimen", "TREATMENT", 300, 319], ["persistent", "OBSERVATION_MODIFIER", 114, 124], ["viruses", "OBSERVATION", 125, 132]]], ["This regimen has showed significant efficacy in monkey trials (Barouch et al., 2015) and it has been announced subsequent to the GVN meeting that the trial is going ahead (www.nih.gov/news-events/news-releases/ nih-partners-launch-hiv-vaccine-efficacy-study).", [["monkey", "ORGANISM", 48, 54], ["This regimen", "TREATMENT", 0, 12], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["efficacy", "OBSERVATION_MODIFIER", 36, 44]]], ["Separate from the prime-boost vaccine efficacy trials, another efficacy trial of a passively transferred monoclonal neutralizing antibody (VRC01) is under way in both South Africa and North America (HVTN 703 and 704 studies) .", [["monoclonal neutralizing antibody", "PROTEIN", 105, 137], ["VRC01", "PROTEIN", 139, 144], ["the prime-boost vaccine efficacy trials", "TREATMENT", 14, 53], ["a passively transferred monoclonal neutralizing antibody", "TREATMENT", 81, 137], ["HVTN", "TEST", 199, 203]]], ["The VRC01 antibody is effective in preventing infection in monkey models and can reduce HIV levels in infected humans (Gray et al., 2016; Lynch et al., 2015) .Approaches to eliminating persistent viruses, part 2Damian Purcell (The Doherty Institute/University of Melbourne) provided an update on approaches to an HIV cure.", [["infection", "DISEASE", 46, 55], ["VRC01 antibody", "GENE_OR_GENE_PRODUCT", 4, 18], ["monkey", "ORGANISM", 59, 65], ["HIV", "ORGANISM", 88, 91], ["humans", "ORGANISM", 111, 117], ["VRC01 antibody", "PROTEIN", 4, 18], ["humans", "SPECIES", 111, 117], ["monkey", "SPECIES", 59, 65], ["HIV", "SPECIES", 88, 91], ["humans", "SPECIES", 111, 117], ["HIV", "SPECIES", 313, 316], ["The VRC01 antibody", "TEST", 0, 18], ["infection in monkey models", "PROBLEM", 46, 72], ["HIV levels", "PROBLEM", 88, 98], ["persistent viruses", "PROBLEM", 185, 203], ["an HIV cure", "TREATMENT", 310, 321], ["infection", "OBSERVATION", 46, 55], ["persistent", "OBSERVATION_MODIFIER", 185, 195], ["viruses", "OBSERVATION", 196, 203]]], ["HIV remains latent despite ART, meaning that treatment must continue for life.", [["HIV", "ORGANISM", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV", "PROBLEM", 0, 3], ["ART", "TREATMENT", 27, 30], ["treatment", "TREATMENT", 45, 54], ["latent", "OBSERVATION", 12, 18]]], ["Latent HIV can be reactivated with certain drugs that activate virus transcription, such as histone deacetylase inhibitors, with the hope that the reactivated virus will then be cleared (the so-called \"shock and kill\" strategy (Deeks, 2012) ).", [["shock", "DISEASE", 202, 207], ["HIV", "ORGANISM", 7, 10], ["histone deacetylase", "GENE_OR_GENE_PRODUCT", 92, 111], ["histone deacetylase", "PROTEIN", 92, 111], ["HIV", "SPECIES", 7, 10], ["HIV", "SPECIES", 7, 10], ["Latent HIV", "PROBLEM", 0, 10], ["certain drugs", "TREATMENT", 35, 48], ["activate virus transcription", "TREATMENT", 54, 82], ["histone deacetylase inhibitors", "TREATMENT", 92, 122], ["the reactivated virus", "PROBLEM", 143, 164], ["HIV", "OBSERVATION", 7, 10]]], ["However, recent clinical trials of these drugs show that their effect is modest and that effects on gene transcription can be non-specific and prolonged (Sogaard et al., 2015) .", [["these drugs", "TREATMENT", 35, 46], ["gene transcription", "TREATMENT", 100, 118]]], ["Newer, more specific, more effective and less toxic alternatives are needed.Approaches to eliminating persistent viruses, part 2Purcell's group has developed assays to measure transcription of HIV mediated more specifically by HIV-1 Tat that lend themselves to high-throughput screens for inhibitors.", [["HIV", "ORGANISM", 193, 196], ["HIV-1", "ORGANISM", 227, 232], ["Tat", "ORGANISM", 233, 236], ["HIV-1 Tat", "PROTEIN", 227, 236], ["HIV", "SPECIES", 193, 196], ["HIV-1", "SPECIES", 227, 232], ["HIV", "SPECIES", 193, 196], ["HIV-1", "SPECIES", 227, 232], ["persistent viruses", "PROBLEM", 102, 120], ["HIV", "PROBLEM", 193, 196], ["inhibitors", "TREATMENT", 289, 299], ["more effective", "OBSERVATION_MODIFIER", 22, 36], ["persistent", "OBSERVATION_MODIFIER", 102, 112], ["viruses", "OBSERVATION", 113, 120]]], ["He described a novel class of drugs, the amidothiazoles, that appear to specifically activate Tatmediated HIV transcription in T-cell lines, with minimal toxicity.", [["T-cell lines", "ANATOMY", 127, 139], ["amidothiazoles", "CHEMICAL", 41, 55], ["toxicity", "DISEASE", 154, 162], ["amidothiazoles", "CHEMICAL", 41, 55], ["amidothiazoles", "SIMPLE_CHEMICAL", 41, 55], ["T-cell lines", "CELL", 127, 139], ["T-cell lines", "CELL_LINE", 127, 139], ["HIV", "SPECIES", 106, 109], ["drugs", "TREATMENT", 30, 35], ["the amidothiazoles", "TREATMENT", 37, 55], ["T-cell lines", "TREATMENT", 127, 139], ["minimal toxicity", "PROBLEM", 146, 162], ["cell lines", "OBSERVATION", 129, 139], ["minimal", "OBSERVATION_MODIFIER", 146, 153], ["toxicity", "OBSERVATION", 154, 162]]], ["Their precise target mode of action is being studied, as is their ability to reactivate HIV from blood samples from infected people.", [["blood samples", "ANATOMY", 97, 110], ["HIV", "ORGANISM", 88, 91], ["blood samples", "ORGANISM_SUBSTANCE", 97, 110], ["people", "ORGANISM", 125, 131], ["people", "SPECIES", 125, 131], ["HIV", "SPECIES", 88, 91], ["HIV", "PROBLEM", 88, 91], ["blood samples", "TEST", 97, 110]]], ["This is a promising approach that should ultimately expand the armamentarium of potential HIV-cure drugs.Approaches to eliminating persistent viruses, part 2Margaret Hellard (Burnet Institute, Melbourne) presented the efforts of her group and collaborators to eliminate HCV transmission through multipronged efforts to cure large numbers of patients.", [["HCV", "DISEASE", 270, 273], ["HIV", "ORGANISM", 90, 93], ["HCV", "ORGANISM", 270, 273], ["patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 341, 349], ["HIV", "SPECIES", 90, 93], ["HCV", "SPECIES", 270, 273], ["cure drugs", "TREATMENT", 94, 104], ["persistent viruses", "PROBLEM", 131, 149], ["HCV transmission", "TREATMENT", 270, 286], ["persistent", "OBSERVATION_MODIFIER", 131, 141], ["viruses", "OBSERVATION", 142, 149]]], ["The efficacy and simplicity of newer DAAs for hepatitis C provides a window to reduce transmission by reducing the numbers of viremic subjects.", [["DAAs", "CHEMICAL", 37, 41], ["hepatitis C", "DISEASE", 46, 57], ["DAAs", "SIMPLE_CHEMICAL", 37, 41], ["newer DAAs", "TREATMENT", 31, 41], ["hepatitis C", "PROBLEM", 46, 57], ["a window", "TREATMENT", 67, 75]]], ["Modelling shows this should be a highly effective strategy, so long as sufficient numbers of people at risk of transmitting HCV can be treated.", [["HCV", "DISEASE", 124, 127], ["people", "ORGANISM", 93, 99], ["HCV", "ORGANISM", 124, 127], ["people", "SPECIES", 93, 99], ["HCV", "SPECIES", 124, 127], ["transmitting HCV", "PROBLEM", 111, 127], ["HCV", "OBSERVATION", 124, 127]]], ["The cost of the newer drugs is coming down in many parts of the world and Australia's approach of universal access is facilitating larger scale treatment uptake.", [["the newer drugs", "TREATMENT", 12, 27], ["universal access", "TREATMENT", 98, 114]]], ["Increased rapid testing for HCV, assessment of liver fibrosis, and treatments administered to transmission networks in communities are likely to be required to achieve these goals (Pedrana et al., 2017) .ArbovirusesArboviruses are some of the most widely distributed viral pathogens that also cause frequent episodes of epidemic disease.", [["liver", "ANATOMY", 47, 52], ["liver fibrosis", "DISEASE", 47, 61], ["liver", "ORGAN", 47, 52], ["ArbovirusesArboviruses", "ORGANISM", 204, 226], ["HCV", "SPECIES", 28, 31], ["Increased rapid testing", "TEST", 0, 23], ["HCV", "PROBLEM", 28, 31], ["liver fibrosis", "PROBLEM", 47, 61], ["treatments", "TREATMENT", 67, 77], ["ArbovirusesArboviruses", "PROBLEM", 204, 226], ["viral pathogens", "PROBLEM", 267, 282], ["epidemic disease", "PROBLEM", 320, 336], ["liver", "ANATOMY", 47, 52], ["fibrosis", "OBSERVATION", 53, 61], ["most widely", "OBSERVATION_MODIFIER", 243, 254], ["distributed", "OBSERVATION_MODIFIER", 255, 266], ["viral pathogens", "OBSERVATION", 267, 282], ["epidemic", "OBSERVATION_MODIFIER", 320, 328], ["disease", "OBSERVATION", 329, 336]]], ["Many factors contribute to the emergence and spread of these viruses, including globalization, changes in vector competence, climate change, and spillover events affecting the vectors and the ensuing victims (Gould et al., 2017) .", [["the emergence", "PROBLEM", 27, 40], ["these viruses", "PROBLEM", 55, 68], ["changes in vector competence", "PROBLEM", 95, 123], ["spillover events", "PROBLEM", 145, 161], ["viruses", "OBSERVATION", 61, 68]]], ["This session provided research information ranging from mosquito control interventions to epidemiological understanding to vaccines and virus-host interactions.ArbovirusesCameron Simmons (University of Melbourne, Australia) described past and present difficulties with controlling dengue virus (DENV) infections globally, and highlighted strategies that are currently being employed against mosquitoes to limit the replication and transmission of many arbovirus infections, including DENV.", [["dengue virus (DENV) infections", "DISEASE", 281, 311], ["arbovirus infections", "DISEASE", 452, 472], ["DENV", "DISEASE", 484, 488], ["dengue virus", "ORGANISM", 281, 293], ["DENV", "ORGANISM", 295, 299], ["mosquitoes", "ORGANISM", 391, 401], ["DENV", "ORGANISM", 484, 488], ["dengue virus", "SPECIES", 281, 293], ["dengue virus", "SPECIES", 281, 293], ["DENV", "SPECIES", 295, 299], ["DENV", "SPECIES", 484, 488], ["research information", "TREATMENT", 22, 42], ["mosquito control interventions", "TREATMENT", 56, 86], ["vaccines", "TREATMENT", 123, 131], ["controlling dengue virus (DENV) infections", "PROBLEM", 269, 311], ["many arbovirus infections", "PROBLEM", 447, 472], ["DENV", "PROBLEM", 484, 488], ["arbovirus infections", "OBSERVATION", 452, 472]]], ["He detailed current approaches employed by the World Mosquito Program (WMP; previously known as Eliminate Dengue) to establish the intracellular bacterium, Wolbachia, in mosquito populations.", [["intracellular", "ANATOMY", 131, 144], ["Dengue", "DISEASE", 106, 112], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 144], ["Dengue", "PROBLEM", 106, 112], ["the intracellular bacterium", "PROBLEM", 127, 154], ["Wolbachia", "PROBLEM", 156, 165], ["Wolbachia", "OBSERVATION", 156, 165]]], ["Wolbachia is a bacterium with the intriguingly ability to limit virus replication in co-infected cells (Moreira et al., 2009) .", [["cells", "ANATOMY", 97, 102], ["cells", "CELL", 97, 102], ["co-infected cells", "CELL_TYPE", 85, 102], ["Wolbachia", "PROBLEM", 0, 9], ["a bacterium", "PROBLEM", 13, 24]]], ["Wolbachia-harbouring mosquitoes have been successfully deployed around Cairns, Australia, and the WMP has initiated similar programs in DENV-endemic areas such as Indonesia, Brazil, Columbia, Vietnam and India.", [["WMP", "CHEMICAL", 98, 101], ["Wolbachia-harbouring mosquitoes", "ORGANISM", 0, 31], ["DENV", "OBSERVATION", 136, 140]]], ["Simmons underlined some of the challenges of the WMP, including communication with the local population, the cost of large-scale implementation, measuring milestones and evidence-based outcomes, and developing methods to measure the impact of Wolbachia on disease incidence.", [["large-scale implementation", "TREATMENT", 117, 143], ["measuring milestones", "PROBLEM", 145, 165], ["Wolbachia on disease incidence", "PROBLEM", 243, 273], ["Wolbachia", "OBSERVATION", 243, 252]]], ["Still, current results and projections look encouraging for this approach to limiting arbovirus infections.ArbovirusesScott Weaver (University of Texas Medical Branch, Galveston, USA), Chair of the GVN task force on Zika virus (ZIKV), provided a timely update on the dramatic emergence of ZIKV in South and Central America in 2016, and a historical view on the spread of ZIKV from Africa to Asia to the South Pacific and now to the Americas (Aliota et al., 2017) .", [["arbovirus infections", "DISEASE", 86, 106], ["ZIKV", "DISEASE", 289, 293], ["arbovirus", "ORGANISM", 86, 95], ["Zika virus", "ORGANISM", 216, 226], ["Zika virus", "SPECIES", 216, 226], ["Zika virus", "SPECIES", 216, 226], ["ZIKV", "SPECIES", 228, 232], ["ZIKV", "SPECIES", 289, 293], ["ZIKV", "SPECIES", 371, 375], ["this approach", "TREATMENT", 60, 73], ["arbovirus infections", "PROBLEM", 86, 106], ["ZIKV", "PROBLEM", 371, 375]]], ["Weaver described the manifestations of the disease in humans (Guillain-Barr\u00e9 syndrome and microcephaly) and the significant impact infection has on the unborn fetus in infected pregnant women.", [["fetus", "ANATOMY", 159, 164], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 62, 85], ["microcephaly", "DISEASE", 90, 102], ["infection", "DISEASE", 131, 140], ["humans", "ORGANISM", 54, 60], ["Guillain-Barr\u00e9 syndrome", "ORGANISM", 62, 85], ["fetus", "ORGANISM", 159, 164], ["women", "ORGANISM", 186, 191], ["humans", "SPECIES", 54, 60], ["women", "SPECIES", 186, 191], ["humans", "SPECIES", 54, 60], ["the disease in humans", "PROBLEM", 39, 60], ["Barr\u00e9 syndrome", "PROBLEM", 71, 85], ["microcephaly", "PROBLEM", 90, 102], ["the significant impact infection", "PROBLEM", 108, 140], ["disease", "OBSERVATION", 43, 50], ["microcephaly", "OBSERVATION", 90, 102], ["significant", "OBSERVATION_MODIFIER", 112, 123], ["impact", "OBSERVATION_MODIFIER", 124, 130], ["infection", "OBSERVATION", 131, 140], ["infected", "OBSERVATION_MODIFIER", 168, 176], ["pregnant", "OBSERVATION", 177, 185]]], ["One of the most interesting recent observations is the precipitous decline in reported Zika cases in 2017.", [["Zika", "DISEASE", 87, 91], ["the precipitous decline", "PROBLEM", 51, 74], ["precipitous", "OBSERVATION_MODIFIER", 55, 66]]], ["The reasons for this are currently unclear though increasing \"herd immunity\" may be a factor.ArbovirusesWeaver highlighted recent advances in ZIKV research, emphasising the large volume of research dedicated over the past few years, and culminating in numerous vaccine candidates under clinical trials and the development of nonhuman primate models to investigate pathogenesis.", [["ArbovirusesWeaver", "CHEMICAL", 93, 110], ["herd", "ORGANISM_SUBDIVISION", 62, 66], ["nonhuman", "ORGANISM", 325, 333], ["primate", "ORGANISM", 334, 341], ["ZIKV", "SPECIES", 142, 146], ["ZIKV research", "TREATMENT", 142, 155], ["clinical trials", "TREATMENT", 286, 301], ["nonhuman primate models", "TREATMENT", 325, 348], ["pathogenesis", "PROBLEM", 364, 376], ["ZIKV", "OBSERVATION", 142, 146], ["large", "OBSERVATION_MODIFIER", 173, 178], ["volume", "OBSERVATION_MODIFIER", 179, 185]]], ["One of the most important considerations from these studies is the potential of cross-reactive flavivirus antibodies (particularly against either DENV or ZIKV) to enhance DENV/ZIKV disease in subsequent infection.", [["DENV/ZIKV disease", "DISEASE", 171, 188], ["infection", "DISEASE", 203, 212], ["flavivirus", "ORGANISM", 95, 105], ["ZIKV", "GENE_OR_GENE_PRODUCT", 154, 158], ["DENV", "ORGANISM", 171, 175], ["ZIKV", "GENE_OR_GENE_PRODUCT", 176, 180], ["cross-reactive flavivirus antibodies", "PROTEIN", 80, 116], ["flavivirus", "SPECIES", 95, 105], ["DENV", "SPECIES", 146, 150], ["ZIKV", "SPECIES", 154, 158], ["DENV", "SPECIES", 171, 175], ["ZIKV", "SPECIES", 176, 180], ["these studies", "TEST", 46, 59], ["cross-reactive flavivirus antibodies", "PROBLEM", 80, 116], ["DENV", "PROBLEM", 146, 150], ["ZIKV", "PROBLEM", 154, 158], ["DENV", "PROBLEM", 171, 175], ["ZIKV disease", "PROBLEM", 176, 188], ["subsequent infection", "PROBLEM", 192, 212], ["most important", "OBSERVATION_MODIFIER", 11, 25], ["flavivirus", "OBSERVATION", 95, 105], ["ZIKV disease", "OBSERVATION", 176, 188], ["infection", "OBSERVATION", 203, 212]]], ["He identified many of the research gaps that still remain, particularly in diagnosis, as many of the current diagnostic tests are cross-reactive but developments with a specific ZIKV anti-NS1 kit look encouraging.", [["NS1", "ORGANISM", 188, 191], ["NS1", "PROTEIN", 188, 191], ["ZIKV", "SPECIES", 178, 182], ["the current diagnostic tests", "TEST", 97, 125]]], ["(GVN is supporting a ZIKV serum bank to aid in the development of better diagnostics).", [["serum", "ANATOMY", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["ZIKV", "SPECIES", 21, 25], ["a ZIKV serum bank", "TREATMENT", 19, 36]]], ["Additionally, the proposed herd immunity generated against ZIKV in the Caribbean and Latin America may hinder the development of vaccines, as it will be difficult to: 1) assess candidate vaccines in na\u00efve populations, and 2) market vaccines in the absence of significant new cases (Ferguson et al., 2016) .", [["ZIKV", "CHEMICAL", 59, 63], ["herd", "ORGANISM", 27, 31], ["ZIKV", "ORGANISM", 59, 63], ["ZIKV", "SPECIES", 59, 63], ["ZIKV", "PROBLEM", 59, 63], ["vaccines", "TREATMENT", 129, 137], ["vaccines", "TREATMENT", 187, 195], ["market vaccines", "TREATMENT", 225, 240]]], ["The principles that underlie the unique pathogenesis and transmission routes of ZIKV still remain unanswered.ArbovirusesRobert Garry (Tulane Medical School, USA) discussed the development of antibodies against Lassa fever virus (LASV) and Ebola virus (EBOV), and provided an overview of the history of these two viruses and efforts to coordinate and establish collaborative networks to provide outreach and education to affected African communities (Yozwiak et al., 2016) .", [["ZIKV", "DISEASE", 80, 84], ["Lassa fever", "DISEASE", 210, 221], ["Ebola virus", "DISEASE", 239, 250], ["ZIKV", "ORGANISM", 80, 84], ["Lassa fever virus", "ORGANISM", 210, 227], ["LASV", "ORGANISM", 229, 233], ["Ebola virus", "ORGANISM", 239, 250], ["EBOV", "ORGANISM", 252, 256], ["antibodies", "PROTEIN", 191, 201], ["Lassa fever virus", "SPECIES", 210, 227], ["Ebola virus", "SPECIES", 239, 250], ["ZIKV", "SPECIES", 80, 84], ["Lassa fever virus", "SPECIES", 210, 227], ["LASV", "SPECIES", 229, 233], ["Ebola virus", "SPECIES", 239, 250], ["EBOV", "SPECIES", 252, 256], ["ZIKV", "PROBLEM", 80, 84], ["antibodies", "PROBLEM", 191, 201], ["Lassa fever virus", "PROBLEM", 210, 227], ["Ebola virus", "PROBLEM", 239, 250], ["these two viruses", "PROBLEM", 302, 319]]], ["He described the generation of human monoclonal antibody cocktails targeting the LASV glycoprotein and the technologies available to produce large quantities of highly specific human monoclonals, which have proven effective in nonhuman primate models (Mire et al., 2017) .", [["human", "ORGANISM", 31, 36], ["LASV", "ORGANISM", 81, 85], ["human", "ORGANISM", 177, 182], ["primate", "ORGANISM", 236, 243], ["human monoclonal antibody cocktails", "PROTEIN", 31, 66], ["LASV glycoprotein", "PROTEIN", 81, 98], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 31, 36], ["LASV", "SPECIES", 81, 85], ["human", "SPECIES", 177, 182], ["human monoclonal antibody cocktails", "TREATMENT", 31, 66], ["the LASV glycoprotein", "TREATMENT", 77, 98]]], ["These developments and the construction of bivalent and trivalent vaccine candidates expressing stabilized LASV and EBOV glycoproteins are encouraging tools against lethal haemorrhagic fever viruses.ArbovirusesMarc Lecuit (Biology of Infection Unit, Institut Pasteur and Inserm, France) described the role of the cellular unfolded protein response (UPR) in the development of ZIKV disease.", [["cellular", "ANATOMY", 313, 321], ["haemorrhagic fever", "DISEASE", 172, 190], ["ZIKV disease", "DISEASE", 376, 388], ["LASV", "ORGANISM", 107, 111], ["EBOV", "ORGANISM", 116, 120], ["lethal haemorrhagic fever viruses", "ORGANISM", 165, 198], ["cellular", "CELL", 313, 321], ["UPR", "GENE_OR_GENE_PRODUCT", 349, 352], ["ZIKV", "CANCER", 376, 380], ["LASV and EBOV glycoproteins", "PROTEIN", 107, 134], ["UPR", "PROTEIN", 349, 352], ["LASV", "SPECIES", 107, 111], ["EBOV", "SPECIES", 116, 120], ["ZIKV", "SPECIES", 376, 380], ["bivalent and trivalent vaccine", "TREATMENT", 43, 73], ["EBOV glycoproteins", "TREATMENT", 116, 134], ["lethal haemorrhagic fever viruses", "PROBLEM", 165, 198], ["ZIKV disease", "PROBLEM", 376, 388], ["protein response", "OBSERVATION", 331, 347], ["ZIKV disease", "OBSERVATION", 376, 388]]], ["He presented evidence that the UPR contributes to neurogenesis and that upregulation of the UPR in neuronal progenitor cells can impact development, resulting in microcephaly in a mouse model.", [["neuronal progenitor cells", "ANATOMY", 99, 124], ["microcephaly", "DISEASE", 162, 174], ["UPR", "GENE_OR_GENE_PRODUCT", 31, 34], ["UPR", "GENE_OR_GENE_PRODUCT", 92, 95], ["neuronal progenitor cells", "CELL", 99, 124], ["mouse", "ORGANISM", 180, 185], ["UPR", "PROTEIN", 31, 34], ["UPR", "PROTEIN", 92, 95], ["neuronal progenitor cells", "CELL_TYPE", 99, 124], ["mouse", "SPECIES", 180, 185], ["mouse", "SPECIES", 180, 185], ["neurogenesis", "PROBLEM", 50, 62], ["microcephaly", "PROBLEM", 162, 174], ["neuronal progenitor cells", "OBSERVATION", 99, 124], ["microcephaly", "OBSERVATION", 162, 174]]], ["He showed compelling data indicating that ZIKV induces the UPR in neuronal progenitor cells; this was reflected in dysregulated neuronal development and reduced brain mass in ZIKV-infected fetal mice (Gladwyn-Ng et al., 2017) .", [["neuronal progenitor cells", "ANATOMY", 66, 91], ["neuronal", "ANATOMY", 128, 136], ["brain mass", "ANATOMY", 161, 171], ["fetal", "ANATOMY", 189, 194], ["ZIKV", "GENE_OR_GENE_PRODUCT", 42, 46], ["UPR", "GENE_OR_GENE_PRODUCT", 59, 62], ["neuronal progenitor cells", "CELL", 66, 91], ["neuronal", "CELL", 128, 136], ["brain", "ORGAN", 161, 166], ["ZIKV", "GENE_OR_GENE_PRODUCT", 175, 179], ["fetal mice", "ORGANISM", 189, 199], ["ZIKV", "PROTEIN", 42, 46], ["UPR", "PROTEIN", 59, 62], ["neuronal progenitor cells", "CELL_TYPE", 66, 91], ["mice", "SPECIES", 195, 199], ["ZIKV", "SPECIES", 42, 46], ["ZIKV", "SPECIES", 175, 179], ["mice", "SPECIES", 195, 199], ["ZIKV", "PROBLEM", 42, 46], ["dysregulated neuronal development", "PROBLEM", 115, 148], ["reduced brain mass", "PROBLEM", 153, 171], ["ZIKV", "PROBLEM", 175, 179], ["ZIKV", "OBSERVATION", 42, 46], ["neuronal progenitor cells", "OBSERVATION", 66, 91], ["dysregulated neuronal", "OBSERVATION", 115, 136], ["brain", "ANATOMY", 161, 166], ["mass", "OBSERVATION", 167, 171]]], ["Therapeutic interventions alleviating the UPR reduced the presentation of microcephaly in ZIKV-infected mice, offering the possibility of therapeutic strategies in this area (Gladwyn-Ng et al., 2018) .Arboviruses and EbolaJohn Fazakerley (The Peter Doherty Institute for Infection & Immunity, Australia) reported on the European Union-funded 'Integrating Chikungunya Research' (ICRES) Programme.", [["microcephaly", "DISEASE", 74, 86], ["ZIKV-infected", "DISEASE", 90, 103], ["Infection & Immunity", "DISEASE", 271, 291], ["Chikungunya", "DISEASE", 355, 366], ["mice", "ORGANISM", 104, 108], ["UPR", "PROTEIN", 42, 45], ["mice", "SPECIES", 104, 108], ["mice", "SPECIES", 104, 108], ["Therapeutic interventions", "TREATMENT", 0, 25], ["microcephaly", "PROBLEM", 74, 86], ["ZIKV", "PROBLEM", 90, 94], ["therapeutic strategies", "TREATMENT", 138, 160], ["Arboviruses", "PROBLEM", 201, 212], ["Infection", "PROBLEM", 271, 280], ["microcephaly", "OBSERVATION", 74, 86]]], ["ICRES consists of 14 international laboratories working to develop new molecular and cellular tools for the study of Chikungunya virus; further the understanding of the virus-vector relationship; develop new diagnostics, antivirals and a vaccine; and advance understanding of the pathogenesis of the disease and its sequelae.", [["cellular", "ANATOMY", 85, 93], ["Chikungunya", "DISEASE", 117, 128], ["cellular", "CELL", 85, 93], ["Chikungunya virus", "ORGANISM", 117, 134], ["Chikungunya virus", "SPECIES", 117, 134], ["new molecular and cellular tools", "PROBLEM", 67, 99], ["the study", "TEST", 104, 113], ["Chikungunya virus", "PROBLEM", 117, 134], ["antivirals", "TREATMENT", 221, 231], ["a vaccine", "TREATMENT", 236, 245], ["the disease", "PROBLEM", 296, 307], ["its sequelae", "PROBLEM", 312, 324], ["new", "OBSERVATION_MODIFIER", 67, 70], ["cellular tools", "OBSERVATION", 85, 99], ["disease", "OBSERVATION", 300, 307]]], ["He also presented two studies of experimental animal models for investigating whether an alphavirus (Semliki Forest virus) that causes encephalitis can persist in the brain and whether an alphavirus (Chikungunya virus) that causes arthralgia can persist in joints.Arboviruses and EbolaMassimo Palmarini (GVN Centre Director at the MRC-University, Glasgow, Scotland) reported on the innate immune response mediated by type I interferon (IFN), and the resulting up-regulation of hundreds of IFN-stimulated genes (ISGs or the \"interferome\"), which provide an immediate barrier to virus infection.", [["brain", "ANATOMY", 167, 172], ["joints", "ANATOMY", 257, 263], ["alphavirus", "DISEASE", 89, 99], ["encephalitis", "DISEASE", 135, 147], ["Chikungunya virus", "DISEASE", 200, 217], ["arthralgia", "DISEASE", 231, 241], ["infection", "DISEASE", 583, 592], ["alphavirus", "ORGANISM", 89, 99], ["Semliki Forest virus", "ORGANISM", 101, 121], ["brain", "ORGAN", 167, 172], ["Chikungunya virus", "ORGANISM", 200, 217], ["joints", "MULTI-TISSUE_STRUCTURE", 257, 263], ["type I interferon", "GENE_OR_GENE_PRODUCT", 417, 434], ["IFN", "GENE_OR_GENE_PRODUCT", 436, 439], ["IFN-stimulated genes", "GENE_OR_GENE_PRODUCT", 489, 509], ["interferome", "GENE_OR_GENE_PRODUCT", 524, 535], ["type I interferon", "PROTEIN", 417, 434], ["IFN", "PROTEIN", 436, 439], ["IFN-stimulated genes", "DNA", 489, 509], ["ISGs", "DNA", 511, 515], ["Semliki", "SPECIES", 101, 108], ["Chikungunya virus", "SPECIES", 200, 217], ["Semliki Forest virus", "SPECIES", 101, 121], ["Chikungunya virus", "SPECIES", 200, 217], ["an alphavirus (Semliki Forest virus", "PROBLEM", 86, 121], ["encephalitis", "PROBLEM", 135, 147], ["an alphavirus (Chikungunya virus", "PROBLEM", 185, 217], ["arthralgia", "PROBLEM", 231, 241], ["Arboviruses", "PROBLEM", 264, 275], ["EbolaMassimo Palmarini", "TREATMENT", 280, 302], ["type I interferon (IFN)", "PROBLEM", 417, 440], ["IFN-stimulated genes", "TREATMENT", 489, 509], ["an immediate barrier", "TREATMENT", 553, 573], ["virus infection", "PROBLEM", 577, 592], ["encephalitis", "OBSERVATION", 135, 147], ["brain", "ANATOMY", 167, 172], ["alphavirus", "OBSERVATION", 188, 198], ["joints", "ANATOMY", 257, 263]]], ["Studies on the type I IFN response have mainly been carried out at a single-species level, often lacking the comparative power necessary to understand key evolutionary features of this pathway.", [["type I IFN", "GENE_OR_GENE_PRODUCT", 15, 25], ["IFN", "PROTEIN", 22, 25]]], ["Palmarini and colleagues determined common and unique properties of the interferomes for multiple vertebrate species and developed an open access webserver to mine the dataset.", [["multiple vertebrate species", "PROBLEM", 89, 116], ["an open access webserver", "TREATMENT", 131, 155]]], ["They reported finding a \"core\" of 62 ISGs, including genes not previously associated with IFN, underscoring the ancestral functions associated with the type IFN response.", [["IFN", "GENE_OR_GENE_PRODUCT", 90, 93], ["ISGs", "DNA", 37, 41], ["IFN", "PROTEIN", 90, 93], ["IFN", "PROTEIN", 157, 160], ["IFN", "PROBLEM", 90, 93], ["the type IFN response", "PROBLEM", 148, 169]]], ["They showed that gene expansion contributed to the evolution of the IFN system and that interferomes are shaped by lineage-specific pressures.", [["IFN", "GENE_OR_GENE_PRODUCT", 68, 71], ["IFN", "PROTEIN", 68, 71], ["gene expansion", "PROBLEM", 17, 31], ["the IFN system", "PROBLEM", 64, 78], ["gene expansion", "OBSERVATION", 17, 31], ["pressures", "OBSERVATION_MODIFIER", 132, 141]]], ["Furthermore, an analysis of genes commonly down-regulated by IFN suggests that epigenetic regulation of transcription is a fundamental aspect of the IFN response.Arboviruses and EbolaJoshua Hayward (Burnet Institute, Australia) noted that viral infections of bats typically produce no signs of clinical disease, raising questions about what innate immune differences might exist between bats and other mammals.", [["viral infections", "DISEASE", 239, 255], ["IFN", "GENE_OR_GENE_PRODUCT", 61, 64], ["IFN", "GENE_OR_GENE_PRODUCT", 149, 152], ["bats", "ORGANISM", 259, 263], ["IFN", "PROTEIN", 61, 64], ["IFN", "PROTEIN", 149, 152], ["an analysis", "TEST", 13, 24], ["epigenetic regulation of transcription", "PROBLEM", 79, 117], ["Arboviruses", "PROBLEM", 162, 173], ["viral infections of bats", "PROBLEM", 239, 263], ["clinical disease", "PROBLEM", 294, 310], ["viral", "OBSERVATION_MODIFIER", 239, 244], ["infections", "OBSERVATION", 245, 255], ["no signs of", "UNCERTAINTY", 282, 293]]], ["The APOBEC3 gene family encodes antiviral DNA cytosine deaminases, which are restriction factors with important roles in the suppression of diverse viruses and genomic parasites.", [["cytosine", "CHEMICAL", 46, 54], ["cytosine", "CHEMICAL", 46, 54], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 4, 11], ["DNA", "CELLULAR_COMPONENT", 42, 45], ["APOBEC3 gene family", "DNA", 4, 23], ["antiviral DNA cytosine deaminases", "PROTEIN", 32, 65], ["restriction factors", "PROTEIN", 77, 96], ["The APOBEC3 gene", "TREATMENT", 0, 16], ["antiviral DNA cytosine deaminases", "TREATMENT", 32, 65], ["restriction factors", "PROBLEM", 77, 96], ["diverse viruses", "PROBLEM", 140, 155], ["genomic parasites", "PROBLEM", 160, 177], ["APOBEC3 gene", "OBSERVATION", 4, 16], ["antiviral DNA cytosine deaminases", "OBSERVATION", 32, 65], ["diverse", "OBSERVATION_MODIFIER", 140, 147], ["viruses", "OBSERVATION", 148, 155], ["genomic parasites", "OBSERVATION", 160, 177]]], ["Hayward and colleagues characterized the megabat (family Pteropodidae) APOBEC3 genes and show that pteropid bats possess the largest and most diverse array of APOBEC3 genes identified in any mammal reported to date.", [["Pteropodidae", "GENE_OR_GENE_PRODUCT", 57, 69], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 71, 78], ["pteropid bats", "ORGANISM", 99, 112], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 159, 166], ["megabat (family Pteropodidae) APOBEC3 genes", "DNA", 41, 84], ["APOBEC3 genes", "DNA", 159, 172], ["APOBEC3 genes", "PROBLEM", 71, 84], ["pteropid bats", "PROBLEM", 99, 112], ["APOBEC3 genes", "PROBLEM", 159, 172], ["largest", "OBSERVATION_MODIFIER", 125, 132], ["most diverse", "OBSERVATION_MODIFIER", 137, 149], ["APOBEC3 genes", "OBSERVATION", 159, 172]]], ["Several bat ABOEC3 proteins have been shown to be capable of restricting retroviral infectivity, using HIV-1 as a model.", [["ABOEC3", "GENE_OR_GENE_PRODUCT", 12, 18], ["retroviral", "ORGANISM", 73, 83], ["HIV-1", "ORGANISM", 103, 108], ["bat ABOEC3 proteins", "PROTEIN", 8, 27], ["HIV-1", "SPECIES", 103, 108], ["retroviral", "SPECIES", 73, 83], ["HIV-1", "SPECIES", 103, 108], ["Several bat ABOEC3 proteins", "TEST", 0, 27], ["restricting retroviral infectivity", "PROBLEM", 61, 95], ["retroviral infectivity", "OBSERVATION", 73, 95]]], ["Hypermutation analysis of the endogenous retroviruses of P. vampyrus support a role for APOBEC3-mediated restriction of ancient bat retroviruses, and a molecular clock analysis indicates that the expansion of APOBEC3 genes coincided with the extinction of pteropid LINE-1 retroelements (Hayward et al., 2013) .", [["retroviruses", "ORGANISM", 41, 53], ["P. vampyrus", "ORGANISM", 57, 68], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 88, 95], ["bat retroviruses", "ORGANISM", 128, 144], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 209, 216], ["LINE-1", "GENE_OR_GENE_PRODUCT", 265, 271], ["APOBEC3", "PROTEIN", 88, 95], ["APOBEC3 genes", "DNA", 209, 222], ["pteropid LINE-1 retroelements", "DNA", 256, 285], ["P. vampyrus", "SPECIES", 57, 68], ["P. vampyrus", "SPECIES", 57, 68], ["Hypermutation analysis", "TEST", 0, 22], ["the endogenous retroviruses", "PROBLEM", 26, 53], ["P. vampyrus support", "TREATMENT", 57, 76], ["APOBEC3-mediated restriction", "TREATMENT", 88, 116], ["ancient bat retroviruses", "PROBLEM", 120, 144], ["a molecular clock analysis", "TEST", 150, 176], ["the expansion of APOBEC3 genes", "PROBLEM", 192, 222], ["pteropid LINE", "TREATMENT", 256, 269], ["endogenous retroviruses", "OBSERVATION", 30, 53], ["APOBEC3 genes", "OBSERVATION", 209, 222]]], ["These findings reveal the first group of antiviral restriction factors identified in bats with extensive diversification and divergence relative to homologues of other mammals.Arboviruses and EbolaDidier Fontenille (Institut Pasteur du Cambodge) described the diversity of arbovirus vectors in Asia.", [["bats", "ORGANISM", 85, 89], ["arbovirus", "ORGANISM", 273, 282], ["antiviral restriction factors", "PROTEIN", 41, 70], ["antiviral restriction factors", "TREATMENT", 41, 70], ["extensive diversification", "PROBLEM", 95, 120], ["Arboviruses", "PROBLEM", 176, 187], ["EbolaDidier", "TREATMENT", 192, 203], ["arbovirus vectors", "TREATMENT", 273, 290], ["antiviral restriction", "OBSERVATION", 41, 62], ["extensive", "OBSERVATION_MODIFIER", 95, 104], ["diversification", "OBSERVATION", 105, 120], ["arbovirus vectors", "OBSERVATION", 273, 290]]], ["Compared to the diversity of vectors, very few arboviruses have been identified beyond the \"big four\": dengue virus (serotypes 1-4); Japanese encephalitis virus; chikungunya virus; and more recently, Zika virus.", [["dengue", "DISEASE", 103, 109], ["Japanese encephalitis", "DISEASE", 133, 154], ["chikungunya virus", "DISEASE", 162, 179], ["arboviruses", "ORGANISM", 47, 58], ["dengue virus", "ORGANISM", 103, 115], ["serotypes 1-4", "ORGANISM", 117, 130], ["Japanese encephalitis virus", "ORGANISM", 133, 160], ["chikungunya virus", "ORGANISM", 162, 179], ["Zika virus", "ORGANISM", 200, 210], ["dengue virus", "SPECIES", 103, 115], ["Japanese encephalitis virus", "SPECIES", 133, 160], ["chikungunya virus", "SPECIES", 162, 179], ["dengue virus", "SPECIES", 103, 115], ["Japanese encephalitis virus", "SPECIES", 133, 160], ["chikungunya virus", "SPECIES", 162, 179], ["Zika virus", "SPECIES", 200, 210], ["very few arboviruses", "PROBLEM", 38, 58], ["dengue virus (serotypes", "PROBLEM", 103, 126], ["Japanese encephalitis virus", "PROBLEM", 133, 160], ["chikungunya virus", "PROBLEM", 162, 179], ["Zika virus", "PROBLEM", 200, 210], ["few", "OBSERVATION_MODIFIER", 43, 46], ["arboviruses", "OBSERVATION", 47, 58]]], ["Strategies for vector control in most Asian countries are few-with rare successes and numerous failures.", [["vector control", "TREATMENT", 15, 29], ["numerous failures", "PROBLEM", 86, 103], ["numerous", "OBSERVATION_MODIFIER", 86, 94], ["failures", "OBSERVATION", 95, 103]]], ["There appear to be several reasons for the vector control stalemate, including a paucity of field research, as well as lack of interest and/or competency in research laboratories.Arboviruses and EbolaFontenille posed a number of questions about the region and the emergence of new viruses, asking: How can we effectively control vectors?", [["EbolaFontenille", "CHEMICAL", 195, 210], ["the vector control stalemate", "TREATMENT", 39, 67], ["Arboviruses", "PROBLEM", 179, 190], ["EbolaFontenille", "TREATMENT", 195, 210], ["appear to be", "UNCERTAINTY", 6, 18], ["new", "OBSERVATION_MODIFIER", 277, 280], ["viruses", "OBSERVATION", 281, 288]]], ["What do we know about the biology and evolution of mosquitoes (for example, Ae. aegypti vs Ae. albopictus), and mosquito-virus co-adaptation in Asia?", [["Ae. aegypti", "ORGANISM", 76, 87], ["Ae. albopictus", "ORGANISM", 91, 105], ["mosquito-virus", "ORGANISM", 112, 126], ["Ae. aegypti", "SPECIES", 76, 87], ["Ae. albopictus", "SPECIES", 91, 105], ["Ae. aegypti", "SPECIES", 76, 87], ["Ae. albopictus", "SPECIES", 91, 105], ["mosquitoes", "PROBLEM", 51, 61]]], ["Should Southeast Asia expect the emergence of Zika virus?", [["Zika virus", "ORGANISM", 46, 56], ["Zika virus", "SPECIES", 46, 56], ["Zika virus", "PROBLEM", 46, 56]]], ["Fontenille reviewed these issues and made recommendations for a more active, holistic research approach involving virologists, zoologists, ecologists, social scientists and the often-neglected entomologists (Roche et al., 2017) .Persistent virusesAnthony L. Cunningham (University of Sydney, Australia) described the \"find me\" and \"eat me\" signals that attract human dermal dendritic cells (dDCs) to Langerhans cells (LCs) infected with herpes simplex virus (HSV), and facilitate recognition and uptake of apoptotic LCs (Botting et al., 2017) .", [["dermal dendritic cells", "ANATOMY", 367, 389], ["dDCs", "ANATOMY", 391, 395], ["Langerhans cells", "ANATOMY", 400, 416], ["LCs", "ANATOMY", 418, 421], ["LCs", "ANATOMY", 516, 519], ["herpes simplex virus", "DISEASE", 437, 457], ["human", "ORGANISM", 361, 366], ["dermal dendritic cells", "CELL", 367, 389], ["dDCs", "CELL", 391, 395], ["Langerhans cells", "CELL", 400, 416], ["LCs", "CELL", 418, 421], ["herpes simplex virus", "ORGANISM", 437, 457], ["HSV", "ORGANISM", 459, 462], ["LCs", "CELL", 516, 519], ["human dermal dendritic cells", "CELL_TYPE", 361, 389], ["dDCs", "CELL_TYPE", 391, 395], ["Langerhans cells", "CELL_TYPE", 400, 416], ["LCs", "CELL_TYPE", 418, 421], ["apoptotic LCs", "CELL_TYPE", 506, 519], ["human", "SPECIES", 361, 366], ["herpes simplex virus", "SPECIES", 437, 457], ["human", "SPECIES", 361, 366], ["herpes simplex virus", "SPECIES", 437, 457], ["HSV", "SPECIES", 459, 462], ["Persistent viruses", "PROBLEM", 229, 247], ["human dermal dendritic cells", "PROBLEM", 361, 389], ["Langerhans cells", "TEST", 400, 416], ["herpes simplex virus", "PROBLEM", 437, 457], ["viruses", "OBSERVATION", 240, 247], ["dendritic cells", "OBSERVATION", 374, 389], ["apoptotic LCs", "OBSERVATION", 506, 519]]], ["He and his colleagues assessed the expression of chemokines by HSV-infected LCs and corresponding chemokine receptors on dDC subsets, as well as apoptotic receptors that may recognize and facilitate their interactions.", [["LCs", "ANATOMY", 76, 79], ["dDC", "ANATOMY", 121, 124], ["HSV", "ORGANISM", 63, 66], ["LCs", "CELL", 76, 79], ["dDC subsets", "CELL", 121, 132], ["chemokines", "PROTEIN", 49, 59], ["LCs", "CELL_TYPE", 76, 79], ["chemokine receptors", "PROTEIN", 98, 117], ["dDC subsets", "CELL_TYPE", 121, 132], ["apoptotic receptors", "PROTEIN", 145, 164], ["HSV", "SPECIES", 63, 66], ["HSV", "PROBLEM", 63, 66], ["infected LCs", "PROBLEM", 67, 79], ["dDC subsets", "TREATMENT", 121, 132]]], ["These studies help to define the mechanisms of uptake and viral antigen transfer between LCs and dDCs, leading to subsequent differential presentation to CD4 + and CD8 + Tcells, which may define potential dendritic cell targets for adjuvants in future mucosal or intradermal vaccines.Persistent virusesZhiwei Chen (AIDS Institute and Department of Microbiology, Hong Kong SAR, China) reported on \"HIV enteropathy\" in acute HIV infection, which is characterized by diarrhea, gastrointestinal inflammation, increased intestinal permeability and malabsorption of nutrients.", [["LCs", "ANATOMY", 89, 92], ["dDCs", "ANATOMY", 97, 101], ["CD4 +", "ANATOMY", 154, 159], ["CD8 + Tcells", "ANATOMY", 164, 176], ["dendritic cell", "ANATOMY", 205, 219], ["mucosal", "ANATOMY", 252, 259], ["gastrointestinal", "ANATOMY", 474, 490], ["intestinal", "ANATOMY", 515, 525], ["AIDS", "DISEASE", 315, 319], ["HIV enteropathy", "DISEASE", 397, 412], ["acute HIV infection", "DISEASE", 417, 436], ["diarrhea", "DISEASE", 464, 472], ["gastrointestinal inflammation", "DISEASE", 474, 503], ["malabsorption", "DISEASE", 543, 556], ["LCs", "CELL", 89, 92], ["dDCs", "CELL", 97, 101], ["CD4", "GENE_OR_GENE_PRODUCT", 154, 157], ["CD8", "GENE_OR_GENE_PRODUCT", 164, 167], ["dendritic cell", "CELL", 205, 219], ["mucosal", "MULTI-TISSUE_STRUCTURE", 252, 259], ["gastrointestinal", "ORGANISM_SUBDIVISION", 474, 490], ["intestinal", "ORGAN", 515, 525], ["LCs", "CELL_TYPE", 89, 92], ["dDCs", "CELL_TYPE", 97, 101], ["CD4", "PROTEIN", 154, 157], ["CD8", "PROTEIN", 164, 167], ["HIV", "SPECIES", 397, 400], ["HIV", "SPECIES", 423, 426], ["HIV", "SPECIES", 397, 400], ["HIV", "SPECIES", 423, 426], ["These studies", "TEST", 0, 13], ["uptake", "PROBLEM", 47, 53], ["viral antigen", "TEST", 58, 71], ["LCs", "TEST", 89, 92], ["CD4", "TEST", 154, 157], ["CD8 + Tcells", "PROBLEM", 164, 176], ["dendritic cell targets", "PROBLEM", 205, 227], ["adjuvants", "TREATMENT", 232, 241], ["mucosal or intradermal vaccines", "TREATMENT", 252, 283], ["Persistent viruses", "PROBLEM", 284, 302], ["HIV enteropathy", "PROBLEM", 397, 412], ["acute HIV infection", "PROBLEM", 417, 436], ["diarrhea", "PROBLEM", 464, 472], ["gastrointestinal inflammation", "PROBLEM", 474, 503], ["increased intestinal permeability", "PROBLEM", 505, 538], ["malabsorption of nutrients", "PROBLEM", 543, 569], ["dendritic cell targets", "OBSERVATION", 205, 227], ["viruses", "OBSERVATION", 295, 302], ["acute", "OBSERVATION_MODIFIER", 417, 422], ["HIV infection", "OBSERVATION", 423, 436], ["diarrhea", "OBSERVATION", 464, 472], ["gastrointestinal", "ANATOMY", 474, 490], ["inflammation", "OBSERVATION", 491, 503], ["increased", "OBSERVATION_MODIFIER", 505, 514], ["intestinal permeability", "OBSERVATION", 515, 538], ["malabsorption", "OBSERVATION", 543, 556]]], ["Inflammatory mediators such as infiltration and activation of CD8 + T-cells, pro-inflammatory cytokines and CD4 T-cell depletion likely contribute to these changes in the intestine following local immune activation.", [["CD8 + T-cells", "ANATOMY", 62, 75], ["CD4 T-cell", "ANATOMY", 108, 118], ["intestine", "ANATOMY", 171, 180], ["CD8", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 108, 111], ["intestine", "ORGAN", 171, 180], ["CD8 + T-cells", "CELL_TYPE", 62, 75], ["pro-inflammatory cytokines", "PROTEIN", 77, 103], ["CD4", "PROTEIN", 108, 111], ["Inflammatory mediators", "PROBLEM", 0, 22], ["infiltration", "PROBLEM", 31, 43], ["CD8", "TEST", 62, 65], ["T-cells", "PROBLEM", 68, 75], ["pro-inflammatory cytokines", "PROBLEM", 77, 103], ["CD4 T-cell depletion", "PROBLEM", 108, 128], ["these changes in the intestine", "PROBLEM", 150, 180], ["local immune activation", "TREATMENT", 191, 214], ["infiltration", "OBSERVATION", 31, 43], ["pro-inflammatory", "OBSERVATION_MODIFIER", 77, 93], ["cell depletion", "OBSERVATION", 114, 128], ["intestine", "ANATOMY", 171, 180], ["local immune activation", "OBSERVATION", 191, 214]]], ["Chen and colleagues have discovered that a subset of gamma-delta T-cells (\u039442PD1+V\u03b42) also may contribute to innate immune activation and mucosal damage during acute HIV infection (Cheung et al., 2017) .", [["gamma-delta T-cells", "ANATOMY", 53, 72], ["mucosal", "ANATOMY", 138, 145], ["acute HIV infection", "DISEASE", 160, 179], ["gamma-delta", "GENE_OR_GENE_PRODUCT", 53, 64], ["\u039442PD1+V\u03b42", "GENE_OR_GENE_PRODUCT", 74, 84], ["mucosal", "ORGAN", 138, 145], ["gamma-delta T-cells", "CELL_LINE", 53, 72], ["\u039442PD1+V\u03b42", "CELL_LINE", 74, 84], ["HIV", "SPECIES", 166, 169], ["HIV", "SPECIES", 166, 169], ["gamma-delta T-cells", "TEST", 53, 72], ["innate immune activation", "PROBLEM", 109, 133], ["mucosal damage", "PROBLEM", 138, 152], ["acute HIV infection", "PROBLEM", 160, 179], ["gamma", "ANATOMY", 53, 58], ["may contribute to", "UNCERTAINTY", 91, 108], ["mucosal", "ANATOMY", 138, 145], ["damage", "OBSERVATION", 146, 152], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["HIV", "OBSERVATION", 166, 169]]], ["These cells may serve as targets for the investigation of diseases with mucosal inflammation, in addition to initial HIV infection at the mucosal surface.Persistent virusesBonnie Howell (Merck, Boston, USA) described the importance of elucidating mechanisms of HIV-1 persistence and developing innovative strategies for treatment and a functional cure.", [["cells", "ANATOMY", 6, 11], ["mucosal", "ANATOMY", 72, 79], ["mucosal surface", "ANATOMY", 138, 153], ["inflammation", "DISEASE", 80, 92], ["HIV infection", "DISEASE", 117, 130], ["cells", "CELL", 6, 11], ["mucosal", "PATHOLOGICAL_FORMATION", 72, 79], ["HIV", "ORGANISM", 117, 120], ["mucosal surface", "MULTI-TISSUE_STRUCTURE", 138, 153], ["HIV-1", "ORGANISM", 261, 266], ["HIV-1", "SPECIES", 261, 266], ["HIV", "SPECIES", 117, 120], ["HIV-1", "SPECIES", 261, 266], ["diseases", "PROBLEM", 58, 66], ["mucosal inflammation", "PROBLEM", 72, 92], ["initial HIV infection at the mucosal surface", "PROBLEM", 109, 153], ["HIV", "PROBLEM", 261, 264], ["innovative strategies", "TREATMENT", 294, 315], ["treatment", "TREATMENT", 320, 329], ["a functional cure", "TREATMENT", 334, 351], ["mucosal", "ANATOMY", 72, 79], ["inflammation", "OBSERVATION", 80, 92], ["HIV", "OBSERVATION_MODIFIER", 117, 120], ["infection", "OBSERVATION", 121, 130], ["mucosal", "ANATOMY", 138, 145], ["surface", "ANATOMY_MODIFIER", 146, 153]]], ["A class of small moleculeshistone deacetylase inhibitors (HDACis)-has been studied as latency-reversing agents, and clinical studies have shown that single and multiple administration results in induced viral RNA transcription and protein in CD4 + T-cells from ART-suppressed HIV+ subjects .", [["CD4 + T-cells", "ANATOMY", 242, 255], ["HDACis", "CHEMICAL", 58, 64], ["small moleculeshistone deacetylase", "GENE_OR_GENE_PRODUCT", 11, 45], ["HDACis", "SIMPLE_CHEMICAL", 58, 64], ["CD4", "GENE_OR_GENE_PRODUCT", 242, 245], ["HIV", "ORGANISM", 276, 279], ["viral RNA", "RNA", 203, 212], ["CD4 + T-cells", "CELL_TYPE", 242, 255], ["HIV", "SPECIES", 276, 279], ["HIV", "SPECIES", 276, 279], ["small moleculeshistone deacetylase inhibitors", "TREATMENT", 11, 56], ["reversing agents", "TREATMENT", 94, 110], ["clinical studies", "TEST", 116, 132], ["induced viral RNA transcription", "PROBLEM", 195, 226], ["protein", "TEST", 231, 238], ["CD4", "TEST", 242, 245], ["ART", "TEST", 261, 264], ["small", "OBSERVATION_MODIFIER", 11, 16], ["moleculeshistone deacetylase", "OBSERVATION", 17, 45]]], ["Furthermore, applying novel screening strategies for latency reversal agents in the presence of a sensitizing agent, such as a HDACi, can be a useful approach in identifying new mechanisms and alternative therapies for latency intervention.", [["HDACi", "CHEMICAL", 127, 132], ["novel screening strategies", "TREATMENT", 22, 48], ["latency reversal agents", "TREATMENT", 53, 76], ["a sensitizing agent", "TREATMENT", 96, 115], ["a HDACi", "TREATMENT", 125, 132], ["alternative therapies", "TREATMENT", 193, 214], ["latency intervention", "TREATMENT", 219, 239]]], ["Notably, the exploration of cure strategies targeting the latent HIV reservoir also highlights a need for new assays and research tools to quantify viral burden in tissue and various body fluids.", [["tissue", "ANATOMY", 164, 170], ["body fluids", "ANATOMY", 183, 194], ["tissue", "TISSUE", 164, 170], ["body", "ORGANISM_SUBDIVISION", 183, 187], ["fluids", "ORGANISM_SUBSTANCE", 188, 194], ["HIV", "SPECIES", 65, 68], ["the exploration", "TEST", 9, 24], ["cure strategies", "TREATMENT", 28, 43], ["the latent HIV reservoir", "TREATMENT", 54, 78], ["new assays", "TEST", 106, 116], ["research tools", "TEST", 121, 135], ["viral burden in tissue and various body fluids", "PROBLEM", 148, 194], ["latent", "OBSERVATION_MODIFIER", 58, 64], ["HIV", "OBSERVATION", 65, 68]]], ["The rare incidence of latently-infected cells, for which robust phenotypic markers are still needed presents a challenge to identifying these cells and measuring changes in viral expression, particularly after therapeutic intervention .Persistent virusesSarah Palmer (Centre for Virus Research, University of Sydney, Australia) reported that full-length HIV sequencing techniques revealed the majority of persistent HIV provirus in cells is genetically defective during antiretroviral therapy (Hiener et al., 2017) .", [["cells", "ANATOMY", 40, 45], ["cells", "ANATOMY", 142, 147], ["cells", "ANATOMY", 432, 437], ["latently-infected", "DISEASE", 22, 39], ["HIV provirus", "DISEASE", 416, 428], ["cells", "CELL", 40, 45], ["cells", "CELL", 142, 147], ["HIV", "ORGANISM", 416, 419], ["cells", "CELL", 432, 437], ["latently-infected cells", "CELL_TYPE", 22, 45], ["HIV", "SPECIES", 416, 419], ["HIV", "SPECIES", 354, 357], ["HIV", "SPECIES", 416, 419], ["latently-infected cells", "PROBLEM", 22, 45], ["robust phenotypic markers", "PROBLEM", 57, 82], ["these cells", "PROBLEM", 136, 147], ["measuring changes in viral expression", "PROBLEM", 152, 189], ["therapeutic intervention", "TREATMENT", 210, 234], ["full-length HIV sequencing techniques", "TEST", 342, 379], ["persistent HIV provirus in cells", "PROBLEM", 405, 437], ["antiretroviral therapy", "TREATMENT", 470, 492], ["rare", "OBSERVATION_MODIFIER", 4, 8], ["incidence", "OBSERVATION_MODIFIER", 9, 18], ["latently", "OBSERVATION_MODIFIER", 22, 30], ["infected cells", "OBSERVATION", 31, 45], ["viral expression", "OBSERVATION", 173, 189], ["viruses", "OBSERVATION", 247, 254], ["persistent", "OBSERVATION_MODIFIER", 405, 415], ["HIV provirus", "OBSERVATION", 416, 428]]], ["However, the distribution of intact proviruses within memory CD4 + T-cell subsets from participants who initiated therapy during either acute or chronic infection showed the proportion of intact provirus was significantly different across cell subsets.", [["memory CD4 + T-cell", "ANATOMY", 54, 73], ["cell", "ANATOMY", 239, 243], ["infection", "DISEASE", 153, 162], ["proviruses", "CELL", 36, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 61, 64], ["provirus", "ORGANISM", 195, 203], ["cell", "CELL", 239, 243], ["memory CD4 + T-cell subsets", "CELL_TYPE", 54, 81], ["participants", "SPECIES", 87, 99], ["intact proviruses", "PROBLEM", 29, 46], ["therapy", "TREATMENT", 114, 121], ["chronic infection", "PROBLEM", 145, 162], ["intact provirus", "PROBLEM", 188, 203], ["intact proviruses", "OBSERVATION", 29, 46], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["chronic", "OBSERVATION_MODIFIER", 145, 152], ["infection", "OBSERVATION", 153, 162], ["intact provirus", "OBSERVATION", 188, 203], ["cell subsets", "OBSERVATION", 239, 251]]], ["Cells expressing the HLA-DR activation marker and effector memory cells contained the highest proportion of intact HIV genomes.", [["Cells", "ANATOMY", 0, 5], ["effector memory cells", "ANATOMY", 50, 71], ["Cells", "CELL", 0, 5], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 21, 27], ["effector memory cells", "CELL", 50, 71], ["HIV", "ORGANISM", 115, 118], ["HLA-DR activation marker", "PROTEIN", 21, 45], ["effector memory cells", "CELL_TYPE", 50, 71], ["HIV genomes", "DNA", 115, 126], ["HIV", "SPECIES", 115, 118], ["HIV", "SPECIES", 115, 118], ["the HLA", "TEST", 17, 24], ["effector memory cells", "PROBLEM", 50, 71], ["intact HIV genomes", "PROBLEM", 108, 126], ["memory cells", "OBSERVATION", 59, 71], ["highest", "OBSERVATION_MODIFIER", 86, 93], ["intact", "OBSERVATION_MODIFIER", 108, 114], ["HIV genomes", "OBSERVATION", 115, 126]]], ["In addition, clonal expansions of intact proviruses were identified indicating that proliferating cells contribute to the latent reservoir.", [["cells", "ANATOMY", 98, 103], ["proviruses", "ORGANISM", 41, 51], ["cells", "CELL", 98, 103], ["proliferating cells", "CELL_TYPE", 84, 103], ["clonal expansions of intact proviruses", "PROBLEM", 13, 51], ["proliferating cells", "PROBLEM", 84, 103], ["the latent reservoir", "TREATMENT", 118, 138], ["clonal", "OBSERVATION_MODIFIER", 13, 19], ["expansions", "OBSERVATION_MODIFIER", 20, 30], ["intact proviruses", "OBSERVATION", 34, 51], ["proliferating cells", "OBSERVATION", 84, 103], ["latent", "OBSERVATION_MODIFIER", 122, 128], ["reservoir", "OBSERVATION_MODIFIER", 129, 138]]], ["The HLA-DR marker identifies cells containing a high frequency of intact HIV genomes; therefore, assays quantifying the persistent HIV reservoir should include these cells.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 166, 171], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 4, 10], ["cells", "CELL", 29, 34], ["HIV", "ORGANISM", 131, 134], ["cells", "CELL", 166, 171], ["HLA-DR marker", "DNA", 4, 17], ["HIV genomes", "DNA", 73, 84], ["HIV", "SPECIES", 73, 76], ["HIV", "SPECIES", 131, 134], ["intact HIV genomes", "PROBLEM", 66, 84], ["assays", "TEST", 97, 103], ["the persistent HIV reservoir", "TREATMENT", 116, 144], ["these cells", "TREATMENT", 160, 171], ["high", "OBSERVATION_MODIFIER", 48, 52], ["intact", "OBSERVATION_MODIFIER", 66, 72], ["HIV genomes", "OBSERVATION", 73, 84], ["persistent", "OBSERVATION_MODIFIER", 120, 130], ["HIV", "OBSERVATION", 131, 134]]], ["Determining the type of cells and cellular mechanisms contributing to persistent replication-competent HIV is crucial for future efforts aimed at HIV eradication.FinaleRicky Mentha (Baker Heart and Diabetes Research Institute, Australia) reported that Aboriginal populations residing in remote locations have limited general knowledge of infectious diseases, modes of transmission, and preventative public health measures.", [["cells", "ANATOMY", 24, 29], ["cellular", "ANATOMY", 34, 42], ["Diabetes", "DISEASE", 198, 206], ["infectious diseases", "DISEASE", 338, 357], ["cells", "CELL", 24, 29], ["cellular", "CELL", 34, 42], ["HIV", "ORGANISM", 103, 106], ["HIV", "ORGANISM", 146, 149], ["HIV", "SPECIES", 103, 106], ["HIV", "SPECIES", 146, 149], ["the type of cells", "PROBLEM", 12, 29], ["cellular mechanisms", "PROBLEM", 34, 53], ["persistent replication", "PROBLEM", 70, 92], ["HIV eradication", "TREATMENT", 146, 161], ["infectious diseases", "PROBLEM", 338, 357], ["preventative public health measures", "TREATMENT", 386, 421], ["persistent", "OBSERVATION_MODIFIER", 70, 80], ["replication", "OBSERVATION", 81, 92], ["Heart", "ANATOMY", 188, 193], ["infectious", "OBSERVATION", 338, 348]]], ["Exposure to an array of communicable diseases is prevalent, and morbidity and mortality are significant.", [["communicable diseases", "DISEASE", 24, 45], ["communicable diseases", "PROBLEM", 24, 45], ["significant", "OBSERVATION_MODIFIER", 92, 103]]], ["Effective partnerships with local Aboriginal stakeholders are critical to improving knowledge of infectious diseases and developing preventative strategies derived from a well-thought-out research agenda.", [["infectious diseases", "DISEASE", 97, 116], ["infectious diseases", "PROBLEM", 97, 116], ["preventative strategies", "TREATMENT", 132, 155], ["infectious", "OBSERVATION", 97, 107]]], ["There are many complexities to address in conducting communicable disease research in remote Aboriginal populations, but it can be done in ethical and culturally sensitive ways that contribute to reducing exposure to povertyrelated infectious disease that impact on morbidity and mortality (Brown et al., 2016) .FinaleKanta Subbarao (WHO Collaborating Centre for Reference and Research on Influenza, Australia) presented recent data on replication and viral properties governing the airborne transmission of influenza virus 2009 pandemic A/H1N1 in a ferret transmission model, and described some of the complex viral and host interactions that influence the transmissibility phenotype of influenza viruses (Sutton et al., 2017) .FinaleFrederick Kristensen (CEPI, Oslo, Norway) described the recently established Coalition for Epidemic Preparedness Innovations (CEPI).", [["infectious disease", "DISEASE", 232, 250], ["influenza", "DISEASE", 508, 517], ["influenza viruses", "DISEASE", 688, 705], ["influenza virus", "ORGANISM", 508, 523], ["A/H1N1", "ORGANISM", 538, 544], ["ferret", "ORGANISM", 550, 556], ["influenza viruses", "ORGANISM", 688, 705], ["influenza virus", "SPECIES", 508, 523], ["ferret", "SPECIES", 550, 556], ["influenza virus 2009 pandemic A/H1N1", "SPECIES", 508, 544], ["ferret", "SPECIES", 550, 556], ["povertyrelated infectious disease", "PROBLEM", 217, 250], ["Influenza", "PROBLEM", 389, 398], ["replication", "TREATMENT", 436, 447], ["viral properties", "TREATMENT", 452, 468], ["influenza virus", "PROBLEM", 508, 523], ["H1N1", "PROBLEM", 540, 544], ["the complex viral and host interactions", "PROBLEM", 599, 638], ["influenza viruses", "PROBLEM", 688, 705], ["infectious", "OBSERVATION", 232, 242], ["complex", "OBSERVATION_MODIFIER", 603, 610], ["viral", "OBSERVATION", 611, 616], ["influenza viruses", "OBSERVATION", 688, 705]]], ["In addition, the European Commission agreed to co-fund some CEPI projects with \u20ac200 million.", [["some CEPI projects", "TREATMENT", 55, 73]]], ["At its launch, CEPI issued a call for proposals to develop vaccines against three viral agents: MERS-coronavirus, Lassa and Nipah virus.", [["MERS-coronavirus, Lassa and Nipah virus", "DISEASE", 96, 135], ["MERS-coronavirus", "ORGANISM", 96, 112], ["Lassa", "ORGANISM", 114, 119], ["Nipah virus", "ORGANISM", 124, 135], ["MERS-coronavirus", "SPECIES", 96, 112], ["Nipah virus", "SPECIES", 124, 135], ["MERS-coronavirus", "SPECIES", 96, 112], ["Nipah virus", "SPECIES", 124, 135], ["vaccines", "TREATMENT", 59, 67], ["MERS", "PROBLEM", 96, 100], ["coronavirus", "PROBLEM", 101, 112], ["Lassa", "PROBLEM", 114, 119], ["Nipah virus", "PROBLEM", 124, 135], ["Nipah virus", "OBSERVATION", 124, 135]]], ["A new call is planned for developing vaccine platforms.The network in 2017On October 1, 2017, Christian Br\u00e9chot, MD, PhD became the new GVN President (http://gvn.org/brechot/).", [["developing vaccine platforms", "TREATMENT", 26, 54]]], ["He previously served as a university professor, hospital practitioner, and head of departments of hepatology and cell biology.", [["cell", "ANATOMY", 113, 117], ["head", "ORGANISM_SUBDIVISION", 75, 79], ["cell", "CELL", 113, 117], ["head", "ANATOMY", 75, 79]]], ["Throughout his career, his research has focused on HBV and HCV, particularly regarding their role in liver cancer and to the molecular mechanisms that drive liver regeneration and cancer.", [["liver cancer", "ANATOMY", 101, 113], ["liver", "ANATOMY", 157, 162], ["cancer", "ANATOMY", 180, 186], ["HCV", "DISEASE", 59, 62], ["liver cancer", "DISEASE", 101, 113], ["liver regeneration", "DISEASE", 157, 175], ["cancer", "DISEASE", 180, 186], ["HBV", "ORGANISM", 51, 54], ["HCV", "ORGANISM", 59, 62], ["liver cancer", "CANCER", 101, 113], ["liver", "ORGAN", 157, 162], ["cancer", "CANCER", 180, 186], ["HBV", "SPECIES", 51, 54], ["HCV", "SPECIES", 59, 62], ["HBV", "PROBLEM", 51, 54], ["HCV", "PROBLEM", 59, 62], ["liver cancer", "PROBLEM", 101, 113], ["liver regeneration", "PROBLEM", 157, 175], ["cancer", "PROBLEM", 180, 186], ["liver", "ANATOMY", 101, 106], ["cancer", "OBSERVATION", 107, 113], ["liver", "ANATOMY", 157, 162], ["regeneration", "OBSERVATION", 163, 175], ["cancer", "OBSERVATION", 180, 186]]], ["Dr. Br\u00e9chot has authored more than 350 articles in medical and scientific journals.The network in 2017While there are new changes to the GVN headquarters staff, several other activities have continued, including the collection of acute and convalescent sera from confirmed Zika patients to aid in developing new diagnostics.", [["sera", "ANATOMY", 253, 257], ["sera", "ORGANISM_SUBSTANCE", 253, 257], ["patients", "ORGANISM", 278, 286], ["patients", "SPECIES", 278, 286], ["acute and convalescent sera", "PROBLEM", 230, 257], ["acute", "OBSERVATION_MODIFIER", 230, 235]]], ["The serum bank is funded by a grant from the Allergan Foundation, and samples are stored at the University of Texas Medical Branch in Galveston, Texas.", [["serum", "ANATOMY", 4, 9], ["samples", "ANATOMY", 70, 77], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["The serum bank", "TEST", 0, 14]]], ["In addition, Shyamasundran Kottilil and colleagues at the Institute of Human Virology in Baltimore have continued a project with the GVN to expand a training model for health care providers using DAA treatment for hepatitis C patients in India (Mathur et al., 2017) .", [["DAA", "CHEMICAL", 196, 199], ["hepatitis C", "DISEASE", 214, 225], ["Human", "ORGANISM", 71, 76], ["patients", "ORGANISM", 226, 234], ["Human", "SPECIES", 71, 76], ["patients", "SPECIES", 226, 234], ["a training model", "TREATMENT", 147, 163], ["health care providers", "TREATMENT", 168, 189], ["DAA treatment", "TREATMENT", 196, 209], ["hepatitis C", "PROBLEM", 214, 225]]], ["Similarly, a pilot study to develop an integrated clinical database to support community-based care of hepatitis B patients in Arunachal Pradesh, India also is under way, and is funded by the John C. Martin Foundation.The network in 2017GVN's HTLV-1 task force members published a commentary recommending the current name for HTLV-1 be changed back to its original name (human T-cell leukemia virus-1), in keeping with its oncogenicity and pathogenesis .", [["hepatitis B", "DISEASE", 103, 114], ["hepatitis B", "ORGANISM", 103, 114], ["patients", "ORGANISM", 115, 123], ["HTLV-1", "ORGANISM", 243, 249], ["HTLV-1", "ORGANISM", 326, 332], ["human T-cell leukemia virus-1", "ORGANISM", 371, 400], ["patients", "SPECIES", 115, 123], ["human", "SPECIES", 371, 376], ["leukemia virus-1", "SPECIES", 384, 400], ["HTLV-1", "SPECIES", 326, 332], ["human T-cell leukemia virus-1", "SPECIES", 371, 400], ["a pilot study", "TEST", 11, 24], ["hepatitis B patients", "TREATMENT", 103, 123], ["HTLV-1", "TREATMENT", 326, 332], ["human T-cell leukemia virus", "PROBLEM", 371, 398], ["pathogenesis", "PROBLEM", 440, 452], ["hepatitis", "OBSERVATION", 103, 112]]], ["Other GVN investigators published work on the oncogenicity of HTLV-1 .", [["HTLV-1", "ORGANISM", 62, 68], ["HTLV-1", "SPECIES", 62, 68]]], ["Members of the GVN task force on Zika virus also published a major review on what has been learned about Zika in the first two years of the epidemic in the Americas, and what gaps remain (Aliota MT et al., 2017) .The network in 2017During 2017, the Network expanded the number of cooperating research centers by adding the M\u00e9rieux Foundation in Lyon, France, and the Rega Institute for Medical Research at the University of Leuven in Belgium (Fig. 1) .", [["Zika virus", "ORGANISM", 33, 43], ["Zika virus", "SPECIES", 33, 43], ["Zika virus", "PROBLEM", 33, 43]]], ["These two new centers are expected to strengthen research on vaccines and collaborative activities in developing countries.Plans for 2018GVN staff will continue to solicit patient serum samples for the Zika serum bank in Galveston, Texas.", [["serum samples", "ANATOMY", 180, 193], ["serum", "ANATOMY", 207, 212], ["patient", "ORGANISM", 172, 179], ["serum samples", "ORGANISM_SUBSTANCE", 180, 193], ["serum", "ORGANISM_SUBSTANCE", 207, 212], ["patient", "SPECIES", 172, 179], ["vaccines", "TREATMENT", 61, 69], ["serum samples", "TEST", 180, 193], ["new", "OBSERVATION_MODIFIER", 10, 13]]], ["Additionally, a project to sequence and conduct phylogenetic analyses of collected Zika virus isolates is continuing in cooperation with the World Reference Centre for Emerging Viruses and Arboviruses (WRCEVA), which is funded by the National Institute of Allergy and Infectious Diseases (USA).Plans for 2018The GVN will host the fifth annual Short Course on Medical Virology for young investigators in the summer of 2018.", [["Emerging Viruses", "DISEASE", 168, 184], ["Allergy and Infectious Diseases", "DISEASE", 256, 287], ["Zika virus", "ORGANISM", 83, 93], ["Zika virus", "SPECIES", 83, 93], ["conduct phylogenetic analyses", "TEST", 40, 69], ["collected Zika virus isolates", "PROBLEM", 73, 102], ["Emerging Viruses", "PROBLEM", 168, 184], ["Arboviruses", "PROBLEM", 189, 200]]], ["The Short Course attracts an international class of 15-20 postdoctoral students and fellows for five days of meetings and lectures with experts in medical virology research and clinical practice.", [["Short", "OBSERVATION_MODIFIER", 4, 9]]], ["It will be co-hosted by the Research Centre for Emerging Infections and Zoonoses at the University of Veterinary Medicine in Hanover, Germany.", [["Infections", "DISEASE", 57, 67], ["Zoonoses", "DISEASE", 72, 80], ["Infections", "OBSERVATION", 57, 67]]]], "356e8013ad530b5b1ef7e3dcb5ec9de7ac8c6abe": [["IntroductionThe current coronavirus pandemic caused by the SARS-CoV2 has rapidly emerged as a global health crisis.", [["coronavirus pandemic", "DISEASE", 24, 44], ["SARS", "DISEASE", 59, 63], ["coronavirus", "ORGANISM", 24, 35], ["SARS-CoV2", "ORGANISM", 59, 68], ["SARS-CoV2", "SPECIES", 59, 68], ["a global health crisis", "PROBLEM", 92, 114]]], ["To date, over four million people have been affected by coronavirus disease 2019 (COVID- 19) worldwide in about 188 countries and the number continues to grow [1] .", [["coronavirus disease", "DISEASE", 56, 75], ["people", "ORGANISM", 27, 33], ["people", "SPECIES", 27, 33], ["coronavirus disease", "PROBLEM", 56, 75], ["COVID", "TEST", 82, 87], ["coronavirus disease", "OBSERVATION", 56, 75]]], ["In the United States alone, confirmed cases and deaths continue to rise, with current estimates at more than 1.9 million positive patients and over 110,000 deaths [1] .", [["deaths", "DISEASE", 48, 54], ["deaths", "DISEASE", 156, 162], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138]]], ["Symptoms range from asymptomatic or mild constitutional symptoms to pneumonia, sepsis and sometimes severe acute respiratory distress syndrome (ARDS) necessitating hospitalization and intensive care unit (ICU) admission [2] .", [["respiratory", "ANATOMY", 113, 124], ["pneumonia", "DISEASE", 68, 77], ["sepsis", "DISEASE", 79, 85], ["acute respiratory distress syndrome", "DISEASE", 107, 142], ["ARDS", "DISEASE", 144, 148], ["Symptoms range", "PROBLEM", 0, 14], ["asymptomatic", "PROBLEM", 20, 32], ["mild constitutional symptoms", "PROBLEM", 36, 64], ["pneumonia", "PROBLEM", 68, 77], ["sepsis", "PROBLEM", 79, 85], ["sometimes severe acute respiratory distress syndrome", "PROBLEM", 90, 142], ["ARDS", "PROBLEM", 144, 148], ["mild", "OBSERVATION_MODIFIER", 36, 40], ["pneumonia", "OBSERVATION", 68, 77], ["sepsis", "OBSERVATION", 79, 85], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory distress syndrome", "OBSERVATION", 113, 142]]], ["The pivotal role of thrombo-inflammation and endothelial injury in the pathogenesis of the disease is being increasingly recognized.", [["endothelial", "ANATOMY", 45, 56], ["endothelial injury", "DISEASE", 45, 63], ["endothelial", "TISSUE", 45, 56], ["thrombo-inflammation", "PROBLEM", 20, 40], ["endothelial injury", "PROBLEM", 45, 63], ["the disease", "PROBLEM", 87, 98], ["thrombo-inflammation", "OBSERVATION", 20, 40], ["endothelial", "ANATOMY", 45, 56], ["injury", "OBSERVATION", 57, 63], ["disease", "OBSERVATION", 91, 98]]], ["Overproduction of proinflammatory cytokines, including tumor necrosis factor (TNF), Interleukin (IL) -6, IL-8, and IL-1\u03b2, is believed to be the cause of what is being termed, \"cytokine release syndrome\" or \"cytokine storm\", a phenomenon which is however not unique to this disease and has been noted in sepsis and sterile inflammation as well.", [["tumor necrosis", "DISEASE", 55, 69], ["sepsis", "DISEASE", 303, 309], ["inflammation", "DISEASE", 322, 334], ["tumor necrosis factor", "GENE_OR_GENE_PRODUCT", 55, 76], ["TNF", "GENE_OR_GENE_PRODUCT", 78, 81], ["Interleukin (IL) -6", "GENE_OR_GENE_PRODUCT", 84, 103], ["IL-8", "GENE_OR_GENE_PRODUCT", 105, 109], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 115, 120], ["proinflammatory cytokines", "PROTEIN", 18, 43], ["TNF", "PROTEIN", 78, 81], ["Interleukin (IL) -6, IL-8", "PROTEIN", 84, 109], ["IL-1\u03b2", "PROTEIN", 115, 120], ["cytokine", "PROTEIN", 176, 184], ["cytokine", "PROTEIN", 207, 215], ["proinflammatory cytokines", "PROBLEM", 18, 43], ["tumor necrosis factor", "PROBLEM", 55, 76], ["TNF", "TEST", 78, 81], ["Interleukin (IL)", "TEST", 84, 100], ["IL", "TEST", 105, 107], ["cytokine release syndrome", "PROBLEM", 176, 201], ["cytokine storm\"", "PROBLEM", 207, 222], ["a phenomenon", "PROBLEM", 224, 236], ["this disease", "PROBLEM", 268, 280], ["sepsis", "PROBLEM", 303, 309], ["sterile inflammation", "PROBLEM", 314, 334], ["proinflammatory cytokines", "OBSERVATION", 18, 43], ["tumor", "OBSERVATION_MODIFIER", 55, 60], ["necrosis", "OBSERVATION", 61, 69], ["sepsis", "OBSERVATION", 303, 309], ["sterile", "OBSERVATION_MODIFIER", 314, 321], ["inflammation", "OBSERVATION", 322, 334]]], ["This exaggerated cytokine response may lead to multiorgan failure and eventually death in some patients [3] .", [["multiorgan", "ANATOMY", 47, 57], ["multiorgan failure", "DISEASE", 47, 65], ["death", "DISEASE", 81, 86], ["patients", "ORGANISM", 95, 103], ["cytokine", "PROTEIN", 17, 25], ["patients", "SPECIES", 95, 103], ["This exaggerated cytokine response", "PROBLEM", 0, 34], ["multiorgan failure", "PROBLEM", 47, 65], ["eventually death", "PROBLEM", 70, 86], ["failure", "OBSERVATION", 58, 65]]], ["In addition to elevations in pro-inflammatory markers, hypercoagulability has been identified to be playing a key role determining prognosis in patients with COVID-19 [4] .", [["hypercoagulability", "DISEASE", 55, 73], ["COVID-19", "CHEMICAL", 158, 166], ["patients", "ORGANISM", 144, 152], ["pro-inflammatory markers", "PROTEIN", 29, 53], ["patients", "SPECIES", 144, 152], ["elevations in pro-inflammatory markers", "PROBLEM", 15, 53], ["hypercoagulability", "PROBLEM", 55, 73], ["COVID", "TEST", 158, 163], ["elevations", "OBSERVATION_MODIFIER", 15, 25], ["pro-inflammatory markers", "OBSERVATION", 29, 53]]], ["In some observational series, thrombotic complications have been noted to be as high as 31% in patients requiring ICU admission and the risk persists even in patients on anticoagulation [5] [6] [7] [8] .IntroductionWe searched for all published, readily accessible, peerreviewed, full articles written in English on PUBMED and EMBASE (between December 1 st , 2019 to June 6 th , 2020) related to thromboembolic complications seen in COVID -19 before writing this review.", [["thrombotic complications", "DISEASE", 30, 54], ["thromboembolic", "DISEASE", 396, 410], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 158, 166], ["5] [6] [7", "SIMPLE_CHEMICAL", 187, 196], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 158, 166], ["thrombotic complications", "PROBLEM", 30, 54], ["anticoagulation", "TREATMENT", 170, 185], ["thromboembolic complications", "PROBLEM", 396, 424], ["COVID", "TEST", 433, 438], ["thromboembolic", "OBSERVATION_MODIFIER", 396, 410], ["complications", "OBSERVATION", 411, 424]]], ["Majority of the articles included retrospective, observational, single or multicenter studies or case reports and correspondences.IntroductionIn this brief narrative review, we discuss the pathophysiological mechanisms, clinical manifestations of thrombotic complications noted in patients with COVID-19 and describe a pragmatic approach for management of anticoagulation strategies in these patients based on the currently available evidence.Pathogenesis and risk factorsCOVID-19 shares multiple similarities with other well defined inflammatory states such as sepsis and sterile inflammation wherein simultaneous rise in pro and antiinflammatory cytokines are seen [9, 10] .", [["thrombotic complications", "DISEASE", 247, 271], ["sepsis", "DISEASE", 562, 568], ["inflammation", "DISEASE", 581, 593], ["COVID-19", "CHEMICAL", 295, 303], ["patients", "ORGANISM", 281, 289], ["patients", "ORGANISM", 392, 400], ["pro and antiinflammatory cytokines", "PROTEIN", 623, 657], ["patients", "SPECIES", 281, 289], ["patients", "SPECIES", 392, 400], ["multicenter studies", "TEST", 74, 93], ["thrombotic complications", "PROBLEM", 247, 271], ["COVID", "TEST", 295, 300], ["a pragmatic approach", "TREATMENT", 317, 337], ["management", "TREATMENT", 342, 352], ["anticoagulation strategies", "TREATMENT", 356, 382], ["Pathogenesis", "PROBLEM", 443, 455], ["risk factorsCOVID", "TEST", 460, 477], ["other well defined inflammatory states", "PROBLEM", 515, 553], ["sepsis", "PROBLEM", 562, 568], ["sterile inflammation", "PROBLEM", 573, 593], ["pro and antiinflammatory cytokines", "TEST", 623, 657], ["well defined", "OBSERVATION_MODIFIER", 521, 533], ["inflammatory", "OBSERVATION", 534, 546], ["sepsis", "OBSERVATION", 562, 568], ["inflammation", "OBSERVATION", 581, 593], ["simultaneous", "OBSERVATION_MODIFIER", 602, 614], ["rise", "OBSERVATION_MODIFIER", 615, 619]]], ["More pertinently, there is evidence of complement activation in COVID-19 by direct endothelial infection which includes release of anaphylotoxin C5a [11] .", [["endothelial", "ANATOMY", 83, 94], ["COVID-19", "CHEMICAL", 64, 72], ["endothelial infection", "DISEASE", 83, 104], ["COVID-19", "CHEMICAL", 64, 72], ["COVID-19", "CELL", 64, 72], ["endothelial", "CELL", 83, 94], ["anaphylotoxin C5a", "GENE_OR_GENE_PRODUCT", 131, 148], ["complement activation in COVID", "PROBLEM", 39, 69], ["direct endothelial infection", "PROBLEM", 76, 104], ["anaphylotoxin C5a", "TREATMENT", 131, 148], ["evidence of", "UNCERTAINTY", 27, 38], ["complement activation", "OBSERVATION", 39, 60], ["endothelial", "ANATOMY", 83, 94], ["infection", "OBSERVATION", 95, 104]]], ["Complement activation as seen in COVID-19 not only drives neutrophil dysfunction leading to susceptibility to secondary infections but also activates the coagulation system thereby propagating a prothrombotic state.", [["neutrophil", "ANATOMY", 58, 68], ["neutrophil dysfunction", "DISEASE", 58, 80], ["infections", "DISEASE", 120, 130], ["COVID-19", "CHEMICAL", 33, 41], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["COVID-19", "GENE_OR_GENE_PRODUCT", 33, 41], ["neutrophil", "CELL", 58, 68], ["neutrophil dysfunction", "PROBLEM", 58, 80], ["secondary infections", "PROBLEM", 110, 130], ["the coagulation system", "TEST", 150, 172], ["a prothrombotic state", "PROBLEM", 193, 214], ["secondary", "OBSERVATION_MODIFIER", 110, 119], ["infections", "OBSERVATION", 120, 130], ["prothrombotic", "OBSERVATION", 195, 208]]], ["Coagulopathy associated with COVID-19 may be explained by the 'two way activation' theory, as seen by thrombocytopenia in critically ill patients (TICP) and the encompassing inflammatory and micro-thrombogenic responses that occur when endothelial insult takes place [12] .", [["endothelial", "ANATOMY", 236, 247], ["Coagulopathy", "DISEASE", 0, 12], ["COVID-19", "CHEMICAL", 29, 37], ["thrombocytopenia", "DISEASE", 102, 118], ["critically ill", "DISEASE", 122, 136], ["COVID-19", "CHEMICAL", 29, 37], ["patients", "ORGANISM", 137, 145], ["endothelial", "CELL", 236, 247], ["patients", "SPECIES", 137, 145], ["Coagulopathy", "PROBLEM", 0, 12], ["COVID", "TEST", 29, 34], ["thrombocytopenia", "PROBLEM", 102, 118], ["the encompassing inflammatory and micro-thrombogenic responses", "PROBLEM", 157, 219], ["endothelial insult", "PROBLEM", 236, 254], ["thrombocytopenia", "OBSERVATION", 102, 118], ["inflammatory", "OBSERVATION_MODIFIER", 174, 186]]], ["While the inflammatory pathway releases cytokines, the activation of microthrombotic pathway is mediated by release of large polymers of Von Willebrand factors (VWF).", [["Von Willebrand factors", "GENE_OR_GENE_PRODUCT", 137, 159], ["VWF", "GENE_OR_GENE_PRODUCT", 161, 164], ["cytokines", "PROTEIN", 40, 49], ["Von Willebrand factors", "PROTEIN", 137, 159], ["VWF", "PROTEIN", 161, 164], ["microthrombotic pathway", "PROBLEM", 69, 92], ["inflammatory", "OBSERVATION_MODIFIER", 10, 22], ["large", "OBSERVATION_MODIFIER", 119, 124]]], ["In the face of sepsis-induced endothelial injury, this reaction is aggravated causing enhanced platelet activation and consumption thrombocytopenia [13] .", [["endothelial", "ANATOMY", 30, 41], ["platelet", "ANATOMY", 95, 103], ["sepsis", "DISEASE", 15, 21], ["endothelial injury", "DISEASE", 30, 48], ["thrombocytopenia", "DISEASE", 131, 147], ["endothelial", "TISSUE", 30, 41], ["platelet", "CELL", 95, 103], ["sepsis", "PROBLEM", 15, 21], ["endothelial injury", "PROBLEM", 30, 48], ["this reaction", "PROBLEM", 50, 63], ["enhanced platelet activation", "PROBLEM", 86, 114], ["consumption thrombocytopenia", "PROBLEM", 119, 147], ["sepsis", "OBSERVATION", 15, 21], ["endothelial injury", "OBSERVATION", 30, 48], ["platelet activation", "OBSERVATION", 95, 114]]], ["In contrast to the typical consumptive coagulopathy and disseminated intravascular coagulation (DIC) profile observed in sepsis, patients with COVID-19 typically have relatively normal coagulation and platelet profiles.", [["intravascular", "ANATOMY", 69, 82], ["platelet", "ANATOMY", 201, 209], ["consumptive coagulopathy", "DISEASE", 27, 51], ["disseminated intravascular coagulation", "DISEASE", 56, 94], ["DIC", "DISEASE", 96, 99], ["sepsis", "DISEASE", 121, 127], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 82], ["patients", "ORGANISM", 129, 137], ["platelet", "CELL", 201, 209], ["patients", "SPECIES", 129, 137], ["the typical consumptive coagulopathy", "PROBLEM", 15, 51], ["disseminated intravascular coagulation", "PROBLEM", 56, 94], ["DIC) profile", "TEST", 96, 108], ["sepsis", "PROBLEM", 121, 127], ["COVID", "TEST", 143, 148], ["platelet profiles", "TEST", 201, 218], ["consumptive", "OBSERVATION_MODIFIER", 27, 38], ["coagulopathy", "OBSERVATION", 39, 51], ["disseminated", "OBSERVATION_MODIFIER", 56, 68], ["intravascular coagulation", "OBSERVATION", 69, 94], ["sepsis", "OBSERVATION", 121, 127], ["coagulation", "OBSERVATION", 185, 196]]], ["Progression to DIC occurs in a minority of patients, rarely developing in survivors [4] .", [["DIC", "DISEASE", 15, 18], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["DIC", "PROBLEM", 15, 18], ["DIC", "OBSERVATION", 15, 18]]], ["Therefore it seems that in keeping with Virchow's triad, thrombosis is driven both by the activation of coagulation factors and endothelium.", [["endothelium", "ANATOMY", 128, 139], ["thrombosis", "DISEASE", 57, 67], ["coagulation factors", "GENE_OR_GENE_PRODUCT", 104, 123], ["endothelium", "TISSUE", 128, 139], ["coagulation factors", "PROTEIN", 104, 123], ["Virchow's triad", "PROBLEM", 40, 55], ["thrombosis", "PROBLEM", 57, 67], ["coagulation factors", "TREATMENT", 104, 123], ["thrombosis", "OBSERVATION", 57, 67]]], ["In-situ immunethrombosis plays a key role to be the unifying mechanism explaining the micro and macrothrombotic manifestations of the disease.", [["immunethrombosis", "DISEASE", 8, 24], ["the micro and macrothrombotic manifestations of the disease", "PROBLEM", 82, 141], ["disease", "OBSERVATION", 134, 141]]], ["It should however be emphasized that in-situ microthrombosis has also been demonstrated in pulmonary and systemic tissue beds in ARDS and sepsis and therefore may not necessarily be unique to this population.Pathogenesis and risk factorsIn addition to the factors mentioned above, these patients have additional risk factors for increased thrombosis, most notable among those being hypoxia, and immobility (made worse by frequent use of prone positioning) [14] [15] [16] .", [["pulmonary", "ANATOMY", 91, 100], ["tissue", "ANATOMY", 114, 120], ["microthrombosis", "DISEASE", 45, 60], ["ARDS", "DISEASE", 129, 133], ["sepsis", "DISEASE", 138, 144], ["thrombosis", "DISEASE", 339, 349], ["hypoxia", "DISEASE", 382, 389], ["pulmonary", "ORGAN", 91, 100], ["tissue", "TISSUE", 114, 120], ["patients", "ORGANISM", 287, 295], ["risk factors", "PROTEIN", 225, 237], ["patients", "SPECIES", 287, 295], ["ARDS", "PROBLEM", 129, 133], ["sepsis", "PROBLEM", 138, 144], ["Pathogenesis", "PROBLEM", 208, 220], ["risk factors", "PROBLEM", 225, 237], ["increased thrombosis", "PROBLEM", 329, 349], ["hypoxia", "PROBLEM", 382, 389], ["immobility", "PROBLEM", 395, 405], ["microthrombosis", "OBSERVATION", 45, 60], ["pulmonary", "ANATOMY", 91, 100], ["systemic tissue", "ANATOMY", 105, 120], ["ARDS", "OBSERVATION", 129, 133], ["sepsis", "OBSERVATION", 138, 144], ["may not necessarily be", "UNCERTAINTY", 159, 181], ["increased", "OBSERVATION_MODIFIER", 329, 338], ["thrombosis", "OBSERVATION", 339, 349], ["hypoxia", "OBSERVATION", 382, 389]]], ["Although not systematically assessed, reduced staffing coupled with isolation precautions which limit frequent position changes and mobility may further predispose patients to a prothrombotic state.Clinical manifestations of thrombosisSince the beginning of the COVID-19 pandemic, serious thrombotic complications have been reported in infected patients especially those that are critically ill [7] .", [["thrombosis", "DISEASE", 225, 235], ["thrombotic complications", "DISEASE", 289, 313], ["patients", "ORGANISM", 164, 172], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 345, 353], ["isolation precautions", "TREATMENT", 68, 89], ["frequent position changes", "PROBLEM", 102, 127], ["a prothrombotic state", "PROBLEM", 176, 197], ["thrombosis", "PROBLEM", 225, 235], ["the COVID", "TEST", 258, 267], ["serious thrombotic complications", "PROBLEM", 281, 313], ["prothrombotic", "OBSERVATION", 178, 191], ["thrombosis", "OBSERVATION", 225, 235], ["serious", "OBSERVATION_MODIFIER", 281, 288], ["thrombotic", "OBSERVATION_MODIFIER", 289, 299], ["complications", "OBSERVATION", 300, 313], ["infected", "OBSERVATION_MODIFIER", 336, 344]]], ["Lung autopsies from patients who died of COVID-19 revealed diffuse alveolar edema, thrombosis, formation of hyaline membrane resembling an ARDS like pattern [16] [17] [18] .Clinical manifestations of thrombosisThe term MicroCLOTS (microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome) secondary to microvascular pulmonary thrombosis has been termed to describe the pulmonary manifestations of the disease [19] .", [["Lung", "ANATOMY", 0, 4], ["alveolar", "ANATOMY", 67, 75], ["hyaline membrane", "ANATOMY", 108, 124], ["microvascular", "ANATOMY", 231, 244], ["lung vessels", "ANATOMY", 254, 266], ["microvascular pulmonary", "ANATOMY", 322, 345], ["pulmonary", "ANATOMY", 389, 398], ["alveolar edema", "DISEASE", 67, 81], ["thrombosis", "DISEASE", 83, 93], ["ARDS", "DISEASE", 139, 143], ["thrombosis", "DISEASE", 200, 210], ["obstructive thromboinflammatory syndrome", "DISEASE", 267, 307], ["microvascular pulmonary thrombosis", "DISEASE", 322, 356], ["COVID-19", "CHEMICAL", 41, 49], ["Lung", "ORGAN", 0, 4], ["patients", "ORGANISM", 20, 28], ["alveolar edema", "PATHOLOGICAL_FORMATION", 67, 81], ["hyaline membrane", "CELLULAR_COMPONENT", 108, 124], ["microvascular", "TISSUE", 231, 244], ["lung vessels", "MULTI-TISSUE_STRUCTURE", 254, 266], ["microvascular pulmonary", "MULTI-TISSUE_STRUCTURE", 322, 345], ["pulmonary", "ORGAN", 389, 398], ["patients", "SPECIES", 20, 28], ["Lung autopsies", "TEST", 0, 14], ["COVID", "TEST", 41, 46], ["diffuse alveolar edema", "PROBLEM", 59, 81], ["thrombosis", "PROBLEM", 83, 93], ["hyaline membrane", "PROBLEM", 108, 124], ["an ARDS like pattern", "PROBLEM", 136, 156], ["thrombosis", "PROBLEM", 200, 210], ["The term MicroCLOTS", "TEST", 210, 229], ["microvascular COVID", "TEST", 231, 250], ["lung vessels obstructive thromboinflammatory syndrome", "PROBLEM", 254, 307], ["microvascular pulmonary thrombosis", "PROBLEM", 322, 356], ["the disease", "PROBLEM", 417, 428], ["diffuse", "OBSERVATION_MODIFIER", 59, 66], ["alveolar", "ANATOMY_MODIFIER", 67, 75], ["edema", "OBSERVATION", 76, 81], ["thrombosis", "OBSERVATION", 83, 93], ["hyaline membrane", "OBSERVATION", 108, 124], ["ARDS", "OBSERVATION", 139, 143], ["thrombosis", "OBSERVATION", 200, 210], ["lung vessels", "ANATOMY", 254, 266], ["obstructive", "OBSERVATION_MODIFIER", 267, 278], ["thromboinflammatory syndrome", "OBSERVATION", 279, 307], ["microvascular", "ANATOMY_MODIFIER", 322, 335], ["pulmonary", "ANATOMY", 336, 345], ["thrombosis", "OBSERVATION", 346, 356], ["pulmonary", "ANATOMY", 389, 398], ["disease", "OBSERVATION", 421, 428]]], ["In fact, micro-thrombosis, sometimes progressing to macro-thrombosis is not only limited to the lungs, other tissue beds have also been noted to be susceptible.", [["lungs", "ANATOMY", 96, 101], ["tissue", "ANATOMY", 109, 115], ["thrombosis", "DISEASE", 15, 25], ["macro-thrombosis", "DISEASE", 52, 68], ["lungs", "ORGAN", 96, 101], ["tissue", "TISSUE", 109, 115], ["micro-thrombosis", "PROBLEM", 9, 25], ["macro-thrombosis", "PROBLEM", 52, 68], ["thrombosis", "OBSERVATION", 15, 25], ["macro-thrombosis", "OBSERVATION", 52, 68], ["not only", "UNCERTAINTY", 72, 80], ["lungs", "ANATOMY", 96, 101]]], ["Increasing reports of thrombotic events, including strokes, pulmonary embolism (PE), as well as, cutaneous and alveolar micro-thrombosis have been noted [18] .", [["pulmonary", "ANATOMY", 60, 69], ["cutaneous", "ANATOMY", 97, 106], ["alveolar", "ANATOMY", 111, 119], ["thrombotic", "DISEASE", 22, 32], ["strokes", "DISEASE", 51, 58], ["pulmonary embolism", "DISEASE", 60, 78], ["PE", "DISEASE", 80, 82], ["pulmonary", "ORGAN", 60, 69], ["thrombotic events", "PROBLEM", 22, 39], ["strokes", "PROBLEM", 51, 58], ["pulmonary embolism", "PROBLEM", 60, 78], ["PE", "PROBLEM", 80, 82], ["cutaneous and alveolar micro-thrombosis", "PROBLEM", 97, 136], ["thrombotic", "OBSERVATION", 22, 32], ["strokes", "OBSERVATION", 51, 58], ["pulmonary", "ANATOMY", 60, 69], ["embolism", "OBSERVATION", 70, 78], ["PE", "OBSERVATION", 80, 82], ["cutaneous", "ANATOMY", 97, 106], ["alveolar", "ANATOMY_MODIFIER", 111, 119]]], ["Various studies reported a wide range of thromboembolic complications including venous (PE, DVT) as well arterial thrombosis.", [["venous", "ANATOMY", 80, 86], ["arterial", "ANATOMY", 105, 113], ["thromboembolic", "DISEASE", 41, 55], ["venous (PE,", "DISEASE", 80, 91], ["DVT", "DISEASE", 92, 95], ["arterial thrombosis", "DISEASE", 105, 124], ["venous", "MULTI-TISSUE_STRUCTURE", 80, 86], ["arterial", "MULTI-TISSUE_STRUCTURE", 105, 113], ["Various studies", "TEST", 0, 15], ["thromboembolic complications", "PROBLEM", 41, 69], ["venous (PE", "PROBLEM", 80, 90], ["DVT", "PROBLEM", 92, 95], ["arterial thrombosis", "PROBLEM", 105, 124], ["thromboembolic", "OBSERVATION", 41, 55], ["venous", "ANATOMY", 80, 86], ["PE", "OBSERVATION", 88, 90], ["DVT", "OBSERVATION", 92, 95], ["arterial", "ANATOMY", 105, 113], ["thrombosis", "OBSERVATION", 114, 124]]], ["Microthrombosis in lungs noted as high as 80% in autopsy of fatal COVID -19 [20] .", [["lungs", "ANATOMY", 19, 24], ["Microthrombosis", "DISEASE", 0, 15], ["COVID", "DISEASE", 66, 71], ["COVID -19", "CHEMICAL", 66, 75], ["lungs", "ORGAN", 19, 24], ["Microthrombosis in lungs", "PROBLEM", 0, 24], ["fatal COVID", "TEST", 60, 71], ["lungs", "ANATOMY", 19, 24], ["high", "OBSERVATION_MODIFIER", 34, 38]]], ["Klok et al reported high incidence of VTE (31%) leading to complications like PE (80%), as well as arterial thrombosis (3.7%) [7] .", [["arterial", "ANATOMY", 99, 107], ["VTE", "DISEASE", 38, 41], ["PE", "DISEASE", 78, 80], ["arterial thrombosis", "DISEASE", 99, 118], ["arterial", "MULTI-TISSUE_STRUCTURE", 99, 107], ["VTE", "PROBLEM", 38, 41], ["complications", "PROBLEM", 59, 72], ["PE", "PROBLEM", 78, 80], ["arterial thrombosis", "PROBLEM", 99, 118], ["PE", "OBSERVATION", 78, 80], ["arterial", "ANATOMY", 99, 107], ["thrombosis", "OBSERVATION", 108, 118]]], ["Table 1 & 2 summarize the various thrombotic complications noted in COVID-19 patients as published as of June 6 th , 2020 obtained by a literature search on PubMed and EMBASE using combinations of the following MeSH terms: COVID-19, SARS-COV2, novel corona virus, thrombosis, thromboembolic complications, pulmonary embolism.", [["pulmonary", "ANATOMY", 306, 315], ["thrombotic complications", "DISEASE", 34, 58], ["SARS-COV2", "DISEASE", 233, 242], ["corona virus", "DISEASE", 250, 262], ["thrombosis", "DISEASE", 264, 274], ["thromboembolic", "DISEASE", 276, 290], ["pulmonary embolism", "DISEASE", 306, 324], ["patients", "ORGANISM", 77, 85], ["COVID-19", "GENE_OR_GENE_PRODUCT", 223, 231], ["corona virus", "ORGANISM", 250, 262], ["pulmonary", "ORGAN", 306, 315], ["patients", "SPECIES", 77, 85], ["the various thrombotic complications", "PROBLEM", 22, 58], ["COVID", "TEST", 223, 228], ["SARS", "PROBLEM", 233, 237], ["novel corona virus", "PROBLEM", 244, 262], ["thrombosis", "PROBLEM", 264, 274], ["thromboembolic complications", "PROBLEM", 276, 304], ["pulmonary embolism", "PROBLEM", 306, 324], ["thrombotic", "OBSERVATION_MODIFIER", 34, 44], ["complications", "OBSERVATION", 45, 58], ["corona virus", "ANATOMY", 250, 262], ["thrombosis", "OBSERVATION", 264, 274], ["thromboembolic complications", "OBSERVATION", 276, 304], ["pulmonary", "ANATOMY", 306, 315], ["embolism", "OBSERVATION", 316, 324]]], ["Table 1 illustrates the observational studies and the most common thrombotic complications noted in these studies were venous thrombosis including PEs.", [["venous", "ANATOMY", 119, 125], ["thrombotic", "DISEASE", 66, 76], ["venous thrombosis", "DISEASE", 119, 136], ["PEs", "DISEASE", 147, 150], ["venous", "MULTI-TISSUE_STRUCTURE", 119, 125], ["the observational studies", "TEST", 20, 45], ["the most common thrombotic complications", "PROBLEM", 50, 90], ["these studies", "TEST", 100, 113], ["venous thrombosis", "PROBLEM", 119, 136], ["PEs", "PROBLEM", 147, 150], ["venous", "ANATOMY", 119, 125], ["thrombosis", "OBSERVATION", 126, 136]]], ["There are also reports of arterial thrombosis including aortic graft thrombosis, mesenteric ischemia, coronary and cerebral thrombosis.", [["arterial", "ANATOMY", 26, 34], ["aortic", "ANATOMY", 56, 62], ["mesenteric", "ANATOMY", 81, 91], ["coronary", "ANATOMY", 102, 110], ["cerebral", "ANATOMY", 115, 123], ["arterial thrombosis", "DISEASE", 26, 45], ["aortic graft thrombosis", "DISEASE", 56, 79], ["mesenteric ischemia", "DISEASE", 81, 100], ["coronary and cerebral thrombosis", "DISEASE", 102, 134], ["arterial", "MULTI-TISSUE_STRUCTURE", 26, 34], ["aortic graft", "MULTI-TISSUE_STRUCTURE", 56, 68], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 81, 91], ["coronary", "MULTI-TISSUE_STRUCTURE", 102, 110], ["cerebral", "ORGAN", 115, 123], ["arterial thrombosis", "PROBLEM", 26, 45], ["aortic graft thrombosis", "PROBLEM", 56, 79], ["mesenteric ischemia", "PROBLEM", 81, 100], ["coronary and cerebral thrombosis", "PROBLEM", 102, 134], ["arterial", "ANATOMY", 26, 34], ["thrombosis", "OBSERVATION", 35, 45], ["aortic", "ANATOMY", 56, 62], ["graft thrombosis", "OBSERVATION", 63, 79], ["mesenteric", "ANATOMY", 81, 91], ["ischemia", "OBSERVATION", 92, 100], ["coronary", "ANATOMY", 102, 110], ["cerebral", "ANATOMY", 115, 123], ["thrombosis", "OBSERVATION", 124, 134]]], ["One unique finding of placental thrombosis has been reported as summarized in Table 2 which warrants further research of vertical transmission [40] .Monitoring and diagnosis of VTE in critically ill patients with COVID-19Non-survivors of COVID-19 to have significant increases in fibrinogen degradation products (FDP), ddimer levels, as well as, prolongation of prothrombin time (PT), with 71.4% meeting diagnostic criteria for DIC [4] .", [["placental", "ANATOMY", 22, 31], ["placental thrombosis", "DISEASE", 22, 42], ["VTE", "DISEASE", 177, 180], ["critically ill", "DISEASE", 184, 198], ["DIC", "DISEASE", 428, 431], ["placental", "ORGAN", 22, 31], ["patients", "ORGANISM", 199, 207], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 280, 290], ["FDP", "SIMPLE_CHEMICAL", 313, 316], ["ddimer", "SIMPLE_CHEMICAL", 319, 325], ["prothrombin", "GENE_OR_GENE_PRODUCT", 362, 373], ["fibrinogen degradation products", "PROTEIN", 280, 311], ["FDP", "PROTEIN", 313, 316], ["prothrombin", "PROTEIN", 362, 373], ["patients", "SPECIES", 199, 207], ["placental thrombosis", "PROBLEM", 22, 42], ["VTE", "PROBLEM", 177, 180], ["COVID", "TEST", 213, 218], ["COVID", "TEST", 238, 243], ["significant increases in fibrinogen degradation products", "PROBLEM", 255, 311], ["FDP), ddimer levels", "TEST", 313, 332], ["prothrombin time", "TEST", 362, 378], ["PT", "TEST", 380, 382], ["DIC", "PROBLEM", 428, 431], ["placental", "ANATOMY", 22, 31], ["thrombosis", "OBSERVATION", 32, 42], ["significant", "OBSERVATION_MODIFIER", 255, 266], ["increases", "OBSERVATION_MODIFIER", 267, 276], ["fibrinogen degradation", "OBSERVATION", 280, 302]]], ["It must however be noted that fibrinogen levels may rise initially as an acute phase reactant and such elevations may not necessarily be specific for COVID-19 [81] .", [["COVID-19", "CHEMICAL", 150, 158], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 30, 40], ["fibrinogen", "PROTEIN", 30, 40], ["fibrinogen levels", "TEST", 30, 47], ["an acute phase reactant", "PROBLEM", 70, 93], ["such elevations", "PROBLEM", 98, 113], ["COVID", "TEST", 150, 155]]], ["Reports of elevated d-dimer levels and fibrinogen are increasingly prevalent in COVID-19 affected patients; leading many institutions to routinely monitor these values.", [["d-dimer", "GENE_OR_GENE_PRODUCT", 20, 27], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 39, 49], ["patients", "ORGANISM", 98, 106], ["fibrinogen", "PROTEIN", 39, 49], ["patients", "SPECIES", 98, 106], ["elevated d-dimer levels", "PROBLEM", 11, 34], ["fibrinogen", "TEST", 39, 49], ["COVID", "TEST", 80, 85], ["these values", "TEST", 155, 167], ["elevated", "OBSERVATION", 11, 19]]], ["These elevations appear to correlate with increased levels of inflammatory markers and may be indicators for disease severity in addition to thrombotic risk [82, 83] .Monitoring and diagnosis of VTE in critically ill patients with COVID-19A high index of clinical suspicion for thrombotic phenomenon and their sequela is warranted for prompt diagnosis.", [["thrombotic", "DISEASE", 141, 151], ["VTE", "DISEASE", 195, 198], ["critically ill", "DISEASE", 202, 216], ["thrombotic phenomenon", "DISEASE", 278, 299], ["patients", "ORGANISM", 217, 225], ["inflammatory markers", "PROTEIN", 62, 82], ["patients", "SPECIES", 217, 225], ["These elevations", "PROBLEM", 0, 16], ["increased levels of inflammatory markers", "PROBLEM", 42, 82], ["disease severity", "PROBLEM", 109, 125], ["thrombotic risk", "PROBLEM", 141, 156], ["VTE", "PROBLEM", 195, 198], ["COVID", "TEST", 231, 236], ["thrombotic phenomenon", "PROBLEM", 278, 299], ["their sequela", "PROBLEM", 304, 317], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["inflammatory markers", "OBSERVATION", 62, 82], ["thrombotic", "OBSERVATION", 141, 151], ["suspicion for", "UNCERTAINTY", 264, 277], ["thrombotic", "OBSERVATION", 278, 288]]], ["Clinical signs and symptoms of thrombosis such as cutaneous manifestations (\"COVID toe\") [84] , overt line thrombosis, arterial or venous clots, unexplained increase in oxygen requirement, or organ dysfunction should raise suspicion and prompt further investigation and/or discussion about therapeutic intervention [7] As new information becomes available, it appears increasingly important to routinely monitor platelet count, PT/aPTT, d-dimer, and fibrinogen to assist in anticipating and managing thrombotic complications.", [["cutaneous", "ANATOMY", 50, 59], ["arterial", "ANATOMY", 119, 127], ["venous clots", "ANATOMY", 131, 143], ["organ", "ANATOMY", 192, 197], ["platelet", "ANATOMY", 412, 420], ["thrombosis", "DISEASE", 31, 41], ["thrombosis", "DISEASE", 107, 117], ["arterial or venous clots", "DISEASE", 119, 143], ["oxygen", "CHEMICAL", 169, 175], ["organ dysfunction", "DISEASE", 192, 209], ["thrombotic complications", "DISEASE", 500, 524], ["oxygen", "CHEMICAL", 169, 175], ["arterial", "MULTI-TISSUE_STRUCTURE", 119, 127], ["venous", "PATHOLOGICAL_FORMATION", 131, 137], ["clots", "ORGANISM_SUBSTANCE", 138, 143], ["oxygen", "SIMPLE_CHEMICAL", 169, 175], ["organ", "ORGAN", 192, 197], ["platelet", "CELL", 412, 420], ["aPTT", "GENE_OR_GENE_PRODUCT", 431, 435], ["d-dimer", "SIMPLE_CHEMICAL", 437, 444], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 450, 460], ["aPTT", "PROTEIN", 431, 435], ["d-dimer", "PROTEIN", 437, 444], ["fibrinogen", "PROTEIN", 450, 460], ["Clinical signs", "PROBLEM", 0, 14], ["symptoms", "PROBLEM", 19, 27], ["thrombosis", "PROBLEM", 31, 41], ["cutaneous manifestations", "PROBLEM", 50, 74], ["overt line thrombosis", "PROBLEM", 96, 117], ["arterial or venous clots", "PROBLEM", 119, 143], ["unexplained increase in oxygen requirement", "PROBLEM", 145, 187], ["organ dysfunction", "PROBLEM", 192, 209], ["prompt further investigation", "TEST", 237, 265], ["therapeutic intervention", "TREATMENT", 290, 314], ["platelet count", "TEST", 412, 426], ["PT/aPTT", "TEST", 428, 435], ["d-dimer", "TEST", 437, 444], ["fibrinogen", "TEST", 450, 460], ["thrombotic complications", "PROBLEM", 500, 524], ["thrombosis", "OBSERVATION", 31, 41], ["toe", "ANATOMY", 83, 86], ["line", "OBSERVATION_MODIFIER", 102, 106], ["thrombosis", "OBSERVATION", 107, 117], ["arterial", "ANATOMY", 119, 127], ["venous", "ANATOMY", 131, 137], ["clots", "OBSERVATION", 138, 143], ["increase", "OBSERVATION_MODIFIER", 157, 165], ["oxygen requirement", "OBSERVATION", 169, 187], ["thrombotic", "OBSERVATION", 500, 510]]], ["It has been reported that d-dimer levels cutoff of 1.5 \u03bcg/mL for predicting venous thromboembolic events has a sensitivity and specificity rate of 85% and 88.5% respectively and a negative predictive value of 94.7% [25] .", [["venous", "ANATOMY", 76, 82], ["venous thromboembolic", "DISEASE", 76, 97], ["d-dimer", "GENE_OR_GENE_PRODUCT", 26, 33], ["venous", "MULTI-TISSUE_STRUCTURE", 76, 82], ["d-dimer levels cutoff", "TEST", 26, 47], ["predicting venous thromboembolic events", "PROBLEM", 65, 104], ["specificity rate", "TEST", 127, 143], ["venous", "ANATOMY", 76, 82], ["thromboembolic", "OBSERVATION", 83, 97]]], ["Nonetheless, decisions for initiation of therapeutic anticoagulation should not be based solely on arbitrary d-dimer levels.Monitoring and diagnosis of VTE in critically ill patients with COVID-19Use of viscoelastrometric tests such as Rotational thromboelastometry (ROTEM) could also be used as an important monitoring tool.", [["VTE", "DISEASE", 152, 155], ["critically ill", "DISEASE", 159, 173], ["d-dimer", "GENE_OR_GENE_PRODUCT", 109, 116], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["therapeutic anticoagulation", "TREATMENT", 41, 68], ["arbitrary d-dimer levels", "TEST", 99, 123], ["VTE", "PROBLEM", 152, 155], ["COVID", "TREATMENT", 188, 193], ["viscoelastrometric tests", "TREATMENT", 203, 227], ["Rotational thromboelastometry (ROTEM)", "TREATMENT", 236, 273]]], ["Short clot formation time (CFT) on INTEM (type of ROTEM to detect Intrinsic pathway abnormality) and EXTEM (type of ROTEM to detect Extrinsic pathway abnormality) and increased maximum clot firmness (MCF) on INTEM, EXTEM, FIBTEM (type of ROTEM to detect fibrinogen abnormality) indicate hypercoagulation and potential for thrombogenesis [85] .", [["clot", "ANATOMY", 6, 10], ["clot", "ANATOMY", 185, 189], ["hypercoagulation", "DISEASE", 287, 303], ["thrombogenesis", "DISEASE", 322, 336], ["clot", "ORGANISM_SUBSTANCE", 6, 10], ["clot", "ORGANISM_SUBSTANCE", 185, 189], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 254, 264], ["fibrinogen", "PROTEIN", 254, 264], ["Short clot formation", "PROBLEM", 0, 20], ["ROTEM", "TEST", 50, 55], ["Intrinsic pathway abnormality", "PROBLEM", 66, 95], ["ROTEM", "TEST", 116, 121], ["Extrinsic pathway abnormality", "PROBLEM", 132, 161], ["increased maximum clot firmness", "PROBLEM", 167, 198], ["ROTEM", "TEST", 238, 243], ["fibrinogen abnormality", "PROBLEM", 254, 276], ["hypercoagulation", "PROBLEM", 287, 303], ["thrombogenesis", "PROBLEM", 322, 336], ["clot", "OBSERVATION", 6, 10], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["maximum", "OBSERVATION_MODIFIER", 177, 184], ["clot", "OBSERVATION", 185, 189], ["firmness", "OBSERVATION_MODIFIER", 190, 198], ["hypercoagulation", "OBSERVATION", 287, 303]]], ["Similarly, Thromboelastography (TEG) directed assessment of hypercoagulation status (short R, K and increased K angle and MA) can be predictive of thromboembolism [86] .", [["thromboembolism", "DISEASE", 147, 162], ["Thromboelastography (TEG)", "TEST", 11, 36], ["directed assessment", "TEST", 37, 56], ["hypercoagulation status", "TEST", 60, 83], ["short R", "TEST", 85, 92], ["K", "TEST", 94, 95], ["increased K angle and MA", "TREATMENT", 100, 124], ["thromboembolism", "PROBLEM", 147, 162], ["hypercoagulation", "OBSERVATION", 60, 76], ["thromboembolism", "OBSERVATION", 147, 162]]], ["Dugar and colleagues recently reported a high incidence of spontaneous echo contrast (SEC) in patients as noted on ultrasound examination of venous system while placing central line which could be precursors for venous thromboembolism (VTE).", [["venous system", "ANATOMY", 141, 154], ["central line", "ANATOMY", 169, 181], ["venous", "ANATOMY", 212, 218], ["venous thromboembolism", "DISEASE", 212, 234], ["VTE", "DISEASE", 236, 239], ["patients", "ORGANISM", 94, 102], ["venous system", "MULTI-TISSUE_STRUCTURE", 141, 154], ["venous", "MULTI-TISSUE_STRUCTURE", 212, 218], ["patients", "SPECIES", 94, 102], ["spontaneous echo contrast", "PROBLEM", 59, 84], ["ultrasound examination", "TEST", 115, 137], ["central line", "TREATMENT", 169, 181], ["venous thromboembolism", "PROBLEM", 212, 234], ["VTE", "PROBLEM", 236, 239], ["venous system", "ANATOMY", 141, 154], ["central line", "OBSERVATION", 169, 181], ["venous", "ANATOMY", 212, 218], ["thromboembolism", "OBSERVATION", 219, 234]]], ["Their findings suggest the potential role of point-of-care ultrasound (POCUS) as a surveillance tool for early detection of patients at higher risk for thrombotic events [87] .Management of anticoagulationThe optimal approach to management of anticoagulation in these patients remains unclear in absence of well conducted trials.", [["thrombotic", "DISEASE", 152, 162], ["patients", "ORGANISM", 124, 132], ["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 268, 276], ["ultrasound", "TEST", 59, 69], ["a surveillance tool", "TEST", 81, 100], ["thrombotic events", "PROBLEM", 152, 169], ["anticoagulation", "TREATMENT", 190, 205], ["management", "TREATMENT", 229, 239], ["anticoagulation", "TREATMENT", 243, 258], ["thrombotic", "OBSERVATION", 152, 162], ["anticoagulation", "OBSERVATION", 190, 205], ["anticoagulation", "OBSERVATION", 243, 258]]], ["There remains major uncertainty in the optimal management of immune-thrombosis as commonly seen in COVID-19.", [["immune-thrombosis", "DISEASE", 61, 78], ["immune-thrombosis", "PROBLEM", 61, 78], ["COVID", "TEST", 99, 104], ["major", "OBSERVATION_MODIFIER", 14, 19], ["uncertainty", "OBSERVATION", 20, 31], ["thrombosis", "OBSERVATION", 68, 78]]], ["Current strategies are heavily influenced by observational reports, case series and empirical institutional protocols.", [["empirical institutional protocols", "TREATMENT", 84, 117]]], ["In asymptomatic and mildly symptomatic patients who do not require hospital admission, ambulation should continue to be the mainstay of thromboprophylaxis.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["ambulation", "TREATMENT", 87, 97], ["thromboprophylaxis", "TREATMENT", 136, 154], ["mildly", "OBSERVATION_MODIFIER", 20, 26], ["symptomatic", "OBSERVATION_MODIFIER", 27, 38], ["thromboprophylaxis", "OBSERVATION", 136, 154]]], ["It is advisable to institute, at minimum, prophylactic anticoagulation in admitted patients without clinical contraindications [7, 88] .", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["prophylactic anticoagulation", "TREATMENT", 42, 70]]], ["Unfractionated heparin and low molecular weight heparin (LMWH) have been successfully used in these patients both prophylactically and therapeutically [89, 90] .", [["heparin", "CHEMICAL", 15, 22], ["heparin", "CHEMICAL", 48, 55], ["LMWH", "CHEMICAL", 57, 61], ["heparin", "SIMPLE_CHEMICAL", 15, 22], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 27, 55], ["LMWH", "SIMPLE_CHEMICAL", 57, 61], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["Unfractionated heparin", "TREATMENT", 0, 22], ["low molecular weight heparin (LMWH)", "TREATMENT", 27, 62]]], ["Higher doses should be considered for those with higher risk patients (eg, obese, active malignancy, prolonged immobility or recent surgery).", [["malignancy", "DISEASE", 89, 99], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["obese", "PROBLEM", 75, 80], ["active malignancy", "PROBLEM", 82, 99], ["prolonged immobility", "PROBLEM", 101, 121], ["recent surgery", "TREATMENT", 125, 139], ["active", "OBSERVATION_MODIFIER", 82, 88], ["malignancy", "OBSERVATION", 89, 99]]], ["As a caveat, it must be noted a high incidence of VTE has been noted even on patients on either prophylactic and therapeutic anticoagulation which makes routine surveillance extremely important [5, 6] .Management of anticoagulationIn addition to the usual indications such as obesity or active malignancy where higher intensity dosing of prophylactic anticoagulation may be warranted, patients with COVID-19 who demonstrate SEC on surveillance imaging may be considered for augmented dosing although high quality data to support routine use of this strategy is currently unavailable.", [["VTE", "DISEASE", 50, 53], ["obesity", "DISEASE", 276, 283], ["malignancy", "DISEASE", 294, 304], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 385, 393], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 385, 393], ["VTE", "PROBLEM", 50, 53], ["prophylactic", "TREATMENT", 96, 108], ["therapeutic anticoagulation", "TREATMENT", 113, 140], ["routine surveillance", "TEST", 153, 173], ["anticoagulation", "TREATMENT", 216, 231], ["obesity", "PROBLEM", 276, 283], ["active malignancy", "PROBLEM", 287, 304], ["prophylactic anticoagulation", "TREATMENT", 338, 366], ["COVID", "TEST", 399, 404], ["surveillance imaging", "TEST", 431, 451], ["augmented dosing", "TREATMENT", 474, 490], ["high quality data", "PROBLEM", 500, 517], ["this strategy", "TREATMENT", 544, 557], ["anticoagulation", "OBSERVATION", 216, 231], ["obesity", "OBSERVATION", 276, 283], ["active", "OBSERVATION_MODIFIER", 287, 293], ["malignancy", "OBSERVATION", 294, 304]]], ["Although some retrospective studies have demonstrated systemic anticoagulation to be associated with improved outcomes in hospitalized patients the conclusions of such observational studies should be interpreted cautiously in the context of limitations such as incomplete adjustment for confounders and specifically \"immortal time bias\" [91] .", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["some retrospective studies", "TEST", 9, 35], ["systemic anticoagulation", "TREATMENT", 54, 78], ["such observational studies", "TEST", 163, 189], ["systemic", "OBSERVATION_MODIFIER", 54, 62], ["anticoagulation", "OBSERVATION", 63, 78]]], ["As such data from small observational studies should not be used to guide institutional guidelines in the absence of robust data to suggest a favorable risk benefit profile for such strategies.", [["small observational studies", "TEST", 18, 45], ["such strategies", "TREATMENT", 177, 192]]], ["Figure 1 provides a pragmatic algorithm for the management of anticoagulation in a patient hospitalized with COVID-19 disease based on the limited available evidence.Management of anticoagulationBesides COVID-19, these patients have multiple other risk factors for development of thrombosis as described above.", [["thrombosis", "DISEASE", 280, 290], ["COVID-19", "CHEMICAL", 203, 211], ["patient", "ORGANISM", 83, 90], ["patients", "ORGANISM", 219, 227], ["patient", "SPECIES", 83, 90], ["patients", "SPECIES", 219, 227], ["a pragmatic algorithm", "TREATMENT", 18, 39], ["the management", "TREATMENT", 44, 58], ["anticoagulation", "TREATMENT", 62, 77], ["COVID-19 disease", "PROBLEM", 109, 125], ["anticoagulationBesides COVID", "TREATMENT", 180, 208], ["thrombosis", "PROBLEM", 280, 290], ["thrombosis", "OBSERVATION", 280, 290]]], ["ICU patients positive for COVID-19 with elevated d-dimer levels and/or clinico-radiological suspicion for thrombosis as noted above should be considered for therapeutic anticoagulation only after careful assessment of their bleeding risk.", [["thrombosis", "DISEASE", 106, 116], ["bleeding", "DISEASE", 224, 232], ["patients", "ORGANISM", 4, 12], ["d-dimer", "GENE_OR_GENE_PRODUCT", 49, 56], ["patients", "SPECIES", 4, 12], ["COVID", "TEST", 26, 31], ["elevated d-dimer levels", "PROBLEM", 40, 63], ["thrombosis", "PROBLEM", 106, 116], ["therapeutic anticoagulation", "TREATMENT", 157, 184], ["careful assessment", "TEST", 196, 214], ["their bleeding risk", "PROBLEM", 218, 237], ["thrombosis", "OBSERVATION", 106, 116]]], ["Choice of agent should be discussed via interdisciplinary consultation and agents selected based on availability, end organ function and administration techniques which emphasize minimization of nursing contact.", [["organ", "ANATOMY", 118, 123], ["organ", "ORGAN", 118, 123], ["agent", "TREATMENT", 10, 15], ["agents", "TREATMENT", 75, 81], ["administration techniques", "TREATMENT", 137, 162]]], ["Active surveillance for thrombosis should continue even after initiation of therapeutic anticoagulation as clot progression has been demonstrated in patients with therapeutic levels of anticoagulation.Management of anticoagulationPatients with COVID-19 who experience a major thromboembolic event such as PE without any additional risk factors should be considered to have had a \"provoked thromboembolic event\" and may need 3-6 months of anticoagulation [92] .", [["clot", "ANATOMY", 107, 111], ["thrombosis", "DISEASE", 24, 34], ["COVID-19", "CHEMICAL", 244, 252], ["thromboembolic", "DISEASE", 276, 290], ["PE", "DISEASE", 305, 307], ["thromboembolic", "DISEASE", 389, 403], ["COVID-19", "CHEMICAL", 244, 252], ["clot", "ORGANISM_SUBSTANCE", 107, 111], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["thrombosis", "PROBLEM", 24, 34], ["therapeutic anticoagulation", "TREATMENT", 76, 103], ["clot progression", "PROBLEM", 107, 123], ["anticoagulation", "TREATMENT", 185, 200], ["COVID", "TREATMENT", 244, 249], ["a major thromboembolic event", "PROBLEM", 268, 296], ["PE", "PROBLEM", 305, 307], ["any additional risk factors", "PROBLEM", 316, 343], ["a \"provoked thromboembolic event", "PROBLEM", 377, 409], ["anticoagulation", "TREATMENT", 438, 453], ["thrombosis", "OBSERVATION", 24, 34], ["clot", "OBSERVATION", 107, 111], ["major", "OBSERVATION_MODIFIER", 270, 275], ["thromboembolic", "OBSERVATION", 276, 290], ["PE", "OBSERVATION", 305, 307], ["thromboembolic", "OBSERVATION", 389, 403]]], ["Minor episodes of DVTs should continue anticoagulation therapy for 2-6 weeks post hospital discharge [93] .", [["DVTs", "DISEASE", 18, 22], ["DVTs", "PROBLEM", 18, 22], ["anticoagulation therapy", "TREATMENT", 39, 62], ["DVTs", "OBSERVATION", 18, 22]]], ["The optimal duration of anticoagulation for those with risk factors, either new or preexisting risk factors (eg atrial fibrillation) may need to be modified according to established guidelines [88] .", [["atrial", "ANATOMY", 112, 118], ["atrial fibrillation", "DISEASE", 112, 131], ["atrial", "MULTI-TISSUE_STRUCTURE", 112, 118], ["anticoagulation", "TREATMENT", 24, 39], ["risk factors", "PROBLEM", 55, 67], ["preexisting risk factors (eg atrial fibrillation", "PROBLEM", 83, 131]]], ["Long term follow up data on thrombotic risk post hospital discharger however remains unclear at this point.", [["thrombotic", "DISEASE", 28, 38]]], ["Antiviral therapies, which may be utilized in certain COVID-19 patients, are potent enzymes inhibitors and can slow down metabolism and prolong duration of action of many medications including direct oral anticoagulants so caution should be exercised regarding their concomitant dosing [88, 94] .", [["oral", "ANATOMY", 200, 204], ["patients", "ORGANISM", 63, 71], ["oral", "ORGANISM_SUBDIVISION", 200, 204], ["patients", "SPECIES", 63, 71], ["Antiviral therapies", "TREATMENT", 0, 19], ["potent enzymes inhibitors", "TREATMENT", 77, 102], ["slow down metabolism", "PROBLEM", 111, 131], ["many medications", "TREATMENT", 166, 182], ["direct oral anticoagulants", "TREATMENT", 193, 219]]], ["Patients should be comprehensively evaluated by the medical team and pharmacists to determine the most appropriate oral anticoagulant.", [["oral", "ANATOMY", 115, 119], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 115, 119], ["Patients", "SPECIES", 0, 8]]], ["Prophylactic anticoagulation should be considered in patients presenting with elevated d-dimer levels but with no suspicion or evidence of thrombosis.", [["thrombosis", "DISEASE", 139, 149], ["patients", "ORGANISM", 53, 61], ["d-dimer", "GENE_OR_GENE_PRODUCT", 87, 94], ["patients", "SPECIES", 53, 61], ["Prophylactic anticoagulation", "TREATMENT", 0, 28], ["elevated d-dimer levels", "PROBLEM", 78, 101], ["thrombosis", "PROBLEM", 139, 149], ["no suspicion", "UNCERTAINTY", 111, 123], ["evidence of", "UNCERTAINTY", 127, 138], ["thrombosis", "OBSERVATION", 139, 149]]], ["Decisions on discharge therapy should be based on hospital protocols, patient specific factors, and multidisciplinary discussions regarding the risk benefit profile of chosen strategies.Special considerationsThe management of anticoagulation in COVID-19 patients extracorporeal membrane oxygenation (ECMO), is even more challenging [95] .", [["extracorporeal membrane", "ANATOMY", 263, 286], ["patient", "ORGANISM", 70, 77], ["patients", "ORGANISM", 254, 262], ["patient", "SPECIES", 70, 77], ["patients", "SPECIES", 254, 262], ["discharge therapy", "TREATMENT", 13, 30], ["anticoagulation in COVID", "TREATMENT", 226, 250], ["extracorporeal membrane oxygenation", "TREATMENT", 263, 298]]], ["Patients with refractory respiratory failure who fail traditional rescue therapies may require veno-venous (VV) ECMO, with a smaller proportion needing veno-arterial (VA) support [95, 96] .", [["respiratory", "ANATOMY", 25, 36], ["veno-arterial", "ANATOMY", 152, 165], ["respiratory failure", "DISEASE", 25, 44], ["Patients", "ORGANISM", 0, 8], ["veno-arterial", "MULTI-TISSUE_STRUCTURE", 152, 165], ["Patients", "SPECIES", 0, 8], ["VV", "SPECIES", 108, 110], ["refractory respiratory failure", "PROBLEM", 14, 44], ["traditional rescue therapies", "TREATMENT", 54, 82], ["veno-venous (VV) ECMO", "TREATMENT", 95, 116], ["veno-arterial (VA) support", "TREATMENT", 152, 178], ["refractory", "OBSERVATION_MODIFIER", 14, 24], ["respiratory failure", "OBSERVATION", 25, 44], ["veno-arterial", "ANATOMY", 152, 165]]], ["Acquired von Willebrand disease, thrombocytopenia, and bleeding are known complications in patients on ECMO [97] [98] [99] [100] .", [["von Willebrand disease", "DISEASE", 9, 31], ["thrombocytopenia", "DISEASE", 33, 49], ["bleeding", "DISEASE", 55, 63], ["ECMO [97] [98] [99]", "CHEMICAL", 103, 122], ["Willebrand", "GENE_OR_GENE_PRODUCT", 13, 23], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Acquired von Willebrand disease", "PROBLEM", 0, 31], ["thrombocytopenia", "PROBLEM", 33, 49], ["bleeding", "PROBLEM", 55, 63], ["known complications", "PROBLEM", 68, 87], ["ECMO", "TREATMENT", 103, 107], ["Willebrand disease", "OBSERVATION", 13, 31], ["thrombocytopenia", "OBSERVATION", 33, 49], ["bleeding", "OBSERVATION", 55, 63]]], ["Studies have described the use of VV ECMO without anticoagulation to reduce bleeding risks, however, the artificial contact surface of ECMO circuit itself causes continuous activation of coagulation, creating a prothrombotic environment [101, 102] .", [["surface", "ANATOMY", 124, 131], ["bleeding", "DISEASE", 76, 84], ["VV", "ORGANISM", 34, 36], ["VV", "SPECIES", 34, 36], ["VV ECMO", "TREATMENT", 34, 41], ["anticoagulation", "TREATMENT", 50, 65], ["bleeding risks", "PROBLEM", 76, 90], ["the artificial contact surface of ECMO circuit", "TREATMENT", 101, 147], ["continuous activation of coagulation", "PROBLEM", 162, 198], ["a prothrombotic environment", "PROBLEM", 209, 236], ["ECMO circuit", "OBSERVATION", 135, 147]]], ["The thrombotic risk is further accentuated in the presence of uninhibited COVID-19 diseases.", [["thrombotic", "DISEASE", 4, 14], ["The thrombotic risk", "PROBLEM", 0, 19], ["uninhibited COVID-19 diseases", "PROBLEM", 62, 91], ["thrombotic", "OBSERVATION", 4, 14]]], ["Management of COVID-19 patients on ECMO is a balance between need for anticoagulation and risk of bleeding and therefore warrants close multidisciplinary discussions of risk benefit profile.", [["COVID", "DISEASE", 14, 19], ["bleeding", "DISEASE", 98, 106], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["COVID", "TEST", 14, 19], ["ECMO", "TREATMENT", 35, 39], ["anticoagulation", "TREATMENT", 70, 85], ["bleeding", "PROBLEM", 98, 106], ["bleeding", "OBSERVATION", 98, 106]]], ["A phase 2 clinical trial is currently underway to assess the efficacy of tPA (tissue plasminogen activator) as salvage therapy for severe ARDS patients (NCT04357730).", [["ARDS", "DISEASE", 138, 142], ["tPA", "GENE_OR_GENE_PRODUCT", 73, 76], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 78, 106], ["patients", "ORGANISM", 143, 151], ["tPA", "PROTEIN", 73, 76], ["patients", "SPECIES", 143, 151], ["tPA (tissue plasminogen activator", "TREATMENT", 73, 106], ["salvage therapy", "TREATMENT", 111, 126], ["severe ARDS patients", "PROBLEM", 131, 151], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["ARDS", "OBSERVATION", 138, 142]]], ["The consistent demonstration of fibrin in the airspaces and lung parenchyma, along with fibrin-platelet microthrombi in the pulmonary vasculature suggests that plasminogen activators may have a role to limit ARDS progression and reduce ARDS-induced mortality.", [["airspaces", "ANATOMY", 46, 55], ["lung parenchyma", "ANATOMY", 60, 75], ["platelet", "ANATOMY", 95, 103], ["pulmonary vasculature", "ANATOMY", 124, 145], ["ARDS", "DISEASE", 208, 212], ["ARDS", "DISEASE", 236, 240], ["fibrin", "GENE_OR_GENE_PRODUCT", 32, 38], ["airspaces", "MULTI-TISSUE_STRUCTURE", 46, 55], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 60, 75], ["fibrin", "GENE_OR_GENE_PRODUCT", 88, 94], ["platelet", "CELL", 95, 103], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 124, 145], ["plasminogen", "GENE_OR_GENE_PRODUCT", 160, 171], ["fibrin", "PROTEIN", 32, 38], ["fibrin", "PROTEIN", 88, 94], ["fibrin in the airspaces and lung parenchyma", "PROBLEM", 32, 75], ["fibrin-platelet microthrombi in the pulmonary vasculature", "PROBLEM", 88, 145], ["plasminogen activators", "PROBLEM", 160, 182], ["ARDS progression", "PROBLEM", 208, 224], ["ARDS", "PROBLEM", 236, 240], ["consistent demonstration of", "UNCERTAINTY", 4, 31], ["fibrin", "OBSERVATION", 32, 38], ["airspaces", "ANATOMY_MODIFIER", 46, 55], ["lung", "ANATOMY", 60, 64], ["parenchyma", "ANATOMY_MODIFIER", 65, 75], ["fibrin", "OBSERVATION", 88, 94], ["platelet microthrombi", "OBSERVATION", 95, 116], ["pulmonary vasculature", "ANATOMY", 124, 145], ["plasminogen activators", "OBSERVATION", 160, 182]]], ["Currently, the routine use of tPA for salvage in severe ARDS patients is not recommended outside clinical trials until safety and efficacy of this treatment strategy is clearly established.Special considerationsPregnant patients with COVID-19 are at higher risk of thrombotic complications.", [["ARDS", "DISEASE", 56, 60], ["thrombotic complications", "DISEASE", 265, 289], ["tPA", "GENE_OR_GENE_PRODUCT", 30, 33], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 220, 228], ["tPA", "PROTEIN", 30, 33], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 220, 228], ["tPA", "TREATMENT", 30, 33], ["salvage", "TREATMENT", 38, 45], ["severe ARDS", "PROBLEM", 49, 60], ["this treatment strategy", "TREATMENT", 142, 165], ["COVID", "TEST", 234, 239], ["thrombotic complications", "PROBLEM", 265, 289], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["ARDS", "OBSERVATION", 56, 60], ["thrombotic", "OBSERVATION_MODIFIER", 265, 275], ["complications", "OBSERVATION", 276, 289]]], ["Despite being mostly healthy and young, there are reports of pregnant patients with COVID-19 disease requiring intensive care admissions and being critically ill [103] .", [["COVID-19 disease", "DISEASE", 84, 100], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["COVID-19 disease", "PROBLEM", 84, 100]]], ["With immunocompromised status and physiological adaptive changes during pregnancy, pregnant women could be more susceptible to COVID-19 infection than the general population [104] .", [["infection", "DISEASE", 136, 145], ["women", "ORGANISM", 92, 97], ["COVID-19", "ORGANISM", 127, 135], ["women", "SPECIES", 92, 97], ["immunocompromised status", "PROBLEM", 5, 29], ["physiological adaptive changes", "PROBLEM", 34, 64], ["COVID-19 infection", "PROBLEM", 127, 145], ["immunocompromised", "OBSERVATION", 5, 22], ["infection", "OBSERVATION", 136, 145]]], ["The thrombogenic risk of COVID-19 is further exacerbated by pregnancy which by itself is a hypercoagulable condition [105] .", [["COVID-19", "CHEMICAL", 25, 33], ["COVID-19", "CHEMICAL", 25, 33], ["COVID-19", "GENE_OR_GENE_PRODUCT", 25, 33], ["COVID", "TEST", 25, 30], ["pregnancy", "PROBLEM", 60, 69], ["a hypercoagulable condition", "PROBLEM", 89, 116], ["thrombogenic", "OBSERVATION_MODIFIER", 4, 16]]], ["Such association of COVID-19 with pregnancy in terms of increasing thromboembolic risk warrants extra caution and requires a multidisciplinary approach to managing anticoagulation in these patients [88] .ConclusionSystemic thrombosis is frequently associated with critically ill COVID-19 patients and may lead to fatal outcomes if not diagnosed and managed appropriately.", [["thromboembolic", "DISEASE", 67, 81], ["ConclusionSystemic thrombosis", "DISEASE", 204, 233], ["COVID-19", "GENE_OR_GENE_PRODUCT", 20, 28], ["patients", "ORGANISM", 189, 197], ["patients", "ORGANISM", 288, 296], ["COVID", "PROTEIN", 20, 25], ["patients", "SPECIES", 189, 197], ["patients", "SPECIES", 288, 296], ["COVID", "TEST", 20, 25], ["pregnancy", "PROBLEM", 34, 43], ["increasing thromboembolic risk", "PROBLEM", 56, 86], ["extra caution", "TREATMENT", 96, 109], ["a multidisciplinary approach", "TREATMENT", 123, 151], ["anticoagulation", "TREATMENT", 164, 179], ["ConclusionSystemic thrombosis", "PROBLEM", 204, 233], ["increasing", "OBSERVATION_MODIFIER", 56, 66], ["thromboembolic", "OBSERVATION", 67, 81], ["thrombosis", "OBSERVATION", 223, 233]]], ["Thrombotic risk commonly persists despite initiation of anticoagulation.", [["Thrombotic", "DISEASE", 0, 10], ["Thrombotic risk", "PROBLEM", 0, 15], ["anticoagulation", "TREATMENT", 56, 71]]], ["Until more information is available, providers should consider prophylactic versus therapeutic anticoagulation based on a combination of patient specific criteria including laboratory results, imaging [88] , clinical suspicion and careful balance of thrombotic and bleeding risks.", [["thrombotic", "DISEASE", 250, 260], ["bleeding", "DISEASE", 265, 273], ["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["prophylactic versus therapeutic anticoagulation", "TREATMENT", 63, 110], ["imaging", "TEST", 193, 200], ["clinical suspicion", "TEST", 208, 226], ["thrombotic and bleeding risks", "PROBLEM", 250, 279], ["thrombotic", "OBSERVATION", 250, 260]]], ["Routine active surveillance guided by clinical and/or radiological assessment is recommended to either pre-empt or aid prompt diagnosis of macrothrombotic events which may be beneficial in guiding anticoagulation strategies.", [["radiological assessment", "TEST", 54, 77], ["macrothrombotic events", "PROBLEM", 139, 161], ["anticoagulation strategies", "TREATMENT", 197, 223]]], ["Larger, well designed prospective studies are urgently needed to further elucidate optimal management strategies to mitigate the thrombotic risks associated with COVID-19.AcknowledgementThe authors would like to acknowledge Dr Megan L Krajewski, MD for critical review and suggestions.AcknowledgementAuthors' contributions SB, SM: Conceptualization, design, interpretation of data, drafting of manuscript and revising for critically important intellectual content.", [["thrombotic", "DISEASE", 129, 139], ["COVID-19", "CHEMICAL", 162, 170], ["COVID-19", "CHEMICAL", 162, 170], ["prospective studies", "TEST", 22, 41], ["optimal management strategies", "TREATMENT", 83, 112], ["the thrombotic risks", "PROBLEM", 125, 145], ["COVID", "TEST", 162, 167], ["critically important intellectual content", "PROBLEM", 422, 463], ["thrombotic", "OBSERVATION", 129, 139]]], ["(SB received research support from NIH/Department of Defense unrelated to this project) Received: 30 June 2020 Accepted: 12 August 2020", [["research support", "TREATMENT", 13, 29]]]], "PMC7304790": [["Inpatients with COVID-19 need psychological first-aidThe sudden outbreak of COVID-19 (a highly infectious disease with about a 6% mortality rate), as well as the substantial shortage of local healthcare providers, personal protective equipment (PPE) and resuscitation devices, has led many to experience panic.1 2 At the end of January 2020, people in Wuhan flooded to the hospitals for diagnosis and treatment, waited in long lines for a hospital bed, witnessed sudden death and suffered from the illness itself.", [["COVID", "DISEASE", 76, 81], ["panic", "DISEASE", 304, 309], ["death", "DISEASE", 470, 475], ["illness", "DISEASE", 498, 505], ["people", "ORGANISM", 342, 348], ["people", "SPECIES", 342, 348], ["COVID", "TREATMENT", 16, 21], ["COVID", "TEST", 76, 81], ["a highly infectious disease", "PROBLEM", 86, 113], ["a 6% mortality rate", "TREATMENT", 125, 144], ["resuscitation devices", "TREATMENT", 254, 275], ["panic", "PROBLEM", 304, 309], ["treatment", "TREATMENT", 401, 410], ["witnessed sudden death", "PROBLEM", 453, 475], ["the illness itself", "PROBLEM", 494, 512]]], ["A study in China found that in the first 2 months of 2020, patients with COVID-19 widely suffered from anxiety, depression and other stress-related symptoms.3 Studies have shown that psychological reactions due to catastrophic events have adverse effects on physical recovery.4 Early psychological intervention through face-to-face care and support can help rebuild trust and self-confidence, reduce physical and mental symptoms and prevent post traumatic stress disorder (PTSD).5 The WHO suggested that psychological first-aid should be provided to those who were impacted when a disaster occurred, as well as in the days or weeks following the disaster, with particular focus on groups that need more attention, including those who lack social support and who are severely affected and in poor health condition.6Difficulties in providing regular psychological first-aidCompared with the usual settings for psychological intervention, we faced the following difficulties in providing psychological first-aid to inpatients in this disaster.", [["anxiety", "DISEASE", 103, 110], ["depression", "DISEASE", 112, 122], ["traumatic stress disorder", "DISEASE", 446, 471], ["PTSD", "DISEASE", 473, 477], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["A study", "TEST", 0, 7], ["COVID", "TEST", 73, 78], ["anxiety", "PROBLEM", 103, 110], ["depression", "PROBLEM", 112, 122], ["other stress-related symptoms", "PROBLEM", 127, 156], ["Studies", "TEST", 159, 166], ["psychological reactions", "PROBLEM", 183, 206], ["catastrophic events", "PROBLEM", 214, 233], ["Early psychological intervention", "TREATMENT", 278, 310], ["physical and mental symptoms", "PROBLEM", 400, 428], ["post traumatic stress disorder", "PROBLEM", 441, 471], ["severely affected", "PROBLEM", 766, 783], ["psychological intervention", "TREATMENT", 908, 934]]], ["First, there was a considerable imbalance between the very limited number of psychological healthcare workers and the widespread, emergent needs of the inpatients.", [["a considerable imbalance", "PROBLEM", 17, 41], ["considerable", "OBSERVATION_MODIFIER", 19, 31], ["imbalance", "OBSERVATION", 32, 41]]], ["In contrast, stress-related and trauma-related symptoms were common to inpatients.3 This discrepancy between clinical demands and limited resources calls for a highly efficient solution.Difficulties in providing regular psychological first-aidSecond, the psychological difficulties of patients changed rapidly, requiring interventions to adapt to their needs in a timely fashion.", [["trauma", "DISEASE", 32, 38], ["patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 285, 293], ["trauma", "PROBLEM", 32, 38], ["related symptoms", "PROBLEM", 39, 55], ["This discrepancy between clinical demands", "PROBLEM", 84, 125], ["a highly efficient solution", "TREATMENT", 158, 185], ["interventions", "TREATMENT", 321, 334]]], ["At the early stage of the pandemic, most of the psychological distress came from the considerable insufficiency of healthcare resources and panic in the community.", [["panic", "DISEASE", 140, 145], ["the psychological distress", "PROBLEM", 44, 70], ["panic", "PROBLEM", 140, 145], ["early stage", "OBSERVATION_MODIFIER", 7, 18], ["considerable", "OBSERVATION_MODIFIER", 85, 97], ["insufficiency", "OBSERVATION", 98, 111]]], ["Many patients had experienced the panic wave of rushing to hospitals and waiting for hospitalisation at the end of January; most patients had family members who were infected and some patients had witnessed or heard of the sudden deaths of their family members due to the infection.", [["panic", "DISEASE", 34, 39], ["deaths", "DISEASE", 230, 236], ["infection", "DISEASE", 272, 281], ["patients", "ORGANISM", 5, 13], ["patients", "ORGANISM", 129, 137], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 129, 137], ["patients", "SPECIES", 184, 192], ["the panic wave", "PROBLEM", 30, 44], ["the infection", "PROBLEM", 268, 281], ["infection", "OBSERVATION", 272, 281]]], ["Later on, the major stressors changed to uncertainties in the treatment and recovery processes.", [["the treatment", "TREATMENT", 58, 71]]], ["Some patients worried they would be kept in the hospital for a very long period due to their infection or even afraid of being thrown away by society, and some were exhausted by the constantly updating test standards.", [["infection", "DISEASE", 93, 102], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["their infection", "PROBLEM", 87, 102], ["infection", "OBSERVATION", 93, 102]]], ["As a result, most of the patients who filled out our questionnaires reported stress symptoms, such as increased vigilance, depression, anxiety, irritability, flashbacks and nightmares, feelings of being discriminated against, or rejected, and loneliness.", [["depression", "DISEASE", 123, 133], ["anxiety", "DISEASE", 135, 142], ["irritability", "DISEASE", 144, 156], ["flashbacks", "DISEASE", 158, 168], ["loneliness", "DISEASE", 243, 253], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["stress symptoms", "PROBLEM", 77, 92], ["increased vigilance", "PROBLEM", 102, 121], ["depression", "PROBLEM", 123, 133], ["anxiety", "PROBLEM", 135, 142], ["irritability", "PROBLEM", 144, 156], ["flashbacks", "PROBLEM", 158, 168], ["nightmares", "PROBLEM", 173, 183]]], ["These symptoms fluctuated periodically due to ever changing stressors and aggravated the patients' chest distress, palpitations, and other physical symptoms.", [["chest", "ANATOMY", 99, 104], ["chest distress", "DISEASE", 99, 113], ["palpitations", "DISEASE", 115, 127], ["patients", "ORGANISM", 89, 97], ["chest", "ORGANISM_SUBDIVISION", 99, 104], ["patients", "SPECIES", 89, 97], ["These symptoms", "PROBLEM", 0, 14], ["the patients' chest distress", "PROBLEM", 85, 113], ["palpitations", "PROBLEM", 115, 127], ["other physical symptoms", "PROBLEM", 133, 156], ["chest", "ANATOMY", 99, 104]]], ["These dynamic changes and the considerable individual variability have challenged the traditional intervention approaches.Difficulties in providing regular psychological first-aidThird, the closed-ward environment has impacted the effectiveness of psychological interventions and limited the application of face-to-face psychological interventions.", [["These dynamic changes", "PROBLEM", 0, 21], ["psychological interventions", "TREATMENT", 248, 275], ["face", "TREATMENT", 307, 311], ["psychological interventions", "TREATMENT", 320, 347], ["dynamic", "OBSERVATION", 6, 13], ["considerable", "OBSERVATION_MODIFIER", 30, 42], ["individual", "OBSERVATION_MODIFIER", 43, 53], ["variability", "OBSERVATION_MODIFIER", 54, 65]]], ["The design of the infectious disease hospital emphasised biomedical safety and fast-construction (The Leishenshan Hospital had 2000 beds and was built in 10 days), at the cost of comfortableness.", [["infectious disease", "DISEASE", 18, 36], ["infectious", "OBSERVATION_MODIFIER", 18, 28]]], ["In the closed ward with white board walls and various ventilation pipes on the roof, patients may feel they were in the temporary plank house on a construction site.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["white board walls", "TREATMENT", 24, 41], ["various ventilation pipes", "TREATMENT", 46, 71], ["ventilation pipes", "OBSERVATION", 54, 71]]], ["This environment could induce depression and uneasiness in patients.", [["depression", "DISEASE", 30, 40], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["depression", "PROBLEM", 30, 40], ["uneasiness", "PROBLEM", 45, 55]]], ["Further, the closed wards make it difficult for face-to-face communication with the patients.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92]]], ["Wearing air-tight PPE with protective glasses, one would have to bear pressure on the lips and foggy glasses when talking.Difficulties in providing regular psychological first-aidTaken together, the above factors have substantially limited the application and effectiveness of the traditional face-to-face psychological diagnosis and interventions.", [["lips", "ANATOMY", 86, 90], ["lips", "ORGANISM_SUBDIVISION", 86, 90], ["air-tight PPE", "TREATMENT", 8, 21], ["protective glasses", "TREATMENT", 27, 45], ["interventions", "TREATMENT", 334, 347], ["lips", "ANATOMY", 86, 90]]], ["It is essential to develop a highly efficient psychological first-aid scheme that can provide full coverage for patients\u2019 psychological difficulties.Development of an onsite-online psychological first-aid modelA potential solution to overcome the shortage of onsite psychological health workers and facilitate communication with patients is a web-based psychological intervention.", [["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 329, 337], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 329, 337], ["patients\u2019 psychological difficulties", "PROBLEM", 112, 148], ["psychological intervention", "TREATMENT", 353, 379]]], ["First, in only using an online intervention, mental health workers outside Hubei Province were unlikely to understand the specific experience and related stress symptoms of patients with COVID-19 as opposed to more conventional mental symptoms.", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["an online intervention", "TREATMENT", 21, 43], ["stress symptoms", "PROBLEM", 154, 169], ["COVID", "TEST", 187, 192], ["more conventional mental symptoms", "PROBLEM", 210, 243]]], ["Furthermore, the communications only through online chat were not effective in establishing trust, which is critical for effective intervention, especially in or after disaster.", [["effective intervention", "TREATMENT", 121, 143]]], ["Therefore, a combination of onsite and online methods is necessary to elaborate the advantages of both online and face-to-face psychological intervention.Development of an onsite-online psychological first-aid modelFigure 1 presents a scheme of our integrated onsite-online psychological intervention model.", [["online methods", "TREATMENT", 39, 53], ["psychological intervention", "TREATMENT", 127, 153]]], ["A rapid assessment, sorting and treatment process was developed by integrating online and offline methods.", [["A rapid assessment", "TEST", 0, 18], ["treatment process", "TREATMENT", 32, 49]]], ["The psychiatrist went into the ward and briefly communicated with each patient to establish initial trust and categorised the patients into different conditions for appropriate interventions.", [["patient", "ORGANISM", 71, 78], ["patients", "ORGANISM", 126, 134], ["patient", "SPECIES", 71, 78], ["patients", "SPECIES", 126, 134], ["appropriate interventions", "TREATMENT", 165, 190]]], ["The information regarding the conditions of the patients was transferred to the online team.Development of an onsite-online psychological first-aid modelWe invited the patients to join online chat groups using their smartphones.", [["patients", "ORGANISM", 48, 56], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 168, 176]]], ["The groups were provided with psychoeducation, as well as simple methods based on cognitive behavioural therapy techniques and social support.", [["psychoeducation", "TREATMENT", 30, 45], ["simple methods", "TREATMENT", 58, 72], ["cognitive behavioural therapy techniques", "TREATMENT", 82, 122], ["social support", "TREATMENT", 127, 141]]], ["Discussions were led regarding what stress and trauma reactions or symptoms are, how to overcome the feelings of fear, helplessness, guilt, how to cope with symptoms and how to deal with the feelings of being discriminated.", [["trauma", "DISEASE", 47, 53], ["helplessness", "DISEASE", 119, 131], ["trauma reactions", "PROBLEM", 47, 63], ["symptoms", "PROBLEM", 67, 75], ["helplessness", "PROBLEM", 119, 131], ["symptoms", "PROBLEM", 157, 165]]], ["We also provided information to the patients on rehabilitation, emotional regulation and sleep.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["rehabilitation", "TREATMENT", 48, 62], ["emotional regulation", "TREATMENT", 64, 84]]], ["Another critical role of the online chat group was that we identified individuals who needed further individualised interventions.", [["further individualised interventions", "TREATMENT", 93, 129]]], ["In addition, the onsite psychiatrist\u2019s weekly follow-up rounds provided necessary onsite help for some difficult cases and maintained the effectiveness of the online consultation for other patients.Development of an onsite-online psychological first-aid modelWe also provided educational online talks and learning materials to other medical staff working at the same site.", [["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["some difficult cases", "PROBLEM", 98, 118]]], ["The information helped the medical staff to identify stress-related symptoms in their daily communications with the patients, so that they could refer patients to the onsite psychiatrist for further diagnosis and intervention.Essential factors in the model and practical recommendationsThe heart of this psychological first-aid model is the integration and coordination of onsite and online mental health resources.", [["heart", "ANATOMY", 290, 295], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 151, 159], ["heart", "ORGAN", 290, 295], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 151, 159], ["stress-related symptoms", "PROBLEM", 53, 76], ["intervention", "TREATMENT", 213, 225], ["heart", "ANATOMY", 290, 295]]], ["While face-to-face evaluation and intervention are critical for effective online support, the online team effectively extended the scope of the psychological first-aid to all patients.Essential factors in the model and practical recommendationsEstablishing the initial trust with the patients in the first brief contact is an essential point to ensure the effectiveness of the online intervention.", [["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 284, 292], ["face evaluation", "TEST", 14, 29], ["intervention", "TREATMENT", 34, 46], ["effective online support", "TREATMENT", 64, 88], ["the online intervention", "TREATMENT", 373, 396]]], ["We found that a high frequency of online individual psychocounselling, at least three sessions per week, at the beginning were usually required for patients who need it.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["high", "OBSERVATION_MODIFIER", 16, 20]]], ["We found that establishing the initial trust with the patients in the first brief contact is essential to make the online consultation effective.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62]]], ["For more accessible communication in a closed ward, the onsite psychiatrist wrote her name and department on the protective gown to let the patients know her quickly by reading the text besides oral self-introduction.", [["oral", "ANATOMY", 194, 198], ["patients", "ORGANISM", 140, 148], ["oral", "ORGANISM_SUBDIVISION", 194, 198], ["patients", "SPECIES", 140, 148]]], ["It is important for patients who have poor identification and orientation due to anxiety to build relationship and trust quickly.", [["anxiety", "DISEASE", 81, 88], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["anxiety", "PROBLEM", 81, 88]]], ["How is your appetite?\u2019, the onsite psychiatrist could perform the initial evaluation and sort patients with different mental conditions without irritating patients (figure 1).", [["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 155, 163], ["the initial evaluation", "TEST", 62, 84], ["different mental conditions", "PROBLEM", 108, 135]]], ["For patients who had lost a family member(s), depressive patients who had negative thoughts or passive behaviors or patients who tended to meltdown due to severe anxiety, an offline session could often lead to a significant improvement.Essential factors in the model and practical recommendationsThe efficient communication and understanding between the onsite psychiatrist and the online team is another essential factor in the model.", [["depressive", "DISEASE", 46, 56], ["meltdown", "DISEASE", 139, 147], ["anxiety", "DISEASE", 162, 169], ["patients", "ORGANISM", 4, 12], ["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 4, 12], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 116, 124], ["severe anxiety", "PROBLEM", 155, 169], ["significant", "OBSERVATION_MODIFIER", 212, 223], ["improvement", "OBSERVATION", 224, 235]]], ["With the ward rounds, the onsite psychiatrist got the first-hand information of the conditions of the patients and timely transferred a summary table to the online team.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110]]], ["During shift meetings, the onsite psychiatrist and the online team worked through each patient\u2019s case to discuss the symptoms and potential intervention strategies for the patient.", [["patient", "ORGANISM", 87, 94], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 87, 94], ["patient", "SPECIES", 172, 179], ["the symptoms", "PROBLEM", 113, 125], ["potential intervention strategies", "TREATMENT", 130, 163]]], ["These shift meetings ensured the alignment of the onsite and online teams to provide precise and effective interventions to all patients.Voices from the inpatientsThe self-reports from the patients support the effectiveness of this model.", [["patients", "ORGANISM", 128, 136], ["inpatients", "ORGANISM", 153, 163], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 128, 136], ["patients", "SPECIES", 189, 197], ["precise and effective interventions", "TREATMENT", 85, 120], ["this model", "TREATMENT", 227, 237]]], ["Many patients have proactively written thank-you letters to the psychiatrist to express their improvements.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["They commented: \u2018Not only was my body treated but also the heart\u2019; \u2018In my most difficult time, I was pulled up by a psychiatrist; thus, I did not fall into the black hole due to the disease and fear\u2019 and \u2018When I first came here, I felt very nervous, feeling increased chest distress and palpitations.", [["body", "ANATOMY", 33, 37], ["heart", "ANATOMY", 59, 64], ["nervous", "ANATOMY", 241, 248], ["chest", "ANATOMY", 268, 273], ["heart\u2019", "DISEASE", 59, 65], ["chest distress", "DISEASE", 268, 282], ["palpitations", "DISEASE", 287, 299], ["body", "ORGANISM_SUBDIVISION", 33, 37], ["heart", "ORGAN", 59, 64], ["nervous", "ANATOMICAL_SYSTEM", 241, 248], ["chest", "ORGANISM_SUBDIVISION", 268, 273], ["the disease", "PROBLEM", 178, 189], ["very nervous", "PROBLEM", 236, 248], ["increased chest distress", "PROBLEM", 258, 282], ["palpitations", "PROBLEM", 287, 299], ["heart", "ANATOMY", 59, 64], ["disease", "OBSERVATION", 182, 189], ["chest", "ANATOMY", 268, 273]]], ["It was the first time for me to feel the spirit is the primary weapon of recovery against the backdrop of this disaster.\u2019Voices from the inpatientsIn one case, the patient lost his father in the outbreak, and his infected mother, who was also in quarantine, was unaware of her husband's death.", [["death", "DISEASE", 287, 292], ["inpatients", "ORGANISM", 137, 147], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171]]], ["The patient had moderate depressive symptoms according to the questionnaire, but he was very passive in expressing himself during the first contact and following online counselling.", [["depressive symptoms", "DISEASE", 25, 44], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["moderate depressive symptoms", "PROBLEM", 16, 44], ["moderate", "OBSERVATION_MODIFIER", 16, 24], ["depressive", "OBSERVATION", 25, 35]]], ["In the second week of offline consultation, the patient burst into tears and talked about his sorrow and worry.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["tears", "PROBLEM", 67, 72]]], ["After that, his online interactions became active, and his symptoms improved.", [["his symptoms", "PROBLEM", 55, 67]]], ["Our practice shows that, in the case of insufficient professional staff on site, the programme we created was suitable for the psychological assistance of socially isolated patients during the sudden outbreak of this highly infectious disease.ImplicationsMany countries have reached a consensus on the goal and significance of psychological assistance for large-scale disasters, and that the implementation needs to be more flexible according to the characteristics of the disasters and accessibility of medical resources.", [["infectious disease", "DISEASE", 224, 242], ["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["this highly infectious disease", "PROBLEM", 212, 242], ["psychological assistance", "TREATMENT", 327, 351], ["medical resources", "TREATMENT", 504, 521], ["infectious", "OBSERVATION", 224, 234]]], ["The outbreak of the COVID-19 pandemic is a severe challenge to resources related to psychological services and routine diagnosis and treatment in various countries.", [["COVID-19", "SPECIES", 20, 28], ["the COVID", "TREATMENT", 16, 25], ["psychological services", "TREATMENT", 84, 106], ["routine diagnosis", "TEST", 111, 128], ["treatment", "TREATMENT", 133, 142]]], ["We feel that this combination of onsite and online approaches can achieve more efficient psychological interventions for promoting rehabilitation, facilitating psychological adaptation and preventing PTSD.", [["PTSD", "DISEASE", 200, 204], ["psychological interventions", "TREATMENT", 89, 116], ["promoting rehabilitation", "TREATMENT", 121, 145], ["psychological adaptation", "TREATMENT", 160, 184], ["PTSD", "PROBLEM", 200, 204]]], ["We believe it could be adopted and adapted further all over the world in a similar dangerous disaster situation which lacks onsite mental health workers, and also in the areas, countries or cultures where mental healthcare is underdeveloped and resources are scarce.", [["cultures", "TEST", 190, 198]]]], "PMC7250784": [["IntroductionAn epidemic is any sudden outburst of a disease within a given population and a pandemic (originating from Greek word pan meaning \u201call\u201d and demos meaning \"people\u201d) is an epidemic that spreads across regions, which could be countries, continents, or the entire world.1 Pandemics have a devastating effect on the morbidity and mortality causing huge public health concern along with economic, social, and political disruption for country.", [["people", "SPECIES", 167, 173], ["a disease", "PROBLEM", 50, 59], ["a pandemic", "PROBLEM", 90, 100], ["disease", "OBSERVATION", 52, 59], ["devastating", "OBSERVATION_MODIFIER", 297, 308], ["huge", "OBSERVATION_MODIFIER", 355, 359]]], ["Throughout history, mankind has witnessed many pandemics including plague, influenza pandemic (Spanish flu), and 2009H1N1 and many more.", [["plague", "DISEASE", 67, 73], ["influenza pandemic", "DISEASE", 75, 93], ["2009H1N1", "SPECIES", 113, 121], ["plague", "PROBLEM", 67, 73], ["influenza", "PROBLEM", 75, 84]]], ["Recently, on 30 Jan 2020, the World Health Organization (WHO) declared a global public health emergency for coronavirus (COVID-19) and subsequently on 11 March 2020, COVID-19 was declared as a pandemic.2 The infectious disease which started with a mysterious pneumonia in 41 patients connected to Huanan seafood market in China on 3 December 2019 had within its grips 1,956,457 cases and 123,481 deaths worldwide till 13 April 2020.", [["coronavirus", "DISEASE", 108, 119], ["infectious disease", "DISEASE", 208, 226], ["pneumonia", "DISEASE", 259, 268], ["deaths", "DISEASE", 396, 402], ["coronavirus", "ORGANISM", 108, 119], ["patients", "ORGANISM", 275, 283], ["patients", "SPECIES", 275, 283], ["coronavirus", "PROBLEM", 108, 119], ["COVID", "TEST", 121, 126], ["COVID", "TEST", 166, 171], ["The infectious disease", "PROBLEM", 204, 226], ["a mysterious pneumonia", "PROBLEM", 246, 268], ["infectious", "OBSERVATION", 208, 218], ["pneumonia", "OBSERVATION", 259, 268]]], ["COVID-19 affected 210 countries around the world along with two international conveyances.", [["COVID", "TEST", 0, 5]]], ["As of 13 April 2020, India had a total of 10,941 positive cases with 368 deaths.3,4", [["deaths", "DISEASE", 73, 79], ["3,4", "CHEMICAL", 80, 83]]]], "PMC7089296": [["IntroductionThe discovery of the smallpox vaccine by Edward Jenner more than 200 years ago was the defining event for the development of vaccinology.", [["the smallpox vaccine", "TREATMENT", 29, 49]]], ["Jenner found that immunisation with a less virulent, but antigenic related, Cowpox Virus protected against the more virulent Smallpox Virus.", [["Cowpox Virus", "ORGANISM", 76, 88], ["Smallpox Virus", "ORGANISM", 125, 139], ["Smallpox Virus", "SPECIES", 125, 139], ["a less virulent", "PROBLEM", 36, 51], ["Cowpox Virus", "PROBLEM", 76, 88], ["the more virulent Smallpox Virus", "PROBLEM", 107, 139], ["less virulent", "OBSERVATION_MODIFIER", 38, 51], ["Smallpox Virus", "OBSERVATION", 125, 139]]], ["The world-wide eradication of smallpox, together with the remarkable reductions in other important infectious diseases of humans such as polio, diphtheria, tetanus, pertussis, measles and mumps underlined the feasibility and utility of vaccination and its economic benefits for the prevention, control and finally the extirpation of infectious diseases (Andre 2003).", [["smallpox", "DISEASE", 30, 38], ["polio, diphtheria, tetanus, pertussis", "DISEASE", 137, 174], ["measles", "DISEASE", 176, 183], ["mumps", "DISEASE", 188, 193], ["infectious diseases", "DISEASE", 333, 352], ["humans", "ORGANISM", 122, 128], ["diphtheria", "ORGANISM", 144, 154], ["tetanus", "ORGANISM", 156, 163], ["humans", "SPECIES", 122, 128], ["humans", "SPECIES", 122, 128], ["smallpox", "TREATMENT", 30, 38], ["polio", "PROBLEM", 137, 142], ["diphtheria", "PROBLEM", 144, 154], ["tetanus", "PROBLEM", 156, 163], ["pertussis", "PROBLEM", 165, 174], ["measles", "PROBLEM", 176, 183], ["mumps", "PROBLEM", 188, 193], ["vaccination", "TREATMENT", 236, 247], ["infectious diseases", "PROBLEM", 333, 352], ["remarkable", "OBSERVATION_MODIFIER", 58, 68], ["reductions", "OBSERVATION_MODIFIER", 69, 79], ["important", "OBSERVATION_MODIFIER", 89, 98], ["infectious", "OBSERVATION", 99, 109]]], ["In veterinary medicine, vaccinology addresses a wider spectrum of challenges.", [["a wider spectrum of challenges", "TREATMENT", 46, 76]]], ["These include the development of cost effective approaches to prevent and control infectious animal diseases, considering animal welfare and focusing on decreasing production costs of animals used as food (Shams 2005).", [["infectious animal diseases", "DISEASE", 82, 108], ["cost effective approaches", "TREATMENT", 33, 58], ["control infectious animal diseases", "PROBLEM", 74, 108], ["infectious", "OBSERVATION_MODIFIER", 82, 92]]], ["In addition, mass vaccination programmes have helped to significantly lower the consumption of veterinary drugs, including antibiotics.", [["mass vaccination programmes", "TREATMENT", 13, 40], ["veterinary drugs", "TREATMENT", 95, 111], ["antibiotics", "TREATMENT", 123, 134], ["mass", "OBSERVATION", 13, 17]]], ["Vaccines also led to reduced negative environmental impacts by eliminating chemical residues in products such as milk, eggs and meat.", [["milk", "ANATOMY", 113, 117], ["eggs", "ANATOMY", 119, 123], ["meat", "ANATOMY", 128, 132], ["milk", "ORGANISM_SUBSTANCE", 113, 117], ["eggs", "ORGANISM_SUBDIVISION", 119, 123], ["meat", "ORGANISM_SUBDIVISION", 128, 132], ["milk", "SPECIES", 113, 117], ["Vaccines", "TREATMENT", 0, 8], ["chemical residues in products", "TREATMENT", 75, 104], ["reduced", "OBSERVATION_MODIFIER", 21, 28], ["negative", "OBSERVATION_MODIFIER", 29, 37], ["environmental impacts", "OBSERVATION", 38, 59], ["chemical residues", "OBSERVATION", 75, 92]]], ["Production losses caused by illnesses can be avoided.IntroductionIn 1890 Emil Behring and Shibasaburo Kitasato developed the principle of serum therapy.", [["serum", "ANATOMY", 138, 143], ["serum", "ORGANISM_SUBSTANCE", 138, 143], ["Production losses", "PROBLEM", 0, 17], ["illnesses", "PROBLEM", 28, 37], ["Shibasaburo Kitasato", "TREATMENT", 90, 110], ["serum therapy", "TREATMENT", 138, 151]]], ["They found that immunity against diphtheria and tetanus toxins resulted from the presence of substances in blood, they called antibodies.", [["blood", "ANATOMY", 107, 112], ["diphtheria", "DISEASE", 33, 43], ["tetanus", "DISEASE", 48, 55], ["diphtheria", "ORGANISM", 33, 43], ["tetanus toxins", "ORGANISM", 48, 62], ["blood", "ORGANISM_SUBSTANCE", 107, 112], ["antibodies", "PROTEIN", 126, 136], ["diphtheria", "PROBLEM", 33, 43], ["tetanus toxins", "PROBLEM", 48, 62], ["substances in blood", "PROBLEM", 93, 112]]], ["Behring and Kitasato were also able to transfer immunity to immunologically na\u00efve animals by using the serum of animals treated with non-lethal doses of a crude toxin preparation (Behring and Kitasato 1890).", [["serum", "ANATOMY", 103, 108], ["Behring", "ORGANISM_SUBSTANCE", 0, 7], ["animals", "ORGANISM", 82, 89], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["a crude toxin preparation", "TREATMENT", 153, 178]]], ["In these early pioneering days Paul Ehrlich discovered that antibodies could act as \u201cmagic bullets\u201d to target cancer cells (Ehrlich 1900).", [["cancer cells", "ANATOMY", 110, 122], ["cancer", "DISEASE", 110, 116], ["Ehrlich", "CANCER", 36, 43], ["cancer cells", "CELL", 110, 122], ["Ehrlich 1900", "CELL", 124, 136], ["antibodies", "PROTEIN", 60, 70], ["cancer cells", "CELL_TYPE", 110, 122], ["Ehrlich 1900", "CELL_LINE", 124, 136], ["target cancer cells", "PROBLEM", 103, 122], ["early", "OBSERVATION_MODIFIER", 9, 14]]], ["Later on, protein sequences and structures of antibodies as well structures and sequences of the genes coding for them were elucidated.", [["antibodies", "PROTEIN", 46, 56], ["protein sequences", "TEST", 10, 27]]], ["The use of mouse hybridomas generated from stable fusions of immortalised myeloma cells with B cells of immunised mice provided highly specific monoclonal antibodies that could be used in therapy (Kohler and Milstein 1975).", [["hybridomas", "ANATOMY", 17, 27], ["myeloma cells", "ANATOMY", 74, 87], ["B cells", "ANATOMY", 93, 100], ["myeloma", "DISEASE", 74, 81], ["mouse", "ORGANISM", 11, 16], ["hybridomas", "CELL", 17, 27], ["myeloma cells", "CELL", 74, 87], ["B cells", "CELL", 93, 100], ["mice", "ORGANISM", 114, 118], ["mouse hybridomas", "CELL_LINE", 11, 27], ["immortalised myeloma cells", "CELL_LINE", 61, 87], ["B cells", "CELL_TYPE", 93, 100], ["monoclonal antibodies", "PROTEIN", 144, 165], ["mouse", "SPECIES", 11, 16], ["mice", "SPECIES", 114, 118], ["mouse", "SPECIES", 11, 16], ["mice", "SPECIES", 114, 118], ["mouse hybridomas", "TREATMENT", 11, 27], ["immortalised myeloma cells", "PROBLEM", 61, 87], ["B cells of immunised mice", "TREATMENT", 93, 118], ["highly specific monoclonal antibodies", "PROBLEM", 128, 165], ["stable", "OBSERVATION_MODIFIER", 43, 49], ["immortalised myeloma cells", "OBSERVATION", 61, 87]]], ["Mouse antibodies initially used in human therapy did not interact well enough with different receptor types resulting in inefficient effector functions and rather short terminal half-lives.", [["Mouse", "ORGANISM", 0, 5], ["human", "ORGANISM", 35, 40], ["Mouse antibodies", "PROTEIN", 0, 16], ["Mouse", "SPECIES", 0, 5], ["human", "SPECIES", 35, 40], ["Mouse", "SPECIES", 0, 5], ["human", "SPECIES", 35, 40], ["Mouse antibodies", "TREATMENT", 0, 16], ["human therapy", "TREATMENT", 35, 48], ["inefficient effector functions", "PROBLEM", 121, 151]]], ["Furthermore, the mouse antibodies were found to induce severe immune responses in humans (for rev. see Carter 2006).", [["mouse", "ORGANISM", 17, 22], ["humans", "ORGANISM", 82, 88], ["mouse antibodies", "PROTEIN", 17, 33], ["mouse", "SPECIES", 17, 22], ["humans", "SPECIES", 82, 88], ["mouse", "SPECIES", 17, 22], ["humans", "SPECIES", 82, 88], ["the mouse antibodies", "TEST", 13, 33]]], ["The development of innovative recombinant DNA technologies, including chimeras and humanisation of mouse antibody molecules, greatly enhanced the clinical efficiency and safety of murine-derived monoclonal antibodies.", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["mouse", "ORGANISM", 99, 104], ["murine", "ORGANISM", 180, 186], ["mouse antibody molecules", "PROTEIN", 99, 123], ["murine-derived monoclonal antibodies", "PROTEIN", 180, 216], ["mouse", "SPECIES", 99, 104], ["murine", "SPECIES", 180, 186], ["mouse", "SPECIES", 99, 104], ["innovative recombinant DNA technologies", "TREATMENT", 19, 58], ["chimeras", "PROBLEM", 70, 78], ["mouse antibody molecules", "PROBLEM", 99, 123]]], ["For almost 15 years, phage display has been used for the selection of specific antigen-binders from artificial libraries of single chain antibodies.", [["single chain antibodies", "PROTEIN", 124, 147], ["specific antigen-binders", "TREATMENT", 70, 94], ["artificial libraries", "TREATMENT", 100, 120], ["single chain antibodies", "PROBLEM", 124, 147]]], ["Filamentous phages have been developed that carry the genetic information to express foreign proteins on their surface.", [["surface", "ANATOMY", 111, 118], ["surface", "CELLULAR_COMPONENT", 111, 118], ["foreign proteins", "PROTEIN", 85, 101], ["foreign proteins", "OBSERVATION", 85, 101]]], ["This assures the coupling of phenotype and genotype during phage amplification and affinity selection.", [["phenotype", "PROBLEM", 29, 38], ["genotype during phage amplification", "TREATMENT", 43, 78], ["affinity selection", "TREATMENT", 83, 101]]], ["The ability to generate large antibody libraries, and the simplified antibody-backbone of a single chain antibody, has made antibody-phage display a powerful tool for the development of new therapeutic agents (for rev. see Hoogenboom et al. 1998; Kontermann and Duebel 2001; Winter et al. 1994).", [["single chain antibody", "PROTEIN", 92, 113], ["large antibody libraries", "PROBLEM", 24, 48], ["the simplified antibody", "TEST", 54, 77], ["a single chain antibody", "TEST", 90, 113], ["antibody", "TEST", 124, 132], ["new therapeutic agents", "TREATMENT", 186, 208], ["large", "OBSERVATION_MODIFIER", 24, 29], ["antibody libraries", "OBSERVATION", 30, 48]]], ["In parallel, new and evolving molecular strategies are helping to enhance affinity, stability and expression levels (Boder et al. 2000; Hanes et al. 2000; for rev. see Kurtzman et al. 2001; Low et al. 1996).", [["expression levels", "TEST", 98, 115], ["parallel", "OBSERVATION_MODIFIER", 3, 11], ["new", "OBSERVATION_MODIFIER", 13, 16], ["molecular strategies", "OBSERVATION", 30, 50]]], ["The high cost of antibody production in mammalian systems has limited the wider use of antibody therapeutics (Scott 2005).", [["antibody production in mammalian systems", "PROBLEM", 17, 57], ["antibody therapeutics", "TREATMENT", 87, 108], ["high", "OBSERVATION_MODIFIER", 4, 8], ["cost", "OBSERVATION_MODIFIER", 9, 13], ["antibody production", "OBSERVATION", 17, 36]]], ["These problems are essentially important for the application of antibody therapeutics in veterinary medicine.", [["antibody therapeutics", "TREATMENT", 64, 85], ["veterinary medicine", "TREATMENT", 89, 108]]], ["Production shortfalls and high costs are providing the impetus for further development of alternative antibody production technologies (Chadd and Chamow 2001; Fischer et al. 2004; Kipriyanov and Le Gall 2004).", [["Production shortfalls", "PROBLEM", 0, 21], ["high costs", "PROBLEM", 26, 36], ["alternative antibody production technologies", "TREATMENT", 90, 134], ["high costs", "OBSERVATION", 26, 36], ["Le", "ANATOMY_MODIFIER", 195, 197], ["Gall", "ANATOMY", 198, 202]]], ["Infectious diseases are on the rise world-wide.", [["Infectious diseases", "DISEASE", 0, 19]]], ["It is estimated that 58% of the 1,407 recognised species of human pathogens are zoonotic, i.e. infect more than one host.", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["human pathogens", "PROBLEM", 60, 75], ["zoonotic", "PROBLEM", 80, 88], ["58%", "OBSERVATION_MODIFIER", 21, 24]]], ["Zoonotic pathogens represent the most likely source of emerging and re-emerging infectious diseases (Woolhouse and Gowtage-Sequeria 2005).", [["infectious diseases", "DISEASE", 80, 99], ["Zoonotic pathogens", "PROBLEM", 0, 18], ["re-emerging infectious diseases", "PROBLEM", 68, 99], ["most likely", "UNCERTAINTY", 33, 44]]], ["Thus, providing solutions for the well-being of animals also impacts human health.", [["human", "ORGANISM", 69, 74], ["human", "SPECIES", 69, 74], ["human", "SPECIES", 69, 74]]], ["The worldwide and dramatic increase of resistances against antibiotics, and the possible presence of residues in meat, milk, eggs and in the environment, has spurred the development of alternative products for the treatment of infectious diseases.", [["meat", "ANATOMY", 113, 117], ["milk", "ANATOMY", 119, 123], ["eggs", "ANATOMY", 125, 129], ["infectious diseases", "DISEASE", 227, 246], ["meat", "ORGANISM_SUBDIVISION", 113, 117], ["milk", "ORGANISM_SUBSTANCE", 119, 123], ["milk", "SPECIES", 119, 123], ["antibiotics", "TREATMENT", 59, 70], ["alternative products", "TREATMENT", 185, 205], ["infectious diseases", "PROBLEM", 227, 246], ["dramatic", "OBSERVATION_MODIFIER", 18, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["residues", "OBSERVATION", 101, 109], ["infectious", "OBSERVATION", 227, 237]]], ["Attempts are especially being made to reduce the quantities of antibiotics used for prophylaxis and growth promotional effects in animals.", [["antibiotics", "TREATMENT", 63, 74], ["prophylaxis", "TREATMENT", 84, 95]]], ["Active vaccination using live virulent or attenuated vaccines is widely used, but has its drawbacks in terms of low levels of immunogenicity, high production cost, antigenic variability between species and possible transfer of genetic material to wild-type strains.", [["Active vaccination", "TREATMENT", 0, 18], ["live virulent", "TREATMENT", 25, 38], ["attenuated vaccines", "TREATMENT", 42, 61], ["low levels of immunogenicity", "PROBLEM", 112, 140], ["high production cost", "PROBLEM", 142, 162], ["antigenic variability between species", "PROBLEM", 164, 201], ["genetic material", "PROBLEM", 227, 243], ["type strains", "PROBLEM", 252, 264], ["low levels", "OBSERVATION_MODIFIER", 112, 122]]], ["Vaccination is also not a feasible option for mammals post-weaning as well as in animals such as broilers, which have a short life-span.", [["broilers", "ORGANISM", 97, 105], ["broilers", "SPECIES", 97, 105], ["Vaccination", "TREATMENT", 0, 11], ["mammals post-weaning", "TREATMENT", 46, 66]]], ["The production of vaccines for veterinary use also needs low cost systems combined with inexpensive application strategies.", [["vaccines", "TREATMENT", 18, 26], ["low cost systems", "TREATMENT", 57, 73], ["inexpensive application strategies", "TREATMENT", 88, 122]]], ["An ideal expression system for recombinant antibodies and antigens should therefore be amenable to genetic modification, inherently safe and economical.", [["recombinant antibodies", "PROTEIN", 31, 53], ["antigens", "PROTEIN", 58, 66], ["recombinant antibodies", "TREATMENT", 31, 53], ["genetic modification", "TREATMENT", 99, 119]]], ["It should provide functional proteins of either high antibody affinity and/or neutralisation or vaccination capacity (Fischer and Schillberg 2004).", [["high antibody affinity", "PROBLEM", 48, 70], ["neutralisation", "PROBLEM", 78, 92], ["vaccination capacity", "TEST", 96, 116]]], ["Systems for the production of antigens and antibodies in transgenic plants have been under development during the last 15 years (for rev. see Giddings et al. 2000; Hood et al. 2002; Koprowski 2005; Ma et al. 2003, 2005b; Stoger et al. 2005a; Streatfield 2005b; Streatfield and Howard 2003; Warzecha and Mason 2003).", [["transgenic plants", "ORGANISM", 57, 74], ["antigens", "PROTEIN", 30, 38], ["antibodies", "PROTEIN", 43, 53], ["the production of antigens", "PROBLEM", 12, 38], ["antibodies in transgenic plants", "PROBLEM", 43, 74]]], ["Plants offer general advantages in terms of production scale and economy, product safety, and ease of storage and distribution (Ma et al. 2005a).", [["general advantages", "TREATMENT", 13, 31], ["production scale", "TREATMENT", 44, 60]]], ["Here we focus on the production of vaccines and therapeutic antibodies in transgenic plants for veterinary applications.", [["therapeutic antibodies", "PROTEIN", 48, 70], ["vaccines", "TREATMENT", 35, 43], ["therapeutic antibodies", "TREATMENT", 48, 70], ["veterinary applications", "TREATMENT", 96, 119]]], ["Recent developments of plantibody and plantigen applications in veterinary medicine are summarised.", [["plantibody and plantigen applications", "TREATMENT", 23, 60], ["veterinary medicine", "TREATMENT", 64, 83]]], ["We discuss advantages and disadvantages of different plant expression systems for veterinary applications, also considering economic issues.Plant-derived vaccines for veterinary purposesThe development and improvement of vaccines are suitable ways to combat infectious diseases in wild and also in domesticated animals.", [["infectious diseases", "DISEASE", 258, 277], ["different plant expression systems", "TREATMENT", 43, 77], ["veterinary applications", "TREATMENT", 82, 105], ["economic issues", "PROBLEM", 124, 139], ["Plant-derived vaccines", "TREATMENT", 140, 162], ["veterinary purposes", "TEST", 167, 186], ["vaccines", "TREATMENT", 221, 229], ["infectious diseases", "PROBLEM", 258, 277], ["improvement", "OBSERVATION_MODIFIER", 206, 217]]], ["Current strategies use intact or inactivated pathogen strains to induce immunity, as well as subunit vaccines, which are commercially produced in bacteria, yeast or mammalian cell cultures.", [["cell cultures", "ANATOMY", 175, 188], ["yeast", "CELL", 156, 161], ["mammalian cell cultures", "CELL", 165, 188], ["yeast or mammalian cell cultures", "CELL_LINE", 156, 188], ["yeast", "SPECIES", 156, 161], ["yeast", "SPECIES", 156, 161], ["inactivated pathogen strains", "PROBLEM", 33, 61], ["subunit vaccines", "TREATMENT", 93, 109], ["bacteria", "PROBLEM", 146, 154], ["yeast", "PROBLEM", 156, 161], ["mammalian cell cultures", "TEST", 165, 188], ["mammalian cell cultures", "OBSERVATION", 165, 188]]], ["In a key patent of 1990 Curtiss and Cardineau described the expression of the Streptococcus mutans surface protein antigen A (SpaA) in transgenic tobacco plants (Curtiss and Cardineau 1990).", [["Streptococcus mutans surface protein antigen A", "GENE_OR_GENE_PRODUCT", 78, 124], ["SpaA", "GENE_OR_GENE_PRODUCT", 126, 130], ["tobacco", "ORGANISM", 146, 153], ["Streptococcus mutans surface protein antigen A", "PROTEIN", 78, 124], ["SpaA", "PROTEIN", 126, 130], ["Streptococcus mutans", "SPECIES", 78, 98], ["tobacco", "SPECIES", 146, 153], ["Streptococcus mutans", "SPECIES", 78, 98], ["tobacco", "SPECIES", 146, 153], ["the Streptococcus mutans", "TEST", 74, 98], ["patent", "OBSERVATION", 9, 15], ["tobacco plants", "OBSERVATION", 146, 160]]], ["Subsequent to this key event Mason and co-workers succeeded in expressing the hepatitis B surface antigen in tobacco (Mason et al. 1992), and in 1993 Usha and co-workers expressed a peptide representing an epitope of the VP1 envelope protein of the Foot-and-Mouth-Disease Virus (FMDV) on the surface of a plant virus particle (Usha et al. 1993).", [["surface", "ANATOMY", 292, 299], ["hepatitis B surface antigen", "CHEMICAL", 78, 105], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 78, 105], ["tobacco", "ORGANISM", 109, 116], ["Foot-and-Mouth-Disease Virus", "ORGANISM", 249, 277], ["FMDV", "ORGANISM", 279, 283], ["surface", "CELLULAR_COMPONENT", 292, 299], ["hepatitis B surface antigen", "PROTEIN", 78, 105], ["VP1 envelope protein", "PROTEIN", 221, 241], ["tobacco", "SPECIES", 109, 116], ["FMDV", "SPECIES", 279, 283], ["tobacco", "SPECIES", 109, 116], ["FMDV", "SPECIES", 279, 283], ["the VP1 envelope protein", "TEST", 217, 241], ["Mouth-Disease Virus", "PROBLEM", 258, 277], ["a plant virus particle", "TREATMENT", 303, 325], ["hepatitis", "OBSERVATION", 78, 87], ["Foot", "ANATOMY", 249, 253], ["Mouth", "ANATOMY", 258, 263], ["Disease", "OBSERVATION", 264, 271], ["plant virus", "OBSERVATION", 305, 316]]], ["Following this pioneering work various veterinary candidate vaccines have been produced using engineered plant viruses and transgenic plants.", [["veterinary candidate vaccines", "TREATMENT", 39, 68], ["engineered plant viruses", "TREATMENT", 94, 118], ["transgenic plants", "TREATMENT", 123, 140], ["plant viruses", "OBSERVATION", 105, 118]]], ["The overview presented here reflects the current situation on plant-based vaccines with a focus on veterinary applications.", [["plant-based vaccines", "TREATMENT", 62, 82], ["veterinary applications", "TREATMENT", 99, 122]]], ["Summaries of plant-based vaccines for both, veterinary as well as human medicine, were published in 2003 (Streatfield and Howard 2003) and 2006 (Joensuu 2006).", [["human", "ORGANISM", 66, 71], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["plant-based vaccines", "TREATMENT", 13, 33]]], ["One major prerequisite for vaccine production in planta is the development of fast, reliable and safe systems for the generation of transgenic plants.", [["vaccine production", "TREATMENT", 27, 45], ["transgenic plants", "TREATMENT", 132, 149]]], ["Since the first report of the successful transformation of plant cells (Fraley et al. 1983), various plant expression systems have been established for molecular farming (for rev. see Fischer and Schillberg 2004; Stoger et al. 2005a, b).", [["cells", "ANATOMY", 65, 70], ["plant cells", "CELL", 59, 70], ["plant cells", "CELL_TYPE", 59, 70], ["plant cells", "PROBLEM", 59, 70], ["various plant expression systems", "TREATMENT", 93, 125], ["plant cells", "OBSERVATION", 59, 70]]], ["Four different methods are now generally used for the production of recombinant proteins (Horn et al. 2004): Generation of stable nuclear transgenic plants, transplastomic plants, transient expression using a plant virus and transient expression via Agrobacterium infiltration.", [["recombinant proteins", "PROTEIN", 68, 88], ["Four different methods", "TREATMENT", 0, 22], ["transplastomic plants", "TREATMENT", 157, 178], ["a plant virus", "TREATMENT", 207, 220], ["Agrobacterium infiltration", "PROBLEM", 250, 276], ["stable", "OBSERVATION_MODIFIER", 123, 129], ["transgenic plants", "OBSERVATION", 138, 155], ["Agrobacterium infiltration", "OBSERVATION", 250, 276]]], ["The production of plants which release the vaccine into a hydroponic medium, as a component of the root exudates, is another possibility, but such production systems are impractical due to the high dilution of the vaccines and the technical facilities required for plant cultivation.", [["root exudates", "ANATOMY", 99, 112], ["root exudates", "TISSUE", 99, 112], ["a hydroponic medium", "PROBLEM", 56, 75], ["the root exudates", "PROBLEM", 95, 112], ["such production systems", "PROBLEM", 142, 165], ["the vaccines", "TREATMENT", 210, 222], ["plant cultivation", "TREATMENT", 265, 282], ["hydroponic medium", "OBSERVATION_MODIFIER", 58, 75], ["root", "ANATOMY", 99, 103], ["exudates", "OBSERVATION", 104, 112], ["another possibility", "UNCERTAINTY", 117, 136]]], ["Model plants such as Arabidopsis thaliana (Table 1, 15, 28, 51, 52, 65) and tobacco (Table 1, 10, 12, 22\u201324, 29, 31, 44, 45, 48, 54, 56) are strong candidates for initial studies to generate stable transgenic plants expressing proteins of interest.", [["Arabidopsis thaliana", "ORGANISM", 21, 41], ["tobacco", "ORGANISM", 76, 83], ["Arabidopsis thaliana", "SPECIES", 21, 41], ["tobacco", "SPECIES", 76, 83], ["Arabidopsis thaliana", "SPECIES", 21, 41], ["tobacco", "SPECIES", 76, 83], ["initial studies", "TEST", 163, 178]]], ["Species with edible leaves, e.g. lettuce (Table 1, 8, 59, 62), alfalfa (Table 1, 4, 5, 8, 11, 36, 47, 62, 64), white clover (Table 1, 63); tubers/fruits, e.g. potato (Table 1, 13, 14, 25, 27, 35, 37, 38, 50, 61), tomato (Table 1, 34, 42, 51) or grains, e.g. maize (Table 1, 18, 26, 58) and barley (Table 1, 46) have also been used for the production of veterinary vaccines.", [["leaves", "ANATOMY", 20, 26], ["fruits", "ANATOMY", 146, 152], ["leaves", "ORGANISM_SUBDIVISION", 20, 26], ["clover", "ORGANISM_SUBDIVISION", 117, 123], ["tubers", "ORGANISM_SUBDIVISION", 139, 145], ["fruits", "ORGANISM_SUBDIVISION", 146, 152], ["tomato", "ORGANISM", 213, 219], ["lettuce", "SPECIES", 33, 40], ["alfalfa", "SPECIES", 63, 70], ["tubers", "SPECIES", 139, 145], ["fruits", "SPECIES", 146, 152], ["potato", "SPECIES", 159, 165], ["tomato", "SPECIES", 213, 219], ["maize", "SPECIES", 258, 263], ["barley", "SPECIES", 290, 296], ["lettuce", "SPECIES", 33, 40], ["alfalfa", "SPECIES", 63, 70], ["white clover", "SPECIES", 111, 123], ["potato", "SPECIES", 159, 165], ["tomato", "SPECIES", 213, 219], ["maize", "SPECIES", 258, 263], ["barley", "SPECIES", 290, 296], ["alfalfa (Table", "TEST", 63, 77], ["white clover", "TEST", 111, 123], ["tubers/fruits", "TEST", 139, 152], ["tomato", "TEST", 213, 219], ["barley (Table", "TEST", 290, 303], ["veterinary vaccines", "TREATMENT", 353, 372], ["edible leaves", "OBSERVATION", 13, 26]]], ["Oral delivery offers ease of application and, via the induction of mucosal immunity, protection against pathogens interacting with host mucosal surfaces (for rev. see Streatfield 2005a).", [["Oral", "ANATOMY", 0, 4], ["mucosal", "ANATOMY", 67, 74], ["mucosal", "ANATOMY", 136, 143], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["mucosal", "MULTI-TISSUE_STRUCTURE", 67, 74], ["mucosal surfaces", "MULTI-TISSUE_STRUCTURE", 136, 152], ["Oral delivery", "TREATMENT", 0, 13], ["mucosal immunity", "TREATMENT", 67, 83], ["pathogens", "PROBLEM", 104, 113]]], ["In contrast, the immunisation of animals via injection predominantly results in a systemic immune response.", [["animals", "ORGANISM", 33, 40], ["the immunisation of animals via injection", "TREATMENT", 13, 54]]], ["Transient expression methods using plant viruses have been established and this yields in high levels of protein accumulation in the host plants by the rapid amplification of an infectious plant viral genome (Table 1, 1, 3, 9, 10, 17, 19, 39, 40, 60).", [["infectious plant viral genome", "DNA", 178, 207], ["Transient expression methods", "PROBLEM", 0, 28], ["plant viruses", "PROBLEM", 35, 48], ["protein accumulation", "PROBLEM", 105, 125], ["an infectious plant viral genome", "PROBLEM", 175, 207], ["protein accumulation", "OBSERVATION", 105, 125], ["infectious", "OBSERVATION_MODIFIER", 178, 188], ["viral genome", "OBSERVATION", 195, 207]]], ["In these reports antigenic peptides were fused to the coding sequence of the viral coat protein to obtain virus-like particles which present the desired peptide.", [["viral coat protein", "PROTEIN", 77, 95], ["antigenic peptides", "PROBLEM", 17, 35], ["the viral coat protein", "TEST", 73, 95], ["virus-like particles", "PROBLEM", 106, 126], ["viral coat protein", "OBSERVATION", 77, 95]]], ["The resulting virions can easily be purified by centrifugation.", [["virions", "ANATOMY", 14, 21], ["The resulting virions", "TREATMENT", 0, 21], ["virions", "OBSERVATION", 14, 21]]], ["Transplastomic plants were developed to improve accumulation of recombinant proteins, as shown for the antigenic peptide 2L21 from the VP2 capsid protein of Canine Parvovirus (CPV).", [["Canine Parvovirus", "DISEASE", 157, 174], ["VP2 capsid", "ORGANISM", 135, 145], ["Canine Parvovirus", "ORGANISM", 157, 174], ["CPV", "ORGANISM", 176, 179], ["recombinant proteins", "PROTEIN", 64, 84], ["VP2 capsid protein", "PROTEIN", 135, 153], ["Canine Parvovirus", "SPECIES", 157, 174], ["Canine Parvovirus", "SPECIES", 157, 174], ["CPV", "SPECIES", 176, 179], ["Transplastomic plants", "TREATMENT", 0, 21], ["accumulation of recombinant proteins", "PROBLEM", 48, 84], ["the antigenic peptide", "TEST", 99, 120]]], ["This peptide has been expressed as an N-terminal translational fusion with the GUS protein in nuclear-transformed Arabidopsis plants at a rather low level (Gil et al. 2001).", [["nuclear", "ANATOMY", 94, 101], ["N", "CHEMICAL", 38, 39], ["GUS", "GENE_OR_GENE_PRODUCT", 79, 82], ["nuclear", "CELLULAR_COMPONENT", 94, 101], ["N-terminal translational fusion", "PROTEIN", 38, 69], ["GUS protein", "PROTEIN", 79, 90], ["an N-terminal translational fusion", "TREATMENT", 35, 69], ["the GUS protein", "TEST", 75, 90], ["transformed Arabidopsis plants", "PROBLEM", 102, 132], ["Arabidopsis plants", "OBSERVATION", 114, 132]]], ["The 2L21 peptide was then fused to GFP or the cholera toxin B subunit, and accumulated in tobacco chloroplasts to a significantly higher level compared with stable transformants (Table 1, 6).", [["chloroplasts", "ANATOMY", 98, 110], ["transformants", "ANATOMY", 164, 177], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["cholera toxin B subunit", "GENE_OR_GENE_PRODUCT", 46, 69], ["tobacco", "ORGANISM", 90, 97], ["transformants", "CELL", 164, 177], ["GFP", "PROTEIN", 35, 38], ["cholera toxin B subunit", "PROTEIN", 46, 69], ["tobacco", "SPECIES", 90, 97], ["The 2L21 peptide", "TREATMENT", 0, 16], ["the cholera toxin B subunit", "TREATMENT", 42, 69], ["tobacco chloroplasts", "OBSERVATION", 90, 110], ["stable", "OBSERVATION_MODIFIER", 157, 163]]], ["Further examples of successful production in transplastomic plants are the heat-labile toxin B subunit (Table 1, 53, 55), a candidate vaccine against enterotoxigenic Escherichia coli (ETEC), and a protective antigen for Bacillus anthracis (Table 1, 41\u201343).", [["enterotoxigenic Escherichia coli", "DISEASE", 150, 182], ["toxin B subunit", "GENE_OR_GENE_PRODUCT", 87, 102], ["enterotoxigenic Escherichia coli", "ORGANISM", 150, 182], ["ETEC", "ORGANISM", 184, 188], ["Bacillus anthracis", "ORGANISM", 220, 238], ["Escherichia coli", "SPECIES", 166, 182], ["Bacillus anthracis", "SPECIES", 220, 238], ["Escherichia coli", "SPECIES", 166, 182], ["ETEC", "SPECIES", 184, 188], ["Bacillus anthracis", "SPECIES", 220, 238], ["successful production in transplastomic plants", "TREATMENT", 20, 66], ["the heat", "TEST", 71, 79], ["a candidate vaccine", "TREATMENT", 122, 141], ["enterotoxigenic Escherichia coli", "PROBLEM", 150, 182], ["a protective antigen", "TEST", 195, 215], ["Bacillus anthracis", "PROBLEM", 220, 238], ["successful", "OBSERVATION_MODIFIER", 20, 30], ["production", "OBSERVATION_MODIFIER", 31, 41]]], ["The advantages of chloroplast transformation have been reviewed (Daniell et al. 2002; Maliga 2002, 2003).", [["chloroplast", "ANATOMY", 18, 29], ["chloroplast", "CELLULAR_COMPONENT", 18, 29], ["chloroplast transformation", "TREATMENT", 18, 44], ["chloroplast transformation", "OBSERVATION", 18, 44]]]], "1fd2c71fc0e5f434d2c9b699f2e1f1e36128934f": [["INTRODUCTIONThe amount of parenchymal involvement in patients with interstitial pneumonia Covid-19 related seems to be associated with a worse prognosis (1) .INTRODUCTIONNowadays 3D reconstruction imaging is expanding its role in clinical medicine (2) (3) (4) (5) .INTRODUCTIONWe describe the use of 3D lung reconstruction of a young lady affected by Covid-19 infection and interstitial pneumonia, to quantitatively assess the lung parenchyma involved.INTRODUCTIONIn March, 2020, a 15-year-old girl was admitted to our Emergency Department, with a 7-day history of fever and anosmia.", [["parenchymal", "ANATOMY", 26, 37], ["interstitial", "ANATOMY", 67, 79], ["lung", "ANATOMY", 303, 307], ["interstitial", "ANATOMY", 374, 386], ["lung parenchyma", "ANATOMY", 427, 442], ["interstitial pneumonia", "DISEASE", 67, 89], ["infection", "DISEASE", 360, 369], ["interstitial pneumonia", "DISEASE", 374, 396], ["fever", "DISEASE", 565, 570], ["anosmia", "DISEASE", 575, 582], ["parenchymal", "TISSUE", 26, 37], ["patients", "ORGANISM", 53, 61], ["lung", "ORGAN", 303, 307], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 427, 442], ["girl", "ORGANISM", 494, 498], ["patients", "SPECIES", 53, 61], ["girl", "SPECIES", 494, 498], ["Covid-19", "SPECIES", 351, 359], ["parenchymal involvement", "PROBLEM", 26, 49], ["interstitial pneumonia", "PROBLEM", 67, 89], ["3D reconstruction imaging", "TEST", 179, 204], ["3D lung reconstruction", "TREATMENT", 300, 322], ["Covid-19 infection", "PROBLEM", 351, 369], ["interstitial pneumonia", "PROBLEM", 374, 396], ["fever", "PROBLEM", 565, 570], ["anosmia", "PROBLEM", 575, 582], ["amount", "OBSERVATION_MODIFIER", 16, 22], ["parenchymal", "ANATOMY_MODIFIER", 26, 37], ["involvement", "OBSERVATION", 38, 49], ["interstitial", "ANATOMY_MODIFIER", 67, 79], ["pneumonia", "OBSERVATION", 80, 89], ["lung", "ANATOMY", 303, 307], ["infection", "OBSERVATION", 360, 369], ["interstitial", "ANATOMY_MODIFIER", 374, 386], ["pneumonia", "OBSERVATION", 387, 396], ["lung", "ANATOMY", 427, 431], ["parenchyma", "ANATOMY_MODIFIER", 432, 442], ["fever", "OBSERVATION", 565, 570]]], ["She had been complaining exertional shortness of breath over the previous 2 days.", [["shortness of breath", "DISEASE", 36, 55], ["exertional shortness of breath", "PROBLEM", 25, 55]]], ["At initial evaluation oxygen saturation was 97% in room air.", [["oxygen", "CHEMICAL", 22, 28], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["initial evaluation oxygen saturation", "TEST", 3, 39]]], ["Chest X-Ray showed no significant consolidation with perihilar infiltrates mainly on the left basal side.INTRODUCTIONHer pharyngeal swab Real-Time Polymerase Chain Reaction (RT-PCR) was positive for Sars-Cov2 infection.INTRODUCTIONAs further investigation the patient underwent Chest-CT.", [["perihilar", "ANATOMY", 53, 62], ["left basal", "ANATOMY", 89, 99], ["infection", "DISEASE", 209, 218], ["Cov2", "GENE_OR_GENE_PRODUCT", 204, 208], ["patient", "ORGANISM", 260, 267], ["patient", "SPECIES", 260, 267], ["Chest X-Ray", "TEST", 0, 11], ["significant consolidation", "PROBLEM", 22, 47], ["perihilar infiltrates", "PROBLEM", 53, 74], ["pharyngeal swab", "TEST", 121, 136], ["Chain Reaction", "TEST", 158, 172], ["RT-PCR", "TEST", 174, 180], ["Sars-Cov2 infection", "PROBLEM", 199, 218], ["further investigation", "TEST", 234, 255], ["Chest-CT", "TEST", 278, 286], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["consolidation", "OBSERVATION", 34, 47], ["perihilar", "ANATOMY_MODIFIER", 53, 62], ["infiltrates", "OBSERVATION", 63, 74], ["left", "ANATOMY_MODIFIER", 89, 93], ["basal", "ANATOMY_MODIFIER", 94, 99], ["pharyngeal", "ANATOMY", 121, 131], ["Cov2", "ANATOMY", 204, 208], ["infection", "OBSERVATION", 209, 218], ["Chest", "ANATOMY", 278, 283]]], ["Non-contrast spiral high isotropic resolution CT acquisition was performed.", [["Non-contrast spiral high isotropic resolution CT acquisition", "TEST", 0, 60]]], ["In the left lower lobe multiple shaded areas of increased density, Ground Glass Opacity (GGO) type, were observed.", [["left lower lobe", "ANATOMY", 7, 22], ["increased density", "PROBLEM", 48, 65], ["Ground Glass Opacity (GGO) type", "PROBLEM", 67, 98], ["left lower lobe", "ANATOMY", 7, 22], ["multiple", "OBSERVATION_MODIFIER", 23, 31], ["shaded", "OBSERVATION_MODIFIER", 32, 38], ["areas", "OBSERVATION_MODIFIER", 39, 44], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["density", "OBSERVATION", 58, 65], ["Ground Glass Opacity", "OBSERVATION", 67, 87], ["GGO", "OBSERVATION_MODIFIER", 89, 92], ["type", "OBSERVATION_MODIFIER", 94, 98]]], ["There were also subpleural parenchymal \"rounded\" consolidations.", [["subpleural parenchymal", "ANATOMY", 16, 38], ["subpleural parenchymal", "PATHOLOGICAL_FORMATION", 16, 38], ["subpleural parenchymal \"rounded\" consolidations", "PROBLEM", 16, 63], ["subpleural", "ANATOMY_MODIFIER", 16, 26], ["parenchymal", "ANATOMY_MODIFIER", 27, 38], ["rounded", "OBSERVATION_MODIFIER", 40, 47], ["\"", "OBSERVATION_MODIFIER", 47, 48], ["consolidations", "OBSERVATION", 49, 63]]], ["Similar changes were seen in the lingular segment.", [["lingular segment", "ANATOMY", 33, 49], ["lingular segment", "MULTI-TISSUE_STRUCTURE", 33, 49], ["Similar changes", "PROBLEM", 0, 15], ["lingular", "ANATOMY_MODIFIER", 33, 41], ["segment", "ANATOMY_MODIFIER", 42, 49]]], ["The CT pattern was reliably related to a viral pneumonia with exclusive left lung involvement (6) .", [["left lung", "ANATOMY", 72, 81], ["pneumonia", "DISEASE", 47, 56], ["lung", "ORGAN", 77, 81], ["The CT pattern", "TEST", 0, 14], ["a viral pneumonia", "PROBLEM", 39, 56], ["exclusive left lung involvement", "PROBLEM", 62, 93], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["pneumonia", "OBSERVATION", 47, 56], ["left", "ANATOMY_MODIFIER", 72, 76], ["lung", "ANATOMY", 77, 81], ["involvement", "OBSERVATION", 82, 93]]], ["Experimental treatment with azithromycin and hydroxychloroquine was started, with progressive improvement of the clinical condition.INTRODUCTIONUsing CT images we performed a 3D advanced segmentation and reconstruction of both lungs, in order to better delineate and quantitatively assess the amount of parenchymal abnormalities.INTRODUCTIONWritten informed consent of the family, for use of imaging and clinical data for research purposes, was obtained.METHODSCT high spatial resolution images with an isotropic voxel size of 1 mm and a smooth filter were used for the segmentation.", [["lungs", "ANATOMY", 227, 232], ["parenchymal", "ANATOMY", 303, 314], ["azithromycin", "CHEMICAL", 28, 40], ["hydroxychloroquine", "CHEMICAL", 45, 63], ["parenchymal abnormalities", "DISEASE", 303, 328], ["azithromycin", "CHEMICAL", 28, 40], ["hydroxychloroquine", "CHEMICAL", 45, 63], ["azithromycin", "SIMPLE_CHEMICAL", 28, 40], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 45, 63], ["lungs", "ORGAN", 227, 232], ["parenchymal", "TISSUE", 303, 314], ["Experimental treatment", "TREATMENT", 0, 22], ["azithromycin", "TREATMENT", 28, 40], ["hydroxychloroquine", "TREATMENT", 45, 63], ["the clinical condition", "PROBLEM", 109, 131], ["CT images", "TEST", 150, 159], ["a 3D advanced segmentation", "TEST", 173, 199], ["reconstruction of both lungs", "TREATMENT", 204, 232], ["parenchymal abnormalities", "PROBLEM", 303, 328], ["imaging", "TEST", 392, 399], ["clinical data", "TEST", 404, 417], ["research purposes", "TEST", 422, 439], ["an isotropic voxel size", "TEST", 500, 523], ["a smooth filter", "TREATMENT", 536, 551], ["progressive", "OBSERVATION_MODIFIER", 82, 93], ["improvement", "OBSERVATION_MODIFIER", 94, 105], ["both", "ANATOMY_MODIFIER", 222, 226], ["lungs", "ANATOMY", 227, 232], ["amount", "OBSERVATION_MODIFIER", 293, 299], ["parenchymal", "ANATOMY_MODIFIER", 303, 314], ["abnormalities", "OBSERVATION", 315, 328], ["size", "OBSERVATION_MODIFIER", 519, 523], ["smooth filter", "OBSERVATION", 538, 551]]], ["The dataset was uploaded on an advanced 3D post-processing platform \"Mimics\" (Materialize, Belgium) and three different segmentation masks were defined: parenchyma, GGO areas, and spot consolidations.", [["parenchyma", "ANATOMY", 153, 163], ["GGO areas", "ANATOMY", 165, 174], ["parenchyma", "TISSUE", 153, 163], ["GGO areas", "PROBLEM", 165, 174], ["spot consolidations", "PROBLEM", 180, 199], ["parenchyma", "ANATOMY", 153, 163], ["GGO", "OBSERVATION", 165, 168], ["spot", "OBSERVATION_MODIFIER", 180, 184], ["consolidations", "OBSERVATION", 185, 199]]], ["Ground-glass opacity (GGO) has been defined as an area of blurry increased lung opacity where vessels and bronchial structures may still be seen, whilst in consolidation such structures are concealed.", [["lung", "ANATOMY", 75, 79], ["vessels", "ANATOMY", 94, 101], ["bronchial structures", "ANATOMY", 106, 126], ["GGO", "DISEASE", 22, 25], ["lung", "ORGAN", 75, 79], ["vessels", "MULTI-TISSUE_STRUCTURE", 94, 101], ["bronchial structures", "MULTI-TISSUE_STRUCTURE", 106, 126], ["Ground-glass opacity (GGO", "PROBLEM", 0, 25], ["blurry increased lung opacity", "PROBLEM", 58, 87], ["vessels and bronchial structures", "PROBLEM", 94, 126], ["consolidation such structures", "PROBLEM", 156, 185], ["-glass opacity", "OBSERVATION", 6, 20], ["GGO", "OBSERVATION_MODIFIER", 22, 25], ["area", "OBSERVATION_MODIFIER", 50, 54], ["blurry", "OBSERVATION_MODIFIER", 58, 64], ["increased", "OBSERVATION_MODIFIER", 65, 74], ["lung", "ANATOMY", 75, 79], ["opacity", "OBSERVATION", 80, 87], ["vessels", "ANATOMY", 94, 101], ["bronchial", "ANATOMY", 106, 115], ["consolidation", "OBSERVATION", 156, 169]]], ["Most commonly, GGO areas suggest inflammatory, or infiltrative interstitial lung disorders, such as interstitial pneumonia.", [["infiltrative interstitial lung", "ANATOMY", 50, 80], ["interstitial", "ANATOMY", 100, 112], ["GGO", "DISEASE", 15, 18], ["interstitial lung disorders", "DISEASE", 63, 90], ["interstitial pneumonia", "DISEASE", 100, 122], ["lung", "ORGAN", 76, 80], ["inflammatory", "PROBLEM", 33, 45], ["infiltrative interstitial lung disorders", "PROBLEM", 50, 90], ["interstitial pneumonia", "PROBLEM", 100, 122], ["inflammatory", "OBSERVATION_MODIFIER", 33, 45], ["infiltrative", "OBSERVATION_MODIFIER", 50, 62], ["interstitial", "ANATOMY_MODIFIER", 63, 75], ["lung", "ANATOMY", 76, 80], ["disorders", "OBSERVATION", 81, 90], ["interstitial", "ANATOMY_MODIFIER", 100, 112], ["pneumonia", "OBSERVATION", 113, 122]]], ["Consolidation conversely is a region of normally compressible lung tissue that has filled with liquid instead of air, and suggest an infiltrative or inflammatory process involving the entire lung tissue.METHODSTwo semi-automatic reconstruction methods were applied.", [["lung tissue", "ANATOMY", 62, 73], ["lung tissue", "ANATOMY", 191, 202], ["lung tissue", "TISSUE", 62, 73], ["lung tissue", "TISSUE", 191, 202], ["Consolidation", "PROBLEM", 0, 13], ["normally compressible lung tissue", "PROBLEM", 40, 73], ["an infiltrative or inflammatory process involving the entire lung tissue", "PROBLEM", 130, 202], ["METHODSTwo semi-automatic reconstruction methods", "TREATMENT", 203, 251], ["normally", "OBSERVATION_MODIFIER", 40, 48], ["compressible", "OBSERVATION_MODIFIER", 49, 61], ["lung", "ANATOMY", 62, 66], ["tissue", "OBSERVATION", 67, 73], ["liquid", "OBSERVATION_MODIFIER", 95, 101], ["air", "OBSERVATION", 113, 116], ["infiltrative", "OBSERVATION_MODIFIER", 133, 145], ["inflammatory", "OBSERVATION", 149, 161], ["entire", "ANATOMY_MODIFIER", 184, 190], ["lung", "ANATOMY", 191, 195], ["tissue", "ANATOMY_MODIFIER", 196, 202]]], ["In particular, the thresholding algorithm, was an effective tool to segment normal lung parenchyma (7) (Figure 1A) , whilst the region-growing algorithm was used for ground glass areas ( Figure 1B ) and spot consolidations ( Figure 1C ).", [["lung parenchyma", "ANATOMY", 83, 98], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 83, 98], ["the thresholding algorithm", "TEST", 15, 41], ["ground glass areas", "PROBLEM", 166, 184], ["spot consolidations", "PROBLEM", 203, 222], ["lung", "ANATOMY", 83, 87], ["parenchyma", "ANATOMY_MODIFIER", 88, 98], ["ground glass", "OBSERVATION", 166, 178], ["spot", "OBSERVATION_MODIFIER", 203, 207], ["consolidations", "OBSERVATION", 208, 222]]], ["In addition, some small areas of consolidation have been manually segmented.METHODSWe measured density values on healthy right lung with Hounsfield values from \u22121024Hu to \u2212543Hu similar to typical range values of pediatric lungs (8) .METHODSBoth GGO and parenchymal consolidations Hounsfield ranges were obtained by making several measurements on a different CT Slices (\u2212957Hu to +1246Hu for GGO areas, and \u2212834Hu to +356Hu for consolidations areas).", [["right lung", "ANATOMY", 121, 131], ["lungs", "ANATOMY", 223, 228], ["parenchymal", "ANATOMY", 254, 265], ["lung", "ORGAN", 127, 131], ["lungs", "ORGAN", 223, 228], ["parenchymal", "TISSUE", 254, 265], ["consolidation", "PROBLEM", 33, 46], ["Hounsfield values", "TEST", 137, 154], ["METHODSBoth GGO and parenchymal consolidations Hounsfield ranges", "PROBLEM", 234, 298], ["a different CT Slices", "TEST", 347, 368], ["GGO areas", "TEST", 392, 401], ["consolidations areas", "PROBLEM", 428, 448], ["some", "OBSERVATION_MODIFIER", 13, 17], ["small", "OBSERVATION_MODIFIER", 18, 23], ["areas", "OBSERVATION_MODIFIER", 24, 29], ["consolidation", "OBSERVATION", 33, 46], ["manually", "OBSERVATION_MODIFIER", 57, 65], ["segmented", "OBSERVATION_MODIFIER", 66, 75], ["density", "OBSERVATION", 95, 102], ["right", "ANATOMY_MODIFIER", 121, 126], ["lung", "ANATOMY", 127, 131], ["Hounsfield values", "OBSERVATION_MODIFIER", 137, 154], ["lungs", "ANATOMY", 223, 228], ["GGO", "OBSERVATION", 246, 249], ["parenchymal", "ANATOMY_MODIFIER", 254, 265], ["consolidations", "OBSERVATION", 266, 280], ["consolidations", "OBSERVATION", 428, 442]]], ["Any transition areas between the two masks have been optimized with Boolean difference operations aimed at better defining the consolidations and GGO boundaries.METHODSEach of the three masks has been 3D reconstructed with a specific mesh quality setup to obtain the highest resolution and the best 3D-2D correspondence.", [["Any transition areas", "PROBLEM", 0, 20], ["the two masks", "TREATMENT", 29, 42], ["Boolean difference operations", "TREATMENT", 68, 97], ["the consolidations", "PROBLEM", 123, 141], ["a specific mesh quality setup", "TREATMENT", 223, 252], ["transition", "OBSERVATION_MODIFIER", 4, 14], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["consolidations", "OBSERVATION", 127, 141], ["GGO boundaries", "OBSERVATION", 146, 160]]], ["In order to obtain an adequate 3D rendering and 3D mesh reconstruction, the model was optimized with the Rhinoceros software (McNeel, USA) to allow adequate 3D visualization for clinical purposes.RESULTSThe 3D reconstructions allowed us to accurately calculate volumes of Lungs, GGO areas, and consolidation spots.", [["Lungs", "ANATOMY", 272, 277], ["Lungs", "ORGAN", 272, 277], ["3D mesh reconstruction", "TREATMENT", 48, 70], ["clinical purposes", "TEST", 178, 195], ["GGO areas", "PROBLEM", 279, 288], ["consolidation spots", "PROBLEM", 294, 313], ["Lungs", "ANATOMY", 272, 277], ["GGO", "OBSERVATION", 279, 282], ["consolidation spots", "OBSERVATION", 294, 313]]], ["Ground glass opacity areas were 5.1% of the entire lung volumes and 11.28% of the left lung.", [["lung", "ANATOMY", 51, 55], ["left lung", "ANATOMY", 82, 91], ["lung", "ORGAN", 51, 55], ["lung", "ORGAN", 87, 91], ["Ground glass opacity areas", "PROBLEM", 0, 26], ["the entire lung volumes", "TEST", 40, 63], ["glass opacity", "OBSERVATION", 7, 20], ["areas", "OBSERVATION_MODIFIER", 21, 26], ["5.1%", "OBSERVATION_MODIFIER", 32, 36], ["entire", "OBSERVATION_MODIFIER", 44, 50], ["lung", "ANATOMY", 51, 55], ["volumes", "ANATOMY_MODIFIER", 56, 63], ["left", "ANATOMY_MODIFIER", 82, 86], ["lung", "ANATOMY", 87, 91]]], ["Consolidation spots represented 0.55% of the entire lung volumes and 1.23% of the left lung.RESULTS3D rendering proved to be a very simple and effective approach for representing the lung anatomy including the distribution/topography of the different pathological areas.", [["lung", "ANATOMY", 52, 56], ["left lung", "ANATOMY", 82, 91], ["lung", "ANATOMY", 183, 187], ["lung", "ORGAN", 52, 56], ["lung", "ORGAN", 87, 91], ["lung", "ORGAN", 183, 187], ["Consolidation spots", "PROBLEM", 0, 19], ["the entire lung volumes", "TEST", 41, 64], ["the lung anatomy", "TEST", 179, 195], ["0.55%", "OBSERVATION_MODIFIER", 32, 37], ["entire", "OBSERVATION_MODIFIER", 45, 51], ["lung", "ANATOMY", 52, 56], ["volumes", "ANATOMY_MODIFIER", 57, 64], ["left", "ANATOMY_MODIFIER", 82, 86], ["lung", "ANATOMY", 87, 91], ["lung", "ANATOMY", 183, 187], ["anatomy", "OBSERVATION", 188, 195], ["different", "OBSERVATION_MODIFIER", 241, 250], ["pathological", "OBSERVATION", 251, 263]]], ["We obtained a series of different 3D volume rendering views to highlight radiological changes as shown in Figures 2A,B .", [["different 3D volume rendering views", "TREATMENT", 24, 59]]], ["We also produced a 3D movie (additional Video online) which shows a more comprehensive rotational rendering overview of the parenchymal changes, interstitial pneumonia related.", [["parenchymal", "ANATOMY", 124, 135], ["interstitial", "ANATOMY", 145, 157], ["pneumonia", "DISEASE", 158, 167], ["parenchymal", "TISSUE", 124, 135], ["the parenchymal changes", "PROBLEM", 120, 143], ["interstitial pneumonia", "PROBLEM", 145, 167], ["parenchymal", "ANATOMY_MODIFIER", 124, 135], ["interstitial", "ANATOMY_MODIFIER", 145, 157], ["pneumonia", "OBSERVATION", 158, 167]]], ["The final rendering was uploaded on a 3D online viewer platform (Sketchfab), which allows the clinical team to explore and navigate the 3D model on a web-link, taking advantage of a very powerful rendering capability with no need for dedicated workstation and additional software.DISCUSSION3D modeling represents a \"paradigm shift\" from the classical descriptions of lung changes based on conventional radiological reformats to 3D volume rendering reconstructions, that could improve the understanding (and communication to families and patients) of the extent and nature of these lung changes.", [["lung", "ANATOMY", 367, 371], ["lung", "ANATOMY", 581, 585], ["lung", "ORGAN", 367, 371], ["patients", "ORGANISM", 537, 545], ["lung", "ORGAN", 581, 585], ["patients", "SPECIES", 537, 545], ["dedicated workstation", "TEST", 234, 255], ["lung changes", "PROBLEM", 367, 379], ["conventional radiological reformats", "TEST", 389, 424], ["3D volume rendering reconstructions", "TREATMENT", 428, 463], ["these lung changes", "PROBLEM", 575, 593], ["lung", "ANATOMY", 367, 371], ["lung", "ANATOMY", 581, 585], ["changes", "OBSERVATION", 586, 593]]], ["In addition, we try to test it as a potential tool for surveillance and comparisons in clinical practice and research activity.DISCUSSIONIn this case we apply advanced 3D segmentation tools to increase the diagnostic information in case of Covid-19 patient.", [["patient", "ORGANISM", 249, 256], ["patient", "SPECIES", 249, 256], ["surveillance", "TEST", 55, 67], ["Covid", "TEST", 240, 245]]], ["In effect, the progressive impairment of lung tissues due to the Sars-Cov2 infection is one of the most threatening phenomenon for people affected by this viral infection (1).", [["lung tissues", "ANATOMY", 41, 53], ["impairment of lung tissues", "DISEASE", 27, 53], ["infection", "DISEASE", 75, 84], ["viral infection", "DISEASE", 155, 170], ["lung tissues", "TISSUE", 41, 53], ["Cov2", "GENE_OR_GENE_PRODUCT", 70, 74], ["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137], ["the progressive impairment of lung tissues", "PROBLEM", 11, 53], ["the Sars-Cov2 infection", "PROBLEM", 61, 84], ["this viral infection", "PROBLEM", 150, 170], ["progressive", "OBSERVATION_MODIFIER", 15, 26], ["impairment", "OBSERVATION", 27, 37], ["lung tissues", "ANATOMY", 41, 53], ["infection", "OBSERVATION", 75, 84], ["viral", "OBSERVATION_MODIFIER", 155, 160], ["infection", "OBSERVATION", 161, 170]]], ["CT has been introduced in many diagnostic algorhytm to manage these patients in order to predict or anticipate severe clinical deterioration (9, 10) .", [["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["CT", "TEST", 0, 2], ["severe clinical deterioration", "PROBLEM", 111, 140], ["severe", "OBSERVATION_MODIFIER", 111, 117]]], ["Detailed extent and quantification of affected lung volume, such as GGO or consolidation areas, could be helpful in the management of this pandemic infection.", [["lung", "ANATOMY", 47, 51], ["infection", "DISEASE", 148, 157], ["lung", "ORGAN", 47, 51], ["affected lung volume", "PROBLEM", 38, 58], ["GGO", "PROBLEM", 68, 71], ["consolidation areas", "PROBLEM", 75, 94], ["this pandemic infection", "PROBLEM", 134, 157], ["affected", "OBSERVATION_MODIFIER", 38, 46], ["lung", "ANATOMY", 47, 51], ["volume", "OBSERVATION", 52, 58], ["GGO", "OBSERVATION", 68, 71], ["consolidation", "OBSERVATION", 75, 88], ["pandemic", "OBSERVATION_MODIFIER", 139, 147], ["infection", "OBSERVATION", 148, 157]]], ["Therefore, accurate quantitative assessment might be useful and included in the CT scan report.DISCUSSIONThe 3D reconstruction and rendering views in addition to provide a comprehensive and self explaining lung \"tissue characterization\" with distribution of the different pathological areas, seems to be able to allow reliable lung volumes calculation with detailed analysis of the compromised areas.DISCUSSIONWe described our algorithm to obtain 3D rendering views and accurate lung volume calculations; it appears to be easily obtainable using a commercial 3D software and potentially reproducible even by using different 3D platforms.", [["lung", "ANATOMY", 206, 210], ["tissue", "ANATOMY", 212, 218], ["lung", "ANATOMY", 327, 331], ["lung", "ANATOMY", 479, 483], ["lung", "ORGAN", 206, 210], ["tissue", "TISSUE", 212, 218], ["lung", "ORGAN", 327, 331], ["lung", "ORGAN", 479, 483], ["accurate quantitative assessment", "TEST", 11, 43], ["the CT scan", "TEST", 76, 87], ["3D reconstruction and rendering views", "TEST", 109, 146], ["the different pathological areas", "PROBLEM", 258, 290], ["reliable lung volumes calculation", "TEST", 318, 351], ["detailed analysis", "TEST", 357, 374], ["3D rendering views", "TEST", 447, 465], ["accurate lung volume calculations", "TEST", 470, 503], ["lung", "ANATOMY", 206, 210], ["lung", "ANATOMY", 327, 331], ["volumes", "OBSERVATION", 332, 339], ["compromised", "OBSERVATION", 382, 393], ["lung", "ANATOMY", 479, 483]]], ["In addition, 3D visualization of lung lesions can provide to the medical staff a wider and self-explaining understanding of the underlying lung pathology of Covid-19 patients.", [["lung lesions", "ANATOMY", 33, 45], ["lung", "ANATOMY", 139, 143], ["lung lesions", "DISEASE", 33, 45], ["lung lesions", "CANCER", 33, 45], ["lung", "ORGAN", 139, 143], ["patients", "ORGANISM", 166, 174], ["patients", "SPECIES", 166, 174], ["lung lesions", "PROBLEM", 33, 45], ["Covid", "TEST", 157, 162], ["lung", "ANATOMY", 33, 37], ["lesions", "OBSERVATION", 38, 45], ["lung", "ANATOMY", 139, 143], ["pathology", "OBSERVATION", 144, 153]]], ["As already reported (11) 3D models can also be used for communication with families and patients and for teacing purposes.DISCUSSIONMoreover, since CT represents an important imaging biomarker and is pivotal to guide pharmacological management and improve ventilation strategies, further implementation of semi-automatic and/or fully automatic (AI-based) algorithms for image processing (12, 13) might be beneficial in order to rapidly and systematically provide accurate data about the extent of lung disease in these patients.DISCUSSIONMain limitation of our study is that it is a single case investigation.", [["lung", "ANATOMY", 497, 501], ["lung disease", "DISEASE", 497, 509], ["patients", "ORGANISM", 88, 96], ["lung", "ORGAN", 497, 501], ["patients", "ORGANISM", 519, 527], ["patients", "SPECIES", 88, 96], ["patients", "SPECIES", 519, 527], ["teacing purposes", "TEST", 105, 121], ["CT", "TEST", 148, 150], ["an important imaging biomarker", "TEST", 162, 192], ["pharmacological management", "TREATMENT", 217, 243], ["ventilation strategies", "TREATMENT", 256, 278], ["semi-automatic", "TEST", 306, 320], ["image processing", "TEST", 370, 386], ["lung disease", "PROBLEM", 497, 509], ["our study", "TEST", 557, 566], ["a single case investigation", "TEST", 581, 608], ["lung", "ANATOMY", 497, 501], ["disease", "OBSERVATION", 502, 509]]], ["Therefore, we can't assess its reproducibility, and its real impact on clinical practice.", [["clinical practice", "TREATMENT", 71, 88]]], ["Our aim is to point out the opportunity and feasibility of this approach in the particular clinical setting of Covid-19 pandemic in order to stimulate its wider use.", [["this approach", "TREATMENT", 59, 72], ["Covid", "TEST", 111, 116]]], ["Further analysis aimed to assess the clinical impact for the management and risk stratification of this novel tool, and its reproducibility in this setting are obviously needed.DATA AVAILABILITY STATEMENTAll datasets presented in this study are included in the article/Supplementary Material.ETHICS STATEMENTWritten informed consent was obtained from the legal guardian/next of kin of the participant for the publication of this case report and any identifying images or information.AUTHOR CONTRIBUTIONSLB and AS: idea for the article.", [["Further analysis", "TEST", 0, 16], ["the management", "TREATMENT", 57, 71], ["this novel tool", "PROBLEM", 99, 114], ["this study", "TEST", 230, 240]]], ["AM: CT-exam.", [["CT-exam", "TEST", 4, 11]]], ["LB: images and video production.", [["video production", "TEST", 15, 31]]], ["AM, AC, FC, MC, and PT: revision and approval of the manuscript.", [["revision", "TREATMENT", 24, 32], ["revision", "OBSERVATION", 24, 32]]]], "PMC7169194": [["INTRODUCTIONA vast spectrum of respiratory diseases caused by tropical pathogens unfamiliar to Western physicians, particularly parasitic and other exotic infections, occurs in Asia where the medical technological infrastructure is less established and often poorly accessible.", [["respiratory", "ANATOMY", 31, 42], ["respiratory diseases", "DISEASE", 31, 51], ["exotic infections", "DISEASE", 148, 165], ["respiratory diseases", "PROBLEM", 31, 51], ["tropical pathogens", "PROBLEM", 62, 80], ["parasitic", "PROBLEM", 128, 137], ["other exotic infections", "PROBLEM", 142, 165], ["respiratory diseases", "OBSERVATION", 31, 51], ["exotic", "OBSERVATION_MODIFIER", 148, 154], ["infections", "OBSERVATION", 155, 165]]], ["Asia is a highly heterogeneous region with vastly different cultures and ethnic constitutions, health\u2010care systems, vaccination programs and socioeconomic developments.", [["a highly heterogeneous region", "PROBLEM", 8, 37], ["vastly different cultures", "PROBLEM", 43, 68], ["vaccination programs", "TREATMENT", 116, 136], ["highly", "OBSERVATION_MODIFIER", 10, 16], ["heterogeneous", "OBSERVATION_MODIFIER", 17, 30], ["vastly different", "OBSERVATION_MODIFIER", 43, 59]]], ["Rampant antibiotic resistance exhibited by respiratory pathogens such as Streptococcus pneumoniae, poverty, malnutrition, over\u2010population, environmental damage, poor public health infrastructure, failure to implement established health\u2010care interventions and host factors such as genetic susceptibility to diseases such as tuberculosis (TB) make it particularly challenging for clinicians in Asia.", [["respiratory pathogens", "DISEASE", 43, 64], ["Streptococcus pneumoniae", "DISEASE", 73, 97], ["malnutrition", "DISEASE", 108, 120], ["over\u2010population", "DISEASE", 122, 137], ["environmental damage", "DISEASE", 139, 159], ["tuberculosis", "DISEASE", 323, 335], ["TB", "DISEASE", 337, 339], ["Streptococcus pneumoniae", "ORGANISM", 73, 97], ["Streptococcus pneumoniae", "SPECIES", 73, 97], ["Streptococcus pneumoniae", "SPECIES", 73, 97], ["Rampant antibiotic resistance", "TREATMENT", 0, 29], ["respiratory pathogens", "PROBLEM", 43, 64], ["Streptococcus pneumoniae", "PROBLEM", 73, 97], ["malnutrition", "PROBLEM", 108, 120], ["over\u2010population", "PROBLEM", 122, 137], ["environmental damage", "PROBLEM", 139, 159], ["poor public health infrastructure", "PROBLEM", 161, 194], ["failure", "PROBLEM", 196, 203], ["health\u2010care interventions", "TREATMENT", 229, 254], ["host factors", "PROBLEM", 259, 271], ["genetic susceptibility to diseases", "PROBLEM", 280, 314], ["tuberculosis", "PROBLEM", 323, 335], ["respiratory pathogens", "OBSERVATION", 43, 64], ["Streptococcus pneumoniae", "OBSERVATION", 73, 97]]], ["The increasing and worrying popularity of smoking remains a prime determinant to weakening host factors in many Asian countries particularly China where 63% of men smoke.1Background diseases such as COPD, diabetes mellitus and HIV infection (with India having the second largest population of infected patients in the world) further complicates the situation.2", [["smoking", "CHEMICAL", 42, 49], ["COPD", "DISEASE", 199, 203], ["diabetes mellitus", "DISEASE", 205, 222], ["HIV infection", "DISEASE", 227, 240], ["men", "ORGANISM", 160, 163], ["patients", "ORGANISM", 302, 310], ["men", "SPECIES", 160, 163], ["HIV", "SPECIES", 227, 230], ["patients", "SPECIES", 302, 310], ["HIV", "SPECIES", 227, 230], ["Background diseases", "PROBLEM", 171, 190], ["COPD", "PROBLEM", 199, 203], ["diabetes mellitus", "PROBLEM", 205, 222], ["HIV infection", "PROBLEM", 227, 240], ["increasing", "OBSERVATION_MODIFIER", 4, 14], ["diseases", "OBSERVATION", 182, 190], ["COPD", "OBSERVATION", 199, 203], ["diabetes mellitus", "OBSERVATION", 205, 222], ["HIV", "OBSERVATION_MODIFIER", 227, 230], ["infection", "OBSERVATION", 231, 240], ["infected", "OBSERVATION", 293, 301]]]], "80c9324d8f3f58388a5c0453f0e7cb7119b27dfc": [["IntroductionInconel 718 (IN718) is a nickel-based austenitic super alloy which can be hardened by precipitation.", [["IntroductionInconel 718", "CHEMICAL", 0, 23], ["IN718", "CHEMICAL", 25, 30], ["nickel", "CHEMICAL", 37, 43], ["nickel", "CHEMICAL", 37, 43], ["nickel", "SIMPLE_CHEMICAL", 37, 43], ["a nickel-based austenitic super alloy", "TREATMENT", 35, 72], ["precipitation", "OBSERVATION", 98, 111]]], ["Due to its superior high-temperature mechanical properties and corrosion resistance, it has wide range of applications in aerospace, nuclear and petrochemical industry [1, 2] .", [["nuclear", "ANATOMY", 133, 140], ["nuclear", "CELLULAR_COMPONENT", 133, 140], ["corrosion resistance", "PROBLEM", 63, 83], ["temperature mechanical properties", "OBSERVATION_MODIFIER", 25, 58], ["corrosion resistance", "OBSERVATION", 63, 83], ["wide", "OBSERVATION_MODIFIER", 92, 96], ["range", "OBSERVATION_MODIFIER", 97, 102]]], ["Inconel also has good weldability as compared to other super alloys of similar chemical characteristics [3] .", [["good", "OBSERVATION_MODIFIER", 17, 21], ["weldability", "OBSERVATION", 22, 33]]], ["Advanced products operating at demanding conditions normally require components with complex geometries and tight tolerances; therefore, IN718 parts are generally difficult and costly to be manufactured by conventional manufacturing processes.", [["Advanced products", "TREATMENT", 0, 17], ["tight tolerances", "OBSERVATION", 108, 124]]], ["Selective laser melting (SLM), a powder bed fusion technique, can produce near net shaped metals parts; however, one of the constraints on current SLM equipment is its limited working volume.IntroductionInconel 718 (IN718) is a nickel-based austenitic super alloy which can be hardened by precipitation.", [["IntroductionInconel 718", "CHEMICAL", 191, 214], ["IN718", "CHEMICAL", 216, 221], ["nickel", "CHEMICAL", 228, 234], ["nickel", "CHEMICAL", 228, 234], ["nickel", "SIMPLE_CHEMICAL", 228, 234], ["Selective laser melting (SLM)", "TREATMENT", 0, 29], ["a powder bed fusion technique", "TREATMENT", 31, 60], ["near net shaped metals parts", "PROBLEM", 74, 102], ["current SLM equipment", "TREATMENT", 139, 160], ["a nickel-based austenitic super alloy", "TREATMENT", 226, 263], ["laser", "OBSERVATION_MODIFIER", 10, 15], ["melting", "OBSERVATION_MODIFIER", 16, 23], ["shaped", "OBSERVATION_MODIFIER", 83, 89], ["metals", "OBSERVATION", 90, 96], ["precipitation", "OBSERVATION", 289, 302]]], ["Due to its superior high-temperature mechanical properties and corrosion resistance, it has wide range of applications in aerospace, nuclear and petrochemical industry [1, 2] .", [["nuclear", "ANATOMY", 133, 140], ["nuclear", "CELLULAR_COMPONENT", 133, 140], ["corrosion resistance", "PROBLEM", 63, 83], ["temperature mechanical properties", "OBSERVATION_MODIFIER", 25, 58], ["corrosion resistance", "OBSERVATION", 63, 83], ["wide", "OBSERVATION_MODIFIER", 92, 96], ["range", "OBSERVATION_MODIFIER", 97, 102]]], ["Inconel also has good weldability as compared to other super alloys of similar chemical characteristics [3] .", [["good", "OBSERVATION_MODIFIER", 17, 21], ["weldability", "OBSERVATION", 22, 33]]], ["Advanced products operating at demanding conditions normally require components with complex geometries and tight tolerances; therefore, IN718 parts are generally difficult and costly to be manufactured by conventional manufacturing processes.", [["Advanced products", "TREATMENT", 0, 17], ["tight tolerances", "OBSERVATION", 108, 124]]], ["Selective laser melting (SLM), a powder bed fusion technique, can produce near net shaped metals parts; however, one of the constraints on current SLM equipment is its limited working volume.", [["Selective laser melting (SLM)", "TREATMENT", 0, 29], ["a powder bed fusion technique", "TREATMENT", 31, 60], ["near net shaped metals parts", "PROBLEM", 74, 102], ["current SLM equipment", "TREATMENT", 139, 160], ["laser", "OBSERVATION_MODIFIER", 10, 15], ["melting", "OBSERVATION_MODIFIER", 16, 23], ["shaped", "OBSERVATION_MODIFIER", 83, 89], ["metals", "OBSERVATION", 90, 96]]], ["There is a need to produce large components by joining smaller SLM parts.", [["large components", "PROBLEM", 27, 43], ["large", "OBSERVATION_MODIFIER", 27, 32], ["components", "OBSERVATION_MODIFIER", 33, 43], ["joining", "OBSERVATION_MODIFIER", 47, 54], ["smaller", "OBSERVATION_MODIFIER", 55, 62], ["SLM parts", "OBSERVATION", 63, 72]]], ["Electron beam welding (EBW) is among the promising joining processes for high quality and deep penetration [4] .", [["Electron beam welding (EBW)", "TREATMENT", 0, 27]]], ["Published literatures include welding of rolled or extruded IN718 by different methods; joining of additively manufactured IN718 by Tungsten Inert Gas (TIG) welding and brazing were performed by few researchers but none is yet to be found for EBW of 3D printed IN718.", [["IN718", "CHEMICAL", 123, 128], ["Tungsten Inert Gas", "CHEMICAL", 132, 150], ["TIG", "CHEMICAL", 152, 155], ["IN718", "SIMPLE_CHEMICAL", 123, 128], ["EBW", "PROTEIN", 243, 246], ["IN718", "PROTEIN", 261, 266], ["Tungsten Inert Gas (TIG) welding", "TREATMENT", 132, 164], ["brazing", "TREATMENT", 169, 176]]], ["The objective of this research is to optimize parameters for EBW of rolled IN718 for best mechanical properties.", [["IN718", "SIMPLE_CHEMICAL", 75, 80]]], ["The results will be used at a later stage as references for comparison against SLM IN718 components after joining by EBW.Literature ReviewVarious methods to join IN718 have been previously investigated.", [["IN718", "GENE_OR_GENE_PRODUCT", 162, 167], ["EBW", "PROTEIN", 117, 120], ["IN718", "PROTEIN", 162, 167]]], ["Laser beam welding and EBW are most widely researched joining methods for conventionally manufactured IN718.", [["IN718", "CHEMICAL", 102, 107], ["IN718", "SIMPLE_CHEMICAL", 102, 107], ["IN718", "PROTEIN", 102, 107], ["Laser beam welding", "TREATMENT", 0, 18]]], ["Whereas, Tungsten Inert Gas (TIG) welding and brazing have been explored for joining of 3D printed IN718.Laser welding of conventionally manufactured IN718Laser welding of IN718 was investigated [5] .", [["Inert Gas", "CHEMICAL", 18, 27], ["TIG", "CHEMICAL", 29, 32], ["IN718", "CHEMICAL", 172, 177], ["TIG", "CHEMICAL", 29, 32], ["IN718", "CHEMICAL", 172, 177], ["Tungsten Inert Gas", "SIMPLE_CHEMICAL", 9, 27], ["IN718", "PROTEIN", 99, 104], ["Tungsten Inert Gas (TIG) welding", "TREATMENT", 9, 41], ["brazing", "TREATMENT", 46, 53], ["Laser welding of conventionally manufactured", "TREATMENT", 105, 149]]], ["Several 1.3mm-thick plates were welded using four different heat inputs ranging from 74.5 J/mm to 126.6 J/mm.", [["Several 1.3mm-thick plates", "TREATMENT", 0, 26], ["four different heat inputs", "TEST", 45, 71], ["1.3mm", "OBSERVATION_MODIFIER", 8, 13]]], ["The heat input was defined as:Laser welding of conventionally manufactured IN718Defect-free and full penetration welds were achieved and had a wider wine-glass shape as the heat input was increased.", [["The heat input", "TREATMENT", 0, 14], ["Laser welding of conventionally manufactured IN718Defect", "TREATMENT", 30, 86], ["the heat input", "TREATMENT", 169, 183], ["glass shape", "OBSERVATION_MODIFIER", 154, 165], ["increased", "OBSERVATION_MODIFIER", 188, 197]]], ["The CO2 laser welding was performed on pre-treated 5mm-thick plates, pre-and post-treated at three different conditions (as received, 955\u00b0C solution treatment, 955\u00b0C solution treatment + aging) [6] .", [["CO2", "CHEMICAL", 4, 7], ["CO2", "CHEMICAL", 4, 7], ["CO2", "SIMPLE_CHEMICAL", 4, 7], ["The CO2 laser welding", "TREATMENT", 0, 21], ["pre-treated 5mm-thick plates", "TREATMENT", 39, 67], ["955\u00b0C solution treatment", "TREATMENT", 134, 158], ["C solution treatment", "TREATMENT", 164, 184]]], ["A minimum power of 6 kW was required for full penetration with optimal focal point on the surface of the weld.", [["surface", "ANATOMY", 90, 97], ["full penetration", "PROBLEM", 41, 57], ["focal", "OBSERVATION_MODIFIER", 71, 76]]], ["Tensile strength of the as-received welded specimen was 1410 MPa as compared to 1380 MPa of the base metal.", [["specimen", "ANATOMY", 43, 51], ["strength", "OBSERVATION_MODIFIER", 8, 16], ["base", "ANATOMY_MODIFIER", 96, 100], ["metal", "ANATOMY_MODIFIER", 101, 106]]], ["The least strength of 980 MPa was obtained for samples pretreated by solution treatment following by aging and no post-weld heat treatment.Joining of additively manufactured IN718Many researchers have studied joining of additively manufactured IN718.", [["samples", "ANATOMY", 47, 54], ["IN718", "CHEMICAL", 244, 249], ["IN718", "CHEMICAL", 244, 249], ["IN718", "SIMPLE_CHEMICAL", 244, 249], ["IN718", "PROTEIN", 244, 249], ["solution treatment", "TREATMENT", 69, 87], ["post-weld heat treatment", "TREATMENT", 114, 138]]], ["Efforts have been made to join SLM IN718 by various methods.", [["IN718", "PROTEIN", 35, 40]]], ["Tungsten Inert Gas welding (TIG) was performed on 3.4-mm thick specimens that were hot isostatic pressed at 1160\u02daC and 105 MPa for three hours.", [["specimens", "ANATOMY", 63, 72], ["Tungsten", "SIMPLE_CHEMICAL", 0, 8], ["Tungsten Inert Gas welding (TIG)", "TREATMENT", 0, 32], ["thick specimens", "TEST", 57, 72], ["Inert", "OBSERVATION_MODIFIER", 9, 14], ["Gas welding", "OBSERVATION", 15, 26], ["105 MPa", "OBSERVATION_MODIFIER", 119, 126]]], ["Although small grains were achieved, large sized cracks were evident in the welded microstructure [7] .Joining of additively manufactured IN718Brazing of 20 x 20 x 4 mm IN718 specimens was investigated using brazing filler metal BrazeLet (BNi-2) held between the specimens at 50 kPa pressure [8] .", [["grains", "ANATOMY", 15, 21], ["IN718 specimens", "ANATOMY", 169, 184], ["specimens", "ANATOMY", 263, 272], ["BNi-2", "CHEMICAL", 239, 244], ["BNi-2", "CHEMICAL", 239, 244], ["small grains", "PROBLEM", 9, 21], ["large sized cracks", "PROBLEM", 37, 55], ["specimens", "TEST", 175, 184], ["brazing filler metal BrazeLet (BNi", "TREATMENT", 208, 242], ["kPa pressure", "TEST", 279, 291], ["small", "OBSERVATION_MODIFIER", 9, 14], ["grains", "OBSERVATION", 15, 21], ["large", "OBSERVATION_MODIFIER", 37, 42], ["sized", "OBSERVATION_MODIFIER", 43, 48], ["cracks", "OBSERVATION", 49, 55], ["welded microstructure", "OBSERVATION", 76, 97], ["manufactured", "OBSERVATION_MODIFIER", 125, 137]]], ["Brazed parts were then cut to 40 x 3 x 4 mm for testing.", [["testing", "TEST", 48, 55], ["40 x 3 x", "OBSERVATION_MODIFIER", 30, 38]]], ["Brazing led to formation of isothermally solidified zone at the center of joint which had 460 HV hardness and surrounded by diffusion affected zone with hardness of 490 HV, as compared to 475 HV hardness of the base metal.", [["joint", "ANATOMY", 74, 79], ["Brazing", "DISEASE", 0, 7], ["joint", "MULTI-TISSUE_STRUCTURE", 74, 79], ["Brazing", "TREATMENT", 0, 7], ["isothermally solidified zone", "PROBLEM", 28, 56], ["isothermally", "OBSERVATION_MODIFIER", 28, 40], ["solidified", "OBSERVATION_MODIFIER", 41, 51], ["zone", "OBSERVATION_MODIFIER", 52, 56], ["joint", "ANATOMY", 74, 79], ["HV hardness", "OBSERVATION_MODIFIER", 94, 105], ["490 HV", "OBSERVATION_MODIFIER", 165, 171], ["base", "ANATOMY_MODIFIER", 211, 215], ["metal", "ANATOMY_MODIFIER", 216, 221]]], ["The shear strength of brazed samples, averaged at 802 MPa, only reached about 77% of that from the base metal.Electron beam welding of rolled IN718Many attempts have been made to join IN718 using electron beam in a vacuum.", [["samples", "ANATOMY", 29, 36], ["IN718", "CHEMICAL", 184, 189], ["IN718", "SIMPLE_CHEMICAL", 184, 189], ["IN718", "PROTEIN", 184, 189], ["a vacuum", "TREATMENT", 213, 221], ["shear", "OBSERVATION_MODIFIER", 4, 9], ["strength", "OBSERVATION_MODIFIER", 10, 18], ["base", "ANATOMY_MODIFIER", 99, 103], ["metal", "ANATOMY_MODIFIER", 104, 109], ["vacuum", "OBSERVATION", 215, 221]]], ["Microhardness measurement was used to characterize the weld and surrounding heat affected zones (HAZ) [9] .", [["Microhardness measurement", "TEST", 0, 25]]], ["Two types of specimens were tested: the asreceived and the solution heat treated and aged.", [["specimens", "ANATOMY", 13, 22], ["specimens", "CANCER", 13, 22], ["specimens", "TEST", 13, 22], ["the solution heat", "TREATMENT", 55, 72]]], ["Although the HAZ in solution pre-treated samples could be identified with microhardness measurement, the surrounding HAZ in asreceived and precipitation pre-treated samples could not be distinguished from the central weld zone.", [["samples", "ANATOMY", 41, 48], ["samples", "ANATOMY", 165, 172], ["HAZ", "SIMPLE_CHEMICAL", 13, 16], ["weld zone", "MULTI-TISSUE_STRUCTURE", 217, 226], ["HAZ", "PROTEIN", 13, 16], ["microhardness measurement", "TEST", 74, 99], ["the surrounding HAZ", "PROBLEM", 101, 120], ["precipitation pre-treated samples", "TREATMENT", 139, 172], ["could not be distinguished", "UNCERTAINTY", 173, 199], ["central", "ANATOMY_MODIFIER", 209, 216], ["weld", "OBSERVATION_MODIFIER", 217, 221], ["zone", "OBSERVATION_MODIFIER", 222, 226]]], ["After metallographic etching, scanning electron microscopy (SEM) examination could identify a HAZ that was within 100 microns for the solution-and-aged pre-treated samples.", [["samples", "ANATOMY", 164, 171], ["metallographic etching", "TREATMENT", 6, 28], ["scanning electron microscopy (SEM) examination", "TEST", 30, 76], ["a HAZ", "PROBLEM", 92, 97], ["the solution", "TEST", 130, 142]]], ["The anodic potentiostatic etching technique was recommended for identifying HAZ in IN718 welds.Electron beam welding of rolled IN718Some researchers depicted that introduction of electron beam oscillations reduced niobium segregation, therefore, improving the weld quality [10] .", [["niobium", "CHEMICAL", 214, 221], ["niobium", "CHEMICAL", 214, 221], ["niobium", "SIMPLE_CHEMICAL", 214, 221], ["HAZ", "PROTEIN", 76, 79], ["The anodic potentiostatic etching technique", "TREATMENT", 0, 43], ["electron beam oscillations reduced niobium segregation", "TREATMENT", 179, 233], ["niobium segregation", "OBSERVATION", 214, 233]]], ["Their experimental IN718 specimens (205 x 105 x 3.1 mm, solution pre-treated) were first welded at heat inputs of 50 J/mm in oscillated conditions, and then subjected to three different post-weld heat treatments.", [["IN718 specimens", "ANATOMY", 19, 34], ["different post-weld heat treatments", "TREATMENT", 176, 211], ["50 J/mm", "OBSERVATION_MODIFIER", 114, 121]]], ["Other researchers showed that increasing heat input would increase the width of the welds along with reduction in microcracks in the weld and HAZ [11, 12] .", [["welds", "ANATOMY", 84, 89], ["increasing heat input", "PROBLEM", 30, 51], ["reduction in microcracks in the weld", "TREATMENT", 101, 137], ["increasing", "OBSERVATION_MODIFIER", 30, 40], ["width", "OBSERVATION_MODIFIER", 71, 76], ["reduction", "OBSERVATION_MODIFIER", 101, 110], ["microcracks", "OBSERVATION_MODIFIER", 114, 125]]], ["Variation in lower values of heat inputs had minimal effect on the mechanical properties of the weld.", [["Variation in lower values of heat inputs", "PROBLEM", 0, 40], ["lower", "ANATOMY_MODIFIER", 13, 18], ["minimal", "OBSERVATION_MODIFIER", 45, 52], ["effect", "OBSERVATION_MODIFIER", 53, 59]]], ["The 2-mm thick rolled sheets were EBW'ed without pre-or post-weld heat treatment.", [["The 2-mm thick rolled sheets", "TREATMENT", 0, 28], ["pre-or post-weld heat treatment", "TREATMENT", 49, 80]]], ["The best mechanical properties of welded specimens (with 884 MPa tensile strength and 489 MPa yield strength) were obtained after EBW at the lowest heat input of 36 J/mm.Electron beam welding of rolled IN718Other researchers investigated the weld geometry due to different base metal conditions [12] .", [["specimens", "ANATOMY", 41, 50], ["welded specimens", "TEST", 34, 50], ["MPa tensile strength", "TEST", 61, 81], ["MPa yield strength", "TEST", 90, 108], ["EBW", "TEST", 130, 133], ["the weld geometry", "TREATMENT", 238, 255], ["different base metal conditions", "PROBLEM", 263, 294], ["welded", "OBSERVATION", 34, 40], ["36 J/mm", "OBSERVATION_MODIFIER", 162, 169]]], ["The weld geometry transitioned from stemless wine glass shape to nail head shape, when sample was pre-heated at 1100\u00b0C for one hour followed by air cooling.", [["head", "ANATOMY", 70, 74], ["sample", "ANATOMY", 87, 93], ["head", "ORGANISM_SUBDIVISION", 70, 74], ["The weld geometry", "TREATMENT", 0, 17], ["air cooling", "TREATMENT", 144, 155], ["weld geometry", "OBSERVATION", 4, 17], ["glass shape", "OBSERVATION", 50, 61], ["nail head", "ANATOMY", 65, 74], ["air cooling", "OBSERVATION", 144, 155]]], ["An alteration was reported in chemical composition of the weld region because of different pre-weld treatments.", [["different pre-weld treatments", "TREATMENT", 81, 110], ["alteration", "OBSERVATION", 3, 13]]], ["There was also an increase in total crack length from 40 \u00b5m to 675 \u00b5m due to pre-heating of the base metal at the same temperature and for the same time duration.Electron beam welding of rolled IN718Effect of processing parameters was also reported [13] .", [["an increase in total crack length", "PROBLEM", 15, 48], ["Electron beam welding", "TREATMENT", 162, 183], ["increase", "OBSERVATION_MODIFIER", 18, 26], ["total", "OBSERVATION_MODIFIER", 30, 35], ["crack", "OBSERVATION_MODIFIER", 36, 41], ["length", "OBSERVATION_MODIFIER", 42, 48], ["base", "ANATOMY_MODIFIER", 96, 100]]], ["The fast heating and cooling rates at lower heat input would (i) reduce the niobium segregation, and (ii) decrease the fractional areas of precipitation of low melting eutectic inter-dendritic brittle phase of carbide and Laves phase.", [["niobium", "CHEMICAL", 76, 83], ["niobium", "CHEMICAL", 76, 83], ["carbide", "CHEMICAL", 210, 217], ["The fast heating", "TREATMENT", 0, 16], ["cooling rates at lower heat input", "TREATMENT", 21, 54], ["the niobium segregation", "PROBLEM", 72, 95], ["low melting eutectic inter-dendritic brittle phase of carbide and Laves phase", "PROBLEM", 156, 233], ["fractional", "OBSERVATION_MODIFIER", 119, 129], ["areas", "OBSERVATION_MODIFIER", 130, 135], ["precipitation", "OBSERVATION_MODIFIER", 139, 152], ["low melting", "OBSERVATION_MODIFIER", 156, 167], ["eutectic inter-dendritic", "OBSERVATION", 168, 192], ["brittle phase", "OBSERVATION", 193, 206]]], ["A wider HAZ was observed when EBW'ed at 120 J/mm heat input level, 70 kV voltage, and 2 m/min welding speed.", [["HAZ", "PROTEIN", 8, 11], ["A wider HAZ", "PROBLEM", 0, 11], ["EBW", "TEST", 30, 33], ["heat input level", "TEST", 49, 65], ["kV voltage", "TEST", 70, 80]]], ["A lower heat input also restricted the maximum penetration depth that can be achieved for the given conditions.", [["A lower heat input", "TREATMENT", 0, 18], ["the maximum penetration depth", "TREATMENT", 35, 64], ["lower heat", "OBSERVATION_MODIFIER", 2, 12]]], ["Two weld passes were attempted for EBW of IN718 plates [14] .", [["Two weld passes", "TREATMENT", 0, 15], ["weld", "OBSERVATION_MODIFIER", 4, 8]]], ["The plates (100 x 120 x 13.35 mm thick) were subjected to the first EBW pass (60 kV, 120 mA, and 11 mm/s) followed by the second pass (60 kV, 30 mA, and 11 mm/s).", [["The plates", "TEST", 0, 10], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The authors then tested their samples at 650\u02daC for mechanical properties at the top, middle and bottom of the thick weld.", [["samples", "ANATOMY", 30, 37], ["mechanical properties at the top", "TREATMENT", 51, 83], ["the thick weld", "TREATMENT", 106, 120], ["mechanical properties", "OBSERVATION", 51, 72], ["middle", "ANATOMY_MODIFIER", 85, 91], ["bottom", "ANATOMY_MODIFIER", 96, 102]]], ["The resulting mechanical properties varied from better to worse from bottom (with smaller grain size) to top (with large grain size) as shown in the following table.", [["The resulting mechanical properties", "PROBLEM", 0, 35], ["mechanical properties", "OBSERVATION_MODIFIER", 14, 35], ["varied", "OBSERVATION_MODIFIER", 36, 42], ["worse", "OBSERVATION_MODIFIER", 58, 63], ["smaller", "OBSERVATION_MODIFIER", 82, 89], ["grain", "OBSERVATION_MODIFIER", 90, 95], ["size", "OBSERVATION_MODIFIER", 96, 100], ["top", "OBSERVATION_MODIFIER", 105, 108], ["large", "OBSERVATION_MODIFIER", 115, 120], ["grain", "OBSERVATION_MODIFIER", 121, 126], ["size", "OBSERVATION_MODIFIER", 127, 131]]], ["An attempt to improve mechanical properties of weldment by specific post-weld heat treatments was made [15] .", [["specific post-weld heat treatments", "TREATMENT", 59, 93]]], ["However, the results were still inferior compared those form the base metal as shown below.Post-weld treatment by friction stirringFriction Stirring Process (FSP) as a post-welding treatment process was investigated [16] .", [["Post-weld treatment", "TREATMENT", 91, 110], ["a post-welding treatment process", "TREATMENT", 166, 198], ["base", "ANATOMY_MODIFIER", 65, 69]]], ["The FSP was conducted using a WC-Co tool (\u00d86 mm, 1.8 mm long).", [["WC", "CHEMICAL", 30, 32], ["Co", "CHEMICAL", 33, 35], ["a WC", "TEST", 28, 32]]], ["To obtain a homogenous material surface, the tool was tilted 3\u00b0 forward from the vertical and argon gas was utilized to prevent surface oxidation.", [["surface", "ANATOMY", 32, 39], ["surface", "ANATOMY", 128, 135], ["argon gas", "TREATMENT", 94, 103], ["surface oxidation", "TREATMENT", 128, 145], ["surface oxidation", "OBSERVATION", 128, 145]]], ["The researchers compared the effectiveness of FSP as a post-weld treatment on IN718 overlap welds, with and without heat treatment (720\u00b0C for 8 hours, 620\u00b0C for 6 hours, 1 x 10 -5 Torr vacuum pressure, then air-cooling).", [["a post-weld treatment", "TREATMENT", 53, 74], ["heat treatment", "TREATMENT", 116, 130], ["Torr vacuum pressure", "TREATMENT", 180, 200]]], ["Hardness of the base material increased by >20% after FSP and >70% after both mechanical and thermal treatments.", [["Hardness of the base material", "PROBLEM", 0, 29], ["FSP", "TEST", 54, 57], ["both mechanical and thermal treatments", "TREATMENT", 73, 111], ["base", "ANATOMY_MODIFIER", 16, 20], ["material", "OBSERVATION_MODIFIER", 21, 29], ["increased", "OBSERVATION_MODIFIER", 30, 39]]], ["The results indicated refinement of grain structure with reduced number of defects after FSP.", [["reduced number of defects", "PROBLEM", 57, 82], ["grain structure", "OBSERVATION", 36, 51], ["reduced", "OBSERVATION_MODIFIER", 57, 64], ["number", "OBSERVATION_MODIFIER", 65, 71], ["defects", "OBSERVATION", 75, 82]]], ["Table 4 summarizes the mechanical properties of the test specimens.", [["specimens", "ANATOMY", 57, 66], ["the test specimens", "TEST", 48, 66]]], ["Majority of published literature focuses on understanding of weld geometry and microstructure, effects of welding parameters on niobium segregation, Lave formation, and ensuing defects in weld and base metal.", [["niobium", "CHEMICAL", 128, 135], ["niobium", "CHEMICAL", 128, 135], ["niobium", "SIMPLE_CHEMICAL", 128, 135], ["Lave", "SIMPLE_CHEMICAL", 149, 153], ["weld geometry and microstructure", "PROBLEM", 61, 93], ["welding parameters on niobium segregation", "TREATMENT", 106, 147], ["Lave formation", "TREATMENT", 149, 163], ["ensuing defects in weld and base metal", "PROBLEM", 169, 207], ["defects", "OBSERVATION", 177, 184], ["weld", "OBSERVATION_MODIFIER", 188, 192], ["base", "ANATOMY_MODIFIER", 197, 201], ["metal", "OBSERVATION_MODIFIER", 202, 207]]], ["Considering favorable consequences of different variables, it may be inferred that there exists a compromise in the selection of the process parameters to mitigate possible defects and achieve quality welds.", [["a compromise", "PROBLEM", 96, 108], ["defects", "PROBLEM", 173, 180], ["compromise", "OBSERVATION", 98, 108], ["defects", "OBSERVATION", 173, 180]]], ["Although many researchers have studied and suggested optimized welding conditions for rolled /extruded IN718, no published data is yet found for EBW of additively manufactured IN718.", [["IN718", "CHEMICAL", 176, 181], ["IN718", "CHEMICAL", 176, 181], ["IN718", "SIMPLE_CHEMICAL", 176, 181], ["IN718", "PROTEIN", 176, 181], ["published data", "TEST", 113, 127]]], ["This paper establishes a reference by presenting EBW results of rolled IN718; the results will then be compared with those from EBW of SLM IN718 in a different paper.ExperimentsThe IN718 plates (305 \u00d7 152 \u00d7 13 mm thick), provided by Huntington Alloys Corporation, were used in this study [18] .", [["The IN718 plates", "TEST", 177, 193], ["this study", "TEST", 277, 287]]], ["The as-received plates conforming to the SAE AMS 5596M / ASTM B670-07 standards had rolling direction (RD) along the plate length (305 mm).", [["ASTM B670", "DNA", 57, 66], ["The as-received plates", "TREATMENT", 0, 22], ["the SAE AMS", "TEST", 37, 48], ["ASTM B670", "TEST", 57, 66], ["plate", "ANATOMY_MODIFIER", 117, 122], ["length", "OBSERVATION_MODIFIER", 123, 129]]], ["Its chemical composition (wt%) was 53.48Ni 18.15Cr 17.88Fe 5.17Nb 3.00Mo 0.98Ti 0.53Al 0.18Co 0.14Cu 0.09Si 0.07Mn and 0.03C.", [["Ni", "CHEMICAL", 40, 42], ["Fe", "CHEMICAL", 56, 58], ["Cu", "CHEMICAL", 98, 100], ["Ni", "CHEMICAL", 40, 42], ["Cr", "CHEMICAL", 48, 50], ["Fe", "CHEMICAL", 56, 58], ["Nb", "CHEMICAL", 63, 65], ["Mo", "CHEMICAL", 70, 72], ["Ti", "CHEMICAL", 77, 79], ["Co", "CHEMICAL", 91, 93], ["Cu", "CHEMICAL", 98, 100], ["Si", "CHEMICAL", 105, 107], ["Mn", "CHEMICAL", 112, 114], ["wt", "TEST", 26, 28], ["Ni", "TEST", 40, 42], ["Cr", "TEST", 48, 50], ["Fe", "TEST", 56, 58], ["Nb", "TEST", 63, 65], ["Mo", "TEST", 70, 72], ["Ti", "TEST", 77, 79], ["0.53Al", "TEST", 80, 86], ["Co", "TEST", 91, 93], ["Cu", "TEST", 98, 100], ["Si", "TEST", 105, 107], ["Mn", "TEST", 112, 114]]], ["Table 5 lists the material mechanical properties.", [["the material mechanical properties", "TREATMENT", 14, 48]]], ["Mechanical properties of rolled IN718 [18] The as-received plate was sectioned using wire-type Electrical Discharge Machining (wire EDM) across the length into nine equal welding coupons (152.4 \u00d7 33.7 \u00d7 13 mm thick).", [["IN718", "CHEMICAL", 32, 37], ["The as-received plate", "TREATMENT", 43, 64], ["wire-type Electrical Discharge Machining (wire EDM", "TREATMENT", 85, 135], ["equal", "OBSERVATION_MODIFIER", 165, 170], ["welding coupons", "OBSERVATION", 171, 186]]], ["The coupons were assembled for welding with uniform spacers to mitigate heat propagation amongst the coupons (Fig. 1) .", [["welding with uniform spacers", "TREATMENT", 31, 59], ["heat propagation", "TREATMENT", 72, 88]]], ["Electron beam weld beads were produced without beam oscillations on the coupons along the rolling direction using the Sciaky EBW system.", [["Electron beam weld beads", "TREATMENT", 0, 24], ["beam oscillations", "PROBLEM", 47, 64], ["weld beads", "OBSERVATION", 14, 24], ["without", "UNCERTAINTY", 39, 46], ["beam oscillations", "OBSERVATION", 47, 64]]], ["The beam was focused on the surface for all coupons.", [["surface", "ANATOMY", 28, 35], ["surface", "CELLULAR_COMPONENT", 28, 35]]], ["Three levels of welding parameters were selected for welding speeds and beam currents.", [["welding parameters", "TREATMENT", 16, 34]]], ["Constant beam voltage of 50 kV and low vacuum pressure <1 \u00b5Torr were used for all experiments.", [["Constant beam voltage", "TEST", 0, 21], ["low vacuum pressure", "TREATMENT", 35, 54], ["Torr", "TREATMENT", 59, 63], ["low vacuum", "OBSERVATION_MODIFIER", 35, 45]]], ["These parameters were selected to produce heat input within the range from 180 to 300 J/mm for deep weld penetration.", [["heat input", "TEST", 42, 52], ["deep weld penetration", "PROBLEM", 95, 116], ["weld penetration", "OBSERVATION", 100, 116]]], ["A total of nine samples, with two replicates for each welding condition, were produced at different welding parameters (Table 6) .ExperimentsAfter welding, the hardness coupons (20 \u00d7 6 \u00d7 13 mm thick) were sectioned from each welded specimen for fractography and microhardness study.", [["samples", "ANATOMY", 16, 23], ["specimen", "ANATOMY", 232, 240], ["nine samples", "TREATMENT", 11, 23], ["each welding condition", "TREATMENT", 49, 71], ["the hardness coupons", "TREATMENT", 156, 176], ["fractography", "TEST", 245, 257], ["microhardness study", "TEST", 262, 281]]], ["The rest were stress relieved (970\u02daC, 1 hour), milled equally on both sides to 6 mm thick, then EDM'ed to tensile specimens according to ASTM E8/E8M standard (Fig. 2) .", [["specimens", "ANATOMY", 114, 123], ["tensile specimens", "TEST", 106, 123]]], ["For fractography and microhardness study, the surface of coupons, perpendicular to the RD and welded section, was hand ground with abrasive papers of 240, 320, 400 and 600 grits on the Buehler Handimet grinder.", [["surface", "ANATOMY", 46, 53], ["hand", "ANATOMY", 114, 118], ["fractography and microhardness study", "TEST", 4, 40]]], ["The coupons were then polished in two steps, first with 5-7 \u00b5m and then with 1 \u00b5m diamond paste.", [["1 \u00b5m diamond paste", "TREATMENT", 77, 95]]], ["Ultrasonic cleaning in isopropyl alcohol was used to clean the samples and to remove remnant abrasives after each step.", [["samples", "ANATOMY", 63, 70], ["isopropyl alcohol", "CHEMICAL", 23, 40], ["isopropyl alcohol", "CHEMICAL", 23, 40], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 23, 40], ["Ultrasonic cleaning in isopropyl alcohol", "TREATMENT", 0, 40]]], ["The hardness samples were etched using the Aqua Regia etchant (33% HCl + 67% HNO3) by swapping with a cotton tip for 25 s to reveal the weld regions.", [["samples", "ANATOMY", 13, 20], ["HCl", "CHEMICAL", 67, 70], ["HNO3", "CHEMICAL", 77, 81], ["HCl", "CHEMICAL", 67, 70], ["HNO3", "CHEMICAL", 77, 81], ["The hardness samples", "TREATMENT", 0, 20], ["the Aqua Regia etchant", "TREATMENT", 39, 61], ["a cotton tip", "TREATMENT", 100, 112]]], ["The 0.1-\u00b5m resolution Olympus STM6 optical microscope was used to observe weld microstructure and measure the weld profile, penetration depth, fusion zone and defects.", [["penetration depth", "PROBLEM", 124, 141], ["fusion zone and defects", "PROBLEM", 143, 166], ["fusion zone", "OBSERVATION", 143, 154], ["defects", "OBSERVATION", 159, 166]]], ["The base metalfusion zone interface was traced, and resultant zone was scaled using image processing to obtain fusion zone area.ExperimentsMicrohardness test on the polished surface was carried out using the Vickers hardness tester (Wilson VH1102) at 100 gf load and 15 s dwell time.", [["surface", "ANATOMY", 174, 181], ["The base metalfusion zone interface", "PROBLEM", 0, 35], ["image processing", "TEST", 84, 100], ["fusion zone area", "TREATMENT", 111, 127], ["ExperimentsMicrohardness test", "TEST", 128, 157], ["base", "ANATOMY_MODIFIER", 4, 8], ["metalfusion", "OBSERVATION_MODIFIER", 9, 20], ["zone", "OBSERVATION_MODIFIER", 21, 25], ["interface", "OBSERVATION_MODIFIER", 26, 35], ["resultant", "OBSERVATION_MODIFIER", 52, 61], ["zone", "OBSERVATION_MODIFIER", 62, 66]]], ["The indentations were made from the weld center through HAZ to the base metal in both directions at two different weld depths of each sample (x = 0.3 and 4.8 mm).", [["sample", "ANATOMY", 134, 140], ["The indentations", "PROBLEM", 0, 16], ["base", "ANATOMY_MODIFIER", 67, 71], ["metal", "ANATOMY_MODIFIER", 72, 77], ["both", "ANATOMY_MODIFIER", 81, 85], ["different", "OBSERVATION_MODIFIER", 104, 113], ["weld", "OBSERVATION_MODIFIER", 114, 118], ["depths", "OBSERVATION_MODIFIER", 119, 125]]], ["At each depth, the distance between two successive indentations was kept at least 0.18 mm to avoid possible work hardening effect from adjacent indentations.", [["work hardening effect", "PROBLEM", 108, 129], ["adjacent indentations", "PROBLEM", 135, 156], ["successive", "OBSERVATION_MODIFIER", 40, 50], ["indentations", "OBSERVATION_MODIFIER", 51, 63], ["indentations", "OBSERVATION_MODIFIER", 144, 156]]], ["Between the two depths, four equally spaced indentations (at weld depths, x = 1.2, 2.1, 3.0 and 3.9) were made along the penetration depth on the weld centerline.ExperimentsTensile tests were carried out on the MTS 810 material tester.", [["four equally spaced indentations", "PROBLEM", 24, 56], ["ExperimentsTensile tests", "TEST", 162, 186], ["two", "OBSERVATION_MODIFIER", 12, 15], ["depths", "OBSERVATION_MODIFIER", 16, 22], ["four", "OBSERVATION_MODIFIER", 24, 28], ["equally", "OBSERVATION_MODIFIER", 29, 36], ["spaced", "OBSERVATION_MODIFIER", 37, 43], ["indentations", "OBSERVATION_MODIFIER", 44, 56], ["penetration", "OBSERVATION_MODIFIER", 121, 132], ["depth", "OBSERVATION_MODIFIER", 133, 138], ["weld", "OBSERVATION_MODIFIER", 146, 150], ["centerline", "OBSERVATION_MODIFIER", 151, 161]]], ["Displacement-control approach was adopted with crosshead speed of 0.5 mm/min and load-cell of 100 kN.", [["cell", "ANATOMY", 86, 90], ["cell", "CELL", 86, 90], ["Displacement-control approach", "TREATMENT", 0, 29], ["crosshead speed", "TEST", 47, 62]]], ["The data acquisition frequency was set at 5 Hz.Weld GeometryTypical \"nail shape\" weld was seen for all samples (Fig. 3) .", [["samples", "ANATOMY", 103, 110], ["The data acquisition frequency", "TEST", 0, 30], ["Weld GeometryTypical \"nail shape", "TREATMENT", 47, 79], ["nail shape", "OBSERVATION", 69, 79]]], ["The large \"nail head\" shape was seen at the beam entrance (top region of the weld) and the slender and sharp \"nail point\" shape was seen at the deepest region of the weld.", [["head", "ANATOMY", 16, 20], ["The large \"nail head\" shape", "PROBLEM", 0, 27], ["the slender and sharp \"nail point\" shape", "PROBLEM", 87, 127], ["large", "OBSERVATION_MODIFIER", 4, 9], ["\"", "OBSERVATION_MODIFIER", 10, 11], ["nail head", "ANATOMY", 11, 20], ["slender", "OBSERVATION_MODIFIER", 91, 98], ["sharp", "OBSERVATION_MODIFIER", 103, 108], ["nail point", "OBSERVATION", 110, 120], ["deepest", "ANATOMY_MODIFIER", 144, 151], ["region", "ANATOMY_MODIFIER", 152, 158], ["weld", "OBSERVATION_MODIFIER", 166, 170]]], ["Different penetration depths, fusion areas, and defects were found depending on the (linear) heat input.", [["Different penetration depths", "PROBLEM", 0, 28], ["fusion areas", "PROBLEM", 30, 42], ["defects", "PROBLEM", 48, 55], ["penetration", "OBSERVATION_MODIFIER", 10, 21], ["depths", "OBSERVATION_MODIFIER", 22, 28], ["fusion areas", "OBSERVATION", 30, 42], ["defects", "OBSERVATION", 48, 55]]], ["Simulation of pore formation was reported for selective laser melting process when a laser beam reacts with metal powder [17] .", [["pore", "ANATOMY", 14, 18], ["pore", "CELLULAR_COMPONENT", 14, 18], ["selective laser melting process", "TREATMENT", 46, 77], ["a laser beam reacts with metal powder", "TREATMENT", 83, 120]]], ["The scanning laser formed a trench filled with molten metal below the beam.", [["The scanning laser", "TREATMENT", 0, 18], ["a trench filled with molten metal", "TREATMENT", 26, 59]]], ["The dynamic molten metal flowed rapidly upward on both sides of the trench, then collapsed and trapped pores after the laser beam passed by.", [["The dynamic molten metal", "TREATMENT", 0, 24], ["the laser beam", "TREATMENT", 115, 129], ["dynamic", "OBSERVATION_MODIFIER", 4, 11], ["molten metal", "OBSERVATION", 12, 24], ["flowed", "OBSERVATION_MODIFIER", 25, 31], ["rapidly", "OBSERVATION_MODIFIER", 32, 39], ["upward", "OBSERVATION_MODIFIER", 40, 46], ["trench", "ANATOMY", 68, 74], ["collapsed", "OBSERVATION", 81, 90], ["trapped", "OBSERVATION_MODIFIER", 95, 102], ["pores", "OBSERVATION_MODIFIER", 103, 108]]], ["Assuming similar pore forming mechanism for energy beams such as laser or electron beam, a pore could be formed in EBW fusion zone due to either solidification shrinkage or trapping of pore from rapidly flowing and collapsing of molten metal.", [["pore", "ANATOMY", 17, 21], ["pore", "ANATOMY", 91, 95], ["pore", "ANATOMY", 185, 189], ["energy beams", "TREATMENT", 44, 56], ["laser or electron beam", "TREATMENT", 65, 87], ["a pore", "TREATMENT", 89, 95], ["solidification shrinkage", "PROBLEM", 145, 169], ["trapping of pore", "PROBLEM", 173, 189], ["solidification shrinkage", "OBSERVATION", 145, 169], ["pore", "OBSERVATION_MODIFIER", 185, 189], ["rapidly", "OBSERVATION_MODIFIER", 195, 202], ["flowing", "OBSERVATION_MODIFIER", 203, 210], ["molten metal", "OBSERVATION", 229, 241]]], ["A low viscous molten metal would fill all pores if time permits, but a molten metal with high viscosity would flow slowly and might solidify too quickly thereby preventing the pores in the weld from being filled.", [["A low viscous molten metal", "TREATMENT", 0, 26], ["a molten metal", "TREATMENT", 69, 83], ["the pores in the weld", "TREATMENT", 172, 193], ["low", "OBSERVATION_MODIFIER", 2, 5], ["viscous molten", "OBSERVATION", 6, 20], ["high viscosity", "OBSERVATION_MODIFIER", 89, 103], ["filled", "OBSERVATION", 205, 211]]], ["Pores were seen only at the weld bottoms of the samples A4 and A7, which were welded at relatively high scanning speeds (787.4 and 914.4 mm/min) and the highest beam current (65 mA).", [["samples", "ANATOMY", 48, 55]]], ["Such conditions would promote fast cooling rates and formation Author name / Procedia Manufacturing 00 (2019) 000-000 of high viscous molten metal that fails to fill the large pores at the weld bottom (Fig. 4) .", [["Such conditions", "PROBLEM", 0, 15], ["fast cooling rates", "TREATMENT", 30, 48], ["high viscous molten metal", "TREATMENT", 121, 146], ["large", "OBSERVATION_MODIFIER", 170, 175], ["pores", "OBSERVATION_MODIFIER", 176, 181], ["weld bottom", "OBSERVATION", 189, 200]]], ["Except for samples A4 and A7 where voids existed at the weld bottom, all other samples were free of defect when viewed at the highest magnification on the Olympus microscope.", [["samples", "ANATOMY", 11, 18], ["samples", "ANATOMY", 79, 86], ["A7", "CELL", 26, 28], ["samples A4 and A7 where voids", "PROBLEM", 11, 40], ["defect", "PROBLEM", 100, 106], ["the Olympus microscope", "TEST", 151, 173], ["defect", "OBSERVATION", 100, 106]]], ["As expected, the heat input directly affected both weld penetration depth and fusion area.", [["the heat input", "TREATMENT", 13, 27], ["fusion area", "TREATMENT", 78, 89], ["weld", "OBSERVATION_MODIFIER", 51, 55], ["penetration", "OBSERVATION_MODIFIER", 56, 67], ["depth", "OBSERVATION_MODIFIER", 68, 73], ["fusion area", "OBSERVATION", 78, 89]]], ["In fact, linear relationships were found for the ranges of experimental parameters in this study .", [["this study", "TEST", 86, 96], ["linear", "OBSERVATION_MODIFIER", 9, 15]]], ["The measured penetration depths and computed fusion zone areas are tabulated in Table 6 with respect to corresponding heat input.", [["The measured penetration depths", "PROBLEM", 0, 31], ["computed fusion zone areas", "TREATMENT", 36, 62], ["penetration", "OBSERVATION_MODIFIER", 13, 24], ["depths", "OBSERVATION_MODIFIER", 25, 31], ["fusion zone", "OBSERVATION", 45, 56]]], ["The coordinate origin is at the beam entrance point, the x-direction indicates the weld depth while the y-direction is along the weld width.", [["the x-direction", "TEST", 53, 68], ["coordinate", "OBSERVATION_MODIFIER", 4, 14], ["origin", "OBSERVATION_MODIFIER", 15, 21], ["weld depth", "OBSERVATION", 83, 93], ["weld width", "OBSERVATION", 129, 139]]], ["Fig. 7 shows microhardness of the typical sample A9 across the weld at different weld depths (x = 0.3 and 4.8 mm).", [["typical", "OBSERVATION_MODIFIER", 34, 41], ["weld", "OBSERVATION_MODIFIER", 63, 67], ["different", "OBSERVATION_MODIFIER", 71, 80], ["weld", "OBSERVATION_MODIFIER", 81, 85], ["depths", "OBSERVATION_MODIFIER", 86, 92]]], ["The fusion zone widths are schematically represented at different weld depths by solid and dashed lines at x = 0.3 mm and x = 4.8 mm respectively.", [["lines", "CELL", 98, 103], ["solid and dashed lines", "CELL_LINE", 81, 103], ["The fusion zone widths", "TREATMENT", 0, 22], ["solid and dashed lines", "TREATMENT", 81, 103], ["fusion", "OBSERVATION", 4, 10], ["zone", "OBSERVATION_MODIFIER", 11, 15], ["widths", "OBSERVATION_MODIFIER", 16, 22], ["weld", "OBSERVATION_MODIFIER", 66, 70], ["depths", "OBSERVATION_MODIFIER", 71, 77], ["solid", "OBSERVATION_MODIFIER", 81, 86], ["dashed lines", "OBSERVATION", 91, 103]]], ["The weld zone is wider at the \"nail head\" location compared to slender width at the \"nail stem.\"", [["head", "ANATOMY", 36, 40], ["nail stem", "ANATOMY", 85, 94], ["head", "ORGANISM_SUBDIVISION", 36, 40], ["nail stem", "TISSUE", 85, 94], ["weld", "OBSERVATION_MODIFIER", 4, 8], ["zone", "OBSERVATION_MODIFIER", 9, 13], ["wider", "OBSERVATION_MODIFIER", 17, 22], ["slender width", "OBSERVATION_MODIFIER", 63, 76], ["nail stem", "ANATOMY", 85, 94]]], ["Table 7 lists microhardness of the same sample measured inside and outside the weld at two different depths, 0.3 mm and 4.8 mm.", [["sample", "ANATOMY", 40, 46], ["weld", "OBSERVATION_MODIFIER", 79, 83], ["two", "OBSERVATION_MODIFIER", 87, 90], ["different", "OBSERVATION_MODIFIER", 91, 100], ["depths", "OBSERVATION_MODIFIER", 101, 107], ["0.3 mm", "OBSERVATION_MODIFIER", 109, 115], ["4.8 mm", "OBSERVATION_MODIFIER", 120, 126]]], ["The bottom half of Table 7 lists the microhardness measured at the weld center along the weld depth.", [["bottom", "OBSERVATION_MODIFIER", 4, 10], ["weld depth", "OBSERVATION", 89, 99]]], ["Typical hardness values for sample A9 (with low heat input of 180.4 J/mm) and those for sample A3 (with high heat input of 249.8 J/mm) are included for comparison.", [["Typical hardness values", "PROBLEM", 0, 23], ["low heat input", "TEST", 44, 58], ["sample A3", "TEST", 88, 97], ["high heat input", "TEST", 104, 119]]], ["It was found that:Microhardness-No obvious hardness variation was observed in the weld, HAZ, and base metal at depth greater than 1.2 mm.Microhardness-Microhardness at weld center near the beam entrance (x = 0.3 mm) is lower than that at the deeper zone (x = 4.8 mm).", [["Microhardness", "PROBLEM", 18, 31], ["obvious hardness variation", "PROBLEM", 35, 61], ["Microhardness", "PROBLEM", 137, 150], ["Microhardness at weld center", "PROBLEM", 151, 179], ["Microhardness", "OBSERVATION", 18, 31], ["No obvious", "UNCERTAINTY", 32, 42], ["hardness variation", "OBSERVATION", 43, 61], ["weld", "OBSERVATION_MODIFIER", 82, 86], ["HAZ", "OBSERVATION_MODIFIER", 88, 91], ["base", "ANATOMY_MODIFIER", 97, 101], ["metal", "OBSERVATION_MODIFIER", 102, 107], ["depth", "OBSERVATION_MODIFIER", 111, 116], ["1.2 mm", "OBSERVATION_MODIFIER", 130, 136], ["Microhardness", "OBSERVATION", 151, 164], ["weld", "OBSERVATION_MODIFIER", 168, 172], ["center", "OBSERVATION_MODIFIER", 173, 179], ["beam", "OBSERVATION_MODIFIER", 189, 193], ["entrance", "OBSERVATION_MODIFIER", 194, 202], ["lower", "OBSERVATION_MODIFIER", 219, 224], ["deeper", "ANATOMY_MODIFIER", 242, 248], ["zone", "ANATOMY_MODIFIER", 249, 253]]], ["The material in the nail head region was (i) exposed to the beam for a longer time, and (ii) surrounded with a larger pool of molten metal in the weld.", [["nail head region", "ANATOMY", 20, 36], ["nail head", "MULTI-TISSUE_STRUCTURE", 20, 29], ["molten metal in the weld", "TREATMENT", 126, 150], ["nail", "ANATOMY_MODIFIER", 20, 24], ["head", "ANATOMY", 25, 29], ["region", "ANATOMY_MODIFIER", 30, 36], ["larger", "OBSERVATION_MODIFIER", 111, 117], ["molten metal", "OBSERVATION", 126, 138]]], ["Both factors would promote grain growth and a softer nail head region.Microhardness-Similar hardness trends were observed regardless of the heat input values.", [["grain", "ANATOMY", 27, 32], ["head", "ANATOMY", 58, 62], ["head", "ORGANISM_SUBDIVISION", 58, 62], ["a softer nail head region", "PROBLEM", 44, 69], ["Microhardness", "PROBLEM", 70, 83], ["grain growth", "OBSERVATION", 27, 39], ["nail head", "ANATOMY", 53, 62]]], ["Micro-hardness (HV)MicrohardnessDistance from weld center (mm) at x=0.3 mm level at x=4.8 mm level at x=1.2 mm level (on the weld centeline) at x=2.1 mm level (on the weld centerline) at x=3 mm level (on the weld centerline) at x=3.9 mm (on the weld centerline) weld zone x=0.3mm weld zone x=4.8mmMicrohardnessx y The slight difference in hardness near the beam entrance and voids at the bottom of weld zone would not affect the tensile test results since both the nail head region and voids were removed during machining to fabricate the tensile specimens.Tensile test resultsAlthough the experimental setup is different from true welding of two separated parts, each tensile specimen is with a full penetration weld that separates the two halves of a specimen.", [["nail head region", "ANATOMY", 465, 481], ["specimens", "ANATOMY", 547, 556], ["specimen", "ANATOMY", 677, 685], ["specimen", "ANATOMY", 753, 761], ["Micro-hardness (HV)MicrohardnessDistance from weld center (mm)", "TREATMENT", 0, 62], ["the weld centeline", "TEST", 121, 139], ["the weld centerline) weld zone", "TREATMENT", 241, 271], ["weld zone", "TEST", 280, 289], ["The slight difference in hardness", "PROBLEM", 314, 347], ["the tensile test", "TEST", 425, 441], ["the tensile specimens", "TEST", 535, 556], ["Tensile test", "TEST", 557, 569], ["the experimental setup", "TREATMENT", 586, 608], ["each tensile specimen", "TEST", 664, 685], ["a full penetration weld", "TREATMENT", 694, 717], ["weld", "OBSERVATION_MODIFIER", 46, 50], ["4.8mm", "OBSERVATION_MODIFIER", 292, 297], ["slight", "OBSERVATION_MODIFIER", 318, 324], ["difference", "OBSERVATION_MODIFIER", 325, 335], ["hardness", "OBSERVATION_MODIFIER", 339, 347], ["nail head", "ANATOMY", 465, 474], ["experimental setup", "OBSERVATION", 590, 608], ["different", "OBSERVATION_MODIFIER", 612, 621]]], ["The tensile test in this would represent an ideal case in welding with complete penetration, precise machining and no misalignment of welded parts.", [["The tensile test", "TEST", 0, 16], ["precise machining", "TREATMENT", 93, 110], ["misalignment of welded parts", "PROBLEM", 118, 146], ["welded", "OBSERVATION", 134, 140]]], ["Pores were found at the weld bottom of samples A4 and A7; however, these defects were machined away when fabricating the tensile specimens.", [["samples", "ANATOMY", 39, 46], ["specimens", "ANATOMY", 129, 138], ["these defects", "PROBLEM", 67, 80], ["the tensile specimens", "TEST", 117, 138], ["defects", "OBSERVATION", 73, 80]]], ["Figure 8 shows consistent stress-strain curves for sample A9 and its replicate.", [["Figure", "TEST", 0, 6], ["consistent stress-strain curves", "PROBLEM", 15, 46]]], ["Figures 9,10 and Table 8 show the mechanical properties of all tested EBW samples.Tensile test resultsWith an exception of one sample (A6, 209.6 J/mm), all sample tensile strengths exceeded the material specification of 837 MPa.", [["EBW samples", "ANATOMY", 70, 81], ["EBW samples", "CANCER", 70, 81], ["Figures", "TEST", 0, 7], ["Tensile test", "TEST", 82, 94], ["A6", "TEST", 135, 137], ["all sample tensile strengths", "TEST", 152, 180]]], ["The elongation of EBW specimens, however, decreased below the specification of 57% when the heat input values were higher than 225 J/mm.", [["EBW specimens", "ANATOMY", 18, 31], ["The elongation of EBW specimens", "TEST", 0, 31], ["the heat input values", "TEST", 88, 109], ["elongation", "OBSERVATION_MODIFIER", 4, 14], ["decreased", "OBSERVATION_MODIFIER", 42, 51]]], ["Perhaps a higher temperature and fast cooling rate associated with higher heat input promotes forming of brittle Laves particles in the microstructure, therefore, degrading the ductility of welded samples.", [["samples", "ANATOMY", 197, 204], ["a higher temperature", "PROBLEM", 8, 28], ["fast cooling rate", "TREATMENT", 33, 50], ["higher heat input", "PROBLEM", 67, 84], ["brittle Laves particles", "PROBLEM", 105, 128], ["higher temperature", "OBSERVATION_MODIFIER", 10, 28], ["brittle", "OBSERVATION_MODIFIER", 105, 112], ["microstructure", "OBSERVATION_MODIFIER", 136, 150]]], ["Material toughness, represented by area under the stress-strain curve, also reduced with increasing of heat input (Table 8 ).", [["Material toughness", "PROBLEM", 0, 18], ["increasing of heat input", "TREATMENT", 89, 113], ["toughness", "OBSERVATION_MODIFIER", 9, 18]]], ["This supported the hypothesis that brittle particles might be the cause when welding at high heat input conditions.", [["brittle particles", "PROBLEM", 35, 52]]], ["Some samples fractured within the weld zone, while other samples fractured randomly and away from the weld.", [["samples", "ANATOMY", 5, 12], ["samples", "ANATOMY", 57, 64], ["Some samples fractured", "PROBLEM", 0, 22], ["other samples fractured", "PROBLEM", 51, 74], ["fractured", "OBSERVATION", 13, 22], ["weld", "OBSERVATION_MODIFIER", 34, 38], ["zone", "OBSERVATION_MODIFIER", 39, 43], ["fractured", "OBSERVATION", 65, 74]]], ["Selected fractured samples were polished along the gage length and chemically etched to confirm that the fractures were actually confined within the weld zone.FractographStudy of fracture surfaces helps to explain the measured ductility results.", [["samples", "ANATOMY", 19, 26], ["fractures", "DISEASE", 105, 114], ["fracture", "DISEASE", 179, 187], ["Selected fractured samples", "PROBLEM", 0, 26], ["the fractures", "PROBLEM", 101, 114], ["fracture surfaces", "PROBLEM", 179, 196], ["fractured", "OBSERVATION", 9, 18], ["fractures", "OBSERVATION", 105, 114], ["weld", "OBSERVATION_MODIFIER", 149, 153], ["zone", "OBSERVATION_MODIFIER", 154, 158], ["fracture", "OBSERVATION", 179, 187]]], ["The relative location of a fractured surface from the weld zone is found after polishing and etching along the gage length of a tensile specimen after testing.", [["surface", "ANATOMY", 37, 44], ["specimen", "ANATOMY", 136, 144], ["surface", "CELLULAR_COMPONENT", 37, 44], ["a fractured surface", "PROBLEM", 25, 44], ["polishing and etching", "TREATMENT", 79, 100], ["a tensile specimen", "TEST", 126, 144], ["testing", "TEST", 151, 158], ["fractured", "OBSERVATION", 27, 36], ["surface", "OBSERVATION_MODIFIER", 37, 44], ["weld", "OBSERVATION_MODIFIER", 54, 58], ["zone", "OBSERVATION_MODIFIER", 59, 63], ["gage length", "OBSERVATION_MODIFIER", 111, 122]]], ["The fractured surfaces on two samples A3 (249.8 J/mm heat input) and A9 (180 J/mm heat input) are shown in Figs.", [["The fractured surfaces", "PROBLEM", 0, 22], ["A3", "TEST", 38, 40], ["J/mm heat input", "TREATMENT", 48, 63], ["A9 (180 J/mm heat input", "TREATMENT", 69, 92], ["fractured", "OBSERVATION_MODIFIER", 4, 13], ["surfaces", "OBSERVATION_MODIFIER", 14, 22]]], ["The brittle sample A3 (50% ductility) fractured at the weld while the more ductile sample A9 (65% ductility) fractured away from the weld.", [["brittle", "OBSERVATION_MODIFIER", 4, 11], ["ductile", "OBSERVATION_MODIFIER", 75, 82], ["weld", "OBSERVATION_MODIFIER", 133, 137]]], ["Shown in Fig. 11a , the weld bead contains no visible crack even when viewing at a high magnification.", [["the weld bead", "TREATMENT", 20, 33], ["visible crack", "PROBLEM", 46, 59], ["no", "UNCERTAINTY", 43, 45], ["visible", "OBSERVATION_MODIFIER", 46, 53], ["crack", "OBSERVATION", 54, 59]]], ["In Fig. 11b , a series of shear bands near the fractured surface, located away from the weld zone and oriented about 45\u00b0 to the tensile loading direction, suggest ductile fracture and are confirmed with the high ductility of 65% in tensile testing ( Table 8 ).", [["surface", "ANATOMY", 57, 64], ["fracture", "DISEASE", 171, 179], ["shear bands", "PROBLEM", 26, 37], ["ductile fracture", "PROBLEM", 163, 179], ["the high ductility", "TEST", 203, 221], ["tensile testing", "TEST", 232, 247], ["fractured", "OBSERVATION_MODIFIER", 47, 56], ["surface", "OBSERVATION_MODIFIER", 57, 64], ["weld", "OBSERVATION_MODIFIER", 88, 92], ["zone", "OBSERVATION_MODIFIER", 93, 97], ["suggest", "UNCERTAINTY", 155, 162], ["ductile fracture", "OBSERVATION", 163, 179], ["high ductility", "OBSERVATION_MODIFIER", 207, 221]]], ["The opposites are found on sample A3 where cracks are initiated and propagated within the weld zone as shown in Fig. 12a .", [["12a", "GENE_OR_GENE_PRODUCT", 117, 120], ["cracks", "PROBLEM", 43, 49], ["cracks", "OBSERVATION_MODIFIER", 43, 49], ["weld", "OBSERVATION_MODIFIER", 90, 94], ["zone", "OBSERVATION_MODIFIER", 95, 99], ["Fig", "OBSERVATION_MODIFIER", 112, 115]]], ["Other secondary cracks, oriented about 90\u00b0 to the tensile loading direction, are visible in the brittle weld zone as shown at the lower left of Fig. 12b .", [["Other secondary cracks", "PROBLEM", 0, 22], ["secondary", "OBSERVATION_MODIFIER", 6, 15], ["cracks", "OBSERVATION", 16, 22], ["lower", "ANATOMY_MODIFIER", 130, 135], ["left", "ANATOMY_MODIFIER", 136, 140], ["Fig", "OBSERVATION", 144, 147]]], ["These facts explain the low ductility of samples when EBW'ed at high heat input greater than 225 J/mm.", [["samples", "ANATOMY", 41, 48], ["EBW", "CHEMICAL", 54, 57], ["the low ductility of samples", "PROBLEM", 20, 48], ["EBW", "TEST", 54, 57], ["low ductility", "OBSERVATION_MODIFIER", 24, 37]]], ["In EBW and selective laser melting, the melting and cooling of molten IN718 forms the dendrite solid solution \u03b3 phase, NbC niobium carbide, and the Laves phase [19] [20] [21] [22] [23] :FractographLiquid Inconel 718 \u2192 \u03b3 + NbC + Laves (2) The Laves phase, forming due to fast cooling of molten IN718, perhaps are present in the weld zone when cooled from a higher weld temperature due to high heat input.", [["dendrite", "ANATOMY", 86, 94], ["IN718", "CHEMICAL", 70, 75], ["NbC niobium", "CHEMICAL", 119, 130], ["molten IN718", "CHEMICAL", 63, 75], ["NbC niobium carbide", "CHEMICAL", 119, 138], ["[19] [20] [21] [22] [23]", "CHEMICAL", 160, 184], ["NbC", "CHEMICAL", 222, 225], ["IN718", "CHEMICAL", 293, 298], ["molten IN718", "SIMPLE_CHEMICAL", 63, 75], ["NbC niobium carbide", "SIMPLE_CHEMICAL", 119, 138], ["[19] [20] [21] [22] [23]", "SIMPLE_CHEMICAL", 160, 184], ["FractographLiquid Inconel 718 \u2192 \u03b3 + NbC", "SIMPLE_CHEMICAL", 186, 225], ["molten IN718", "SIMPLE_CHEMICAL", 286, 298], ["molten IN718", "PROTEIN", 63, 75], ["selective laser melting", "TREATMENT", 11, 34], ["the melting", "TREATMENT", 36, 47], ["cooling of molten", "TREATMENT", 52, 69], ["NbC niobium carbide", "TEST", 119, 138], ["the Laves phase", "TEST", 144, 159], ["FractographLiquid", "TEST", 186, 203], ["Inconel", "TEST", 204, 211], ["\u03b3", "TEST", 218, 219], ["NbC", "TEST", 222, 225], ["Laves", "TEST", 228, 233], ["The Laves phase", "TEST", 238, 253], ["fast cooling of molten", "TREATMENT", 270, 292], ["a higher weld temperature", "PROBLEM", 354, 379], ["high heat input", "PROBLEM", 387, 402], ["selective", "OBSERVATION_MODIFIER", 11, 20], ["laser", "OBSERVATION_MODIFIER", 21, 26], ["weld", "ANATOMY_MODIFIER", 327, 331], ["zone", "ANATOMY_MODIFIER", 332, 336]]], ["Such brittle phases would be responsible for the brittle nature of the specimen.ConclusionsElectron beam welding of rolled Inconel 718 was performed.", [["specimen", "ANATOMY", 71, 79], ["Inconel 718", "CHEMICAL", 123, 134], ["specimen", "CANCER", 71, 79], ["Such brittle phases", "PROBLEM", 0, 19], ["the brittle nature of the specimen", "PROBLEM", 45, 79]]], ["This study showed: 1) Voids can be formed at the weld bottom when welded at high beam power at high welding speed.", [["Voids", "SIMPLE_CHEMICAL", 22, 27], ["This study", "TEST", 0, 10]]], ["The only two welded samples containing voids, out of nine samples in this study, were welded at beam power of 3250 W (65 mA, 50 kV) and at welding speed faster than 0.78 m/min.", [["samples", "ANATOMY", 20, 27], ["two welded samples containing voids", "PROBLEM", 9, 44], ["this study", "TEST", 69, 79], ["two", "OBSERVATION_MODIFIER", 9, 12], ["welded", "OBSERVATION", 13, 19], ["voids", "OBSERVATION_MODIFIER", 39, 44]]], ["2) All samples but one sample exhibit higher tensile strength than the specification for rolled IN718 (837 MPa).", [["samples", "ANATOMY", 7, 14], ["sample", "ANATOMY", 23, 29], ["All samples", "TEST", 3, 14], ["higher", "OBSERVATION_MODIFIER", 38, 44], ["tensile strength", "OBSERVATION", 45, 61]]], ["The ductility also exceeded the specification except when joining at heat input above 225 J/mm.", [["ductility", "OBSERVATION_MODIFIER", 4, 13]]], ["3) The heat inputs dictate fracture behavior of EBW'ed IN718.", [["fracture", "DISEASE", 27, 35], ["IN718", "PROTEIN", 55, 60], ["The heat inputs", "PROBLEM", 3, 18], ["fracture behavior", "PROBLEM", 27, 44], ["fracture", "OBSERVATION", 27, 35]]], ["A low heat input resulted in strong welds since the ductile fracture surface occurred in the base material and outside of the weld zone.", [["surface", "ANATOMY", 69, 76], ["fracture", "DISEASE", 60, 68], ["A low heat input", "PROBLEM", 0, 16], ["the ductile fracture surface", "PROBLEM", 48, 76], ["low heat", "OBSERVATION_MODIFIER", 2, 10], ["strong", "OBSERVATION_MODIFIER", 29, 35], ["ductile", "OBSERVATION_MODIFIER", 52, 59], ["fracture", "OBSERVATION", 60, 68], ["surface", "OBSERVATION_MODIFIER", 69, 76], ["base", "ANATOMY_MODIFIER", 93, 97], ["weld", "ANATOMY_MODIFIER", 126, 130], ["zone", "ANATOMY_MODIFIER", 131, 135]]], ["In contrast, a high heat input resulted in brittle fracture inside the weld zone.", [["fracture", "DISEASE", 51, 59], ["a high heat input", "PROBLEM", 13, 30], ["brittle fracture inside the weld zone", "PROBLEM", 43, 80], ["brittle", "OBSERVATION_MODIFIER", 43, 50], ["fracture", "OBSERVATION", 51, 59], ["weld", "OBSERVATION_MODIFIER", 71, 75], ["zone", "OBSERVATION_MODIFIER", 76, 80]]], ["The brittleness perhaps caused by the presence of Laves phase formed by fast cooling in the weldRecommendationsa) Studying the microstructure of the weld and confirming the presence of brittle Laves particles in a weld zone when joining at high heat input. b) Comparing EBW results of rolled samples versus those from samples produced by selective laser melting. c) Improving the mechanical properties of EBW'ed IN718 with different post processing techniques before tensile testing.", [["samples", "ANATOMY", 292, 299], ["samples", "ANATOMY", 318, 325], ["EBW'ed IN718", "CELL_LINE", 405, 417], ["The brittleness", "PROBLEM", 0, 15], ["Laves phase", "PROBLEM", 50, 61], ["brittle Laves particles", "PROBLEM", 185, 208], ["rolled samples", "PROBLEM", 285, 299], ["selective laser melting", "TREATMENT", 338, 361], ["different post processing techniques", "TREATMENT", 423, 459], ["tensile testing", "TEST", 467, 482], ["brittle", "OBSERVATION_MODIFIER", 185, 192], ["Laves", "OBSERVATION", 193, 198], ["mechanical properties", "OBSERVATION_MODIFIER", 380, 401]]]]}